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This report highlights changes in general practice activity 
in Australia over the most recent decade (April 2001 to 
March 2011) of the BEACH program, a national cross-
sectional study of general practice activity.  Over this 
time 9801 participating GPs provided details of  981,000 
GP–patient encounters. The report highlights changes 
that have occurred in the characteristics of general 
practitioners and the patients they see, the problems 
managed, and the treatments provided. Changes in 
prevalence of overweight and obesity, smoking status 
and alcohol use, are also described for subsamples of 
more than 30,000 adults and 3,000 children each year.
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Summary 
This book brings 10 years of data together from the BEACH (Bettering the Evaluation and 
Care of Health) program, to identify changes that have occurred over the decade 2001–02 to 
2010–11 in the characteristics of GPs and the patients they see, the problems they manage 
and the treatments they provide. 
BEACH is a continuous cross-sectional national study that began in April 1998. Every year 
each of about 1,000 randomly selected GPs records details of 100 consecutive encounters on 
structured paper recording forms, and provides information about themselves and their 
practice. BEACH is the only continuous randomised study of general practice activity in the 
world, and the only national program that provides direct linkage of management (such as 
prescriptions, referrals, investigations) to the problem under management.  
Changes in the population influence GP clinical work. With an ageing population a growing 
part of the GP workload involves older patients with multiple chronic diseases. 
GPs are the first port of call in the Australian health care system. There is a universal health 
insurance scheme (Medicare) which paid (in part or in whole) for 118.1 million general 
practice consultations in 2010–11 (up from 101 million in 2001–02), 5.3 services per person.  
This report is based on information from 9,801 participating GPs, about almost 1 million  
GP-patient encounters. Smaller studies are undertaken with subsamples of the BEACH 
encounters. Results for substudies on patient body mass index, smoking status and alcohol 
consumption are included in this report.  
A companion report, General practice activity in Australia 2010–11, describes the 2010–11 
annual results in more detail, <purl.library.usyd.edu.au/sup/9781920899868>. 
The GP participants 
Between 2001–02 and 2010–11: 
• the age and sex distribution GP participants changed: the proportion being female 
increased from 36% to 38%; the proportion of participants aged 35–44 years decreased 
from 27% to 17%; the proportion aged 55 years or more increased (from 29% to 42%). 
• an increasing proportion of participants graduated overseas and there were changes in 
the geographic distribution of the overseas countries of graduation.  
• the proportion of GP participants holding Fellowship of the RACGP significantly 
increased, from 35% to 52%. 
• the proportion of GPs spending: 40 or less hours per weeks in direct patient care 
increased from 42% to 54%; 60 or more hours decreased from 43% to 34%. 
• GPs moved away from solo and small group practices to larger practices, of 5–9 
(increasing from 35 to 39%) and 10 or more individual GPs (10% to 22%).  
• a decreasing proportion of GP participants worked in practices providing their own 
after-hours care, (from 42% to 30%) or providing it in cooperation with other practices 
(19% to 14%). Deputising services became more widely used. 
• the proportion of GPs with a computer available at their major practice increased from 
90% to 98% and there was a steady increase in the proportion indicating they use a 
computer for clinical purposes to some extent. 
 x 
• an increase in short surgery consultations from 1.1% to 2.3%, of Medicare/DVA-
claimable encounters, may be related to increased practice nurse involvement. Long 
surgery consultations did not change overall. Encounters claimable as GP mental health 
care items and health assessments significantly increased.  
• the length of consultations did not change over the decade, Medicare/DVA-claimable 
encounters lasting an average 15 minutes (median 13 minutes) in all years. 
The patients at encounters  
Between 2001–02 and 2010–11: 
• patients aged 45 years or more, particularly those 75 years and over, accounted for an 
increasing proportion of encounters.  
• encounters with new patients to the practice decreased (from 9% to 7%). The proportion 
of encounters with patients holding a Commonwealth concession card remained 
relatively stable and there was no change in the proportion with Indigenous patients or 
with patients from a Non-English-speaking background. 
• there was a significant increase in the number of patient reasons given for their 
encounter (RFEs), from 149 to 156 per 100 encounters. When extrapolated this equates to 
about 35 million extra RFEs presented nationally. 
• symptoms or complaints were the most frequent type of RFE but their frequency 
decreased. There were increased patient requests for: test results (a 70% increase); 
administrative procedures (doubled); medications, treatments and therapeutics (e.g. 
repeat prescriptions) (22%); diagnostic and preventative procedures (e.g. immunisation) 
(11%). 
• patients presented for their diabetes increased by 40%, equating to a national increase of 
650,000 encounters with this RFE. Requests for a referral doubled, and presentations for 
depression increased by 15%, coinciding with the Better Access initiative. RFEs relating 
to headaches and neck complaints, asthma, back complaints and throat complaints all 
decreased over the decade.  
Problems managed at encounters 
GPs managed more problems at encounters in 2010–11 (153 per 100 encounters) than in 
2001–02 (143 per 100), suggesting 36.8 million more problems managed by GPs nationally in 
2010–11. This was reflected in an increased management rate of chronic conditions, from  
49 per 100 encounters in 2001–02 to 53 per 100, suggesting 13.5 million more GP contacts 
with chronic problems in Australia in 2010–11 than in 2001–02.  
There were significant increases in the management rate of problems classified as ‘diagnostic 
and preventive procedures’, ‘results’ and ‘administrative procedures’, suggesting: 5.4 million 
more contacts with problems classed as ‘diagnostic and preventive procedures’; 1.1 million 
more test result contacts; and 900,000 more contacts with problems classified as 
administrative were managed in 2010–11 than in 2001–02. 
Problems related to the respiratory system remained the most common type of problem 
managed. There were significant increases in the management rate of some problems types. 
When extrapolated to general practice across Australia these suggest that when compared 
with 2001–02, in 2010–11 there were 7.9 million more ‘general and unspecified’ problems 
managed; 4.7 million endocrine and metabolic problems; 4.1 million more psychological 
problems; 2.6 million more digestive problems; 980,000 more urological problems and 
950,000 more male genital system problems. 
 xi 
The most common individual problems managed in general practice over the decade were 
hypertension, check-up, immunisation/vaccination, and upper respiratory tract infection.  
Over the decade there were significant increases in the management rate of depression, 
diabetes, general check-ups, prescriptions, oesophageal disease, test results and abnormal 
test results (which may reflect the increase in the rate of pathology testing) pregnancy, atrial 
fibrillation, vitamin/nutritional deficiency, administrative procedures. There were 
significant decreases in the management rate of asthma, sprain/strain and menopausal 
problems managed over the decade. The increases in the management rate of the above 
chronic conditions may be related to increases in the proportion of GP encounters accounted 
for by older patients. Introduction of Medicare items for health assessments at specified ages 
may have contributed to the increased rate of general check-ups.  
Management actions 
Medications 
The number of medications prescribed, GP supplied, or advised for the over-the-counter 
purchase significantly decreased, from 73 to 69 per 100 problems managed. Prescribed 
medications decreased from 61 to 56 per 100 problems managed – so an average 5.5 fewer 
prescriptions were written for every 100 problems managed in 2010–11 than 10 years earlier. 
This was counteracted by an increase in the number of medications supplied by the GP, from 
5 to 7 per 100 problems managed. The majority of these were vaccines, and rates for many of 
them increased significantly over the period. There was no change in the rate at which OTC 
medications were advised for over-the-counter purchase. 
There were many changes in prescription rates of specific drug groups including increases in 
prescription of agents acting on the renin-angiotensin system; psychoanaleptics; serum 
lipid-modifying agents; antithrombotics; and thyroid medications. Conversely, there were 
decreases in prescriptions for psycholeptics, drugs for obstructive airways disease, and 
systemic anti-inflammatory medications. 
One of the individual medications with the greatest increase was oxycodone, with an 
extrapolated estimated 1.5 million more prescriptions made in 2010–11 than 10 years earlier. 
There were significant decreased prescribing rates of some specific drug including: 
simvastatin, celecoxib, and cefaclor monohydrate. 
Clinical treatments 
Between 2001–02 and 2010–11: 
• GP use of clinical treatments decreased from 27 to 23 per 100 problems. The drop 
occurred in 2004–05 coinciding with the introduction of practice nurse item numbers. 
Since then the rate has steadily increased but remained lower in 2010–11 than in 2001–02.  
• general advice and education was the most common clinical treatment provided.  
• counselling and advice about nutrition and weight fell from 4 to 3 per 100 problems 
managed. We estimate 730,000 fewer occasions of provision of counselling and advice 
about nutrition and weight given in 2010–11 than in 2001–02.  
• there was an increased use of clinical treatment(s) in management of tobacco abuse, from 
0.3 to 0.6 per 100 encounters and this equates to 410,000 more occasions on which clinical 
treatments were provided for tobacco abuse nationally in 2010–11. 
 xii 
Procedures 
Procedures increased from 10 to 11 per 100 problems managed and this was reflected in 
higher rates of dressings/pressure/compression/tamponade, and local injections (excluding 
all local injection/infiltrations performed for immunisations). Female genital check up/pap 
smear remained the problem most often managed with a procedure.  
Referrals 
Referrals to other health providers increased, from 7 to 9 per 100 problems influenced by 
increases in those to medical specialists, allied health services, and emergency departments.  
This suggests there were about 6 million more referrals made nationally in 2010–11 than in 
2001–02. Over time there was also an increasing likelihood that the patient would receive at 
least one referral at encounter (at 13% in 2010–11 compared with 10% in 2001–02). 
Referrals to medical specialists increased, particularly those to cardiologists, with marginal 
increases in referrals to urologists and gastroenterologists. 
Referrals to allied health services increased from 1.6 to 2.8 per 100 problems managed, 
particularly to psychologists – results suggest about 600,000 more referrals to psychologists 
in 2010–11 than in 2001–02. Referrals to podiatrists or chiropodists, and to dentists also 
increased, with marginal increases in those to dietitians or nutritionists, and 
physiotherapists.  
There was also a significant increase in the rate of referrals to emergency departments and a 
marginal decrease in the rate of referral/admission to hospitals. 
Tests and investigations 
Between 2001–02 and 2010–11: 
• pathology tests ordered increased by 37%, from 22 to 30 orders per 100 problems, the rise 
occurring in the early part of the decade, with no further increase since 2006–07 and the 
proportion of problems managed that were tested increased from 11% to 13% 
• likelihood of pathology testing increased from 14% to 18% of encounters which is over 
7 million additional encounters at which pathology was ordered in 2010–11 
• imaging orders also increased (but to a lesser degree), most of this change also occurred 
in the earlier part of the decade.  
The largest increase was in orders for chemical pathology, followed by haematology and 
microbiology tests. Orders for ultrasound increased from 1.7 tests to 2.5 per 100 problems 
managed. Orders for computerised tomography increased from 0.5 to 0.7 per 100.  
Practice nurse 
Between 2005–06 and 2010–11, the proportion of encounters involving a practice nurse 
doubled from 4%to 8.0%. The proportion of problems in which they were involved in 
management increased significantly from 3% to 5%. Extrapolation of these results to national 
Medicare claims for GP consultations in these years suggests that practice nurses were 
actively involved in provision of care at about 10.3 million encounters in 2010–11, about 
6.1 million more than in 2005–06. They took over an increasing proportion (23% to 38%) of 
the procedures at the GP encounters. Practice nurse provision of clinical treatments (such as 
advice and health education) remained infrequently recorded. 
 xiii 
The proportion of practice nurse activity encounters for which a practice nurse item number 
was recorded did not significantly change between 2005–06 and 2010–11, sitting between 
35% and 45%.  
Between 2005–06 and 2010–11, there were decreases in the following procedures conducted 
by the practice nurse: dressing/pressure/compression; repair/fixation; electrical tracing; 
excisions/removals/ biopsies. International normalised ratio (INR) blood testing done by a 
nurse rose from 2 to 7 per 100 practice nurse encounters. 
Substudies of patient risk factors 
Alcohol consumption (n = 30,000–34,000 per year): Between 2001–02 and 2010–11 prevalence 
of at-risk alcohol consumption among adults (18+ years) remained static at about 25–26%.  
Smoking (n = 31,000–34,000 per year): Among adults (18+ years) there were decreases in 
prevalence of current daily smoking (18% to 15%) and occasional smoking (4.1% to 2.7%). 
Body mass index: 
Adults (n = 30,000–32,000 per year): Between 2001–02 and 2010–11 prevalence of overweight 
and obesity in adults (18+ years) increased from 55% to 62%. Prevalence of obesity rose from 
22% to 27% and this increase was apparent in males and females. Prevalence of overweight 
rose from 34% to 35%.  
Children (n = 3,000–4,000): Prevalence of overweight and obesity in children (aged 2–17 years) 
remained static from 2001–02 to 2010–11, with 10–11% of children being obese and about 
18% overweight.  
 
  
 
 
1 Introduction 
This report is the 30th book in the series from the Bettering the Evaluation of Care and 
Health (BEACH) program. It includes summary results from the most recent 10 years of the 
program, from 2001–02 to 2010–11 inclusive. 
BEACH is a continuous national study of general practice activity in which ever-changing 
random samples of about 1,000 general practitioners (GPs) participate in a year. Each 
participating GP records details of 100 consecutive GP-patient encounters with consenting 
patients. BEACH is run by the Family Medicine Research Centre (FMRC) at the University of 
Sydney. The program is supported financially by government instrumentalities and private 
industry (see Acknowledgments). 
BEACH began in April 1998, and at the end of its 13th year (March 2011) its database 
included records for 1,283,100 GP–patient encounters from 12,831 participating GPs, 
representing about 8,800 individual GPs, almost half the sample frame from which the GP 
samples are drawn. Annual results from the BEACH study are published each year. The 
most recent annual report is General practice activity in Australia 2010–11,1 available at 
<purl.library.usyd.edu.au/sup/9781920899868>. 
From April 1998 the BEACH program was conducted by the FMRC, University of Sydney, in 
collaboration with the Australian Institute of Health and Welfare (AIHW), under the AIHW 
Act. The collaboration ceased in March 2011. Since then, the FMRC has continued to conduct 
the BEACH program. 
This book brings the most recent 10 years of data together to identify changes that have 
occurred over the decade 2001–02 to 2010–11 in the GP workforce, the patients they see, the 
problems managed and the treatments they provide. This report is based on information 
from 9,801 participating GPs, about almost 1 million GP-patient encounters.  
The structure of this report follows the usual approach of the annual BEACH reports. Ten 
years of results are provided about the GPs, the patients and the problems managed, 
followed by an overview of management, specific chapters for each type of management 
action and a chapter on practice nurse activity. Changes in prevalence of some risk factors 
are also presented. 
Each chapter contains an overview of the section (including definitions where relevant), and 
a brief description of the major findings, followed by the results tables. In the tables, 
statistically significant changes in results between 2001–02 and 2010–11 are marked. The 
national effect of significant change can be estimated by extrapolating the BEACH results to 
all GP Medicare claimed encounters. The method adopted for extrapolation of the effect of a 
change is described in Section 2.9. Examples of extrapolation of a measured change are also 
provided in each chapter from Chapter 5 to Chapter 13 inclusive. The reader can apply this 
method to any significant change in the BEACH data presented in terms of rate per 100 
encounters, to gain an estimate of the size of the national effect of this change. 
In this report, changes over time in (for example) GP management actions for a specific 
problem, or changes in the problems managed for a selected group of patients, are not 
generally investigated. However, this type of specific analyses for morbidities classed in the 
National Health Priority Areas2 was published in July 2009 in General practice in Australia, 
health priorities and policies 1998 to 2008.3  
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1.1 Background 
In December 2010, the population of Australia was estimated to be 22.48 million people.4 
Like the rest of the developed world, Australia has an ageing population: the median age 
(the age at which half the population is older and half is younger) increased by 5.2 years over 
two decades, from 32.1 years at 30 June 1990 to 37.3 years at 30 June 2011. Over the next 
several decades, population ageing is projected to have significant implications for Australia, 
including for health.5 As life expectancy improves, people are living longer with disease, so 
that a greater part of the GP workload will involve management of older patients with 
multiple chronic diseases. 
Australia’s health expenditure in 2008–09 was $112.8 billion, an average $5,190 per 
Australian, and 9.0% of GDP in 2008–09. Governments funded 69.7%, with the remainder 
(31.1%) being paid by the non-government sector.6 
GPs are usually the first port of call in the Australian health care system. Payment for GP 
visits is largely on a fee-for-service system, there being no compulsory patient lists or 
registration. People are free to see multiple practitioners and visit multiple practices of their 
choice. There is a universal medical insurance scheme (managed by Medicare Australia), 
which covers all or most of a person’s costs for a GP visit.  
In 2008 in Australia, there were 24,029 practising primary care practitioners (vocationally 
recognised GPs and other medical practitioners), making up 23,188 full-time equivalents 
(based on a 40 hour week), or 107.9 per 100,000 people.7  
In 2009–10, about 83% of the Australian population claimed at least one GP service from 
Medicare (personal communication, Department of Health and Ageing (DoHA), June 2010). 
From April 2010 to March 2011, Medicare paid rebates for about 118.1 million general 
practice services (excluding practice nurse items),8 at an average of about 5.3 GP visits per 
head of population or 6.3 visits per person who visited at least once. This equates to about 2.3 
million GP-patient encounters per week.  
While Medicare statistics provide information about frequencies and costs of visits claimed 
from Medicare for GP services, they cannot tell us about the content of these visits. The 
BEACH program fills this gap. 
BEACH gives us some understanding of the content of these encounters and of the services 
and treatments that GPs provide. The BEACH program aims to: 
• provide a reliable and valid data collection process for general practice that is responsive 
to the ever-changing needs of information users 
• establish an ongoing database of GP–patient encounter information 
• assess patient risk factors and health states, and their relationship with service activity. 
Users of the BEACH data might wish to consolidate information from multiple national data 
sources. Integration of data from multiple sources can provide a more comprehensive 
picture of the health and health care of the Australian community. It is therefore important 
that readers are aware of how the BEACH data differ from those drawn from other sources. 
A summary of differences between those data collected in BEACH and those in the Medicare 
Benefits Schedule, the Pharmaceutical Benefits Scheme and the National Health Survey is 
available in General practice activity in Australia 2010–11 (Section 1.3).1 The BEACH program 
has generated many papers on a wide variety of topics in journals and professional 
magazines. A full list is available at <www.fmrc.org.au>. 
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2 Methods 
In summary: 
• each year, BEACH involves a new random sample of about 1,000 GPs 
• each GP records details about 100 doctor–patient encounters of all types  
• the GP sample is a rolling (ever-changing) sample, with about 20 GPs participating in 
any 1 week, 50 weeks a year 
• each GP can be selected only once per quality assurance (QA) triennium (that is, once 
every 3 years) 
• the encounter information is recorded by the GPs on structured paper encounter forms 
(Appendix 1) 
• GP participants also complete a questionnaire about themselves and their practice 
(Appendix 2). 
2.1 Sampling methods 
The source population includes all vocationally registered GPs and all general practice 
registrars who claimed a minimum of 375 general practice A1 Medicare items in the most 
recently available 3-month Medicare data period (which equates to 1,500 A1 Medicare claims 
a year). This ensures inclusion of the majority of part-time GPs, while excluding those who 
are not in private practice but claim for a few consultations a year. 
The Medicare Statistics section of the DoHA updates the sample frame from the Medicare 
records quarterly, leaving out of the sample frame any GPs already randomly sampled in the 
current triennium, and draws a new sample from those currently in the sample frame. This 
ensures the timely addition of new entries to the profession, and timely exclusion of those 
GPs who have stopped practising, or have already participated or been approached in the 
current triennium. 
2.2 Recruitment methods 
The randomly selected GPs are approached by letter, posted to the address provided by the 
DoHA. 
• Over the following 10 days, the telephone numbers generated from the Medicare data 
are checked using the electronic white and yellow pages. This is necessary because many 
of the telephone numbers provided from the Medicare data are incorrect. 
• The GPs are then telephoned in the order they were approached and, referring to the 
approach letter, asked whether they will participate. 
• This initial telephone contact with the practice often indicates that the selected GP has 
moved elsewhere, but is still in practice. Where new address and/or telephone number 
can be obtained, these GPs are followed up at their new address. 
• GPs who agree to participate are set an agreed recording date several weeks ahead. 
• A research pack is sent to each participant before the planned start date. 
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• Each GP receives a telephone reminder early in the agreed recording period – this also 
provides the GP with an opportunity to ask questions about the recording process. 
• GPs can use a ‘freecall’ (1800) number to ring the research team with any questions 
during their recording period. 
• Non-returns are followed up by regular telephone calls for 3 months. 
• Participating GPs earn clinical audit points towards their QA requirements through the 
Royal Australian College of General Practitioners (RACGP) and/or the Australian 
College of Rural and Remote Medicine (ACRRM). As part of this QA process, each 
receives an analysis of his or her results with those of nine other de-identified GPs who 
recorded at about the same time. Comparisons with the national average and with 
targets relating to the National Health Priority Areas are also provided. In addition, GPs 
receive some educational material related to the identification and management of 
patients who smoke or consume alcohol at hazardous levels. Additional points can be 
earned if the participant chooses to do a follow-up audit of smoking and alcohol 
consumption among a sample of patients about 6 months later. 
2.3 Ethics approval and informed patient consent 
Ethics approval for this study was obtained from the Human Ethics Committee of the 
University of Sydney and from the Ethics Committee of the Australian Institute of Health 
and Welfare. 
Although the data collected by the GPs is not sufficient to identify an individual patient, 
informed consent for inclusion of the encounter details is required from each patient. GPs are 
instructed to ensure that all patients presenting during their recording period are provided 
with a Patient Information card (Appendix 3) and that they ask the patient if they are happy 
for their data to be included in the study. If the patient refuses, details of the encounter are 
not recorded. This is in accordance with the requirements for ethics approval for the BEACH 
program. 
2.4 Data elements 
BEACH includes three interrelated data collections: GP characteristics, encounter data and 
patient health status. An example of the form used to collect the encounter data and the data 
on patient health status is included in Appendix 1. The GP characteristics questionnaire is 
provided in Appendix 2. The GP characteristic and encounter data collected are summarised 
below. Patient health status data are described in Section 2.6. 
GP profile form (Appendix 2) 
• GP characteristics: age and sex, years in general practice, number of direct patient care 
hours worked per week, country of graduation, postgraduate general practice training 
status, Fellow of the RACGP status, Fellow of the Australian College of Rural and 
Remote Medicine status, usual bulk-billing behaviour, use of computers at work, work 
undertaken in other clinical settings. 
• Practice characteristics: postcode and GP Division of major practice, number of 
individual, and number of full-time equivalent GPs working in the practice, number of 
individual and number of full-time equivalent practice nurses working in the practice, 
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usual after-hours care arrangements, whether the practice is accredited, whether it is a 
teaching practice. 
Encounter recording form (Appendix 1) 
• Encounter data: date of consultation, type of consultation (direct/indirect) (tick box 
options), up to three MBS/DVA item numbers (where applicable), and other payment 
source (where applicable) (tick boxes). 
• Patient data: date of birth, sex and postcode of residence. Tick boxes (yes/no options) 
are provided for Commonwealth concession cardholder, holder of a Repatriation health 
card (from DVA), non-English-speaking background (patient self-report – a language 
other than English is the primary language at home), Aboriginal person (self-
identification), and Torres Strait Islander person (self-identification). Space is provided 
for up to three patient reasons for encounter (RFEs) (see ‘Glossary’). 
• The problems managed at encounter (at least one and up to four). Tick boxes are 
provided to denote the status of each problem as new or continuing for the patient and 
whether the problem is considered by the GP to be work-related. 
• Management of each problem, including: 
– medications prescribed, supplied by the GP and advised for over-the-counter 
purchase including brand name, form (where required), strength, regimen, status 
(whether new or continuing medication for this problem for this patient) and 
number of repeats 
– other treatments provided for each problem, including counselling, advice and 
education, and procedures undertaken, and whether the recorded other treatment 
was provided by practice nurse (tick box) 
– new referrals to medical specialists, allied health services, emergency departments, 
and hospital admissions 
– investigations, including pathology tests, imaging and other investigations ordered 
at the encounter. 
2.5 The BEACH relational database 
The BEACH relational database is described diagrammatically in Figure 2.1. Note that: all 
variables can be directly related to GP and patient characteristics, and to the encounter; RFEs 
have only an indirect relationship with problems managed, as a patient may describe one 
RFE (such as ‘repeat prescriptions’) that is related to multiple problems managed, or several 
RFEs (such as ‘runny nose’ and ‘cough’) that relate to a single problem (such as upper 
respiratory tract infection) managed at the encounter (see Section 6.3); all types of 
management are directly related to the problem being managed.  
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The encounter 
• date 
• direct (face to face) 
— Medicare/DVA item 
number(s) claimable 
— workers compensation 
— other paid 
— no charge 
• indirect (e.g. telephone) 
Patient substudies (SAND) 
• risk factors 
— body mass 
— smoking status 
— alcohol consumption  
• other topics 
Management of each problem 
Medications (up to four per problem) 
• prescribed 
• over-the-counter advised 
• provided by GP 
— drug class 
— drug group 
— generic 
— brand name 
— strength 
— regimen 
— number of repeats  
— drug status (new/continued) 
 
Other treatments (up to two per 
problem) 
• procedural treatments 
• clinical treatments (e.g. advice, 
counselling) 
• practice nurse involvement 
 
Other management 
• referrals (up to two) 
— to specialists 
— to allied health professionals 
— to emergency departments 
— hospital admissions 
• pathology tests ordered (up to five) 
• imaging ordered (up to three) 
GP characteristics 
• age and sex 
• years in general practice 
• country of graduation 
• direct patient care hours/week 
• usual bulk-billing practice 
• postgraduate GP qualifications 
• FRACGP status (yes/no) 
• FACRRM status (yes/no) 
• currently a registrar (yes/no) 
• clinical use of computers  
Practice characteristics 
• practice size (no. & FTE GPs) 
• practice nurse(s) (no. & FTE) 
• after-hours arrangements 
 postcode and GP Division 
• teaching practice (yes/no) 
Problems managed 
• diagnosis/problem label 
• problem status (new/old) 
• work-related problem status 
The patient 
• age and sex 
• practice status (new/old) 
• Commonwealth concession 
card status 
• DVA Status 
• postcode of residence 
• NESB/Indigenous status 
• reasons for encounter 
Note: FTE—full-time equivalent; FRACGP—Fellow of the Royal 
Australian College of General practitioners; FACRRM—Fellow 
of the Australian College of Rural and Remote Medicine; 
DVA—Department of Veterans’ Affairs; NESB—non-English-
speaking background; SAND—Supplementary Analysis of 
Nominated Data. 
Figure 2.1: The BEACH relational database 
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2.6 Supplementary Analysis of Nominated Data  
A section at the bottom of each recording form investigates aspects of patient health or 
health care delivery in general practice not covered by the consultation-based data. These 
additional substudies are referred to as SAND, Supplementary Analysis of Nominated Data. 
• Each year the 12 month data period is divided into 10 blocks, each of 5 weeks, with three 
substudies per block. The research team aims to include data from about 100 GPs in each 
block.  
• Each GP’s pack of 100 forms is made up of 40 forms that ask for the start and finish times 
of the encounter, and include questions about patient risk factors: patient height and 
weight (used to calculate body mass index, BMI), alcohol intake and smoking status 
(patient self-report). The methods and results of topics in the SAND substudies for 
alcohol consumption, smoking status and BMI are reported in Chapter 14. The start and 
finish times collected on these encounters are used to calculate the length of consultation. 
The length of consultation for Medicare-claimable encounters is reported in Section 5.3. 
• The remaining 60 forms in each pack are divided into two blocks of 30, so each SAND 
block includes about 3,000 records. Some topics are repeated to increase sample size. 
Different questions are asked of the patient in each block and these vary throughout the 
year. 
• The order of SAND sections is rotated in the GP recording pack, so that 40 patient risk 
factor forms may appear first, second or third in the pad. Rotation of ordering ensures 
there was no order effect on the quality of the information collected. 
Abstracts of results and the research tools used in all SAND substudies from April 1998 to 
March 2011 have been published. Those: 
• from April 1998 to March 1999 were published in Measures of health and health care delivery 
in general practice in Australia9 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: 
abstracts and research tools 1999–200610 
• conducted between August 2006 and March 2010 have been published in each of the 
general practice activity annual reports11-14 
• conducted in the 2010–11 BEACH year are provided in Chapter 15 of the companion 
publication General practice activity in Australia 2010–11.1 
Abstracts of results for all SAND substudies are also available on the FMRC’s website 
<www.fmrc.org.au/publications/SAND_abstracts.htm>. 
2.7 Statistical methods 
The analysis of all BEACH data was conducted with Statistical Analysis System (SAS) 
version 9.1.3.15 When originally published, data from 2001–02 to 2004–05 were analysed 
using SAS version 6.1216 (with additional programming to adjust for the cluster sample study 
design). In this report (and others published since 2007) these data have been re-analysed 
using SAS version 9.1.3 (which adjusts for the cluster design without the need for additional 
programming). This has resulted in slightly tighter confidence intervals and minor variations 
in point estimates (of up to 0.1) when compared with data published in earlier annual 
reports for the 1998–99 to 2004–05 data years. 
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BEACH is a single stage cluster sample study design, each 100 encounters forming a cluster 
around each GP participant. In cluster samples, variance needs to be adjusted to account for 
correlation between observations within clusters. Procedures in SAS version 9.1.3 are used to 
calculate the intracluster correlation and adjust the confidence intervals accordingly.15 
Post-stratification weighting of encounter data adjusts for any variance in the characteristics 
of the participating GPs from those of the sample frame from which they were drawn, and 
for the varying activity level of each GP (measured by the number of claims each has made 
in the previous 12 months from Medicare Australia). The final sample of encounters shows 
excellent precision when the age–sex distribution of the patients is compared with the 
distribution in all Medicare-claimed services of this type.14 
The encounter is the primary unit of inference. Proportions (percentages) are used when 
describing the distribution of an event that can arise only once at a consultation (for example, 
age, sex), or to describe the distribution of events within a class of events (for example, 
problem A as a percentage of total problems). Due to rounding, proportions may not always 
add to exactly 100%. 
Rates per 100 encounters are used when an event can occur more than once at the 
consultation (for example, RFEs, problems managed or medications). 
Rates per 100 problems are also used when a management event can occur more than once 
per problem managed. In general, the results present the number of observations (n), the rate 
per 100 encounters and the 95% confidence interval. 
The statistical significance of changes in characteristics of the GPs is tested using the  
chi-square test statistic. However, in general, the results for events occurring at GP–patient 
encounters are presented as the rate per 100 problems managed, and the rate per 100 
encounters, 95% confidence interval. 
• Changes over time in the frequency of these events are judged significant (that is, a real 
change has occurred) if the two sets of confidence intervals do not overlap. For example, 
Result A: 11.5 per 100 encounters (95% CI: 11.3–11.7) is significantly less than Result B: 
11.9 per 100 encounters (95% CI: 11.8–12.0). 
• If the two sets of confidence intervals butt together the difference is regarded as 
marginal. For example, Result A: 11.5 per 100 encounters (95% CI: 11.3–11.7) is 
marginally lower than Result B: 11.9 (95% CI: 11.7–12.1). 
• If they overlap, then no change was measured. 
• All difference discussed in this report are statistically significant differences unless 
otherwise stated. 
2.8 Changes over time 
For the 10 years 2001–02 to 2010–11, patient reasons for encounter and problems managed 
are reported as rates per 100 encounters. In the past, rates per 100 encounters have also been 
used when measuring changes in each of the management actions (prescriptions, other 
treatments, referrals, pathology and imaging tests ordered). However, there has been a 
significant increase in the number of problems managed per encounter. This means that at 
each encounter, there is an increased chance of a management action occurring, without any 
change in the management practise of GPs. All management actions are therefore reported in 
two ways – as rates per 100 problems managed and as rates per 100 encounters. In describing 
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changes over time, the rates per 100 problems are reported as the primary measure, but the 
rates per 100 encounters are used as the basis for extrapolation to the number of events 
occurring across the country in one year compared with another (see Section 2.9). 
Readers should be aware that there may be discrepancies between data in this report and 
data published in earlier BEACH reports. SAS version 9.1.315 was used for all analyses in this 
report, but some changes in method or approach have occurred occasionally over the  
10 years of results.  
Data presented in this report are comparable for each result across all data years. Where 
methodological changes have occurred, the data have either: 
• been recalculated using the new method (for example, body mass index was recalculated 
due to a change in the WHO body mass index groupings) 
• been regrouped for comparability (where this occurs, it is noted in the footnotes of the 
table) (an example is the combined presentation of home visits and institutional visits in 
Chapter 5 because the MBS now has only one item number for both. In previously 
published data it was possible to differentiate the two. 
• been omitted from this report (if recalculation or grouping was not possible). Where data 
are omitted, this is noted as not applicable (N/A) or not available (NAv), as appropriate. 
In measuring changes over time, the 2010–11 results are compared with those from 2001–02 
wherever possible. However, as in any long-term research program, changes occur over the 
years. For example, practice nurse activity data were not collected until 2005–06, so the 
changes are only considered between 2005–06 and 2010–11. 
Each table includes the most frequent events occurring in 2010–11, and the comparative 
results for each of the earlier year. In addition, each table includes data for events that were 
more frequent in past year(s), but were no longer in the most frequent arising in 2010–11.  
Results are in general presented in decreasing order of 2010–11 frequency. 
The direction and type of change between 2001–02 and 2010–11 is indicated for each result in 
the far right column of the tables: 
• / indicates a statistically significant linear (on line of best fit) change 
• / indicates a marginally significant linear (on line of best fit) change 
• § indicates a non-linear significant or marginal change 
• — indicates there was no change. 
2.9 Extrapolated national estimates 
Extrapolations can be used to estimate the number of occurrences of a selected event at GP 
encounters in Australia at a single time point or to estimate the total national effect of 
changes. 
Where the results demonstrate a significant change over time, the estimated national change 
across total GP Medicare services from 2001–02 to 2010–11 can be calculated using the 
method detailed below. Note that extrapolations are always based on rate per 100 encounters 
rather than rate per 100 problems because there is no independent measure of the number of 
problems managed in Australian general practice. In contrast, the number of national 
encounters can be drawn from Medicare claims data. 
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Examples of extrapolated national change are given in each chapter in the report from 
Chapter 5 to Chapter 13 inclusive. 
When extrapolating measured change over the decade to national estimates, we: 
• divide the ‘rate per 100 encounters’ of the selected event for 2001–02 by 100, and then 
multiply by the total number of general practitioner service items claimed through 
Medicare in 2001–02, 99.9 million (rounded to the nearest 100,000, see Table 2.1) to give 
the estimated national number of events in 2001–02.  
• repeat the process using data from 2010–11.  
The difference between the two estimates gives the estimated national change in the 
frequency of that event between 2001–02 and 2010–11. Estimates are rounded to the nearest 
100,000 if more than a million and to the nearest 10,000 if below a million. It is possible to use 
this method to calculate the national effect of any significant change in a single result over 
any two time points. For example, extrapolations in the practice nurse chapter are based on 
changes between 2005–06 and 2010–11. 
Change is expressed as the estimated increase or decrease over the study period, in the 
number of general practice contacts for that event (for example, an increase or decrease in the 
number of GP management contacts with problem X); or an increase or decrease in the 
number of times a particular medication type was prescribed in Australia in 2010–11, when 
compared with 2001–02. 
Extrapolations can also be made using data from a single time point to estimate the number 
of occasions that an event occurs in general practice encounters nationally in a specific year. 
When extrapolating from a single time point we: 
• divide the ‘rate per 100 encounters’ of the selected event by 100, and then multiply by the 
total number of general practitioner service items claimed through Medicare in that year 
(rounded to the nearest 100,000, see Table 2.1) to give the estimated national number of 
events in that year. 
Table 2.1 provides the total number of general practice professional service items claimed 
from Medicare in each financial year from 2001–02 to 2010–11. In this report, extrapolations 
are calculated using the number of GP Medicare items claimed rounded to the nearest 
100,000.  
Table 2.1: Number of general practice professional services claimed from Medicare Australia each 
financial year, 2001–02 to 2010–11 (‘000) 
 2001–02 2002–03 2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11(a) 
Number of GP  
MBS items  99,921 96,919 96,330 98,180 101,095 103,433 109,518 113,045 116,646 118,126 
Rounded number of 
GP MBS items 99,900 96,900 96,300 98,200 101,100 103,400 109,500 113,000 116,600 118,100 
(a) Medicare data for the 2010–11 year included data from the April 2010 to March 2011 quarters because the 2010–11 financial year data 
were not available at the time of preparation of this report. 
Source: Medicare statistics.8 
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Example of extrapolation: Change in the number of problems managed by GPs 
nationally  
There was a significant increase in the number of problems managed at encounter, from 
143.4 per 100 encounters in 2001–02 to 152.5 in 2010–11 (see Table 7.2). The calculation used 
to extrapolate the effect of this change across Australia is:  
(143.4/100) x 99.9 million = 143.3 million problems managed nationally in 2001–02, and 
(152.5/100) x 118.1 million = 180.1 million problems managed nationally in 2010–11.  
This suggests there were 36.9 million (180.1 million minus 143.2 million) more problems 
managed at GP-patient encounters in Australia in 2010–11 than in 2001–02.  
This is the result of the compound effect of the increase in the number of problems managed 
by GPs at encounters plus the increased number of visits over the decade across Australia. 
Considerations and limitations in extrapolations 
The extrapolations to the total events occurring nationally in any one year are only estimates. 
They may provide: 
• an underestimate of the true ‘GP workload’ of a condition/treatment because the 
extrapolations are made to GP Medicare items claimed, not to the total number of GP 
encounters per year – an additional 5% or so of BEACH encounters annually include 
encounters paid by sources other than Medicare, such as DVA, state governments, 
workers compensation insurance, and employers. 
• an underestimate of activities of relatively low frequency with a skewed distribution 
across individual GPs. For example, a study of early uptake of some enhanced primary 
care items by GPs demonstrated that almost half the enhanced primary care items 
claimed through the MBS came from about 6% of active GPs.17 Where activity is so 
skewed across the practising population, a national random sample will provide an 
underestimate of activity because the sample reflects the population rather than the 
minority. 
Further, the base numbers used in the extrapolations are rounded to the nearest 100,000, and 
extrapolation estimates are rounded to the nearest 100,000 if more than a million and to the 
nearest 10,000 if below a million. However, the rounding has been applied to all years, so the 
effect on measures of change will be very small. Therefore, the extrapolation still provides an 
indication of the size of the effect of measured change nationally. 
Extrapolations are based on the unit of the encounter because the number of national 
encounters is quantifiable using Medicare claims data. However, the reader should be aware 
that where an event can occur more than once per encounter, the extrapolation represents 
the number of occasions at which that event occurs in general practice encounters, rather 
than the number of encounters where that event occurs.  
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2.10 Changes to data elements and reporting 
methods 
Some changes in data elements and reporting methods have occurred since the BEACH 
study began in April 1998. 
Two changes were made to the BEACH form from 2005–06 onwards to capture practice 
nurse activity associated with the GP–patient consultations. From 2005–06 onwards: 
• GPs could record multiple (up to three) Medicare item numbers 
• in the ‘other treatments’ section, for each problem managed, the GP was asked to tick the 
practice nurse box if the treatment recorded was provided by the practice nurse rather 
than by the GP. If the box was not ticked, the research team assumed that the GP 
provided the recorded treatment. 
These changes have implications for the reporting of Medicare/DVA-claimable encounters 
(Chapter 5), other treatments (Chapter 10) and practice nurse activity (Chapter 13). 
Medicare/DVA-claimable encounters 
For the first 7 years of the BEACH program (1998–99 to 2004–05), where a Medicare item 
number was claimable for the encounter, the GP was instructed to record only one item 
number. Where multiple item numbers (for example, an item for ‘standard surgery 
consultation’ and a procedural item number) were claimable for an encounter, the GP was 
instructed to record the lower of these (usually an A1 item number). For reporting purposes 
Medicare-claimable encounters were broken down according to the item number recorded 
by the GP as claimable (either through Medicare or through DVA) for the encounter. 
In this report the Medicare/DVA claimable encounters count only one item number per 
Medicare/DVA-claimable encounter for comparability with previous years (see Chapter 5). 
Practice nurse Medicare-claimable encounters are not reported in Chapter 5. 
The selection of one item number was done on a priority basis: consultation item numbers 
override incentive item numbers, which override procedural item numbers, which override 
other Medicare item numbers. 
Practice nurse activity 
The research team began to capture practice nurse activity (in 2005–06) due to the 
introduction of four new MBS item numbers in November 2004, which covered some 
selected activities done by a practice nurse on behalf of a medical practitioner.18 
The primary aim of BEACH is to describe general practice activity. Before 2005–06, ‘general 
practice activity’ was described in terms of GP–patient encounters, and this was considered 
close to equivalent to ‘general practitioner activity’. However, the introduction of the practice 
nurse item numbers meant that, if practice nurse activity associated with the GP–patient 
encounter was not included, the content of the consultation was not fully described. 
Chapter 13 provides a breakdown of the practice nurse Medicare items claimed, the 
morbidity managed with the assistance of the practice nurse, and the other treatments given 
by the practice nurse as recorded by the GP participants from 2005–06 to 2010–11. 
12
When viewing these results, it must be remembered that these practice nurse data do not 
include activities done by the practice nurse during the GP’s BEACH recording period that 
were performed outside the recorded encounter. These could include Medicare-claimable 
activities (for example, immunisations/vaccinations) provided under instruction from the 
GP but not provided at the time of the encounter recorded in BEACH, or provision of other 
activities not currently claimable from Medicare (for example, dietary advice on a one-to-one 
basis, or in a group situation). 
Other treatments 
In Chapter 10 ‘Other treatments’, all recorded clinical and procedural treatments are 
included, irrespective of whether they were provided by the GP or by the practice nurse. 
2.11 Classification of data 
The following data elements are classified according to the International Classification of 
Primary Care – Version 2 (ICPC-2), a product of the World Organization of Family Doctors 
(Wonca):19 
• patient reasons for encounter (RFEs) 
• problems managed 
• clinical treatments (for example, counselling, advice) 
• procedural treatments 
• referrals 
• investigations ordered (including pathology, imaging and other investigations). 
The ICPC-2 is used in more than 45 countries as the standard for data classification in 
primary care. It is accepted by the WHO in the WHO Family of International 
Classifications,20 and is the declared national standard in Australia for reporting of health 
data from general practice and patient self-reported health information.21 
The ICPC-2 has a biaxial structure, with 17 chapters on one axis (each with an alphabetic 
code) and seven components on the other (numeric codes) (Figure 2.2). Chapters are based 
on body systems, with additional chapters for psychological and social problems. 
Component 1 includes symptoms and complaints. Component 7 covers diagnoses, and can 
also be divided to provide data about infections, injuries, neoplasms, congenital anomalies 
and ‘other’ diagnoses. 
Components 2 to 6 cover the process of care, and are common throughout all chapters. The 
processes of care, including referrals, other (non-pharmacological) treatments and orders for 
pathology and imaging, are classified in these process components of ICPC-2. Component 2 
(diagnostic, screening and prevention) is also often applied in describing the problem 
managed (for example, check-up, immunisation). The components are standard and 
independent throughout all chapters.  
The ICPC-2 is an excellent epidemiological tool. The diagnostic and symptomatic rubrics 
were selected for inclusion on the basis of their relative frequency in primary care settings, or 
because of their relative importance in describing the health of the community. It has about 
1,370 rubrics, and these are sufficient for meaningful analyses. However, reliability of data 
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entry using ICPC-2 alone, requires a thorough knowledge of the classification for correct 
classification of a concept to be ensured. 
 
                    
 Components A B D F H K L N P R S T U W X Y Z  
 1. Symptoms, complaints                    
 2. Diagnostic, screening, prevention                   
 3. Treatment, procedures, medication                   
 4. Test results                   
 5. Administrative                   
 6. Other                   
 7. Diagnoses, disease                   
 A General L Musculoskeletal U Urinary 
 B Blood, blood-forming N Neurological W Pregnancy, family planning 
 D Digestive P Psychological X Female genital  
 F Eye R Respiratory Y Male genital  
 H Ear S Skin Z Social  
 K Circulatory T Metabolic, endocrine, nutritional   
 
Figure 2.2: The structure of the International Classification of Primary Care – Version 2 (ICPC–2) 
 
In 1995, recognising a need for a coding and classification system for general practice 
electronic health records, the Family Medicine Research Centre (then the Family Medicine 
Research Unit) developed a clinical terminology classified according to the ICPC, now called 
ICPC-2 PLUS.22 This is an interface terminology, developed from all the terms used by GPs 
in studies such as the Australian Morbidity and Treatment Survey 1990–91 (113,468 
encounters),23 the country and metropolitan general practice study 1990–91 
(51,277 encounters), the Morbidity and Therapeutic Index 1992–1998 (a clinical audit tool that 
was available to GPs) (400,00 encounters), and BEACH 1998–2010 (about 1.2 million 
encounters), which together make up about 2.7 million encounter records, involving more 
than 4 million free text descriptions of problems managed and a further 4 million for patient 
reasons for encounter. These terms are classified according to ICPC-2 to ensure international 
standards for reporting. Readers interested in seeing how coding works can download the 
ICPC-2 PLUS Demonstrator at <www.fmrc.org.au/icpc2plus/demonstrator.htm>. 
When the free-text data are received from the GPs, trained secondary coders (who are 
undergraduate students studying health information management or medical science) code 
the data in more specific terms using ICPC-2 PLUS. This ensures high coder reliability and 
automatic classification of the concept, and provides the ability to ‘ungroup’ such 
ICPC-2 rubrics as ‘other diseases of the circulatory system’ and select a specific disease from 
the terms within it. 
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Presentation of data classified in ICPC-2 
Statistical reporting is almost always at the level of the ICPC-2 classification (for example, 
acute otitis media/myringitis – ICPC-2 code H71). However, there are some exceptions 
where data are grouped either above the ICPC-2 level or across the ICPC-2 level. These 
grouped codes are defined in Appendix 4, available at: 
<purl.library.usyd.edu.au/sup/9781920899875>. 
Reporting morbidity with groups of ICPC-2 codes 
When recording problems managed, GPs may not always be very specific. For example, in 
recording the management of hypertension, they may simply record the problem as 
‘hypertension’. In ICPC-2, ‘hypertension, unspecified’ is classified as ‘uncomplicated 
hypertension’ (code K86). There is another code for ‘complicated hypertension’ (K87). In 
some cases the GP may simply have failed to specify that the patient had hypertension with 
complications. The research team therefore feels that for national data reporting, it is more 
reliable to group the codes K86 and K87 and label this ‘Hypertension*’ – the asterisk 
indicating that multiple ICPC-2 codes (as in this example) or ICPC-2 PLUS codes (see below) 
are included. Appendix 4, Table A4.1 lists codes included in these groups. 
Reporting morbidity with groups of ICPC-2 PLUS codes 
In other cases a concept can be classified within (but be only part of) multiple ICPC-2 codes. 
For example, osteoarthritis is classified in ICPC-2 in multiple broader codes according to site 
– for example, L92 – shoulder syndrome (includes bursitis, frozen shoulder, osteoarthritis of 
shoulder, rotator cuff syndrome). When reporting osteoarthritis in this publication, all the 
more specific osteoarthritis ICPC-2 PLUS terms are grouped within all the appropriate 
ICPC-2 codes. This group is labelled ‘Osteoarthritis*’ – the asterisk again indicating multiple 
codes, but in this case they are PLUS codes rather than ICPC-2 codes. Appendix 4, Table A4.1 
lists codes included in these groups. 
Reporting chronic morbidity 
Chronic conditions are medical conditions characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last 6 months or more, a pattern of 
recurrence or deterioration, a poor prognosis, and consequences or sequelae that affect an 
individual’s quality of life. 
To identify chronic conditions, a chronic condition list24 classified according to ICPC-2 was 
applied to the BEACH data set. In general reporting, both chronic and non-chronic 
conditions (for example, diabetes and gestational diabetes) may be grouped together (for 
example, diabetes – all*). When reporting chronic morbidity, only problems regarded as 
chronic are included in the analysis. Where the group used for the chronic analysis differs 
from that used in other analyses in this report, it is marked with a double asterisk. Codes 
included in the chronic groups are provided in Appendix 4, Table A4.2. 
Reporting pathology and imaging test orders 
All the pathology and imaging tests are coded very specifically in ICPC-2 PLUS, but ICPC-2 
classifies pathology and imaging tests very broadly (for example, a test of cardiac enzymes is 
classified in K34 – Blood test associated with the cardiovascular system; a CT scan of the 
lumbar spine is classified as L41 – Diagnostic radiology/imaging of the musculoskeletal 
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system). In Australia, the Medicare Benefits Schedule (MBS) classifies pathology and 
imaging tests in groups that are relatively well recognised. The team therefore regrouped all 
pathology and imaging ICPC-2 PLUS codes into MBS standard groups. This allows 
comparison of data between data sources. Such groups are marked with an asterisk, and 
inclusions provided in Appendix 4, Tables A4.8 and A4.9. 
Classification of pharmaceuticals 
Pharmaceuticals that are prescribed, provided by the GP or advised for over-the-counter 
purchase are coded and classified according to an in-house classification, the Coding Atlas 
for Pharmaceutical Substances (CAPS). 
This is a hierarchical structure that facilitates analysis of data at a variety of levels, such as 
medication class, medication group, generic composition and brand name. 
Strength and regimen are independent fields that, when combined with the CAPS code, give 
an opportunity to derive the prescribed daily dose for any prescribed medication or group of 
medications. 
CAPS is mapped to the Anatomical Therapeutic Chemical (ATC)25 classification, which is the 
Australian standard for classifying medications at the generic level. 
The ATC has a hierarchical structure with five levels. For example: 
• Level 1: C – Cardiovascular system 
• Level 2: C10 – Serum lipid reducing agents 
• Level 3: C10A – Cholesterol and triglyceride reducers 
• Level 4: C10AA – HMG CoA reductase inhibitors 
• Level 5: C10AA01 – Simvastatin (the generic drug). 
Reporting pharmaceutical data 
For pharmaceutical data, there is the choice of reporting in terms of the CAPS coding scheme 
or the ATC. They each have advantages in different circumstances. 
In the CAPS system, a new drug enters at the product and generic level, and is immediately 
allocated a generic code. Therefore, the CAPS classification uses a bottom-up approach. 
In the ATC, a new generic drug type may initially enter the classification at any level (1 to 5), 
not necessarily always at the generic level. Reclassification to lower ATC levels may occur 
later. Therefore, the ATC uses a top-down approach. 
When analysing medications across time, a generic medication that is initially classified to a 
higher ATC level will not be identifiable in that data period, and may result in 
under-enumeration of that drug during earlier data collection periods. 
In measuring changes in medications over time, the team chose to report at Level 2 of the 
ATC (which is more stable over time than Level 3), and in CAPS for the generic-level drugs. 
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2.12 Quality assurance 
All morbidity and therapeutic data elements were secondarily coded by staff entering key 
words or word fragments, and selecting the required term or label from a pick list. This was 
then automatically coded and classified. A quality assurance program to ensure reliability of 
data entry includes ongoing development of computer-aided error checks (‘locks’) at the 
data entry stage, and a physical check of samples of data entered against those on the 
original recording form. Further logical data checks are conducted through SAS on a regular 
basis. 
2.13 Validity and reliability 
A discussion of the reliability and validity of the BEACH program has been published 
elsewhere.26 This section touches on some aspects of reliability and validity of active data 
collection from general practice that should be considered by the reader. 
In the development of a database such as BEACH, data gathering moves through specific 
stages: GP sample selection, cluster sampling around each GP, GP data recording, secondary 
coding and data entry. At each stage the data can be invalidated by the application of 
inappropriate methods. The methods adopted to ensure maximum reliability of coding and 
data entry were described above. The statistical techniques adopted to ensure valid analysis and 
reporting of recorded data are described in Section 2.7. Previous work has demonstrated the 
extent to which a random sample of GPs recording information about a cluster of patients 
represents all GPs and all patients attending GPs.27 Other studies have reported the degree to 
which GP-reported patient RFEs and problems managed accurately reflect those recalled by the 
patient28 and the reliability of secondary coding of RFEs29 and problems managed.23 The validity 
of ICPC as a tool with which to classify the data has also been investigated in earlier work.30 
However, the question of the extent to which the GP-recorded data are a reliable and valid 
reflection of the content of the encounter must also be considered. In many primary care 
consultations, a clear pathophysiological diagnosis is not reached. Bentsen31 and Barsky32 
suggest that a firm and clear diagnosis is not apparent in about half of GPs’ consultations, 
and others suggest the proportion may be even greater.33 Further, studies of general 
ambulatory medical practice have shown that a large number of patients presenting to a 
primary care practitioner are without a serious physical disorder.34,35 As a result, it is often 
necessary for a practitioner to record a problem in terms of symptoms, signs, patient 
concerns, or the service that is requested, such as immunisation. For this reason, this report 
refers to patient ‘problems’ rather than ‘diagnoses’. 
A number of studies have demonstrated wide variance in the way a GP perceives the patient’s 
RFE, and the manner in which the GP describes the problem under management. In a direct 
observational study of consultations via a one-way mirror, Bentsen demonstrated differences in 
the way practitioners labelled problems, and suggested that clinical experience may be an 
important influence on the identification of problems within the consultation.31 Two other 
factors that might affect GPs’ descriptions of patient RFEs have been identified: even when 
individuals select the same stimuli, some label each stimulus separately whereas others 
cluster them under one label, and individuals differ in the number of stimuli they select 
(selective perception).36 
The extent to which therapeutic decisions may influence the diagnostic label selected has also 
been discussed. Howie37 and Anderson34 argue that, while it is assumed that the diagnostic 
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process used in general practice is one of symptom diagnosis  management, the therapeutic 
method may well be selected on the basis of the symptom, and the diagnostic label chosen last. 
They suggest that the selection of the diagnostic label is therefore influenced by the 
management decision already made. 
Anderson has also pointed out that the therapeutic decision may be influenced by fashion, and, 
in turn, this affects the selection of the problem label. He gives the example of a rise in the 
occurrence of neurotic depression in parallel with a decrease in the use of menopause as a 
diagnosis in the United Kingdom, and suggests this may be the result of a change in the 
preferred treatment from oestrogen therapy to antidepressants.34 This should be remembered 
when considering the changes in general practice described in this report. 
Alderson contends that to many practitioners ‘diagnostic accuracy is only important to the 
extent that it will assist them in helping the patient’. He further suggests that if major symptoms 
are readily treatable, some practitioners may feel no need to define the problem in diagnostic 
terms.38 Crombie stated that in the second and third national morbidity surveys in the United 
Kingdom there was ‘enormous variability in the rates at which doctors perceive and record 
illnesses’. He concluded that the probable cause arose from the different ways in which GPs 
gave priority in their perceptions and recording of certain morbidities, while discounting or 
ignoring others. He was unable to account statistically for this variation by the effect of 
geography, age, sex or class differences in the practice populations.39 Differences in the way 
male and female GPs label problems also appear to be independent of such influences.40 
These problems are inherent in the nature of general practice. Knottnerus argues that the 
GP is confronted with a fundamentally different pattern of problems from the medical 
specialist, the GP often having to draw up general diagnostic hypotheses related to 
probability, severity and consequences.41 Anderson suggests that morbidity statistics from 
family practice should therefore be seen as ‘a reflection of the physician’s diagnostic opinions 
about the problems that patients bring to them rather than an unarguable statement of the 
problems managed’.34 In any case, doctors base their actions on problems as they perceive 
them. 
While these findings on limitations in the reliability and validity of practitioner-recorded 
morbidity should be kept in mind, they apply equally to data drawn from medical records, 
whether paper or electronic, as they do to active data collection methods.42,43 There is as yet 
no more reliable method of gaining detailed data about morbidity and its management in 
general practice. Further, irrespective of the differences between individual GPs in their 
labelling of the problems, morbidity data collected by GPs in active data collection methods 
have been shown to provide a reliable overview of the morbidity managed in general 
practice.44 
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3 The samples 
For annual response rates and measures of representativeness of individual annual GP 
samples, please see the annual report for each year in question. 
Table 3.1 shows the number of encounter records contained in each year of the BEACH 
program since April 2001, and the size of the database for those 10 years for each variable 
(weighted), upon which all comparisons over time described in this report are based. 
Table 3.1: Annual summary of data sets, 2001–02 to 2010–11 (final weighted data) 
Variable 2001–02 2002–03 2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 
Total 10 
years 
General 
practitioners 983 1,008 1,000 953 1,017 930 953 1,011 988 958 9,801 
Encounters 96,973 100,987 98,877 94,386 101,993 91,805 95,898 96,688 101,349 95,839 974,795 
Reasons for 
encounter 144,654 152,341 148,521 141,215 153,309 138,434 146,696 151,282 157,071 149,005 1,482,528 
Problems 
managed 139,092 146,336 144,674 137,330 149,088 136,333 145,078 149,462 155,373 146,141 1,448,907 
Medications 101,350 104,813 103,210 95,816 106,493 93,193 98,439 102,737 108,001 100,817 1,014,869 
Other 
treatments 51,130 53,676 50,775 51,632 44,504 41,011 49,130 49,048 53,243 50,235 494,384 
Referrals 10,167 11,261 11,507 10,890 12,242 11,230 12,017 13,251 13,481 13,526 119,572 
Imaging 7,645 8,678 8,121 7,840 9,003 8,229 9,143 9,469 9,877 9,370 87,374 
Pathology 30,086 33,234 34,831 34,652 39,358 38,963 41,375 44,066 45,594 43,313 385,472 
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4 The participating GPs 
4.1 Characteristics of the participating GPs 
In BEACH, each GP participant completes a profile questionnaire about themselves and the 
major practice at which they are employed (see Appendix 2). Over the 10 years, the questions 
have occasionally been altered to improve the quality and clarity of the data collected, or to 
investigate topics not previously surveyed as they become relevant. Therefore, for some 
characteristics we have data over the full 10-year period, and for some, shorter periods. 
Over the period 2001–02 to 2010–11 some trends have emerged in the characteristics of GP 
BEACH participants (Table 4.1). The most noticeable changes over the 10 years are listed 
below and some are presented in Figure 4.1. 
• The feminisation of the general practice workforce is reflected in the growing proportion 
of GP participants who are female. The proportion of female participants increased from 
35.8% in 2001–02 to 38.3% in 2010–11. This change reflects change in the sample frame of 
all recognised GPs claiming more than 375 general practice Medicare items of service in 
the previous quarter (32.5% in 2001–0245 and 37.8% in 2010–11), as provided each year by 
DoHA, from Medicare claims data. As reported last year (2009–10), the ‘spike’ occurring 
in that year was the result of female GPs being over-represented in the sample provided 
by DoHA when compared with the national sample frame (as may occasionally happen 
in the random sampling process).14  
• From 2001–02 to 2010–11 there was a significant change in the age distribution of 
participants, with a decrease in the proportion aged 35–44 years (from 26.8% to 16.7%), 
and an increase in the proportion aged 55 years and over (from 29.4% to 42.1%). Again, 
these changes reflect the differences in the sample frame from Medicare claims data, 
where a decrease was observed from 27.1%45 to 19.9% for GPs aged 35–44 years, and an 
increase from 28.8%45 to 41.3% for GPs aged 55 years or older. 
• The increasing age of GPs was reflected in the increasing proportion of GPs who had 
worked in general practice for 20 years or longer, from 50.5% in 2001–02 to 64.3% in 
2010–11. 
• There was a significant increase in the proportion of GPs working 21–40 hours per week 
on direct patient care (from 41.6% in 2001–02 to 54.0% in 2010–11), and a significant 
decrease in the proportion working 41–60 hours (42.8% in 2001–02 to 34.2% in 2010–11) 
or more than 60 hours (from 4.1% to 2.4%) in direct patient care. 
• There was a significant decrease over the decade in the proportion of Australian GPs 
who had graduated from their primary medical degree in Australia, from 76.1% in  
2001–02 to 69.2% in 2010–11. There were also significant changes in the geographic 
distribution of country of graduation for those trained overseas. 
• There was a significant increase in the proportion of participants who provide < 25% of 
their consultations in a language other than English (from 17.8% in 2003–04 to 21.9% in 
2010–11), and a reduction in the proportion who were doing so at > 50% of their 
consultations, from 2.4% to 1.9% over the same period. 
• The proportion of GP participants holding Fellowship of the RACGP significantly 
increased, from 35.3% in 2001–02 to 52.1% in 2010–11. 
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4.2 Characteristics of participants’ major practice 
Over the period 2001–02 to 2010–11 some trends have emerged in the characteristics of the 
GP participants’ major practices (Table 4.2). The most noticeable changes over the 10 years 
are listed below.  
• The proportion of participants in solo practice significantly decreased between 2001–02 
and 2010–11, and the proportion in smaller practices of 2–4 GPs also decreased. There 
was an associated significant increase in the proportion of GPs working in practices with 
5–9 individual GPs, from 34.8% in 2001–02 to 38.6% in 2010–11. The proportion of 
practices with 10 or more individual GPs more than doubled over the decade, from 
10.0% in 2001–02 to 22.2% in 2010–11. Data were not available for 2007–08 and 2008–09, 
as the question was altered to capture full-time equivalent GPs at the practice instead of 
number of individuals. However from 2009–10, both data elements were captured. 
• There was a significant reduction in the proportion of GPs working in practices that 
provide their own after-hours services, from 41.6% in 2001–02 to 29.8% in 2010–11. The 
proportion at practices providing after-hours services in cooperation with other practices 
also decreased, from 19.4% in 2001–02 to 14.3% in 2010–11. However, the proportion of 
GPs working in practices who use a deputising service for provision of after-hours care 
increased significantly over the 10-year period, from 46.4% in 2001–02 to 52.1% in  
2010–11. Multiple responses were allowed to this question. 
• The proportion of GPs with a computer available at their major practice increased 
significantly, from 89.8% in 2001–02 to 98.0% in 2010–11. Actual use of the computer has 
only been collected since 2004–05. From then on, there was a steady increase in the 
proportion of GPs indicating that they use a computer to some extent in their clinical 
activity. 
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(a) Multiple responses across these options were allowed. 
Note:  FRACGP – Fellows of the Royal Australian College of General Practitioners; own A.H. – the practice provides its own after-hours 
service for their patients; Co-op A.H. – the practice provides after-hours services in a cooperative arrangement with  
other practices. 
Figure 4.1: Selected characteristics of participating GPs and their practices, 2001–02 and 2010–11 
 
Per cent 
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Table 4.1: C
haracteristics of participating G
Ps, 2001–02 to 2010–11 
 
Per cent of participating G
Ps
(a) 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
G
P characteristic 
(n = 983) 
 
(n = 1,008) 
 
(n = 1,000) 
 
(n = 953) 
 
(n = 1,017) 
 
(n = 930) 
 
(n = 953) 
 
(n = 1,011) 
 
(n = 988) 
 
(n = 958) 
S
ex  
(χ
29  = 46.0, p < 0.0001) (m
issing n) 
(0) 
 
(0) 
 
(0) 
 
(0) 
 
(0) 
 
(0) 
 
(0) 
 
(0) 
 
(0) 
 
(0) 
 
M
ale 
64.2 
 
64.8 
 
67.3 
 
67.9 
 
62.8 
 
65.9 
 
63.2 
 
67.5 
 
56.4 
 
61.7 
 
Fem
ale 
35.8 
 
35.2 
 
32.7 
 
32.1 
 
37.2 
 
34.1 
 
36.8 
 
32.5 
 
43.6 
 
38.3 
A
ge  
(χ
227  = 185.8, p < 0.0001) (m
issing n)  
(1) 
 
(0) 
 
(1) 
 
(1) 
 
(18) 
 
(11) 
 
(8) 
 
(4) 
 
(6) 
 
(6) 
 
< 35 years 
7.1 
 
7.3 
 
5.8 
 
9.0 
 
4.7 
 
6.8 
 
7.8 
 
2.6 
 
7.1 
 
6.5 
 
35–44 years 
26.8 
 
26.6 
 
24.9 
 
25.5 
 
22.2 
 
22.6 
 
22.2 
 
14.0 
 
21.4 
 
16.7 
 
45–54 years 
36.7 
 
35.2 
 
36.5 
 
31.8 
 
34.3 
 
35.6 
 
36.4 
 
37.5 
 
36.7 
 
34.7 
 
55+ years 
29.4 
 
30.9 
 
32.7 
 
33.6 
 
38.7 
 
35.0 
 
33.5 
 
45.9 
 
34.8 
 
42.1 
Years in general practice  
(χ
236  = 252.2, p < 0.001) (m
issing n) 
(4) 
 
(6) 
 
(9) 
 
(5) 
 
(13) 
 
(13) 
 
(7) 
 
(6) 
 
(7) 
 
(8) 
 
< 2 years 
0.3 
 
0.6 
 
1.3 
 
0.4 
 
0.6 
 
0.6 
 
0.6 
 
0.1 
 
1.1 
 
1.0 
 
2–5 years 
7.3 
 
7.5 
 
5.4 
 
10.3 
 
4.9 
 
7.9 
 
9.9 
 
3.4 
 
8.9 
 
8.5 
 
6–10 years 
13.5 
 
13.5 
 
10.7 
 
12.6 
 
12.1 
 
11.1 
 
12.9 
 
5.7 
 
12.3 
 
9.9 
 
11– 19 years 
28.5 
 
28.0 
 
28.1 
 
25.4 
 
24.0 
 
23.5 
 
20.6 
 
19.3 
 
23.3 
 
16.3 
 
20+ years 
50.5 
 
50.4 
 
54.6 
 
51.3 
 
58.5 
 
57.0 
 
55.9 
 
71.5 
 
54.3 
 
64.3 
S
essions per w
eek  
(χ
214  = 49.6, p < 0.0001) (m
issing n) 
(15) 
 
(8) 
 
(7) 
 
(8) 
 
(6) 
 
(7) 
 
(9) 
 
(6) 
 
. . 
 
. . 
 
< 6 per w
eek 
16.2 
 
18.7 
 
17.2 
 
14.4 
 
17.3 
 
17.0 
 
15.4 
 
12.4 
 
N
A
v 
 
N
A
v 
 
6–10 per w
eek 
68.8 
 
67.9 
 
69.2 
 
74.2 
 
70.7 
 
73.4 
 
73.7 
 
78.0 
 
N
A
v  
 
N
A
v 
 
11+ per w
eek 
15.0 
 
13.4 
 
13.6 
 
11.4 
 
12.0 
 
9.6 
 
10.9 
 
9.6 
 
N
A
v 
 
N
A
v 
(continued) 
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Table 4.1 (continued): C
haracteristics of participating G
Ps, 2001–02 to 2010–11 
 
Per cent of participating G
Ps
(a) 
G
P characteristic 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
(n = 983) 
 
(n = 1,008) 
 
(n = 1,000) 
 
(n = 953) 
 
(n = 1,017) 
 
(n = 930) 
 
(n = 953) 
 
(n = 1,011) 
 
(n = 988) 
 
(n = 958) 
D
irect patient care hours per w
eek 
 (χ
232  = 113.4, p < 0.0001) (m
issing n) 
. . 
 
(12) 
 
(28) 
 
(29) 
 
(34) 
 
(28) 
 
(25) 
 
(16) 
 
(15) 
 
(16) 
 
≤ 10 
N
A
v 
 
0.8 
 
0.4 
 
0.3 
 
0.8 
 
1.0 
 
0.3 
 
0.3 
 
0.3 
 
0.6 
 
11–20 
N
A
v 
 
10.7 
 
10.0 
 
8.7 
 
9.8 
 
11.3 
 
8.7 
 
7.3 
 
10.3 
 
8.7 
 
21–40 
N
A
v 
 
41.6 
 
42.4 
 
49.2 
 
47.1 
 
47.9 
 
52.4 
 
49.5 
 
56.2 
 
54.0 
 
41–60 
N
A
v 
 
42.8 
 
42.3 
 
37.9 
 
39.0 
 
36.9 
 
36.6 
 
40.2 
 
30.8 
 
34.2 
 
61+ 
N
A
v 
 
4.1 
 
4.9 
 
3.9 
 
3.4 
 
2.9 
 
1.9 
 
2.7 
 
2.4 
 
2.4 
P
lace of graduation
(b)  
(χ
254  = 90.6, p = 0.001) (m
issing n) 
(0) 
 
(0) 
 
(1) 
 
(1) 
 
(5) 
 
(1) 
 
(3) 
 
(2) 
 
(1) 
 
(3) 
 
A
ustralia 
76.1 
 
72.0 
 
73.6 
 
69.9 
 
72.0 
 
73.6 
 
73.5 
 
74.3 
 
70.6 
 
69.2 
 
O
verseas 
23.9 
 
28.0 
 
26.4 
 
30.2 
 
28.0 
 
26.4 
 
26.5 
 
25.7 
 
29.4 
 
30.8 
 
 
A
sia 
8.7 
 
10.0 
 
9.5 
 
10.9 
 
10.9 
 
10.1 
 
9.8 
 
8.3 
 
9.8 
 
12.2 
 
 
U
nited K
ingdom
/Ireland 
7.6 
 
9.1 
 
7.2 
 
7.6 
 
8.1 
 
7.3 
 
6.8 
 
10.3 
 
8.8 
 
7.4 
 
 
A
frica and M
iddle E
ast 
3.7 
 
4.4 
 
5.4 
 
5.4 
 
4.5 
 
5.1 
 
4.3 
 
3.8 
 
5.2 
 
5.8 
 
 
E
urope 
1.8 
 
1.7 
 
2.3 
 
3.8 
 
2.1 
 
1.7 
 
2.6 
 
1.9 
 
2.0 
 
2.9 
 
 
N
ew
 Zealand 
0.5 
 
2.2 
 
1.0 
 
1.3 
 
1.9 
 
1.4 
 
1.4 
 
1.1 
 
1.9 
 
1.4 
 
 
O
ther 
1.6 
 
0.6 
 
1.0 
 
1.3 
 
0.6 
 
0.8 
 
1.6 
 
0.3 
 
1.6 
 
1.2 
(continued) 
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Table 4.1 (continued): C
haracteristics of participating G
Ps, 2001–02 to 2010–11 
 
Per cent of participating G
Ps
(a) 
G
P characteristic 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
(n = 983) 
 
(n = 1,008) 
 
(n = 1,000) 
 
(n = 953) 
 
(n = 1,017) 
 
(n = 930) 
 
(n = 953) 
 
(n = 1,011) 
 
(n = 988) 
 
(n = 958) 
C
onsultations in languages other than 
E
nglish
(c) (χ
221  = 37.6, p = 0.01)  
. . 
 
. . 
 
(6) 
 
(1) 
 
(9) 
 
(0) 
 
(4) 
 
(3) 
 
(3) 
 
(5) 
 
< 25%
 
N
A
v 
 
N
A
v 
 
17.8 
 
21.7 
 
20.9 
 
18.1 
 
20.4 
 
17.6 
 
18.5 
 
21.9 
 
25–50%
 
N
A
v 
 
N
A
v 
 
2.9 
 
2.4 
 
3.6 
 
1.6 
 
3.1 
 
3.5 
 
3.6 
 
2.9 
 
> 50%
 
N
A
v 
 
N
A
v 
 
2.4 
 
3.4 
 
3.5 
 
2.9 
 
3.6 
 
3.0 
 
1.8 
 
1.9 
C
urrently in a G
P
 training program
  
(χ
29  = 17.2, p = 0.046) (m
issing n) 
(36) 
2.6 
 
(53) 
2.9 
 
(14) 
4.4 
 
(10) 
3.5 
 
(13) 
2.6 
 
(13) 
2.9 
 
(4) 
2.9 
 
(8) 
1.5 
 
(6) 
3.6 
 
(8) 
3.2 
Fellow
 of R
A
C
G
P
  
(χ
29  = 190.1, p < 0.0001) (m
issing n) 
(5) 
35.3 
 
(8) 
35.5 
 
(10) 
33.5 
 
(9) 
42.3 
 
(14) 
40.7 
 
(6) 
46.3 
 
(5) 
50.2 
 
(7) 
39.7 
 
(4) 
53.5 
 
(4) 
52.1 
(a) 
M
issing data rem
oved. 
(b) 
For this variable p = 0.02 – significant change w
hen com
paring A
ustralia w
ith all overseas countries com
bined; p < 0.0001 – significant change in the distribution of overseas countries in w
hich G
P
s had graduated 
from
 their prim
ary m
edical degree.  
(c) 
D
ata for all three groupings only available from
 2003–04 onw
ard. 
N
ote: R
A
C
G
P
 – R
oyal A
ustralian C
ollege of G
eneral P
ractitioners; N
A
v – not available. 
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Table 4.2: C
haracteristics of practices in w
hich participating G
Ps w
orked, 2001–02 to 2010–11 
 
Per cent of participating G
Ps
(a) 
G
P characteristic 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
(n = 983) 
 
(n = 1,008) 
 
(n = 1,000) 
 
(n = 953) 
 
(n = 1,017) 
 
(n = 930) 
 
(n = 953) 
 
(n = 1,011) 
 
(n = 988) 
 
(n = 958) 
P
ractice location by R
R
M
A
 
(χ
254  = 93.7, p = 0.001) (m
issing n) 
(0) 
 
(0) 
 
(2) 
 
(1) 
 
(0) 
 
(0) 
 
(1) 
 
(0) 
 
(0) 
 
(0) 
 
C
apital 
69.3 
 
64.7 
 
62.4 
 
64.9 
 
68.8 
 
63.9 
 
67.8 
 
66.8 
 
62.4 
 
64.1 
 
O
ther m
etropolitan 
8.1 
 
8.5 
 
6.4 
 
6.7 
 
6.8 
 
7.3 
 
7.0 
 
10.0 
 
8.5 
 
6.1 
 
Large rural 
5.9 
 
5.1 
 
7.0 
 
5.4 
 
5.9 
 
7.9 
 
6.9 
 
5.5 
 
7.3 
 
6.2 
 
S
m
all rural 
4.9 
 
7.7 
 
7.0 
 
6.9 
 
6.0 
 
5.4 
 
4.7 
 
6.1 
 
7.1 
 
7.2 
 
O
ther rural 
10.5 
 
12.0 
 
14.2 
 
13.0 
 
11.1 
 
13.6 
 
11.3 
 
10.3 
 
13.3 
 
14.8 
 
R
em
ote central 
0.5 
 
0.6 
 
0.9 
 
1.3 
 
0.5 
 
1.0 
 
0.7 
 
0.4 
 
0.4 
 
0.8 
 
O
ther rem
ote, offshore 
0.8 
 
1.4 
 
2.0 
 
1.8 
 
0.9 
 
1.1 
 
1.5 
 
0.9 
 
1.1 
 
0.8 
P
r actice location by A
S
G
C
  
(χ
236  = 48.4, p = 0.08) (m
issing n) 
(0) 
 
(0) 
 
(2) 
 
(2) 
 
(0) 
 
(0) 
 
(1) 
 
(0) 
 
(0) 
 
(0) 
 
M
ajor cities 
71.4 
 
69.4 
 
65.4 
 
67.6 
 
72.1 
 
66.3 
 
72.2 
 
73.4 
 
69.2 
 
69.2 
 
Inner regional 
17.3 
 
19.1 
 
21.8 
 
20.1 
 
18.8 
 
22.7 
 
17.4 
 
18.0 
 
20.2 
 
20.6 
 
O
uter regional 
10.1 
 
9.3 
 
10.1 
 
10.1 
 
7.8 
 
9.4 
 
8.6 
 
7.2 
 
9.1 
 
8.8 
 
R
em
ote 
0.9 
 
1.6 
 
1.6 
 
1.5 
 
0.8 
 
1.3 
 
1.3 
 
0.9 
 
1.1 
 
1.2 
 
V
ery rem
ote 
0.3 
 
0.7 
 
1.0 
 
0.7 
 
0.6 
 
0.3 
 
0.5 
 
0.5 
 
0.3 
 
0.3 
S
ize of practice – N
um
ber of G
P
s  
(χ
221  = 147.3, p < 0.0001) (m
issing n)  
(4) 
 
(8) 
 
(10) 
 
(6) 
 
(9) 
 
(6) 
 
. . 
 
. . 
 
( 11) 
 
(12) 
 
S
olo 
15.3 
 
13.7 
 
10.6 
 
12.3 
 
13.1 
 
8.2 
 
N
A
v 
 
N
A
v 
 
9.2 
 
10.8 
 
2–4 G
P
s 
39.8 
 
38.4 
 
37.8 
 
36.4 
 
35.2 
 
35.7 
 
N
A
v 
 
N
A
v 
 
30.0 
 
28.4 
 
5–9 G
P
s 
34.8 
 
36.1 
 
38.7 
 
37.7 
 
38.4 
 
40.3 
 
N
A
v  
 
N
A
v 
 
41.4 
 
38.6 
 
10+ G
P
s 
10.0 
 
11.8 
 
12.9 
 
13.6 
 
13.3 
 
15.8 
 
N
A
v 
 
N
A
v 
 
19.5 
 
22.2 
(continued) 
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Table 4.2 (continued): C
haracteristics of practices in w
hich participating G
Ps w
orked, 2001–02 to 2010–11 
 
Per cent of participating G
Ps
(a) 
G
P characteristic 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
(n = 983) 
 
(n = 1,008) 
 
(n = 1,000) 
 
(n = 953) 
 
(n = 1,017) 
 
(n = 930) 
 
(n = 953) 
 
(n = 1,011) 
 
(n = 988) 
 
(n = 958) 
S
ize of practice – Full-tim
e equivalents 
(χ
29  = 18.5, p = 0.03) (m
issing n)  
. . 
 
. . 
 
. . 
 
. . 
 
. . 
 
. . 
 
(23) 
 
(8) 
 
(51) 
 
(40) 
 
< 2 
N
A
v 
 
N
A
v 
 
N
A
v 
 
N
A
v 
 
N
A
v 
 
N
A
v 
 
17.6 
 
19.6 
 
15.2 
 
17.2 
 
2– < 5 G
P
s 
N
A
v 
 
N
A
v 
 
N
A
v 
 
N
A
v 
 
N
A
v 
 
N
A
v 
 
41.2 
 
42.9 
 
48.9 
 
43.6 
 
5– < 10 G
P
s 
N
A
v 
 
N
A
v 
 
N
A
v 
 
N
A
v 
 
N
A
v 
 
N
A
v 
 
31.9 
 
29.4 
 
28.8 
 
29.6 
 
10+ G
P
s 
N
A
v 
 
N
A
v 
 
N
A
v 
 
N
A
v 
 
N
A
v 
 
N
A
v 
 
9.3 
 
8.1 
 
7.2 
 
9.6 
A
fter-hours arrangem
ents
(b) (m
issing n) 
(0) 
 
(5) 
 
(5) 
 
(8) 
 
(14) 
 
(3) 
 
(6) 
 
(6) 
 
(2) 
 
(4) 
 
P
ractice does its ow
n  
 
(χ
29  = 122.2, p < 0.0001) 
41.6 
 
42.9 
 
43.6 
 
35.9 
 
34.6 
 
34.6 
 
33.2 
 
28.9 
 
29.1 
 
29.8 
 
C
ooperative w
ith other practices 
 
(χ
29  = 24.7, p = 0.003) 
19.4 
 
16.7 
 
20.0 
 
16.2 
 
15.7 
 
15.5 
 
14.6 
 
15.1 
 
17.8 
 
14.3 
 
D
eputising service 
 
(χ
29  = 60.9, p < 0.0001) 
46.4 
 
47.6 
 
43.8 
 
45.8 
 
50.8 
 
48.1 
 
49.5 
 
57.9 
 
53.1 
 
52.1 
C
om
puter available at practice
(c) 
(χ
27  = 96.8, p < 0.0001) (m
issing n) 
(0) 
89.8 
 
(5) 
91.7 
 
(6) 
95.1 
 
(14) 
93.7 
 
(19) 
94.5 
 
(0) 
96.6 
 
(7) 
96.7 
 
N
A
v 
 
N
A
v 
 
(1) 
98.0 
C
om
puter use by individual G
P
s
(d) 
(χ
26  = 78.3, p < 0.0001) (m
issing n) 
N
A
v 
 
N
A
v 
 
N
A
v 
 
(54) 
89.0 
 
(60) 
91.5 
 
(71) 
93.7 
 
(63) 
94.2 
 
(3) 
94.6 
 
(1) 
97.7 
 
(1) 
95.6 
(a) 
M
issing data rem
oved. 
(b) 
M
ultiple responses w
ere allow
ed. 
(c) 
D
ata refer to com
puter use at the m
ajor practice and m
ay not reflect the use of com
puters by individual G
P
s for clinical and/or adm
inistrative purposes. 
(d) 
D
ata refer to com
puter use by individual G
Ps. 
N
ote: N
A
v – not available; R
R
M
A
 – R
ural, R
em
ote and M
etropolitan A
reas classification; A
S
G
C
 – A
ustralian Standard G
eographical C
lassification. 
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5 The encounters 
This chapter includes details about the encounters in general practice from each of the most 
recent 10 years of the BEACH study from 2001–02 to 2010–11. The direction and type of 
change from 2001–02 to 2010–11 is indicated for each result in the far right column of the 
tables: / indicates a statistically significant linear change, / indicates a marginally 
significant linear change, § indicates a non-linear significant or marginal change, and — 
indicates there was no change. 
Significant linear changes in rates per 100 encounters can be extrapolated to estimate the 
national increase or decrease in the measured event between 2001–02 and 2010–11. Some 
examples of extrapolated change are provided. The method used to extrapolate to national 
change estimates is described in Section 2.9. 
5.1 Content of the encounters 
Table 5.1 provides an overview of the changes over time from data in BEACH between  
2001–02 and 2010–11, and highlights the many changes that occurred during that decade.  
The number of patient reasons for encounter recorded by the GP increased significantly over 
the decade, from 149.2 RFEs per 100 encounters in 2001–02 to 155.5 per 100 encounters in 
2010–11. Changes in the individual types of RFEs are investigated in Chapter 6. 
An increase in the rate of problems managed occurred over the decade, from 143.4 per 100 
encounters in 2001–02 to 152.5 per 100 encounters in 2010–11. This represents an additional 
36.8 million problems managed in general practice in 2010–11 than a decade earlier. There 
was also a significant increase in the rate of chronic problems managed, from 49.3 per 100 
encounters in 2001–02 to 53.1 per 100 in 2010–11. This represents an estimated additional 13.5 
million chronic problems managed in general practice nationally in 2010–11 than in 2001–02. 
Further details about the types of changes in problems managed are presented in Chapter 7. 
The changes in management actions described below are measured in terms of rates per 100 
encounters. As there was a significant increase in the number of problems managed at 
encounters, it may be more informative to consider changes in management actions in terms 
of rates per 100 problems managed as described in Chapters 8 to 12, inclusive. 
There was no change in the rate of medications recorded per 100 encounters over the decade. 
However, there was a change in the pattern used to supply medications, with an increase in 
medications supplied by the GP, from 7.6 per 100 encounters to 10.3 per 100. This increase 
equated to an additional 4.6 million medications supplied by the GP in 2010–11 than in  
2001–02. Specific changes in the types of medications recorded are detailed in Chapter 9. 
There was a significant increase in the number of procedural treatments performed in 
general practice between 2001–02 and 2010–11, from 13.8 per 100 encounters to 16.9 per 
100 encounters. This linear increase represents an additional 6.2 million procedures 
performed in 2010–11. More detail about this increase is found in Chapter 10. 
The rate at which clinical treatments (such as advice and counselling) were recorded varied 
over the decade, and no overall linear change was apparent between 2001–02 and 2010–11. 
Between 2001–02 and 2004–05 there was no change in the rate of clinical treatments, but the 
rate then dropped dramatically from 39.2 per 100 encounters in 2004–05 to 29.2 per 100 
encounters in 2005–06. Since then it has gradually increased, and in 2010–11 was 35.5 per 100 
encounters. These changes are described in further detail in Chapter 10. 
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Referrals increased over the decade 2001–02 to 2010–11 from 10.5 per 100 encounters to 14.1 
per 100. This represented 6.2 million more referrals nationally in 2010–11 than a decade 
earlier. The increase was reflected in increased referrals to medical specialists, allied health 
services and emergency departments, and is described further in Chapter 11. 
Orders for pathology and imaging tests also increased between 2001–02 and 2010–11  
(Table 5.1). These changes are reported in greater detail in Chapter 12. 
5.2 Medicare/DVA claimable encounters 
Table 5.2 provides a summary of Medicare/DVA-claimable encounters recorded in BEACH, 
expressed as a proportion of all Medicare/DVA-claimable encounters. Between 2001–02 and 
2004–05 only one item number was recorded on the BEACH encounter form. In 2005–06 this 
increased to three items, to capture practice nurse item numbers and other additional 
information about the Medicare items used in general practice.  
To allow comparability of data only one item number per Medicare/DVA-claimable item per 
encounter was counted in Table 5.2. The selection of one item number per encounter was 
based on priority whereby: consultation item numbers override practice incentive payment 
item numbers, which override procedural item numbers, which override other Medicare 
item numbers. Table 5.2 includes only items claimable by GPs and shows that: 
• short surgery consultations increased from 1.1% of Medicare/DVA-claimable encounters 
in 2001–02 to 2.3% in 2010–11. Previous research suggests that part of this increase is 
related to increasing practice nurse involvement associated with encounters.46 
• long surgery consultations did not change overall. However, after a significant increase 
in the first half of the decade peaking at 10.5% in 2004–05, long consultations remained 
steady until 2007–08 then dropped, and in 2010–11 represented 7.8% of Medicare/DVA-
claimable encounters. 
• encounters claimable under chronic disease management items, GP mental health care 
items and health assessments all significantly increased. 
The decrease in long surgery consultations and rise in chronic disease management items 
both occurred in 2007–08, and may be attributed to an increased use of chronic disease 
management items (including GP management plans and team care arrangements) to 
manage patients with chronic conditions requiring longer consultations, rather than an item 
for long surgery consultations. 
In May 2010 changes were made to the Medicare Benefits Schedule (MBS) that combined the 
existing Medicare items for home visits, consultations at hospitals and consultations at other 
institutions.47 To allow the comparison of changes over time we have applied this change to 
all previous years in the decade, and now report a single line for ‘Home and institution 
visits’. There was no change in home and institution visits (together) between 2001–02 and 
2010–11. Unfortunately, this change to the MBS no longer allows the measurement of home 
visits made by GPs through the MBS. Last year we showed that home visits had halved over 
the previous decade, from 1.5 per 100 encounters in 2000–01 to 0.7 per 100 in 2009–10.48 We 
are investigating alternative methods to capture this important information about GP work 
practices on future BEACH recording forms. 
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5.3 Consultation length 
In the subsample study for length of consultation that included start and finish times, there 
was no significant change in the mean length of consultation between 2001–02 and 2010–11 
for A1 Medicare/DVA-claimable encounters, nor for all Medicare/DVA-claimable 
encounters (Table 5.3). 
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Table 5.1: Sum
m
ary of m
orbidity and m
anagem
ent, 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
Variable 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 
(n = 96,688) 
 (n = 101,349)  
(n = 95,839) 
R
easons for encounter 
149.2 
(147.4–150.9)   
150.9 
(149.0–152.7)  
150.2 
(148.4–152.0)  
149.6 
(147.8–151.5)   
150.3 
(148.4–152.2)   
150.8 
(148.9–152.7)  
153.0 
(151.1–154.8)  
156.5 
(154.7–158.2)   
155.0 
(153.1–156.8)   
155.5 
(153.5–157.5)  
 
P
roblem
s m
anaged 
143.4 
(141.7–145.2)  
144.9 
(143.0–146.8)  
146.3 
(144.4–148.2)  
145.5 
(143.6–147.4)  
146.2 
(144.2–148.2)  
148.5 
(146.4–150.6)  
151.3 
(149.2–153.4)  
154.6 
(152.6–156.5)  
153.3 
(151.1–155.5)  
152.5 
(150.2–154.7) 
 
 
N
ew
 problem
s 
55.1 
(53.8–56.5) 
 
56.9 
(55.5–58.4) 
 
55.9 
(54.5–57.3) 
 
55.2 
(53.8–56.5) 
 
56.9 
(55.5–58.2) 
 
56.5 
(55.1–57.9) 
 
57.7 
(56.3–59.1) 
 
57.4 
(56.0–58.7) 
 
59.1 
(57.6–60.5) 
 
57.8 
(56.4–59.3) 
—
 
 
C
hronic problem
s 
49.3 
(47.7–50.9) 
 
49.1 
(47.4–50.8) 
 
51.9 
(50.2–53.7) 
 
51.8 
(50.1–53.5) 
 
52.2 
(50.3–54.1) 
 
53.4 
(51.7–55.1) 
 
54.1 
(52.2–56.0) 
 
57.0 
(55.2–58.7) 
 
54.2 
(52.3–56.2) 
 
53.1 
(51.2–55.0) 

 
 
W
ork-related 
3.0 
(2.7–3.2) 
 
N
A
v 
 
N
A
v 
 
3.1 
(2.8–3.5) 
 
2.8 
(2.6–3.1) 
 
2.9 
(2.6–3.1) 
 
2.8 
(2.6–3.1) 
 
2.8 
(2.6–3.0) 
 
2.5 
(2.3–2.7) 
 
2.5 
(2.3–2.7) 

 
M
edications 
104.5 
(102.2–106.9)   
103.8 
(101.4–106.2)  
104.4 
(102.1–106.7)  
101.5 
(99.3–103.8) 
 
104.4 
(101.8–107.0)   
101.5 
(99.2–103.9) 
 
102.7 
(100.3–105.0)  
106.3 
(104.0–108.5)   
106.6 
(103.6–109.5)   
105.2 
(102.8–107.6)  
—
 
 
P
rescribed 
88.0 
(85.6–90.4) 
 
84.3 
(81.8–86.9) 
 
86.0 
(83.6–88.5) 
 
83.4 
(81.2–85.6) 
 
85.8 
(83.3–88.4) 
 
83.3 
(81.0–85.5) 
 
82.4 
(80.3–84.6) 
 
86.4 
(84.1–88.6) 
 
83.4 
(80.6–86.2) 
 
85.1 
(82.9–87.3) 
—
 
 
G
P
-supplied 
7.6 
(6.6–8.7) 
 
9.3 
(8.0–10.6) 
 
8.6 
(7.6–9.6) 
 
8.1 
(7.3–8.8) 
 
8.8 
(8.2–9.5) 
 
8.9 
(8.2–9.6) 
 
10.1 
(9.5–10.7) 
 
11.0 
(10.2–11.8) 
 
13.6 
(12.7–14.6) 
 
10.3 
(9.5–11.2) 

 
 
A
dvised O
TC
 
8.9 
(8.2–9.6) 
 
10.2 
(9.3–11.1) 
 
9.8 
(9.0–10.5) 
 
10.1 
(9.2–10.9) 
 
9.8 
(9.0–10.5) 
 
9.4 
(8.7–10.1) 
 
10.1 
(9.3–10.9) 
 
8.9 
(8.3–9.4) 
 
9.5 
(8.7–10.3) 
 
9.8 
(9.0–10.5) 
—
 
O
ther treatm
ents 
51.9 
(49.5–54.2) 
 
51.8 
(49.3–54.3) 
 
51.4 
(48.9–53.8) 
 
54.7 
(52.1–57.3) 
 
43.6 
(41.5–45.8) 
 
44.7 
(42.3–47.0) 
 
51.2 
(48.9–53.6) 
 
50.7 
(48.5–52.9) 
 
52.5 
(49.8–55.3) 
 
52.4 
(49.8–55.1) 
§ 
 
C
linical 
38.1 
(36.1–40.1) 
 
37.2 
(35.0–39.4) 
 
36.6 
(34.5–38.7) 
 
39.2 
(37.1–41.4) 
 
29.2 
(27.3–31.1) 
 
29.5 
(27.6–31.4) 
 
34.5 
(32.5–36.5) 
 
34.0 
(32.1–35.9) 
 
35.0 
(32.6–37.4) 
 
35.5 
(33.2–37.8) 
§ 
 
P
rocedural 
13.8 
(13.1–14.5) 
 
14.6 
(13.9–15.3) 
 
14.7 
(14.0–15.5) 
 
15.5 
(14.6–16.4) 
 
14.4 
(13.7–15.1) 
 
15.2 
(14.4–16.0) 
 
16.7 
(15.9–17.5) 
 
16.7 
(16.0–17.5) 
 
17.5 
(16.5–18.6) 
 
16.9 
(16.1–17.8) 

 
(continued) 
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Table 5.1 (continued): Sum
m
ary of m
orbidity and m
anagem
ent, 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
Variable 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 
(n = 96,688) 
 (n = 101,349)  
(n = 95,839) 
R
eferrals 
10.5 
(10.1–10.9) 
 
11.2 
(10.7–11.6) 
 
11.6 
(11.1–12.2) 
 
11.5 
(11.1–12.0) 
 
12.0 
(11.5–12.5) 
 
12.2 
(11.7–12.7) 
 
12.5 
(12.0–13.0) 
 
13.7 
(13.2–14.2) 
 
13.3 
(12.8–13.8)  
14.1 
(13.5–14.7) 

 
 
M
edical specialist 
7.3 
(7.0–7.6) 
 
7.6 
(7.3–8.0) 
 
7.9 
(7.5–8.2) 
 
7.7 
(7.4–8.1) 
 
8.2 
(7.8–8.5) 
 
8.1 
(7.7–8.4) 
 
8.0 
(7.6–8.3) 
 
9.0 
(8.7–9.3) 
 
8.4 
(8.1–8.8) 
 
8.6 
(8.2–9.0) 

 
 
A
llied health services 
2.3 
(2.1–2.4) 
 
2.5 
(2.3–2.7) 
 
2.6 
(2.4–2.8) 
 
2.7 
(2.5–2.9) 
 
2.9 
(2.7–3.1) 
 
3.1 
(2.9–3.3) 
 
3.4 
(3.2–3.7) 
 
3.9 
(3.6–4.1) 
 
3.9 
(3.7–4.2) 
 
4.2 
(3.9–4.5) 

 
 
H
ospital 
0.4 
(0.4–0.5) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 

 
 
E
m
ergency departm
ent 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.3–0.4) 

 
 
O
ther referrals 
0.4 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.3 
(0.2–0.4) 
 
0.4 
(0.3–0.5) 
 
0.6 
(0.5–0.7) 

 
P
athology 
31.0 
(29.7–32.4) 
 
32.9 
(31.4–34.4) 
 
35.2 
(33.7–36.8) 
 
36.7 
(35.2–38.2) 
 
38.6 
(36.9–40.3) 
 
42.4 
(40.7–44.2) 
 
43.1 
(41.3–45.0) 
 
45.6 
(43.8–47.4) 
 
45.0 
(43.1–46.9) 
 
45.2 
(43.4–47.0) 

 
Im
aging 
7.9 
(7.5–8.2) 
 
8.6 
(8.2–9.0) 
 
8.2 
(7.8–8.6) 
 
8.3 
(8.0–8.6) 
 
8.8 
(8.4–9.2) 
 
9.0 
(8.6–9.3) 
 
9.5 
(9.2–9.9) 
 
9.8 
(9.4–10.2) 
 
9.7 
(9.3–10.1) 
 
9.8 
(9.4–10.2) 

 
O
ther investigations 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
1.0 
(0.9–1.1) 
 
1.1 
(0.9–1.2) 
 
1.0 
(0.8–1.1) 
 
1.0 
(0.9–1.1) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.7–0.8) 
§ 
(a) 
The direction and type of change is indicated for each result: 
/
 indicates a statistically significant linear change, § indicates a non-linear significant or m
arginal change, and —
 indicates there w
as no change. 
N
ote: C
I – confidence interval; N
A
v – not available; O
TC
 – over-the-counter. 
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Table 5.2: Type of encounter, sum
m
ary of annual results (G
P only item
s), 2001–02 to 2010–11 
 
Percentage distribution of M
edicare/D
VA
-claim
able encounters (95%
 C
I) 

(a) 
 
 
M
B
S/D
VA
 consultation 
category 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
(n = 84,196) 
 
(n = 89,068) 
 
(n = 86,244) 
 
(n = 81,582) 
 
(n = 89,011) 
 
(n = 79,847) 
 
(n = 83,376) 
 
(n = 86,069) 
 (n = 89,113)  (n = 83,903) 
S
hort surgery consultations 
1.1 
(0.9–1.3) 
 
1.2 
(1.0–1.4) 
 
1.1 
(0.9–1.4) 
 
1.0 
(0.8–1.3) 
 
1.0 
(0.8–1.1) 
 
1.1 
(0.9–1.4) 
 
1.2 
(1.0–1.4) 
 
1.6 
(1.4–1.8) 
 
2.2 
(1.9–2.5) 
 
2.3 
(2.0–2.6) 

 
S
tandard surgery 
consultations 
84.1 
(83.1–85.0) 
 
82.8 
(81.8–83.9) 
 
82.4 
(81.2–83.6) 
 
82.3 
(81.0–83.5) 
 
83.7 
(82.7–84.7) 
 
83.3 
(82.4–84.3) 
 
82.1 
(81.0–83.3) 
 
83.9 
(83.0–84.8) 
 
82.0 
(80.9–83.2) 
 
82.6 
(81.6–83.6) 
—
 
Long surgery consultations 
8.7 
(8.0–9.3) 
 
9.6 
(8.9–10.2) 
 
9.7 
(9.0–10.4) 
 
10.5 
(9.7–11.2) 
 
9.8 
(9.1–10.5) 
 
10.0 
(9.3–10.6) 
 
9.9 
(9.2–10.5) 
 
7.7 
(7.1–8.2) 
 
8.3 
(7.7–8.9) 
 
7.8 
(7.2–8.4) 
§ 
P
rolonged surgery 
consultations 
0.7 
(0.5–0.8) 
 
0.8 
(0.6–0.9) 
 
0.7 
(0.5–0.9) 
 
0.8 
(0.6–0.9) 
 
0.7 
(0.5–0.8) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.5–0.8) 
 
0.5 
(0.3–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
—
 
H
om
e and institution visits 
1.8 
(1.5–2.1) 
 
1.7 
(1.4–2.0) 
 
1.8 
(1.4–2.2) 
 
1.2 
(1.0–1.4) 
 
1.4 
(1.1–1.7) 
 
1.2 
(0.9–1.4 ) 
 
1.1 
(0.7–1.6) 
 
1.1 
(0.9–1.3) 
 
1.0 
(0.7–1.2) 
 
1.2 
(0.8–1.6) 
§ 
R
esidential aged care facility 
1.0 
(0.7–1.3) 
 
1.2 
(0.9–1.6) 
 
1.2 
(0.9–1.4) 
 
1.2 
(0.8–1.6) 
 
1.3 
(0.9–1.6) 
 
1.3 
(1.0–1.6) 
 
1.2 
(0.9–1.5) 
 
1.3 
(1.0–1.5) 
 
1.3 
(0.9–1.6) 
 
1.5 
(1.2–1.9) 
—
 
C
hronic disease 
m
anagem
ent 
0.1 
(0.0–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.2 
(0.1–0.2) 
 
0.3 
(0.2–0.4) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.6) 
 
0.9 
(0.8–1.1) 
 
1.0 
(0.8–1.1) 
 
1.0 
(0.9–1.2) 

 
G
P
 m
ental health care 
N
A
v 
 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.2 
(0.2–0.3) 
 
0.8 
(0.7–0.9) 
 
1.0 
(0.9–1.1) 
 
1.2 
(1.1–1.4) 
 
1.2 
(1.1–1.4) 

 
H
ealth ass essm
ent 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 

 
Incentive paym
ents 
0.0
Ŧ 
(0.0–0.0) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 

 
O
ther item
s 
2.4 
(1.9–3.0) 
 
2.4 
(1.8–3.0) 
 
2.7 
(2.0–3.5) 
 
2.6 
(1.7–3.4) 
 
1.6 
(1.3–1.8) 
 
1.4 
(1.1–1.6) 
 
1.9 
(1.5–2.4) 
 
1.5 
(1.2–1.9) 
 
2.1 
(1.2–2.9) 
 
1.3 
(1.1–1.5) 
§ 
(a) 
The direction and type of change is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change, § indicates a non-linear significant or m
arginal 
change, and —
 indicates there w
as no change. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 encounters. 
N
ote: Includes item
s that w
ere recorded as claim
able through the M
edicare Benefits Schedule/D
epartm
ent of V
eterans’ A
ffairs (D
V
A
), counting one item
 per encounter. C
I – confidence interval; M
B
S
 – M
edicare Benefits 
S
chedule; N
A
v – not available. 
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Table 5.3: C
onsultation length (m
inutes), 2001–02 to 2010–11 
 
C
onsultation length (m
inutes) 
Variable 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
A
1 M
edicare/D
VA
 item
s  
(A
, B
, C
, D
) (a) 
(n = 35,104) 
 
(n = 34,886) 
 
(n = 31,844) 
 
(n = 30,683) 
 
(n = 32,830) 
 
(n = 33,758) 
 
(n = 29,956) 
 
(n = 33,025) 
 
(n = 31,442) 
 
(n = 30,099) 
 
M
ean 
14.9 
(14.7–15.2) 
 
14.8 
(14.5–15.1) 
 
15.0 
(14.7–15.3) 
 
15.1 
(14.8–15.4) 
 
14.9 
(14.6–15.1) 
 
14.9 
(14.7–15.2) 
 
14.8 
(14.6–15.1) 
 
14.4 
(14.2–14.6) 
 
15.0 
(14.7–15.2) 
 
14.7 
(14.4–15.0) 
 
M
edian 
13.0 
 
13.0 
 
13.0 
 
13.0 
 
13.0 
 
13.0 
 
13.0 
 
13.0 
 
13.0 
 
13.0 
 
M
ode 
10.0 
 
10.0 
 
10.0 
 
10.0 
 
10.0 
 
10.0 
 
10.0 
 
10.0 
 
10.0 
 
10.0 
 
R
ange 
1–155 
 
1–165 
 
1–120 
 
1–120 
 
1–110 
 
1–155 
 
1–110 
 
1–120 
 
1–148 
 
1–89 
A
ll M
edicare/D
VA
-claim
able 
encounters (G
P item
s) 
(n = 36,142) 
 
(n = 35,861) 
 
(n = 32,839) 
 
(n = 31,510) 
 
(n = 34,11 1) 
 
(n = 35,201) 
 
(n = 31,722) 
 
(n = 34,783) 
 
(n = 33,613) 
 
(n = 32,257) 
 
M
ean 
15.0 
(14.8–15.3) 
 
14.9 
(14.6–15.2) 
 
15.1 
(14.9–15.4) 
 
15.2 
(14.9–15.5) 
 
15.0 
(14.7–15.2) 
 
15.1 
(14.8–15.3) 
 
15.1 
(14.8–15.3) 
 
14.6 
(14.4–14.9) 
 
15.3 
(15.0–15.5) 
 
15.0 
(14.8–15.3) 
 
M
edian 
13.0 
 
13.0 
 
14.0 
 
13.0 
 
13.0 
 
13.0 
 
13.0 
 
13.0 
 
14.0 
 
13.0 
 
M
ode 
10.0 
 
10.0 
 
10.0 
 
10.0 
 
10.0 
 
10.0 
 
10.0 
 
10.0 
 
10.0 
 
10.0 
 
R
ange 
1–180 
 
1–165 
 
1–175 
 
1–180 
 
1–110 
 
1–155 
 
1–110 
 
1–120 
 
1–148 
 
1–95 
(a) 
A
1 M
edicare item
s – G
roup A includes: 3, 4, 13, 19, 20; G
roup B includes: 23, 24, 25, 33, 35; G
roup C
 includes: 36, 37, 38, 40, 43; G
roup D
 includes: 44, 47, 48, 50, 51. 
N
ote: D
V
A
 – A
ustralian G
overnm
ent D
epartm
ent of V
eterans’ A
ffairs.
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6 The patients 
This chapter includes data about the patients who participated in the BEACH study, 
including their characteristics and their reasons for encounter (RFEs), from each of the most 
recent 10 years of the BEACH study from 2001–02 to 2010–11. The direction and type of 
change from 2001–02 to 2010–11 is indicated for each result in the far right column of the 
tables: / indicates a statistically significant linear change, / indicates a marginally 
significant linear change, § indicates a non-linear significant or marginal change, and — 
indicates there was no change. 
Significant linear changes in rates per 100 encounters can be extrapolated to estimate the 
national increase or decrease in the measured event between 2001–02 and 2010–11. Some 
examples of extrapolated change are provided. The method used to extrapolate to national 
change estimates is described in Section 2.9. 
6.1 Age and sex distribution of patients at 
encounter 
Figure 6.1 and Table 6.1 show the age and sex distribution of patients at BEACH encounters 
from 2001–02 to 2010–11. Over this period there was no significant change in the proportion 
of encounters with male and female patients. The proportion of encounters with patients 
aged less than 45 years decreased from 48.6% to 43.4%, while over the same period the 
proportion with patients aged 45 years and over increased from 51.4% to 56.6%. Specifically, 
the biggest increase occurred in encounters with patients aged 75 years and over and the 
biggest decrease was in encounters with patients aged 25–44 years of age. When 
extrapolated, even with the increased number of encounters nationally, the number of 
encounters with patients aged less than 45 years only increased by about 2.7 million over the 
decade, while the number of encounters with older patients increased by about 15.5 million 
nationally. The relationship between patient age, general practice attendance rates and the 
age distribution of the Australian population was investigated in Chapter 4 of General practice 
in Australia, health priorities and policies 1998 to 2008.3 
6.2 Other patient characteristics 
Over the decade there was a significant decrease in the proportion of encounters with 
patients who were new to the practice (from 9.2% in 2001–02 to 7.3% in 2010–11). The 
proportion of encounters with patients holding a Commonwealth concession card was 
relatively stable across the decade. Between 2003–04 and 2010–11, the proportion of 
encounters with patients holding a repatriation health card decreased by about a third. There 
was no significant change in the proportion of encounters with patients from a Non-English-
speaking background or with Indigenous patients (Table 6.1). 
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0
10
20
30
40
50
60
70
2001–02 42.6 57.4 2.0 4.9 6.4 9.5 25.8 26.3 12.3 12.8
2010–11 42.9 57.1 1.8 4.6 5.5 8.7 22.8 27.7 13.3 15.7
Male Female <1 year 1–4 
years
5–14 
years
15–24 
years
25–44 
years
45–64 
years
65–74 
years
75+ 
years
 
Note: Data with patient age or sex missing were removed.  
Figure 6.1: Age and sex distribution of patients at encounters, 2001–02 and 2010–11 (95% 
confidence interval) 
6.3 Patient reasons for encounter 
RFEs are those concerns and expectations that patients bring to the GP. International interest 
in reasons for encounter has been developing over the past three decades. RFEs reflect the 
patient’s demand for care, and can provide an indication of service use patterns that may 
benefit from intervention on a population level.49 
Participating GPs were asked to record at least one and up to three patient RFEs in words as 
close as possible to those used by the patient, before the diagnostic or management process 
had begun. RFEs can be expressed in terms of one or more symptoms (for example, ‘itchy 
eyes’, ‘chest pain’), in diagnostic terms (for example, ‘about my diabetes’, ‘for my 
hypertension’), a request for a service (‘I need more scripts’, ‘I want a referral’), an expressed 
fear of disease, or a need for a check-up. 
Patient RFEs can have a one-to-one, one-to-many, many-to-one and many-to-many 
relationship to problems managed. That is, the patient may describe a single RFE that relates 
to a single problem managed at the encounter, one RFE that relates to multiple problems, 
multiple symptoms that relate to a single problem managed at the encounter, or multiple 
RFEs that relate to multiple problems managed at the encounter. 
Number of reasons for encounter 
Table 6.2 shows that between 2004–05 and 2010–11 there was a decrease in the proportion of 
encounters involving a single RFE, from 61.4% to 57.6% in 2010–11. To balance this there was 
an increase in the proportion of encounters with multiple RFEs, encounters with two RFEs 
Per cent of encounters 
Patient characteristics 
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increasing from 27.6% in 2004–05 to 29.4% of all encounters in 2010–11, and encounters with 
three RFEs increasing from 11.0% to 13.0%. We estimate that the extrapolated effect of this 
change means there were about 12 million more encounters nationally where two or three 
RFEs were reported in 2010–11 than in 2001–02. 
Reasons for encounter by ICPC-2 component 
The distribution of patient RFEs by ICPC-2 component is presented in Table 6.3. 
Symptoms and diagnoses 
• RFEs expressed in terms of a symptom or complaint (for example, ‘tired’, ‘feeling 
anxious’) were the most frequent. However, the presentation rate of symptoms or 
complaints decreased significantly, from 71.5 per 100 encounters in 2001–02 to 66.8 per 
100 encounters in 2010–11. 
• Interestingly, the rate of RFEs relating to specific diagnoses (including infections, 
injuries, neoplasms, congenital anomalies, and other diagnoses) decreased significantly 
between 2001–02 and 2004–05, then increased to a rate in 2010–11 similar to the rate in 
2001–02. 
Processes of care 
• The rate of patient attendance to request test results increased by about 70%, equating to 
an estimated 4.8 million more encounters nationally with a RFE of this type in 2010–11 
than in 2001–02 when extrapolated. 
• The rate of requests for an administrative procedure (such as a sickness certificate) 
doubled, equating to an estimated increase of approximately 1.8 million requests for an 
administrative procedure nationally between 2001–02 and 2010–11 when extrapolated. 
• Patient requests for medications, treatments and therapeutics (such as repeat 
prescriptions) increased by about 20%, equating to an estimated 5.2 million more such 
requests in 2010–11 than in 2001–02. 
• Patient requests for diagnostic and preventative treatments (such as immunisation) also 
increased from 22.6 per 100 encounters in 2001–02 to 25.1 per 100 encounters in 2010–11. 
Reasons for encounter by ICPC-2 chapter 
Table 6.4 shows that between 2001–02 and 2010–11: 
• there was a significant increase in the overall rate of RFEs, from 149.2 per 100 encounters 
in 2001–02 to 155.5 per 100 encounters in 2010–11. This increase when extrapolated 
equates to about 35 million extra RFEs nationally in 2010–11 than in 2001–02. 
• the rate of general and unspecified RFEs increased by a third. When extrapolated, this 
equates to an approximate national increase of 17.7 million general and unspecified RFEs 
between 2001–02 and 2010–11. 
• the rate of RFEs relating to the blood system increased by about 45%, this is likely linked 
to increased INR testing (as discussed in Chapter 12). 
• RFEs related to psychological problems increased by about 15% and RFEs related to the 
male genital system increased by 30%.  
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• significant decreases in RFEs related to musculoskeletal and neurological systems. 
• there were marginal decreases in rates of RFEs related to ear and respiratory problems. 
Most frequent patient reasons for encounter 
Table 6.5 shows that between 2001–02 and 2010–11: 
• the rate of requests for a check up (all types) significantly increased from 13.3 per 100 
encounters in 2001–02 to 15.2 in 2008–09. It then decreased to 13.7 per 100 encounters in 
2010–11, which is not significantly different from the 2001–02 rate.  
• the rate at which patients cited a need for prescription(s) as a RFE increased by about 
24%, equating to 4.5 million more encounters with this RFE in 2010–11 than in 2001–02. 
• the rate of RFEs for test results increased by about 70% and the rate of RFEs relating to 
the need for a blood test increased by over a third. 
• patients presenting for their diabetes increased by 40%, equating when extrapolated to 
an estimated increase of 650,000 encounters with this RFE. 
• RFEs relating to headaches and neck complaints decreased by a third. 
• the rate at which patients presented with asthma as a RFE decreased by one quarter. 
• RFEs of back complaints and throat complaints decreased by about 20%. 
• the rate of request for referral as an RFE doubled. 
• the rate of depression as a patient RFE increased by 15%, this increase coinciding with 
the introduction of the Better Access initiative.50 
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Table 6.1: C
haracteristics of patients at encounters, 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
Patient characteristics 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
S
ex (m
issing n) (b) 
(809) 
 
(911) 
 
(932) 
 
(809) 
 
(788) 
 
(765) 
 
(876) 
 
(867) 
 
(931) 
 
(888) 
. . 
M
ale 
42.6 
(41.9–43.3) 
 
42.2 
(41.4–42.9) 
 
42.6 
(41.8–43.3) 
 
43.5 
(42.7–44.3) 
 
44.0 
(43.2–44.7) 
 
43.7 
(42.9–44.5) 
 
42.9 
(42.1–43.7) 
 
42.4 
(41.5–43.3) 
 
43.1 
(42.3–43.9) 
 
42.9 
(42.0–43.7)  
—
 
Fem
ale 
57.4 
(56.7–58.1) 
 
57.8 
(57.0–58.6) 
 
57.4 
(56.7–58.2) 
 
56.5 
(55.7–57.3) 
 
56.0 
(55.3–56.8) 
 
56.3 
(55.5–57.1) 
 
57.1 
(56.3–57.9) 
 
57.6 
(56.7–58.5) 
 
56.9 
(56.1–57.7) 
 
57.1 
(56.3–58.0) 
—
 
A
ge group (m
issing n) (b) 
(760) 
 
(895) 
 
(905) 
 
(925) 
 
(769) 
 
(779) 
 
(784) 
 
(704) 
 
(781) 
 
(771) 
 
 
< 1 year 
2.0 
(1.9–2.1) 
 
1.9 
(1.8–2.1) 
 
1.8 
(1.7–1.9) 
 
1.9 
(1.8–2.1) 
 
2.1 
(1.9–2.2) 
 
1.8 
(1.7–2.0) 
 
2.0 
(1.8–2.1) 
 
2.0 
(1.8–2.1) 
 
2.1 
(1.9–2.3 ) 
 
1.8 
(1.7–2.0) 
—
 
 
1–4 years 
4.9 
(4.6–5.2) 
 
5.0 
(4.7–5.3) 
 
4.6 
(4.3–4.8) 
 
4.3 
(4.0–4.7) 
 
4.3 
(4.0–4.5) 
 
4.1 
(3.9–4.4) 
 
4.3 
(4.1–4.6) 
 
4.2 
(4.0–4.4) 
 
4.7 
(4.5–5.0) 
 
4.6 
(4.3–4.9)  
—
 
 
5–14 years 
6.4 
(6.1–6.7) 
 
6.6 
(6.3–6.9) 
 
5.9 
(5.6–6.3) 
 
5.8 
(5.5–6.1) 
 
6.0 
(5.7–6.3) 
 
5.6 
(5.3–5.9) 
 
5.5 
(5.2–5.8) 
 
5.3 
(5.1–5.6) 
 
5.7 
(5.4–6.0) 
 
5.5 
(5.2–5.8)  

 
 
15–24 years 
9.5 
(9.1–10.0) 
 
10.1 
(9.7–10.4) 
 
9.6 
(9.2–10.1) 
 
9.0 
(8.6–9.4) 
 
9.4 
(9.0–9.8) 
 
9.1 
(8.6–9.5) 
 
9.5 
(9.0–9.9) 
 
8.4 
(8.0–8.9) 
 
8.6 
(8.2–9.0) 
 
8.7 
(8.3–9.1) 

 
 
25–44 years 
25.8 
(25.1–26.5) 
 
25.7 
(24.9–26.4)  
 
24.1 
(23.4–24.8) 
 
24.4 
(23.7–25.1) 
 
23.9 
(23.2–24.7) 
 
23.3 
(22.6–24.0) 
 
23.4 
(22.7–24.1) 
 
21.4 
(20.7–22.1) 
 
22.9 
(22.1–23.6) 
 
22.8 
(22.0–23.5)  

 
 
45–64 years 
26.3 
(25.7–26.8) 
 
26.5 
(25.9–27.0) 
 
27.2 
(26.7–27.7) 
 
28.0 
(27.4–28.6) 
 
27.6 
(27.0–28.2) 
 
28.2 
(27.6–28.7) 
 
28.1 
(27.5–28.6) 
 
29.1 
(28.5–29.6) 
 
28.2 
(27.7–28.8) 
 
27.7 
(27.1–28.2)  

 
 
65–74 years 
12.3 
(11.8–12.8) 
 
11.6 
(11.1–12.0) 
 
12.4 
(11.9–12.9) 
 
12.6 
(12.1–13.2) 
 
12.2 
(11.7–12.6) 
 
12.7 
(12.2–13.2) 
 
12.6 
(12.1–13.1) 
 
13.4 
(12.9–13.9) 
 
12.7 
(12.2–13.2) 
 
13.3 
(12.7–13.8) 
—
 
 
75+ years 
12.8 
(12.0–13.5) 
 
12.7 
(11.9–13.4) 
 
14.4 
(13.6–15.2) 
 
13.9 
(13.1–14.7) 
 
14.6 
(13.7–15.4) 
 
15.2 
(14.4–16.0) 
 
14.7 
(13.9–15. 5) 
 
16.2 
(15.4–17.0) 
 
15.1 
(14.3–16.0) 
 
15.7 
(14.8–16.6)  

 
(continued) 
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Table 6.1 (continued): C
haracteristics of patients at encounters, 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
Patient characteristics 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
O
ther characteristics
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
ew
 patient to practice 
9.2 
(8.5–9.9) 
 
9.9 
(9.1–10.8) 
 
9.3 
(8.6–10.0) 
 
9.1 
(8.4–9.9) 
 
9.1 
(8.3–9.9) 
 
8.7 
(7.9–9.4) 
 
8.6 
(7.8–9.4) 
 
5.9 
(5.5–6.3) 
 
7.7 
(7.1–8.3) 
 
7.3 
(6.6–7.9) 

 
 
C
om
m
onw
ealth concession 
 
card 
46.1 
(44.6–47.6) 
 
45.0 
(43.4–46.5) 
 
46.6 
(45.1–48.2) 
 
47.5 
(46.0–49.0) 
 
45.4 
(43.8–47.0) 
 
45.4 
(43.8–46.9) 
 
45.5 
(44.0–47.1) 
 
45.7 
(44.3–47.0) 
 
45.9 
(44.3–47.4) 
 
44.9 
(43.3–46.4) 
—
 
 
R
epatriation health card 
3.7 
(3.4–4.0) 
 
3.7 
(3.4–4.0) 
 
3.9 
(3.6–4.2) 
 
3.6 
(3.3–3.8) 
 
3.4 
(3.1–3.6) 
 
3.4 
(3.2–3.7) 
 
3.1 
(2.8–3.3) 
 
3.1 
(2.9–3.4) 
 
2.9 
(2.7–3.2) 
 
2.5 
(2.3–2.7) 

 
 
N
on-E
nglish-speaking 
 
background 
11.1 
(9.1–13.2) 
 
12.0 
(10.1–13.8) 
 
10.8 
(8.7–12.8) 
 
12.1 
(10.1–14.1) 
 
10.8 
(9.0–12.5) 
 
8.0 
(6.5–9.5) 
 
11.0 
(9.2–12.8) 
 
10.4 
(8.7–12.1) 
 
9.0 
(7.3–10.6) 
 
10.7 
(8.9–12.5) 
—
 
 
A
boriginal person and/or 
 
Torres S
trait Islander 
1.1 
(0.8–1.4) 
 
1.2 
(0.9–1.4) 
 
1.8 
(1.3–2.3) 
 
1.5 
(1.1–2.0) 
 
1.0 
(0.7–1.2) 
 
1.0 
(0.7–1.3) 
 
1.0 
(0.8–1.3) 
 
0.9 
(0.6–1.1) 
 
1.3 
(1.0–1.6) 
 
1.2 
(0.9–1.5) 
—
 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change, § indicates a non-
linear significant or m
arginal change, and —
 indicates there w
as no change. 
(b) 
M
issing data rem
oved. 
N
ote: C
I – confidence interval. 
Table 6.2: N
um
ber of patient reasons for encounter, 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
N
um
ber of reasons  
for encounter 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 149,005) 
O
ne R
FE
 
61.8 
(60.6–63.0) 
 
60.7 
(59.5–61.9) 
 
61.0 
(59.9–62.2) 
 
61.4 
(60.2–62.6) 
 
60.9 
(59.7–62.2) 
 
60.6 
(59.4–61.9) 
 
58.9 
(57.7–60.2) 
 
56.6 
(55.5–57.8) 
 
57.7 
(56.5–58.9) 
 
57.6 
(56.3–58.8) 

 
Tw
o R
FE
s 
27.2 
(26.5–28.0) 
 
27.8 
(27.1–28.4) 
 
27.7 
(27.0–28.4) 
 
27.6 
(26.9–28.3) 
 
27.8 
(27.1–28.5) 
 
27.9 
(27.2–28.7) 
 
29.1 
(28.5–29.8) 
 
30.3 
(29.6–30.9) 
 
29.7 
(29.0–30.4) 
 
29.4 
(28.7–30.1) 

 
Three R
FE
s 
11.0 
(10.3–11.6) 
 
11.6 
(10.8–12.3) 
 
11.3 
(10.5–12.0) 
 
11.0 
(10.3–11.7) 
 
11.2 
(10.5–11.9) 
 
11.4 
(10.7–12.2) 
 
11.9 
(11.2–12.6) 
 
13.1 
(12.4–13.8) 
 
12.6 
(11.9–13.4) 
 
13.0 
(12.3–13.8) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, and —
 indicates there w
as no change. 
N
ote: C
I – confidence interval; R
FE – reason for encounter. 
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Table 6.3: Patient reasons for encounter by IC
PC
-2 com
ponent, 2001–02 to 2010–11 
 
R
ate per 100 encounters
 (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
IC
PC
 com
ponent 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 
(n = 96,688) 
 (n = 101,349)  
(n = 95,839) 
S
ym
ptom
s and com
plaints 
71.5 
(69.7–73.4) 
 
71.5 
(69.5–73.6) 
 
69.1 
(67.3–71.0) 
 
68.7 
(66.8–70.6) 
 
67.0 
(65.2–68.8) 
 
65.2 
(63.4–67.0) 
 
65.1 
(63.2–67.0) 
 
66.3 
(64.6–68.0) 
 
65.0 
(63.1–67.0) 
 
66.8 
(64.7–68.9) 

 
D
iagnosis, diseases 
29.9 
(28.5–31.3) 
 
28.6 
(27.1–30.0) 
 
27.7 
(26.4–28.9) 
 
27.2 
(26.0–28.4) 
 
29.5 
(28.1–30.9) 
 
30.6 
(28.9–32.2) 
 
30.4 
(28.9–32.0) 
 
30.3 
(28.8–31.8) 
 
30.7 
(29.1–32.4) 
 
30.9 
(29.4–32.4) 
§ 
 
Infections 
8.0 
(7.5–8.5) 
 
7.6 
(7.1–8.1) 
 
7.5 
(7.0–8.0) 
 
7.1 
(6.6–7.5) 
 
8.4 
(7.7–9.0) 
 
8.1 
(7.6–8.7) 
 
8.0 
(7.5–8.5) 
 
8.0 
(7.5–8.5) 
 
8.0 
(7.5–8.6) 
 
7.8 
(7.3–8.3) 
—
 
 
Injuries 
4.0 
(3.8–4.2) 
 
4.4 
(4.2–4.6) 
 
4.3 
(4.1–4.6) 
 
4.4 
(4.2–4.6) 
 
4.4 
(4.2–4.7) 
 
4.3 
(4.1–4.5) 
 
4.5 
(4.3–4.7) 
 
4.3 
(4.1–4.5) 
 
4.6 
(4.4–4.9) 
 
4.4 
(4.2–4.7) 

 
 
N
eoplasm
s 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.1) 
 
1.0 
(0.9–1.1) 
 
1.2 
(1.0–1.3) 
 
1.2 
(1.0–1.3) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 

 
 
C
ongenital anom
alies 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 

 
 
O
ther diagnoses, diseases 
16.6 
(15.7–17.6) 
 
15.2 
(14.2–16.3) 
 
14.6 
(13.7–15.5) 
 
14.5 
(13.6–15.4) 
 
15.4 
(14.4–16.4) 
 
16.7 
(15.5–17.9) 
 
16.5 
(15.3–17.6) 
 
16.7 
(15.6–17.8) 
 
16.7 
(15.6–17.9) 
 
17.3 
(16.3–18.4) 
§ 
D
iagnostic and preventive 
procedures 
22.6 
(21.7–23.6) 
 
23.7 
(22.8–24.7) 
 
24.0 
(23.1–25.0) 
 
23.4 
(22.6–24.3) 
 
24.3 
(23.4–25. 3) 
 
24.8 
(23.9–25.7) 
 
25.6 
(24.7–26.5) 
 
26.9 
(26.0–27.8) 
 
27.0 
(26.0–27.9) 
 
25.1 
(24.1–26.2) 

 
M
edications, treatm
ents and 
therapeutics 
11.9 
(11.3–12.4) 
 
13.0 
(12.4–13.6) 
 
14.4 
(13.7–15.1) 
 
14.5 
(13.8–15.3) 
 
14.4 
(13.7–15.1) 
 
14.2 
(13.5–14.8) 
 
15.1 
(14.3–15.8) 
 
15.3 
(14.6–15.9) 
 
14.1 
(13.4–14.8) 
 
14.5 
(13.8–15.2) 

 
R
esults 
4.7 
(4.4–5.0) 
 
5.4 
(5.0–5.7) 
 
6.0 
(5.7–6.4) 
 
6.8 
(6.4–7.2) 
 
6.5 
(6.1–6.9) 
 
6.9 
(6.5–7.3) 
 
7.6 
(7.2–8.1) 
 
7.8 
(7.4–8.2) 
 
8.1 
(7.7–8.6) 
 
8.0 
(7.5–8.5) 

 
R
eferrals and other R
FE
s 
7.2 
(6.7–7.7) 
 
7.0 
(6.6–7.5) 
 
7.2 
(6.8–7.6) 
 
7.3 
(6.9–7.8) 
 
6.9 
(6.5–7.4) 
 
7.3 
(6.9–7.8) 
 
6.8 
(6.4–7.2) 
 
7.5 
(7.0–7.9) 
 
7.6 
(7.2–8.1) 
 
7.5 
(7.1–7.9) 
—
 
A
dm
inistrative 
1.3 
(1.2–1.5) 
 
1.6 
(1.5–1.8) 
 
1.8 
(1.6–1.9) 
 
1.7 
(1.5–1.8) 
 
1.7 
(1.5–1.8) 
 
1.8 
(1.7–2.0) 
 
2.3 
(2.2–2.5) 
 
2.4 
(2.2–2.6) 
 
2.4 
(2.2–2.6) 
 
2.6 
(2.4–2.8) 

 
Total R
FEs 
149.2 
(147.4–150.9)  
150.9 
(149.0–152.7)  
150.2 
(148.4–152.0)  
149.6 
(147.8–151.5)  
150.3 
(148.4–152.2)  
150.8 
(148.9–152.7)  
153.0 
(151.1–154.8)  
156.5 
(154.7–158.2)  
155.0 
(153.1–156.8)  
155.5 
(153.5–157.5) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, § indicates a non-linear significant or m
arginal change, and —
 indicates 
there w
as no change. 
N
ote: C
I – confidence interval; R
FE – reason for encounter. 
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Table 6.4: Patient reasons for encounter by IC
PC
-2 chapter, 2001–02 to 2010–11 
 
R
ate per 100 encounters
 (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
IC
PC
-2 C
hapter 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 
(n = 95,839) 
G
eneral and unspecified 
30.8 
(29.9–31.8) 
 
34.6 
(33.5–35.6) 
 
36.1 
(35.1–37.2) 
 
36.5 
(35.5–37.6) 
 
36.3 
(35.2–37.4) 
 
37.7 
(36.7–38.8) 
 
40.1 
(38.9–41.2) 
 
40.6 
(39.6–41.7) 
 
42.7 
(41.5–43.9) 
 
41.0 
(39.8–42.3) 

 
R
espiratory 
23.4 
(22.6–24.2) 
 
23.0 
(22.0–24.0) 
 
21.4 
(20.6–22.2) 
 
20.6 
(19.7–21.4) 
 
21.9 
(21.1–22.7) 
 
20.7 
(19.9–21.6) 
 
20.6 
(19.8–21.5) 
 
22.0 
(21.2–22.9) 
 
22.8 
(21.9–23.8) 
 
21.7 
(20.9–22.6) 

 
M
usculoskeletal 
17.8 
(17.3–18.4) 
 
16.8 
(16.2–17.3) 
 
16.4 
(15.8–16.9) 
 
16.7 
(16.0–17.3) 
 
16.4 
(15.8–16.9) 
 
16.1 
(15.6–16.6) 
 
15.4 
(14.9–15.9) 
 
16.1 
(15.5–16.6) 
 
15.4 
(14.7–16.2) 
 
15.3 
(14.9–15.8) 

 
S
kin 
14.4 
(13.9–14.9) 
 
14.7 
(14.3–15.2) 
 
15.1 
(14.5–15.8) 
 
15.6 
(15.0–16.2) 
 
15.0 
(14.5–15.6) 
 
15.7 
(15.1–16.3) 
 
15.4 
(14.8–16.1) 
 
15.1 
(14.6–15.6) 
 
14.8 
(14.3–15.3) 
 
15.3 
(14.8–15.8) 
—
 
C
ardiovascular 
11.4 
(10.8–11.9) 
 
10.6 
(10.0–11.1) 
 
10.6 
(10.1–11.2) 
 
10.5 
(10.0–11.0) 
 
10.8 
(10.2–11.3) 
 
11.2 
(10.7–11.8) 
 
11.2 
(10.6–11.8) 
 
11.5 
(10.9–12.0) 
 
10.0 
(9.5–10.5) 
 
10.5 
(10.0–11.1) 
—
 
D
igestive 
10.6 
(10.2–11.0) 
 
10.4 
(10.0–10.8) 
 
10.7 
(10.3–11.1) 
 
9.9 
(9.5–10.3) 
 
9.9 
(9.5–10.3) 
 
10.1 
(9.7–10.5) 
 
10.3 
(10.0–10.7) 
 
9.8 
(9.4–10.1) 
 
9.8 
(9.5–10.1) 
 
10.2 
(9.8–10.6) 
—
 
P
sychological 
7.8 
(7.3–8.3) 
 
7.3 
(6.9–7.7) 
 
7.3 
(6.9–7.7) 
 
7.6 
(7.2–8.0) 
 
7.8 
(7.3–8.3) 
 
7.5 
(7.1–7.8) 
 
7.8 
(7.5–8.2) 
 
8.7 
(8.2–9.1) 
 
8.5 
(8.0–8.9) 
 
9.0 
(8.6–9.4) 

 
E
ndocrine and m
etabolic 
6.4 
(6.1–6.7) 
 
6.0 
(5.7–6.3) 
 
6.1 
(5.8–6.5) 
 
6.1 
(5.8–6.5) 
 
6.2 
(5.8–6.5 ) 
 
6.4 
(6.1–6.8) 
 
6.5 
(6.1–6.8) 
 
6.9 
(6.5–7.3) 
 
6.1 
(5.8–6.4) 
 
6.5 
(6.2–6.9) 
—
 
Fem
ale genital system
 
5.5 
(5.1–5.8) 
 
6.1 
(5.7–6.5) 
 
5.1 
(4.8–5.5) 
 
5.0 
(4.6–5.4) 
 
5.1 
(4.8–5.5) 
 
5.1 
(4.7–5.4) 
 
5.2 
(4.8–5.6) 
 
5.3 
(4.9–5.6) 
 
4.7 
(4.4–5.1) 
 
5.0 
(4.6–5.3) 
—
 
N
eurological 
5.4 
(5.2–5.6) 
 
5.7 
(5.5–6.0) 
 
5.3 
(5.1–5.6) 
 
5.1 
(4.9–5.4) 
 
4.9 
(4.7–5.2) 
 
4.9 
(4.7–5.2) 
 
4.8 
(4.6–5.0) 
 
4.8 
(4.6–5.0) 
 
4.4 
(4.1–4.6) 
 
4.6 
(4.4–4.9) 

 
E
ar 
4.1 
(3.9–4.3) 
 
3.9 
(3.8–4.1) 
 
3.7 
(3.5–3.9) 
 
3.9 
(3.7–4.1) 
 
3.9 
(3.7–4.1) 
 
3.5 
(3.4–3.7) 
 
3.6 
(3.4–3.8) 
 
3.7 
(3.5–3.9) 
 
3.6 
(3.4–3.8) 
 
3.7 
(3.5–3.9) 

 
P
regnancy and fam
ily planning 
3.5 
(3.2–3.7) 
 
3.6 
(3.3–3.9) 
 
3.7 
(3.4–3.9) 
 
3.4 
(3.2–3.6) 
 
3.4 
(3.1–3.6) 
 
3.3 
(3.0–3.6) 
 
3.2 
(3.0–3.5) 
 
3.1 
(2.8–3.3) 
 
3.4 
(3.2–3.7) 
 
3.4 
(3.1–3.7) 
—
 
U
rology 
2.5 
(2.4–2.7) 
 
2.4 
(2.3–2.6) 
 
2.5 
(2.4–2.7) 
 
2.5 
(2.4–2.7) 
 
2.6 
(2.5–2.8) 
 
2.6 
(2.4–2.7) 
 
2.5 
(2.4–2.7) 
 
2.7 
(2.5–2.8) 
 
2.6 
(2.5–2.8) 
 
2.7 
(2.6–2.9) 
—
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Table 6.4 (continued): Patient reasons for encounter by IC
PC
-2 chapter, 2001–02 to 2010–11 
 
R
ate per 100 encounters
 (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
IC
PC
-2 C
hapter 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 
(n = 95,839) 
E
ye 
2.5 
(2.4–2.7) 
 
2.7 
(2.5–2.9) 
 
2.7 
(2.6–2.8) 
 
2.7 
(2.6–2.9) 
 
2.8 
(2.6–2.9) 
 
2.5 
(2.4–2.7) 
 
2.5 
(2.4–2.6) 
 
2.6 
(2.4–2.7) 
 
2.3 
(2.2–2.5) 
 
2.4 
(2.3–2.6) 
—
 
B
lood 
1.1 
(1.0–1.2) 
 
1.0 
(0.9–1.1) 
 
1.3 
(1.1–1.4) 
 
1.2 
(1.1–1.4) 
 
1.2 
(1.0–1.3) 
 
1.2 
(1.1–1.4) 
 
1.4 
(1.2–1.5) 
 
1.4 
(1.3–1.6) 
 
1.4 
(1.2–1.5) 
 
1.6 
(1.4–1.8) 

 
M
ale genital system
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.1) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 
 
1.2 
(1.1–1.3) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 
 
1.2 
(1.1–1.4) 
 
1.3 
(1.2–1.3) 

 
S
ocial problem
s 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
1.1 
(1.0–1.2) 
 
0.9 
(0.9–1.0) 
 
1.2 
(1.1–1.3) 
 
1.0 
(0.9–1.1) 
—
 
Total R
FEs 
149.2 
(147.4–150.9)   
150.9 
(149.0–152.7)   
150.2 
(148.4–152.0)   
149.6 
(147.8–151.5)   
150.3 
(148.4–152.2)   
150.8 
(148.9–152.7)   
153.0 
(151.1–154.8)   
156.5 
(154.7–158.2)   
155.0 
(153.1–156.8)   
155.5 
(153.5–157.5) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginal change, and —
 indicates there w
as no change. 
N
ote: C
I – confidence interval; R
FE – reason for encounter. 
 
42
Table 6.5: M
ost frequent patient reasons for encounter, 2001–02 to 2010–11 
 
R
ate per 100 encounters
 (95%
 C
I) 
 
Patient reason  
for encounter 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 
(n = 95,839) 
C
heck-up – all* 
13.3 
(12.7–14.0) 
 
13.6 
(12.9–14.2) 
 
14.1 
(13.4–14.8) 
 
13.4 
(12.8–14.0) 
 
14.1 
(13.4–14.8) 
 
14.6 
(13.9–15.2) 
 
14.5 
(13.8–15.1) 
 
15.2 
(14.5–15.8) 
 
13.9 
(13.3–14.5) 
 
13.7 
(13.0–14.3) 
§ 
P
rescription – all* 
9.7 
(9.2–10.3) 
 
10.7 
(10.2–11.3) 
 
12.1 
(11.5–12.7) 
 
12.2 
(11.5–12.8) 
 
12.0 
(11.3–12.7) 
 
11.8 
(11.2–12.4) 
 
12.5 
(11.9–13.2) 
 
12.6 
(12.0–13.2) 
 
11.6 
(11.0–12.2) 
 
12.0 
(11.4–12.7) 

 
Test results* 
4.7 
(4.4–5.0) 
 
5.4 
(5.0–5.7) 
 
6.0 
(5.7–6.4) 
 
6.8 
(6.4–7.2) 
 
6.5 
(6.1–6.9) 
 
6.9 
(6.5–7.3) 
 
7.6 
(7.2–8.1) 
 
7.8 
(7.4–8.2) 
 
8.1 
(7.7–8.6) 
 
8.0 
(7.5–8.5) 

 
C
ough 
6.5 
(6.1–6.9) 
 
6.7 
(6.3–7.2) 
 
6.2 
(5.8–6.6) 
 
5.9 
(5.5–6.2) 
 
6.4 
(6.0–6.8) 
 
5.8 
(5.4–6.2) 
 
6.2 
(5.8–6.7) 
 
6.8 
(6.3–7.2) 
 
6.9 
(6.4–7.3) 
 
6.7 
(6.3–7.1) 
—
 
Im
m
unisation/vaccination – all* 
4.6 
(4.2–5.0) 
 
4.7 
(4.3–5.1) 
 
4.4 
(4.0–4.9) 
 
4.3 
(3.9–4.8) 
 
4.8 
(4.4–5.2) 
 
4.3 
(3.9–4.7) 
 
4.8 
(4.4–5.1) 
 
5.3 
(4.8–5.7) 
 
6.5 
(5.9–7.0) 
 
4.8 
(4.4–5.3) 
—
 
B
ack com
plaint* 
3.8 
(3.6–4.1) 
 
3.5 
(3.3–3.8) 
 
3.5 
(3.2–3.7) 
 
3.4 
(3.2–3.6) 
 
3.4 
(3.2–3.7) 
 
3.2 
(3.0–3.4) 
 
3.2 
(3.0–3.4) 
 
3.1 
(2.9–3.3) 
 
3.1 
(2.9–3.3) 
 
3.1 
(3.0–3.3) 

 
Throat com
plaint 
3.8 
(3.5–4.0) 
 
3.8 
(3.5–4.1) 
 
3.4 
(3.1–3.6) 
 
3.5 
(3.3–3.8) 
 
3.3 
(3.0–3.5) 
 
3.3 
(3.1–3.6) 
 
3.3 
(3.0–3.6) 
 
3.2 
(2.9–3.5) 
 
2.9 
(2.7–3.2) 
 
3.1 
(2.8–3.4) 

 
R
ash* 
2.8 
(2.6–3.0) 
 
2.8 
(2.6–2.9) 
 
2.8 
(2.6–2.9) 
 
2.9 
(2.7–3.1) 
 
2.6 
(2.5–2.8) 
 
2.8 
(2.6–3.0) 
 
2.5 
(2.3–2.6) 
 
2.6 
(2.5–2.8) 
 
2.4 
(2.2–2.6) 
 
2.7 
(2.5–2.9) 
—
 
A
dm
inistrative procedure – all* 
1.3 
(1.2–1.5) 
 
1.6 
(1.5–1.8) 
 
1.8 
(1.6–1.9) 
 
1.7 
(1.5–1.8) 
 
1.7 
(1.5–1.8) 
 
1.8 
(1.7–2.0) 
 
2.3 
(2.2–2.5) 
 
2.4 
(2.2–2.6) 
 
2.4 
(2.2–2.6) 
 
2.6 
(2.4–2.8) 

 
B
lood test – all* 
1.9 
(1.7–2.1) 
 
2.1 
(1.9–2.3) 
 
2.1 
(2.0–2.3) 
 
2.2 
(2.0–2.4) 
 
2.3 
(2.1–2.5) 
 
2.5 
(2.3–2.7) 
 
2.6 
(2.4–2.8) 
 
2.8 
(2.6–3.1) 
 
2.4 
(2.2–2.7) 
 
2.6 
(2.4–2.8) 

 
D
epression* 
1.9 
(1.8–2.0) 
 
1.9 
(1.7–2.0) 
 
1.8 
(1.7–1.9) 
 
1.9 
(1.7–2.0) 
 
1.9 
(1.7–2.0) 
 
1.9 
(1.8–2.1) 
 
2.0 
(1.9–2.2) 
 
2.1 
(1.9–2.2) 
 
2.2 
(2.0–2.3) 
 
2.2 
(2.1–2.4) 

 
U
pper respiratory tract 
infection 
2.3 
(2.1–2.6) 
 
2.2 
(1.9–2.4) 
 
1.9 
(1.7–2.1) 
 
1.7 
(1.5–2.0) 
 
2.4 
(2.0–2.7) 
 
2.4 
(2.1–2.7) 
 
2.2 
(2.0–2.5) 
 
2.3 
(2.0–2.6) 
 
2.2 
(1.9–2.5) 
 
2.0 
(1.8–2.3) 
—
 
Fever 
2.0 
(1.8–2.2) 
 
2.2 
(1.9–2.5) 
 
1.9 
(1.7–2.1) 
 
1.8 
(1.6–2.0) 
 
2.2 
(1.9–2.5) 
 
1.8 
(1.6–2.0) 
 
2.1 
(1.8–2.5) 
 
1.9 
(1.7–2.1) 
 
2.2 
(2.0–2.5) 
 
2.0 
(1.8–2.3) 
—
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Table 6.5 (continued): M
ost frequent patient reasons for encounter, 2001–02 to 2010–11 
 
R
ate per 100 encounters
((95%
 C
I) 
 
Patient reason  
for encounter 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 
(n = 95,839) 
H
ypertension* 
2.1 
(1.8–2.3) 
 
1.8 
(1.6–2.0) 
 
1.9 
(1.6–2.1) 
 
1.7 
(1.5–1.9) 
 
1.9 
(1.6–2.1) 
 
2.1 
(1.8–2.5) 
 
2.1 
(1.8–2.3) 
 
2.1 
(1.9–2.4) 
 
2.0 
(1.7–2.3) 
 
1.9 
(1.7–2.2) 
—
 
O
bservation/health 
education/advice – all* 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.4 
(1.3–1.5) 
 
1.5 
(1.3–1.7) 
 
1.4 
(1.3–1.6) 
 
1.7 
(1.5–1.8) 
 
1.8 
(1.6–2.0) 
 
1.6 
(1.5–1.8) 
 
1.9 
(1.7–2.1) 
 
1.8 
(1.5–2.1) 

 
A
bdom
inal pain* 
2.1 
(2.0–2.2) 
 
1.9 
(1.8–2.1) 
 
2.0 
(1.9–2.2) 
 
1.9 
(1.8–2.0) 
 
1.8 
(1.7–1.9) 
 
1.8 
(1.7–1.9) 
 
1.8 
(1.6–1.9) 
 
1.7 
(1.6–1.9) 
 
1.6 
(1.5–1.7) 
 
1.8 
(1.7–1.9) 

 
S
kin sym
ptom
/com
plaint, other 
1.3 
(1.1–1.5) 
 
1.3 
(1.2–1.5) 
 
1.4 
(1.2–1.5) 
 
1.5 
(1.3–1.6) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.3–1.5) 
 
1.5 
(1.4–1.6) 
 
1.6 
(1.5–1.7) 
 
1.5 
(1.4–1.7) 
—
 
E
ar pain/earache 
1.7 
(1.6–1.9) 
 
1.7 
(1.5–1.8) 
 
1.6 
(1.4–1.7) 
 
1.6 
(1.5–1.7) 
 
1.6 
(1.5–1.7) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.3–1.6) 
 
1.3 
(1.2–1.4) 
 
1.5 
(1.3–1.6) 

 
H
eadache 
2.0 
(1.9–2.2) 
 
2.1 
(1.9–2.3) 
 
1.8 
(1.6–1.9) 
 
1.7 
(1.6–1.8) 
 
1.7 
(1.6–1.8) 
 
1.6 
(1.4–1.7) 
 
1.6 
(1.5–1.8) 
 
1.6 
(1.4–1.7) 
 
1.5 
(1.4–1.6) 
 
1.4 
(1.3–1.6) 

 
D
iabetes – all* 
1.0 
(0.9–1.1) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
1.3 
(1.1–1.4) 
 
1.2 
(1.1–1.4) 
 
1.2 
(1.0–1.3) 
 
1.4 
(1.3–1.6) 

 
S
neezing/nasal congestion 
1.5 
(1.3–1.7) 
 
1.7 
(1.4–2.0) 
 
1.3 
(1.1–1.5) 
 
1.4 
(1.2–1.6) 
 
1.3 
(1.1–1.6) 
 
1.1 
(0.9–1.2) 
 
1.4 
(1.2–1.6) 
 
1.3 
(1.1–1.5) 
 
1.6 
(1.3–1.8) 
 
1.4 
(1.2–1.7) 
—
 
W
eakness/tiredness 
1.5 
(1.4–1.6) 
 
1.5 
(1.3–1.6) 
 
1.5 
(1.4–1.6) 
 
1.7 
(1.5–1.8) 
 
1.3 
(1.2–1.4) 
 
1.4 
(1.2–1.5) 
 
1.4 
(1.2–1.5) 
 
1.5 
(1.4–1.6) 
 
1.4 
(1.3–1.5) 
 
1.3 
(1.2–1.5) 
—
 
K
nee sym
ptom
/com
plaint 
1.4 
(1.3–1.5) 
 
1.3 
(1.2–1.4) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.3–1.5 ) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.2–1.4) 
 
1.4 
(1.2–1.5) 
 
1.3 
(1.2–1.4) 
—
 
A
nxiety* 
1.1 
(1.0–1.2) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.2 
(1.0–1.3) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.3) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
—
 
D
iarrhoea 
1.4 
(1.3–1.5) 
 
1.6 
(1.4–1.7) 
 
1.4 
(1.3–1.6) 
 
1.4 
(1.3–1.5) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.2–1.5) 
 
1.4 
(1.3–1.6) 
 
1.3 
(1.2–1.4) 
 
1.2 
(1.1–1.4) 
 
1.2 
(1.1–1.3) 

 
S
houlder sym
ptom
/com
plaint 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.2) 
 
1.0 
(0.9–1.1) 
 
1.3 
(1.1–1.4) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.0 
(0.9–1.1) 
 
1.4 
(1.3–1.5) 
 
1.1 
(1.0–1.3) 
 
1.2 
(1.1–1.2) 
—
 
V
ertigo/dizziness 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.2 
(1.1–1.3) 
 
1.1 
(1.1–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.0 
(0.9–1.0) 
 
1.1 
(1.1–1.2) 
—
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Table 6.5 (continued): M
ost frequent patient reasons for encounter, 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
Patient reason  
for encounter 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 
(n = 95,839) 
S
w
elling (skin)* 
1.1 
(1.0–1.2) 
 
1.0 
(1.0–1.1) 
 
1.1 
(1.0–1.3) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
—
 
O
ther referrals N
E
C
 
0.5 
(0.4–0.5) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.0) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 

 
S
leep disturbance 
1.3 
(1.1–1.4) 
 
1.1 
(1.0–1.3) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.4) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.1) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
—
 
Foot/toe com
plaint 
1.2 
(1.1–1.3) 
 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.1) 
 
1.1 
(1.0–1.1) 

 
O
ther reason for encounter 
N
E
C
 
1.0 
(0.9–1.2) 
 
1.0 
(0.8–1.2) 
 
1.1 
(0.9–1.2) 
 
1.0 
(0.9–1.2) 
 
1.0 
(0.8–1.1) 
 
1.0 
(0.9–1.2) 
 
0.7 
(0.6–0.9) 
 
0.8 
(0.7–1.0) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.8–1.1) 
—
 
C
hest pain 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.2) 
 
1.3 
(1.2–1.4) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.1) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.9–1.0) 

 
Leg/thigh com
plaint 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.0 
(0.9–1.1) 
 
1.0 
(1.0–1.1) 
 
0.9 
(0.8–1.0) 
 
1.0 
(1.0–1.1) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 

 
V
om
iting 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.3) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0 ) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 

 
N
eck com
plaint 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.2) 
 
0.9 
(0.9–1.0) 
 
1.0 
(0.9–1.2) 
 
0.9 
(0.8–1.1) 
 
0.9 
(0.8–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–1.0) 
 
0.8 
(0.8–0.9) 

 
A
sthm
a 
1.1 
(1.0–1.2) 
 
1.1 
(0.9–1.2) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.8) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 

 
O
ral contraception* 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 

 
Total R
FEs 
149.2 
(147.4–150.9)   
150.9 
(149.0–152.7)   
150.2 
(148.4–152.0)   
149.6 
(147.8–151.5)   
150.3 
(148.4–152.2)   
150.8 
(148.9–152.7)   
153.0 
(151.1–154.8)   
156.5 
(154.7–158.2)   
155.0 
(153.1–156.8)   
155.5 
(153.5–157.5) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change, and —
 indicates 
there w
as no change. 
* 
Includes m
ultiple IC
P
C
-2 or IC
P
C
-2 P
LU
S
 codes (see A
ppendix 4, Table A
4.1, <purl.library.usyd.edu.au/sup/9781920899875>). 
N
ote: C
I – confidence interval; N
O
S
 – not otherw
ise specified; R
FE
 – reason for encounter; N
E
C
 – not elsew
here classified. Includes only R
FE
s recorded in at least one year at a rate >= 1.0 per 100 encounters 
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7 Problems managed 
A ‘problem managed’ is a formal statement of the provider’s understanding of a health 
problem presented by the patient, family or community, and can be described in terms of a 
disease, symptom or complaint, social problem, or ill-defined condition managed at the 
encounter. As GPs were instructed to record each problem at the most specific level possible 
from the information available, the problem managed may at times be limited to the level of 
a presenting symptom. 
At each patient encounter, up to four problems could be recorded by the GP. A minimum of 
one problem was compulsory. The status of each problem to the patient – new (first 
presentation to a medical practitioner) or old (follow-up of previously managed problem) – 
was also indicated. The concept of a principal diagnosis, which is often used in hospital 
statistics, is not adopted in studies of general practice where multiple problem management 
is the norm rather than the exception. Further, the range of problems managed at the 
encounter often crosses multiple body systems and may include undiagnosed symptoms, 
psychosocial problems or chronic disease, which makes the designation of a principal 
diagnosis difficult. Thus the order in which the problems were recorded by the GP is not 
significant. 
This chapter includes data about the problems managed in general practice from each of the 
most recent 10 years of the BEACH study from 2001–02 to 2010–11. The direction and type of 
change from 2001–02 to 2010–11 is indicated for each result in the far right column of the 
tables: / indicates a statistically significant liner change, / indicates a marginally 
significant linear change, § indicates a non-linear significant or marginal change, and — 
indicates there was no change. 
Significant linear changes in rate per 100 encounters can be extrapolated to estimate the 
national increase or decrease in the measured event between 2001–02 and 2010–11. Some 
examples of extrapolated change are provided. The method used to extrapolate to national 
change estimates is described in Section 2.9. 
There are two ways to describe the relative frequency of problems managed: as a percentage 
of all problems managed in the study, or as a rate of problems managed per 100 encounters. 
Where groups of problems are reported (for example, cardiovascular problems), it must be 
remembered that more than one of that type of problem (such as hypertension and heart 
failure) may have been managed at a single encounter. In considering these results, the 
reader must be mindful that a rate per 100 encounters for a single ungrouped problem (for 
example, asthma, 2.2 per 100 encounters) can be regarded as equivalent to ‘asthma is 
managed at 2.2% of encounters’, and can be extrapolated (with the methods described in 
Section 2.9) to accurately estimate the number of national encounters involving management 
of the selected problem. This is not the case for grouped concepts (ICPC-2 chapters and those 
marked with asterisks in the tables) for which extrapolations represent the number of 
problem contacts involving the management of the grouped concept at general practice 
encounters nationally. This is because multiple problems (within the selected group) can be 
recorded within a single encounter. In order to estimate the number of encounters nationally 
that involve management of the grouped concept the extrapolation would have to be based 
on the proportion of encounters involving at least one of the concepts within the group.  
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7.1 Number of problems managed 
GPs are asked to record information about the management of up to four problems at each 
encounter. Table 7.1 shows the number of problems managed at each encounter over time. 
There were increases in the proportion of encounters at which two, three and four problems 
were managed, and a decrease in encounters where only one problem was managed. When 
extrapolated to all GP encounters in Australia, this indicates there were 6.9 million more 
occasions where two problems were managed, 3.6 million more occasions where three 
problems were managed, and 1.5 million more occasions where four problems were 
managed by GPs in Australia in 2010–11 than in 2001–02. 
There was a significant increase in the average number of problems managed at encounter, 
from 143.4 per 100 encounters in 2001–02 to 152.5 in 2010–11 (Table 7.2). This suggests there 
were an additional 36.8 million problems managed at GP encounters in Australia in 2010–11 
than in 2001–02. This was reflected in a significant increase in the management rate of 
chronic conditions (Table 7.6). 
7.2 Problems managed by ICPC-2 component 
Problems managed in general practice may also be examined using the components of the 
ICPC-2 classification to provide a more thorough understanding of the types of problems 
managed during general practice encounters. Table 7.2 lists the distribution of problems 
managed by ICPC-2 component. In the BEACH program, participating GPs are instructed to 
record the problem being managed at the encounter at the highest diagnostic level possible 
using the currently available evidence. 
There were significant increases in the management rate of problems described and classified 
as ‘diagnostic and preventive procedures’, ‘results’ and ‘administrative procedures’ between 
2001–02 and 2010–11 (Table 7.2). Extrapolated to the national general practice encounters, 
these increases represent: 
• 5.4 million additional contacts with problems classified as ‘diagnostic and preventive 
procedures’ in 2010–11 than in 2001–02 
• 1.1 million more test result contacts in 2010–11 than in 2001–02 
• 900,000 more contacts with problems classified as administrative were managed in  
2010–11 than in 2001–02. 
The management rate of problems described and classified as ‘diagnoses and diseases’ 
showed non-linear changes over the decade. The rate of these problems did not change 
significantly between 2001–02 and 2010–11. However, the rate did increase significantly from 
2001–02 to 2007–08, then decreased to 2006–07 levels in 2010–11. There were also significant 
changes in the rates of the types of diagnoses and diseases managed: the management of 
problems classified as neoplasms and ‘other’ diagnoses increased, and problems classified as 
infections decreased from 2001–02 to 2010–11. 
There was no change in the management rate of problems described and classified as 
‘symptoms and complaints’ (Table 7.2). 
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7.3 Problems managed by ICPC-2 chapter and 
individual problems managed 
Problems managed at general practice encounters classified by ICPC-2 chapter are described 
in Table 7.3 for all years from 2001–02 to 2010–11. Problems related to the respiratory system 
remained the most common type of problem managed since 2001–02, but there were 
statistically significant non-linear changes in their management rate: decreasing significantly 
from 2001–02 to 2007–08, then increasing in 2009–10 followed by a significant decrease from 
2009–10 to 2010–11. It is likely that the increase in the management rate in 2009–10 was 
related to the concern regarding H1N1 influenza. A similar pattern of change is shown in the 
management rate of immunisation/vaccination problems (described in Table 7.4), in 
particular respiratory immunisations.1,14,51  
Management of problems related to the cardiovascular system also showed non-linear 
change over the decade. The management rate increased significantly from 2001–02 to  
2008–09. It then decreased significantly from 2008–09 to 2009–10 and remained at the lower 
rate in 2010–11 (Table 7.3).  
There were significant increases in the management rate of problems classified as ‘general 
and unspecified’, endocrine and metabolic, psychological, and those related to the, digestive, 
urological, male genital and blood systems (Table 7.3). When extrapolated to general practice 
encounters across Australia, these changes represent: 
• 7.9 million more contacts with problems classified as ‘general and unspecified’ in  
2010–11 than in 2001–02 
• 4.7 million more contacts with endocrine and metabolic problems 
• 4.1 million more contacts with psychological problems  
• 2.6 million more contacts with digestive problems  
• 980,000 more contacts with urological problems  
• 950,000 more contacts with problems classified to the male genital system 
• 590,000 more contacts with problems related to the blood system in 2010–11 than in 
2001–02. 
The most common individual problems managed are described in Table 7.4 for all years 
from 2001–02 to 2010–11. The most common problems managed in general practice over the 
decade were hypertension, check-up, immunisation/vaccination, and upper respiratory tract 
infection.  
There were significant non-linear changes in some of the most common individual problems, 
described in Table 7.4.  
• The management rate of immunisation/vaccinations did not change between 2001–02 
(4.7 per 100 encounters) and 2010–11 (5.5). However there was a significant spike in the 
management rate in 2009–10 (7.3 per 100) that coincided with the concern about H1N1 
influenza. 
• The management rate of lipid disorders also showed non-linear change over the decade. 
There was a statistically significant linear increase from 2001–02 to 2008–09. This was 
followed by a significant decrease from 2008–09 to 2010–11, returning to a rate similar to 
the 2003–04 rate (Table 7.4).  
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There were several significant changes in the management rate of the problems described in 
Table 7.4. For example, there were statistically significant increases in the management rate 
of depression, diabetes, general check-ups, prescriptions, oesophageal disease, test results, 
pregnancy, atrial fibrillation, vitamin/nutritional deficiency, administrative procedures and 
abnormal test results. There were also decreases in the management rate of asthma, 
sprain/strain and menopausal problems managed over the decade. When extrapolated to 
the general practice encounters across Australia, these changes represent: 
• 1.6 million more depression contacts in 2010–11 than in 2001–02 
• 1.6 million more diabetes contacts 
• 1.4 million more contacts with general check-up 
• 1.1 million more contacts for prescriptions  
• 920,000 more oesophageal disease contacts  
• 1.1 million more contacts for test results and 600,000 more for abnormal test results  
• 750,000 more pregnancy contacts  
• 840,000 more atrial fibrillation contacts  
• 1.1 million more contacts with vitamin/nutritional deficiency problems  
• 900,000 more contacts for administrative procedures 
• 200,000 fewer asthma contacts  
• 140,000 fewer sprain/strain contacts  
• 570,000 fewer contacts with menopausal problems in 2010–11 than in 2001–02. 
The increase in the management rate of test results and abnormal test results may reflect the 
increase in the rate of pathology ordering over the decade (see Chapter 12). 
The increases in the management rate of the chronic conditions: diabetes, depression, 
oesophageal disease and atrial fibrillation may be related to increases in the proportion of GP 
encounters accounted for by older patients from 2001–02 to 2010–11 (see Chapter 6). National 
initiatives for the prevention and management of chronic diseases (such as the National 
Chronic Disease Strategy,52 and MBS items for chronic disease management53) are also likely 
to have contributed to the increases seen in the management rates of these conditions.  
The MBS items for health assessments including: the annual assessment of patients aged  
75 years and over; the health assessment for 45–49 year olds at risk of developing chronic 
disease; an assessment of 40–49 year olds at risk of Type 2 diabetes;53 may have contributed 
to the increased rate of general check-ups.  
The management rate of URTI decreased marginally from 6.2 per 100 encounters in 2001–02 
to 5.4 in 2010–11. However, the large increase in the number of GP encounters provided in 
Australia (99.9 million in 2001–02 and 118.1 million in 2010–11) outweighed this decrease, 
resulting in about 180,000 more GP consultations for URTI nationally in 2010–11 than in 
2001–02.  
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7.4 Most common new problems 
Table 7.5 shows the most frequently managed new problems between 2001–02 and 2010–11. 
There was no change in the management rate of all new problems over this time. 
The most common new problems managed in general practice over the decade were upper 
respiratory tract infection, immunisation/vaccination, check-up and acute bronchitis/ 
bronchiolitis. Only three significant changes in the most common new problems were 
identified over the decade.  
• The management rate of new check-ups increased significantly and is likely due to the 
ageing population and new MBS items (as discussed above).  
• The rate of new immunisation/vaccinations did not change between 2001–02 and  
2010–11. However there was a spike in the rate in 2009–10 that coincides with the 
concern regarding H1N1 influenza (as discussed above). 
• There was a marginal decrease in the management rate of acute otitis media/myringitis 
(Table 7.5). When extrapolated, this decrease represents 50,000 fewer occasions where 
acute otitis media/myringitis was managed as a new problem in Australia in 2010–11 
than in 2001–02. 
7.5 Most frequently managed chronic problems 
Table 7.6 shows the most frequently managed chronic problems between 2001–02 and  
2010–11. The management rate of chronic conditions significantly increased from 49.3 per 
100 encounters in 2001–02 to 53.1 per 100 in 2010–11, suggesting approximately 13.5 million 
more contacts with chronic problems in Australia in 2010–11 than in 2001–02. 
The most common chronic problems managed in general practice were non-gestational 
hypertension, depressive disorder, non-gestational diabetes, chronic arthritis and lipid 
disorders (Table 7.6). 
As discussed in Section 7.3, the Australian Government has invested considerable resources 
in the prevention and management of chronic disease.52,53 A main reason for this focus is the 
ageing population54 and the associated expected fiscal pressure (especially health care costs).5 
From 2001–02 to 2010–11, there were significant increases in the management rate of 
depressive disorder, non-gestational diabetes, oesophageal disease, atrial fibrillation, and 
hypothyroidism. There were also significant decreases in the management rate of asthma 
and migraine (Table 7.6). Many of the changes noted in Table 7.6 are also noted in Table 7.4 
and discussed in Section 7.3. 
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Table 7.1: N
um
ber of problem
s m
anaged at an encounter, 2001–02 to 2010–11 
 
Per cent of encounters (95%
 C
I) 
 
N
um
ber of problem
s 
m
anaged at encounter 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
O
ne problem
 
67.7 
(66.6–68.8) 
 
66.9 
(65.8–68.1) 
 
66.2 
(65.0–67.3) 
 
66.5 
(65.3–67.7) 
 
66.4 
(65.1–67.6) 
 
65.0 
(63.7–66.2) 
 
63.0  
(61.7–64.3) 
 
60.8 
(59.6–61.9) 
 
62.2  
(60.9–63.5) 
 
62.6  
(61.2–63.9) 

 
Tw
o problem
s 
23.1 
(22.4–23.7) 
 
23.4 
(22.6–24.1) 
 
23.8 
(23.1–24.5) 
 
23.6 
(22.9–24.3) 
 
23.4 
(22.7–24.1) 
 
24.0 
(23.3–24.8) 
 
25.4  
(24.7–26.2) 
 
26.7 
(26.1–27.4) 
 
25.4  
(24.7–26.1) 
 
25.4  
(24.6–26.1) 

 
Three problem
s 
7.3 
(6.9–7.7) 
 
7.6 
(7.2–8.0) 
 
7.7 
(7.2–8.1) 
 
7.7 
(7.3–8.2) 
 
7.9 
(7.4–8.4) 
 
8.5 
(8.1–9.0) 
 
8.8  
(8.3–9.3) 
 
9.7  
(9.2–10.1) 
 
9.2  
(8.7–9.7) 
 
9.2  
(8.6–9.7) 

 
Four problem
s 
1.9 
(1.6–2.2) 
 
2.1 
(1.7–2.5) 
 
2.4 
(2.0–2.8) 
 
2.2 
(1.8–2.5) 
 
2.3 
(2.1–2.6) 
 
2.5 
(2.2–2.7) 
 
2.7  
(2.4–3.0) 
 
2.8  
(2.6–3.1) 
 
3.2  
(2.8–3.5) 
 
2.9  
(2.6–3.3) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change. 
N
ote: C
I – confidence interval. 
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Table 7.2: Problem
s m
anaged by IC
PC
-2 com
ponent, 2001–02 to 2010–11  
 
R
ate per 100 encounters
 (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
IC
PC
-2 com
ponent 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
D
iagnosis, diseases 
98.2 
(96.7–99.8) 
 
97.9 
(96.2–99.5) 
 
99.2 
(97.5–100.9) 
 
98.9 
(97.1–100.7) 
 
100.2 
(98.4–102.1) 
 
101.3 
(99.6–103.0) 
 
102.6 
(100.7–104.4)  
105.3 
(103.6–107.1)  
102.2 
(100.3–104.1)  
101.1 
(99.2–103.0) 
§ 
 
Infections 
26.5 
(25.8–27.3) 
 
26.5 
(25.7–27.2) 
 
25.5 
(24.7–26.3) 
 
24.6 
(23.8–25.3) 
 
25.9 
(25.2–26.7) 
 
24.7 
(24.0–25.4) 
 
25.1 
(24.3–25.8) 
 
25.1 
(24.4–25.8) 
 
25.0 
(24.2–25.7) 
 
24.8 
(24.1–25.6) 

 
 
Injuries 
7.2 
(6.9–7.5) 
 
7.5 
(7.2–7.8) 
 
7.2 
(6.9–7.5) 
 
7.3 
(7.0–7.6) 
 
7.4 
(7.0–7.7) 
 
7.5 
(7.2–7.7) 
 
7.3 
(7.0–7.7) 
 
7.2 
(6.9–7.4) 
 
6.9 
(6.6–7.2) 
 
7.1 
(6.8–7.3) 
—
 
 
N
eoplasm
s 
3.5 
(3.2–3.7) 
 
3.7 
(3.4–4.0) 
 
4.3 
(3.9–4.7) 
 
4.3 
(3.9–4.7) 
 
4.1 
(3.8–4.3) 
 
4.5 
(4.2–4.9) 
 
4.5 
(4.1–4.9) 
 
4.7 
(4.4–5.0) 
 
4.7 
(4.3–5.0) 
 
4.3 
(4.1–4.6) 

 
 
C
ongenital anom
alies 
0.6 
(0.5–0.7) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 
—
 
 
O
ther diagnoses, 
diseases 
60.4 
(58.8–62.0) 
 
59.6 
(57.9–61.3) 
 
61.6 
(59.8–63.4) 
 
61.9 
(60.2–63.7) 
 
62.1 
(60.2–64.0) 
 
63.9 
(62.1–65.6) 
 
64.9 
(63.0–66.9) 
 
67.8 
(66.0–69.5) 
 
64.9 
(63.0–66.9) 
 
64.2 
(62.2–66.1) 

 
S
ym
ptom
s and 
com
plaints 
26.9 
(26.1–27.7) 
 
26.7 
(25.9–27.5) 
 
26.4 
(25.6–27.2) 
 
26.4 
(25.5–27.3) 
 
25.7 
(24.9–26.5) 
 
26.7 
(25.9–27.4) 
 
27.8 
(27.0–28.6) 
 
27.6 
(26.8–28.4) 
 
26.7 
(25.9–27.5) 
 
28.2 
(27.4–29.1) 
—
 
D
iagnostic and 
preventive procedures 
12.4 
(11.7–13.0) 
 
13.5 
(12.8–14.2) 
 
13.6 
(12.9–14.4) 
 
13.3 
(12.6–14.0) 
 
13.7 
(13.1–14.4) 
 
13.8 
(13.0–14.5) 
 
14.2 
(13.5–14.8) 
 
14.9 
(14.2–15.7) 
 
16.9 
(16.0–17.7) 
 
15.1 
(14.3–15.9) 

 
M
edications, treatm
ents 
and therapeutics 
3.3 
(3.0–3.6) 
 
3.6 
(3.3–3.8) 
 
4.0 
(3.6–4.3) 
 
3.6 
(3.3–3.9) 
 
3.2 
(3.0–3.5) 
 
3.2 
(2.9–3.5) 
 
2.9 
(2.7–3.2) 
 
3.3 
(3.0–3.6) 
 
3.4 
(3.1–3.8) 
 
3.7 
(3.4–4.1) 
—
 
R
esults 
1.1 
(0.9–1.2) 
 
1.1 
(0.9–1.2) 
 
1.2 
(1.1–1.4) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.3–1.6) 
 
1.6 
(1.4–1.7) 
 
1.8 
(1.6–1.9) 
 
1.5 
(1.4–1.7) 
 
1.8 
(1.6–2.0) 
 
1.9 
(1.7–2.1) 

 
R
eferrals and other 
R
FE
s 
1.1 
(1.0–1.3) 
 
1.7 
(1.5–1.9) 
 
1.3 
(1.1–1.4) 
 
1.3 
(1.2–1.5) 
 
1.2 
(1.1–1.4) 
 
1.3 
(1.2–1.5) 
 
1.2 
(1.0–1.3) 
 
1.0 
(0.9–1.1) 
 
1.3 
(1.1–1.4) 
 
1.3 
(1.1–1.5) 
—
 
A
dm
inistrative 
0.4 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.6) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.7–0.8) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.3) 

 
Total problem
s  
143.4 
(141.7–145.2)  
144.9 
(143.0–146.8)  
146.3 
(144.4–148.2)  
145.5 
(143.6–147.4)  
146.2 
(144.2–148.2)  
148.5 
(146.4–150.6)  
151.3 
(149.2–153.4)  
154.6 
(152.6–156.5)  
153.3 
(151.1–155.5)  
152.5 
(150.2–154.7) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, § indicates a non-linear significant or m
arginal change, and —
 indicates 
there w
as no change. 
N
ote: C
I – confidence interval; R
FE – reason for encounter. 
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Table 7.3: Problem
s m
anaged by IC
PC
-2 chapter, 2001–02 to 2010–11 
 
R
ate per 100 encounters
 (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
IC
PC
-2 C
hapter 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
R
espiratory 
21.4 
(20.7–22.0) 
 
20.6 
(20.0–21.3) 
 
20.1 
(19.5–20.7) 
 
19.2 
(18.6–19.9) 
 
20.6 
(19.9–21.3) 
 
19.6 
(18.9–20.3) 
 
19.5 
(18.8–20.1) 
 
20.8 
(20.2–21.5) 
 
22.2 
(21.4–22.9) 
 
20.4 
(19.7–21.1) 
§ 
G
eneral and unspecified 
14.8 
(14.1–15.5) 
 
15.8 
(15.2–16.4) 
 
15.0 
(14.4–15.5) 
 
15.1 
(14.5–15.7) 
 
15.1 
(14.5–15.7) 
 
16.2 
(15.7–16.8) 
 
17.8 
(17.1–18.5) 
 
17.0 
(16.4–17.7) 
 
19.4 
(18.6–20.2) 
 
19.2 
(18.5–20.0) 

 
S
kin 
16.1 
(15.6–16.6) 
 
16.5 
(16.0–17.0) 
 
16.9 
(16.2–17.6) 
 
17.3 
(16.6–18.0) 
 
16.7 
(16.1–17.2) 
 
17.6 
(16.9–18.2) 
 
17.2 
(16.5–17.9) 
 
17.0 
(16.5–17.5) 
 
16.5 
(15.9–17.1) 
 
16.7 
(16.2–17.2) 
—
 
C
ardiovascular 
16.1 
(15.4–16.8) 
 
16.0 
(15.3–16.7) 
 
16.8 
(16.1–17.5) 
 
16.2 
(15.5–16.9) 
 
16.9 
(16.1–17.7) 
 
17.4 
(16.7–18.1) 
 
17.6 
(16.8–18.3) 
 
18.5 
(17.8–19.3) 
 
16.7 
(16.0–17.4) 
 
16.6 
(15.9–17.4) 
§ 
M
usculoskeletal 
17.5 
(17.0–18.0) 
 
17.1 
(16.5–17.6) 
 
17.1 
(16.6–17.6) 
 
17.7 
(17.1–18.2) 
 
17.2 
(16.7–17.7) 
 
17.1 
(16.6–17.6) 
 
17.3 
(16.7–17.8) 
 
17.3 
(16.8–17.8) 
 
16.8 
(16.1–17.6) 
 
16.6 
(16.1–17.1) 
—
 
E
ndocrine and m
etabolic 
10.4 
(10.0–10.9) 
 
10.6 
(10.2–11.0) 
 
11.3 
(10.8–11.8) 
 
11.7 
(11.2–12.3) 
 
11.6 
(11.0–12.1) 
 
12.1 
(11.6–12.6) 
 
12.9 
(12.3–13.5) 
 
13.5 
(12.9–14.0) 
 
12.6 
(12.1–13.2) 
 
12.8 
(12.2–13.3) 

 
P
sychological 
10.6 
(10.1–11.2) 
 
10.3 
(9.8–10.8) 
 
10.8 
(10.3–11.4) 
 
11.4 
(10.8–12.0) 
 
11.1 
(10.5–11.7) 
 
10.9 
(10.5–11.4) 
 
11.5 
(10.9–12.0) 
 
12.4 
(11.9–12.9) 
 
12.1 
(11.6–12.7) 
 
12.4 
(11.9–12.9) 

 
D
igestive 
9.9 
(9.6–10.2) 
 
10.1 
(9.8–10.4) 
 
10.5 
(10.2–10.8) 
 
9.9 
(9.6–10.2) 
 
10.1 
(9.8–10.4) 
 
10.4 
(10.1–10.7) 
 
10.7 
(10.4–11.1) 
 
10.5 
(10.2–10.8) 
 
10.7 
(10.3–11.0) 
 
10.6 
(10.3–10.9) 

 
Fem
ale genital system
 
6.1 
(5.7–6.4) 
 
6.6 
(6.2–7.0) 
 
5.9 
(5.5–6.3) 
 
5.7 
(5.3–6.1) 
 
5.8 
(5.4–6.2) 
 
5.7 
(5.3–6.1) 
 
5.8 
(5.4–6.2) 
 
6.1 
(5.7–6.6) 
 
5.5 
(5.1–5.8) 
 
5.5 
(5.2–5.9) 
—
 
P
regnancy and fam
ily 
planning 
4.0 
(3.7–4.2) 
 
4.2 
(3.9–4.5) 
 
4.2 
(3.9–4.5) 
 
3.8 
(3.6–4.1) 
 
3.8 
(3.6–4.1) 
 
3.9 
(3.6–4.2) 
 
3.9 
(3.6–4.2) 
 
3.7 
(3.4–3.9) 
 
3.8 
(3.6–4.1) 
 
3.9 
(3.6–4.2) 
—
 
E
ar 
4.2 
(4.0–4.4) 
 
4.0 
(3.8–4.2) 
 
4.0 
(3.8–4.1) 
 
4.1 
(3.9–4.2) 
 
4.0 
(3.8–4.2) 
 
3.8 
(3.6–3.9) 
 
3.8 
(3.6–3.9) 
 
3.9 
(3.7–4.1) 
 
3.7 
(3.5–3.8) 
 
3.9 
(3.7–4.1) 
—
 
N
eurological 
3.7 
(3.5–3.9) 
 
4.2 
(4.0–4.4) 
 
3.9 
(3.8–4.1) 
 
3.6 
(3.5–3.8) 
 
3.6 
(3.4–3.8) 
 
3.7 
(3.6–3.9) 
 
3.6 
(3.4–3.7) 
 
3.8 
(3.6–3.9) 
 
3.5 
(3.3–3.6) 
 
3.7 
(3.6–3.9) 
—
 
U
rology 
2.8 
(2.7–3.0) 
 
2.8 
(2.7–3.0) 
 
3.0 
(2.9–3.2) 
 
3.0 
(2.9–3.2) 
 
3.1 
(2.9–3.2) 
 
3.1 
(3.0–3.3) 
 
3.1 
(3.0–3.3) 
 
3.3 
(3.2–3.5) 
 
3.2 
(3.1–3.4) 
 
3.2 
(3.1–3.4) 

 
E
ye 
2.5 
(2.4–2.6) 
 
2.6 
(2.5–2.7) 
 
2.7 
(2.6–2.9) 
 
2.7 
(2.5–2.8) 
 
2.8 
(2.6–2.9) 
 
2.7 
(2.5–2.8) 
 
2.6 
(2.4–2.7) 
 
2.7 
(2.6–2.8) 
 
2.5 
(2.3–2.6) 
 
2.5 
(2.4–2.6) 
—
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Table 7.3 (continued): Problem
s m
anaged by IC
PC
-2 chapter, 2001–02 to 2010–11 
 
R
ate per 100 encounters
 (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
IC
PC
-2 C
hapter 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
M
ale genital system
 
1.3 
(1.2–1.4) 
 
1.4 
(1.3–1.5) 
 
1.6 
(1.5–1.7) 
 
1.8 
(1.6–1.9) 
 
1.9 
(1.7–2.0) 
 
1.8 
(1.7–2.0) 
 
1.8 
(1.7–1.9) 
 
2.0 
(1.9–2.2) 
 
1.9 
(1.7–2.0) 
 
1.9 
(1.7–2.0) 

 
B
lood 
1.3 
(1.2–1.4) 
 
1.4 
(1.3–1.5) 
 
1.7 
(1.5–1.8) 
 
1.6 
(1.4–1.8) 
 
1.5 
(1.4–1.6) 
 
1.7 
(1.5–1.9) 
 
1.6 
(1.5–1.8) 
 
1.5 
(1.3–1.6) 
 
1.5 
(1.4–1.6) 
 
1.6 
(1.5–1.7) 

 
S
ocial problem
s 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.5–0.7) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
—
 
Total problem
s 
143.4 
(141.7–145.2)  
144.9 
(143.0–146.8)  
146.3 
(144.4–148.2)  
145.5 
(143.6–147.4)  
146.2 
(144.2–148.2)  
148.5 
(146.4–150.6)  
151.3 
(149.2–153.4)  
154.6 
(152.6–156.5)  
153.3 
(151.1–155.5)  
152.5 
(150.2–154.7) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, § indicates a non-linear significant or m
arginal change,  
and —
 indicates there w
as no change. 
N
ote: C
I – confidence interval. 
Table 7.4: M
ost frequently m
anaged problem
s, 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
Problem
 m
anaged 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
H
ypertension* 
9.0 
(8.5–9.5) 
 
8.8 
(8.4–9.3) 
 
9.2 
(8.7–9.7) 
 
8.9 
(8.4–9.4) 
 
9.4 
(8.9–10.0) 
 
9.6 
(9.1–10.0) 
 
9.9 
(9.4–10.5) 
 
10.1 
(9.6–10.6) 
 
9.1 
(8.6–9.6) 
 
8.7 
(8.2–9.2) 
—
 
C
heck-up – all* 
5.8 
(5.4–6.1) 
 
6.4 
(6.0–6.8) 
 
6.4 
(5.9–6.9) 
 
6.3 
(5.9–6.7) 
 
6.4 
(6.0–6.8) 
 
6.6 
(6.2–7.0) 
 
6.3 
(6.0–6.7) 
 
6.7 
(6.3–7.1) 
 
6.6 
(6.3–7.0) 
 
6.4 
(6.1–6.8) 

 
 
G
eneral check-up* 
1.8 
(1.6–1.9) 
 
1.9 
(1.8–2.1) 
 
1.8 
(1.7–2.0) 
 
2.1 
(1.9–2.2) 
 
2.1 
(1.9–2.2) 
 
2.4 
(2.2–2.6) 
 
2.5 
(2.3–2.7) 
 
2.5 
(2.3–2.7) 
 
3.0 
(2.7–3.2) 
 
2.7 
(2.5–2.9) 

 
 
Fem
ale genital  
check-up* 
1.6 
(1.4–1.7) 
 
1.8 
(1.6–2.0) 
 
1.8 
(1.6–2.0) 
 
1.8 
(1.6–2.0) 
 
1.8 
(1.6–2.0) 
 
1.7 
(1.5–1.9) 
 
1.8 
(1.6–2.0) 
 
2.0 
(1.8–2.3) 
 
1.7 
(1.5–1.9) 
 
1.7 
(1.5–1.9) 
—
 
 
C
ardiac check-up* 
1.1 
(1.0–1.3) 
 
1.1 
(0.9–1.2) 
 
1.2 
(1.0–1.3) 
 
1.0 
(0.9–1.1) 
 
1.2 
(1.0–1.3) 
 
1.3 
(1.1–1.5) 
 
1.2 
(1.0–1.4) 
 
1.3 
(1.1–1.5) 
 
1.0 
(0.8–1.1) 
 
1.1 
(1.0–1.3) 
—
 
(continued) 
54
Table 7.4 (continued): M
ost frequently m
anaged problem
s, 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
Problem
 m
anaged 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
Im
m
unisation/ 
vaccination – all* 
4.7 
(4.3–5.1) 
 
4.6 
(4.3–5.0) 
 
4.7 
(4.3–5.2) 
 
4.6 
(4.2–5.1) 
 
5.0 
(4.6–5.4) 
 
4.7 
(4.3–5.2) 
 
5.2 
(4.8–5.6) 
 
5.7 
(5.2–6.2) 
 
7.3 
(6.7–7.8) 
 
5.5 
(5.0–6.0) 
§ 
U
pper respiratory  
tract infection 
6.2 
(5.8–6.6) 
 
6.4 
(6.0–6.8) 
 
5.5 
(5.1–5.8) 
 
5.6 
(5.2–5.9) 
 
6.2 
(5.8–6.6) 
 
5.8 
(5.3–6.2) 
 
6.2 
(5.7–6.7) 
 
6.1 
(5.7–6.6) 
 
6.0 
(5.5–6.4) 
 
5.4 
(5.1–5.8) 

 
D
epression* 
3.4 
(3.2–3.6) 
 
3.5 
(3.3–3.7) 
 
3.6 
(3.4–3.9) 
 
3.7 
(3.5–3.9) 
 
3.6 
(3.4–3.8) 
 
3.7 
(3.5–3.9) 
 
4.0 
(3.8–4.2) 
 
4.3 
(4.0–4.5) 
 
4.3 
(4.0–4.5) 
 
4.2 
(4.0–4.4) 

 
D
iabetes – all* 
3.1 
(2.9–3.3) 
 
2.9 
(2.7–3.1) 
 
3.3 
(3.1–3.5) 
 
3.2 
(3.0–3.4) 
 
3.5 
(3.3–3.8) 
 
3.6 
(3.4–3.9) 
 
3.9 
(3.6–4.1) 
 
4.1 
(3.9–4.3) 
 
3.7 
(3.5–3.9) 
 
4.0 
(3.7–4.2) 

 
A
rthritis – all* 
3.8 
(3.5–4.0) 
 
3.7 
(3.5–3.9) 
 
4.0 
(3.8–4.2) 
 
3.9 
(3.7–4.2) 
 
3.8 
(3.6–4.0) 
 
3.7 
(3.5–3.9) 
 
3.6 
(3.4–3.8) 
 
3.8 
(3.6–4.0) 
 
3.9 
(3.6–4.3) 
 
3.6 
(3.4–3.9) 
—
 
 
O
steoarthritis* 
2.6 
(2.4–2.8) 
 
2.6 
(2.4–2.7) 
 
2.8 
(2.6–3.0) 
 
2.8 
(2.6–3.0) 
 
2.7 
(2.5–2.9) 
 
2.6 
(2.4–2.8) 
 
2.6 
(2.4–2.8) 
 
2.8 
(2.6–2.9) 
 
2.9 
(2.6–3.2) 
 
2.7 
(2.5–2.9) 
—
 
Lipid disorders 
2.9 
(2.7–3.1) 
 
3.0 
(2.8–3.2) 
 
3.1 
(2.9–3.4) 
 
3.3 
(3.1–3.6) 
 
3.4 
(3.1–3.7) 
 
3.5 
(3.2–3.7) 
 
3.7 
(3.4–4.0) 
 
3.9 
(3.7–4.2) 
 
3.5 
(3.2–3.7) 
 
3.1 
(2.8–3.3) 
§ 
B
ack com
plaint* 
2.6 
(2.4–2.8) 
 
2.6 
(2.4–2.8) 
 
2.7 
(2.5–2.8) 
 
2.8 
(2.6–3.0) 
 
2.6 
(2.5–2.8) 
 
2.6 
(2.5–2.8) 
 
2.7 
(2.6–2.9) 
 
2.7 
(2.6–2.9) 
 
2.7 
(2.5–2.9) 
 
2.7 
(2.5–2.9) 
—
 
A
cute bronchitis/ 
bronchiolitis 
2.7 
(2.5–2.9) 
 
2.6 
(2.4–2.8) 
 
2.4 
(2.2–2.6) 
 
2.4 
(2.2–2.6) 
 
2.5 
(2.3–2.7) 
 
2.2 
(2.1–2.4) 
 
2.4 
(2.2–2.6) 
 
2.6 
(2.4–2.8) 
 
2.4 
(2.2–2.6) 
 
2.5 
(2.3–2.7) 
—
 
P
rescription – all* 
1.9 
(1.6–2.1) 
 
2.0 
(1.8–2.2) 
 
2.3 
(2.0–2.6) 
 
2.1 
(1.8–2.3) 
 
2.0 
(1.7–2.2) 
 
2.2 
(1.9–2.4) 
 
2.0 
(1.7–2.2) 
 
2.1 
(1.9–2.4) 
 
2.3 
(2.0–2.6) 
 
2.5 
(2.2–2.8) 

 
O
esophageal disease 
1.8 
(1.7–2.0) 
 
1.9 
(1.8–2.1) 
 
2.2 
(2.0–2.4) 
 
2.1 
(2.0–2.3) 
 
2.4 
(2.2–2.5) 
 
2.3 
(2.1–2.5) 
 
2.3 
(2.2–2.5) 
 
2.5 
(2.3–2.7) 
 
2.5 
(2.3–2.7) 
 
2.3 
(2.1–2.5) 

 
A
sthm
a 
2.8 
(2.7–3.0) 
 
2.7 
(2.6–2.9) 
 
2.6 
(2.4–2.7) 
 
2.3 
(2.2–2.5) 
 
2.3 
(2.1–2.4) 
 
2.3 
(2.1–2.4) 
 
2.2 
(2.0–2.3) 
 
2.2 
(2.1–2.3) 
 
2.1 
(1.9–2.3) 
 
2.2 
(2.0–2.3) 

 
A
nxiety* 
1.6 
(1.5–1.8) 
 
1.5 
(1.4–1.7) 
 
1.7 
(1.6–1.9) 
 
1.7 
(1.6–1.9) 
 
1.8 
(1.6–2.0) 
 
1.7 
(1.6–1.9) 
 
1.8 
(1.6–1.9) 
 
1.9 
(1.8–2.1) 
 
1.8 
(1.6–1.9) 
 
1.9 
(1.8–2.1) 

 
Test results* 
1.1 
(0.9–1.2) 
 
1.1 
(0.9–1.2) 
 
1.2 
(1.1–1.4) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.3–1.6) 
 
1.6 
(1.4–1.7) 
 
1.8 
(1.6–1.9) 
 
1.5 
(1.4–1.7) 
 
1.8 
(1.6–2.0) 
 
1.9 
(1.7–2.1) 

 
(continued) 
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Table 7.4 (continued): M
ost frequently m
anaged problem
s, 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
Problem
 m
anaged 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
U
rinary tract infection* 
1.6 
(1.5–1.7) 
 
1.7 
(1.6–1.8) 
 
1.7 
(1.6–1.8) 
 
1.7 
(1.6–1.8) 
 
1.8 
(1.6–1.9) 
 
1.6 
(1.5–1.8) 
 
1.6 
(1.5–1.7) 
 
1.7 
(1.6–1.8) 
 
1.8 
(1.6–1.9) 
 
1.8 
(1.7–1.9) 

 
C
ontact derm
atitis 
1.9 
(1.8–2.0) 
 
1.9 
(1.8–2.0) 
 
1.8 
(1.6–1.9) 
 
1.9 
(1.8–2.0) 
 
1.8 
(1.7–1.9) 
 
1.9 
(1.8–2.0) 
 
1.8 
(1.7–1.9) 
 
1.9 
(1.8–2.0) 
 
1.6 
(1.5–1.7) 
 
1.7 
(1.6–1.8) 

 
S
leep disturbance 
1.6 
(1.5–1.8) 
 
1.6 
(1.4–1.7) 
 
1.6 
(1.5–1.7) 
 
1.7 
(1.5–1.9) 
 
1.6 
(1.5–1.7) 
 
1.6 
(1.4–1.7) 
 
1.6 
(1.5–1.7) 
 
1.6 
(1.4–1.7) 
 
1.5 
(1.3–1.6) 
 
1.5 
(1.4–1.6) 
—
 
P
regnancy* 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–1.0) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.8) 
 
0.9 
(0.8–1.0) 
 
1.3 
(1.1–1.4) 
 
1.3 
(1.2–1.5) 
 
1.3 
(1.1–1.4) 
 
1.4 
(1.3–1.6) 
 
1.4 
(1.3–1.6) 

 
G
astroenteritis* 
1.6 
(1.5–1.7) 
 
1.7 
(1.6–1.9) 
 
1.7 
(1.5–1.8) 
 
1.5 
(1.4–1.7) 
 
1.5 
(1.4–1.7) 
 
1.7 
(1.5–1.8) 
 
1.7 
(1.5–1.8) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.3–1.6) 
 
1.4 
(1.3–1.5) 

 
S
prain/strain* 
1.8 
(1.7–1.9) 
 
1.7 
(1.5–1.8) 
 
1.6 
(1.5–1.7) 
 
1.7 
(1.5–1.9) 
 
1.8 
(1.6–1.9) 
 
1.5 
(1.4–1.7) 
 
1.6 
(1.4–1.7) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.3–1.6) 
 
1.4 
(1.3–1.5) 

 
S
inusitis acute/chronic 
1.4 
(1.3–1.5) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.2–1.4) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 
 
1.4 
(1.3–1.5) 
 
1.3 
(1.2–1.4) 
 
1.4 
(1.2–1.5) 
 
1.3 
(1.2–1.5) 
 
1.3 
(1.2–1.4) 
—
 
A
trial fibrillation/flutter 
0.7 
(0.6–0.8) 
 
0.6 
(0.6–0.7) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.3 
(1.2–1.4) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 

 
V
itam
in/nutritional 
deficiency 
0.4 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.7) 
 
0.9 
(0.8–1.0) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.0–1.3) 
 
1.3 
(1.1–1.4) 

 
V
iral disease, other/N
O
S
 
1.5 
(1.3–1.7) 
 
1.4 
(1.2–1.6) 
 
1.3 
(1.2–1.5) 
 
1.2 
(1.1–1.4) 
 
1.2 
(1.0–1.4) 
 
1.1 
(0.9–1.2) 
 
1.2 
(1.1–1.4) 
 
1.2 
(1.0–1.4) 
 
1.1 
(1.0–1.3) 
 
1.2 
(1.0–1.4) 
—
 
Ischaem
ic heart disease* 
1.3 
(1.1–1.4) 
 
1.2 
(1.1–1.3) 
 
1.4 
(1.2–1.5) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.2–1.4) 
 
1.1 
(1.0–1.2) 
 
1.3 
(1.2–1.4) 
 
1.2 
(1.0–1.3) 
 
1.1 
(1.0–1.3) 
—
 
S
olar keratosis/sunburn 
1.0 
(0.9–1.2) 
 
1.2 
(1.0–1.3) 
 
1.3 
(1.1–1.5) 
 
1.3 
(1.1–1.6) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 
 
1.4 
(1.1–1.6) 
 
1.2 
(1.1–1.4) 
 
1.3 
(1.1–1.4) 
 
1.1 
(1.0–1.3) 
—
 
A
dm
inistrative procedure 
– all* 
0.4 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.6) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.7–0.8) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.3) 

 
A
bnorm
al test results* 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.8) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 

 
 (continued) 
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Table 7.4 (continued): M
ost frequently m
anaged problem
s, 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
Problem
 m
anaged 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
M
alignant neoplasm
, skin 
0.9 
(0.7–1.0) 
 
0.8 
(0.7–0.9) 
 
1.1 
(0.9–1.3) 
 
1.2 
(1.0–1.4) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.3) 
 
1.2 
(1.0–1.4) 
 
1.2 
(1.1–1.4) 
 
1.3 
(1.1–1.4) 
 
1.1 
(1.0–1.2) 

 
O
ral contraception* 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
1.4 
(1.2–1.5) 
 
1.3 
(1.2–1.4) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.2–1.4) 
 
1.1 
(1.0–1.3) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 

 
A
cute otitis m
edia/ 
m
yringitis 
1.3 
(1.2–1.4) 
 
1.3 
(1.2–1.4) 
 
1.2 
(1.1–1.3) 
 
1.2 
(1.1–1.3) 
 
1.2 
(1.0–1.3) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 

 
B
ursitis/tendonitis/ 
synovitis N
O
S
 
1.0 
(0.9–1.0) 
 
0.9 
(0.9–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.9–1.0) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.1) 

 
Tonsillitis* 
1.1 
(1.0–1.3) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.0 
(0.9–1.2) 
 
1.1 
(1.0–1.2) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.2) 
—
 
O
bservation/health 
education/advice – all* 
0.7 
(0.6–0.7) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
1.1 
(0.9–1.3) 
 
1.0 
(0.8–1.3) 

 
Fracture* 
1.1 
(1.0–1.1) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.0 
(1.0–1.1) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.9–1.0) 
 
0.9 
(0.8–0.9) 
 
0.9 
(0.9–1.0) 

 
O
steoporosis 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.7 
(0.6–0.8) 
—
 
M
enopausal com
plaint 
1.4 
(1.3–1.5) 
 
1.5 
(1.3–1.6) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–0.9) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.8) 

 
Total problem
s 
143.4 
(141.7–145.2)  
144.9 
(143.0–146.8)  
146.3 
(144.4–148.2)  
145.5 
(143.6–147.4)  
146.2 
(144.2–148.2)  
148.5 
(146.4–150.6)  
151.3 
(149.2–153.4)  
154.6 
(152.6–156.5)  
153.3 
(151.1–155.5)  
152.5 
(150.2–154.7) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change, 
 § indicates a non-linear significant or m
arginal change, and —
 indicates there w
as no change. 
* 
Includes m
ultiple IC
P
C
-2 or IC
P
C
-2 P
LU
S
 codes (see 4.1). 
N
ote: C
I – confidence interval; N
O
S
 – not otherw
ise specified. This table includes individual problem
s w
hich w
ere m
anaged at >= 1.0 per 100 encounters in any year. 
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Table 7.5: M
ost frequently m
anaged new
 problem
s, 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
N
ew
 problem
 m
anaged 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
U
pper respiratory tract 
infection 
4.7 
(4.4–5.1) 
 
5.1 
(4.7–5.5) 
 
4.2 
(3.8–4.5) 
 
4.3 
(4.0–4.6) 
 
4.8 
(4.4–5.2) 
 
4.4 
(4.1–4.8) 
 
4.8 
(4.4–5.2) 
 
4.7 
(4.4–5.0) 
 
4.6 
(4.3–5.0) 
 
4.1 
(3.8–4.5) 
—
 
Im
m
unisation/ 
vaccination – all* 
2.7 
(2.4–3.0) 
 
2.9 
(2.6–3.2) 
 
2.9 
(2.6–3.3) 
 
2.7 
(2.4–3.1) 
 
2.7 
(2.5–3.0) 
 
2.8 
(2.5–3.1) 
 
2.8 
(2.5–3.0) 
 
2.8 
(2.5–3.1) 
 
4.3 
(3.9–4.7) 
 
3.0 
(2.7–3.3) 
§ 
C
heck-up – all* 
1.8 
(1.7–2.0) 
 
2.2 
(2.0–2.4) 
 
2.1 
(1.9–2.3) 
 
2.2 
(2.0–2.4) 
 
2.2 
(2.1–2.4) 
 
2.5 
(2.3–2.7) 
 
2.5 
(2.3–2.7) 
 
2.5 
(2.3–2.7) 
 
2.8 
(2.6–3.0) 
 
2.7 
(2.4–2.9) 

 
A
cute bronchitis/ 
bronchiolitis 
1.9 
(1.7–2.0) 
 
1.9 
(1.7–2.1) 
 
1.8 
(1.6–1.9) 
 
1.7 
(1.5–1.9) 
 
1.9 
(1.7–2.1) 
 
1.6 
(1.5–1.7) 
 
1.7 
(1.6–1.9) 
 
1.9 
(1.8–2.1) 
 
1.7 
(1.6–1.9) 
 
1.8 
(1.7–2.0) 
—
 
G
astroenteritis* 
1.2 
(1.1–1.4) 
 
1.3 
(1.2–1.5) 
 
1.3 
(1.2–1.5) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.2–1.5) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
—
 
U
rinary tract infection* 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.1) 
 
1.1 
(1.0–1.1) 
 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.2) 
 
1.0 
(0.9–1.1) 
 
1.0 
(1.0–1.1) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
—
 
S
prain/strain* 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.0) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
—
 
V
iral disease, other/N
O
S
 
1.0 
(0.9–1.2) 
 
1.1 
(0.9–1.2) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.1) 
 
0.9 
(0.7–1.0) 
 
0.9 
(0.7–1.0) 
 
0.9 
(0.7–1.0) 
—
 
S
inusitis acute/chronic  
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.7 
(0.7–0.8) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–0.9) 
 
0.9 
(0.8–1.0) 
—
 
A
cute otitis m
edia/ 
m
yringitis 
1.0 
(0.9–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.8–0.9) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.8) 
 
0.8 
(0.7–0.8) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 

 
Total new
 problem
s 
55.1 
(53.8–56.5) 
 
56.9 
(55.5–58.4) 
 
55.9 
(54.5–57.3) 
 
55.2 
(53.8–56.5) 
 
56.9 
(55.5–58.2) 
 
56.5 
(55.1–57.9) 
 
57.7 
(56.3–59.1) 
 
57.4 
(56.0–58.7) 
 
59.1 
(57.6–60.5) 
 
57.8 
(56.4–59.3) 
—
 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change,  
and —
 indicates there w
as no change. 
* 
Includes m
ultiple IC
P
C
-2 or IC
P
C
-2 P
LU
S
 codes (see A
ppendix 4, Table A
4.1, <purl.library.usyd.edu.au/sup/9781920899875>. 
N
ote: C
I – confidence interval; N
O
S
 – not otherw
ise specified. This table includes individual new
 problem
s w
hich w
ere m
anaged at >= 1.0 per 100 encounters in any year. 
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Table 7.6: M
ost frequently m
anaged chronic problem
s, 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
C
hronic problem
 
m
anaged 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
H
ypertension 
(non-gestational)** 
9.0 
(8.5–9.5) 
 
8.8 
(8.3–9.3) 
 
9.2 
(8.7–9.7) 
 
8.9 
(8.4–9.4) 
 
9.4 
(8.9–10.0) 
 
9.5 
(9.0–10.0) 
 
9.9 
(9.3–10.4) 
 
10.1 
(9.6–10.6) 
 
9.1 
(8.6–9.5) 
 
8.7 
(8.2–9.1) 
—
 
D
epressive disorder** 
3.4 
(3.2–3.6) 
 
3.5 
(3.3–3.7) 
 
3.6 
(3.4–3.8) 
 
3.7 
(3.5–3.9) 
 
3.6 
(3.4–3.8) 
 
3.7 
(3.5–3.9) 
 
4.0 
(3.7–4.2) 
 
4.2 
(4.0–4.4) 
 
4.2 
(4.0–4.5) 
 
4.2 
(3.9–4.4) 

 
D
iabetes  
(non-gestational)** 
3.1 
(2.9–3.3) 
 
2.9 
(2.7–3.1) 
 
3.3 
(3.0–3.5) 
 
3.2 
(3.0–3.4) 
 
3.5 
(3.3–3.7) 
 
3.6 
(3.4–3.9) 
 
3.8 
(3.6–4.1) 
 
4.1 
(3.8–4.3) 
 
3.7 
(3.5–3.9) 
 
4.0 
(3.7–4.2) 

 
C
hronic arthritis** 
3.8 
(3.5–4.0) 
 
3.7 
(3.5–3.9) 
 
4.0 
(3.8–4.2) 
 
3.9 
(3.7–4.1) 
 
3.8 
(3.5–4.0) 
 
3.7 
(3.5–3.9) 
 
3.6 
(3.4–3.8) 
 
3.8 
(3.6–4.0) 
 
3.9 
(3.6–4.3) 
 
3.7 
(3.5–3.9) 
—
 
Lipid disorders* 
2.9 
(2.7–3.1) 
 
3.0 
(2.8–3.2) 
 
3.1 
(2.9–3.4) 
 
3.3 
(3.1–3.6) 
 
3.4 
(3.1–3.7) 
 
3.5 
(3.2–3.7) 
 
3.7 
(3.4–4.0) 
 
3.9 
(3.7–4.2) 
 
3.5 
(3.2–3.7) 
 
3.1 
(2.8–3.3) 
§ 
O
esophageal disease 
1.8 
(1.7–2.0) 
 
1.9 
(1.8–2.1) 
 
2.2 
(2.0–2.4) 
 
2.1 
(2.0–2.3) 
 
2.4 
(2.2–2.5) 
 
2.3 
(2.1–2.5) 
 
2.3 
(2.2–2.5) 
 
2.5 
(2.3–2.7) 
 
2.5 
(2.3–2.7) 
 
2.3 
(2.1–2.5) 

 
A
sthm
a 
2.8 
(2.7–3.0) 
 
2.7 
(2.6–2.9) 
 
2.6 
(2.4–2.7) 
 
2.3 
(2.2–2.5) 
 
2.3 
(2.1–2.4) 
 
2.3 
(2.1–2.4) 
 
2.2 
(2.0–2.3) 
 
2.2 
(2.1–2.3) 
 
2.1 
(1.9–2.3) 
 
2.2 
(2.0–2.3) 

 
A
trial fibrillation/flutter 
0.7 
(0.6–0.8) 
 
0.6 
(0.6–0.7) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.3 
(1.2–1.4) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 

 
Ischaem
ic heart disease** 
1.3 
(1.1–1.4) 
 
1.2 
(1.1–1.3) 
 
1.4 
(1.2–1.5) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.2–1.4) 
 
1.1 
(1.0–1.2) 
 
1.3 
(1.2–1.4) 
 
1.2 
(1.0–1.3) 
 
1.1 
(1.0–1.3) 
—
 
M
alignant neoplasm
 of skin 
0.9 
(0.7–1.0) 
 
0.8 
(0.7–0.9) 
 
1.1 
(0.9–1.3) 
 
1.2 
(1.0–1.4) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.3) 
 
1.2 
(1.0–1.4) 
 
1.2 
(1.1–1.4) 
 
1.3 
(1.1–1.4) 
 
1.1 
(1.0–1.2) 

 
C
hronic obstructive 
pulm
onary disease 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.8–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 

 
B
ack syndrom
e w
ith 
radiating pain** 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.1) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–0.9) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
—
 
O
besity (B
M
I > 30) 
0.8 
(0.6–0.9) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.6 
(0.5–0.6) 
 
0.8 
(0.6–0.9) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.7) 
 
0.8 
(0.6–1.0) 
—
 
(continued) 
59
Table 7.6 (continued): M
ost frequently m
anaged chronic problem
s, 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
C
hronic problem
 
m
anaged 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
H
ypothyroidism
/ 
m
yxoedem
a 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.8) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.7–0.8) 

 
O
steoporosis 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.7 
(0.6–0.8) 
—
 
M
igraine 
0.8 
(0.8–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 

 
H
eart failure 
0.7 
(0.6–0.8) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
—
 
C
hronic skin ulcer 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.6–0.7) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.6) 
—
 
G
out 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
—
 
S
houlder syndrom
e 
(excluding arthritis)** 
0.4 
(0.4–0.5) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.5–0.6) 

 
D
em
entia (including senile, 
A
lzheim
er’s) 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.3–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.3–0.5) 
 
0.6 
(0.4–0.7) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
—
 
A
nxiety disorder** 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
—
 
S
chizophrenia 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
—
 
Total chronic problem
s 
49.3 
(47.7–50.9) 
 
49.1 
(47.4–50.8) 
 
51.9 
(50.2–53.7) 
 
51.8 
(50.1–53.5) 
 
52.2 
(50.3–54.1) 
 
53.4 
(51.7–55.1) 
 
54.1 
(52.2–56.0) 
 
57.0 
(55.2–58.7) 
 
54.2 
(52.3–56.2) 
 
53.1 
(51.2–55.0) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change, § indicates a non-
linear significant or m
arginal change, and —
 indicates there w
as no change. 
** 
Indicates that this group differs from
 that used for analysis in other sections of this chapter, as only chronic conditions w
ere included in this analysis (see Appendix 4, Table A4.2, 
<purl.library.usyd.edu.au/sup/9781920899875>). 
N
ote: C
I – confidence interval; B
M
I – body m
ass index. This table includes individual chronic problem
s w
hich w
ere m
anaged at > 0.5 per 100 encounters in any year, and any other significant differences of interest.
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8 Overview of management 
This chapter provides an overview of problem management in general practice from each of 
the most recent 10 years of the BEACH study from 2001–02 to 2010–11. As discussed in 
Chapter 2 – Methods, we can consider changes in GP management actions over time in terms 
of the number of the selected action per 100 GP-patient encounters, or in terms of the number 
of problems managed. If the number of problems managed on average at encounters has not 
changed it would not matter which way we analysed the data to measure change. 
However, as reported in Chapter 7, there was a significant increase in the number of 
problems managed by GPs over the decade of this study. If we simply compared 
management actions (e.g. number of prescriptions) as a rate per 100 encounters, we would be 
ignoring the fact that more problems were managed in 2010–11 than in 2001–02, and if more 
problems are managed, more management actions should result, without any change having 
occurred in GP use of the selected management action. 
In this, and the following management chapters, we report changes over time in two ways: 
• rate (of the selected action) per 100 problems managed. 
• rate (of the selected action) per 100 encounters. 
The rate per 100 problems managed gives the clearer idea of how GP management actions 
have changed. The rate per 100 encounters is used as the basis of extrapolation to national 
estimated change.  
The direction and type of change from 2001–02 to 2010–11 is indicated for each result in the 
far right column of the tables: / indicates a statistically significant linear change, / 
indicates a marginally significant linear change, § indicates a non-linear significant or 
marginal change, and — indicates there was no change.  
Examples of extrapolations are provided in each of the specific management chapters 
(Chapters 9 to 12, inclusive). The method used to extrapolate to national change estimates is 
described in Section 2.9. 
Between 2001–02 and 2010–11, some trends emerged in management actions per 100 
problems managed (Table 8.1a). Most noticeably, as a rate per 100 problems managed: 
• the rate of all medications (prescribed, GP supplied or advised for the over-the-counter 
purchase) significantly decreased, from 72.9 per 100 problems managed in 2001–02 to 
69.0 per 100 in 2010–11. 
• the rate of prescribed medications significantly decreased, from 61.3 per 100 problems 
managed in 2001–02 to 55.8 per 100 in 2010–11. 
• the rate of GP-supplied medications significantly increased, from 5.3 per 100 problems 
managed in 2001–02 to 8.9 per 100 in 2009–10, but then significantly decreased to 6.8 per 
100 in 2010–11. The noticeable spike in 2009–10 coincided with the H1N1 virus 
pandemic, and a similar increase was noted in influenza vaccines (see Chapter 9, Section 
9.2). The overall change, however, was a significant increase over the 10 years. 
• the rate of clinical treatments decreased significantly from 26.5 per 100 problems in  
2001–02 to 23.0 per 100 in 2010–11. The rate was steady between 2001–02 and 2004–05, 
and then decreased significantly coincident with the introduction of practice nurse item 
numbers. From 2004–05 the rate steadily increased so that it was again significantly 
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higher in 2010–11 than in 2004–05. However, over the decade from 2001–02 to 2010–11, 
the observed result was a significant decrease. 
• there was an increase in the rate at which procedural treatments were undertaken, from 
9.6 per 100 problems managed in 2001–02 to 11.1 per 100 problems in 2010–11. 
• the rate of referrals to other health providers significantly increased, from 7.3 to 9.3 per 
100 problems between 2001–02 and 2010–11, influenced by a significant increase in 
referrals to: medical specialists (5.1 to 5.6), allied health services (1.6 to 2.8), and 
emergency departments (0.1 to 0.2 per 100 problems). 
• the rate of pathology tests ordered significantly increased by 37%, from 21.6 per 100 
problems in 2001–02 to 29.6 in 2010–11. This change mainly occurred in the early part of 
the decade, with no further significant increase occurring between 2006–07 and 2010–11. 
• the rate of imaging orders increased significantly, from 5.5 per 100 problems in 2001–02 
to 6.4 per 100 in 2010–11, but as with pathology, this change mostly occurred in the 
earlier part of the decade. No increase was noted between 2005–06 and 2010–11. 
Similar changes can be observed for each of these areas, in the percentage of problems for 
which at least one management type was provided (Table 8.2a). This reflects a change in the 
likelihood of each action eventuating for a problem.  
The proportion of problems for which at least one: 
• management action of any type (medication or other treatment, referral or investigation) 
was given decreased significantly between the two time points, from 87.3% of problems 
in 2001–02 to 85.9% in 2010–11. 
• medication was provided in the management of the problem decreased significantly 
(from 58.0% of problems in 2001–02 to 54.0% in 2010–11), particularly prescribed 
medications, which decreased from 49.8% to 44.7% over this time. The latter reflects the 
reduction in the rate of prescribed medications reported above and shown in Table 8.1a. 
• GP-supplied medication was given in the management of a problem, increased 
significantly from 4.3% of problems in 2001–02 to 7.2% in 2009–10, decreasing 
significantly again to 5.4% in 2010–11. This pattern reflects the change in GP-supplied 
medication observed above and shown in Table 8.1a. 
• clinical treatment was provided decreased significantly between 2001–02 (23.4%of 
problems) and 2010–11 (20.9%). As with the rate of clinical treatments in Table 8.1a, the 
decrease was noted around the introduction of practice nurse item numbers in 2005–06, 
and from that point increased again. Over the decade, however, the change was a 
significant decrease between 2001–02 and 2010–11. 
• procedure was done significantly increased from 9.1% in 2001–02 to 10.4% in 2010–11. 
• referral was given increased significantly (from 7.3% of problems in 2001–02 to 9.2% in 
2010–11), particularly to medical specialists (5.1% to 5.7%), allied health services (1.6% to 
2.7%), and emergency departments (0.1% in 2001–02 to 0.2% in 2010–11). 
• investigation was ordered, from 15.3% in 2001–02 to 18.2% in 2010–11. In 2001–02, the 
likelihood of at least one pathology test being ordered was 10.8%, and that of at least one 
imaging test being ordered was 5.0%. By 2010–11 these proportions had significantly 
increased to 13.3% and 5.7% of problems, respectively (Table 8.2a). 
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Table 8.1a: Sum
m
ary of m
anagem
ent (rate per 100 problem
s), 2001–02 to 2010–11 
 
R
ate per 100 problem
s (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
M
anagem
ent type 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  (n = 146,141) 
M
edications 
72.9 
(71.4–74.3) 
 
71.6 
(70.1–73.1) 
 
71.3 
(70.0–72.7) 
 
69.8 
(68.3–71.2) 
 
71.4 
(69.9–72.9) 
 
68.4 
(67.0–69.7) 
 
67.9 
(66.5–69.2) 
 
68.7 
(67.5–70.0) 
 
69.5 
(67.9–71.1) 
 
69.0 
(67.6–70.3) 

 
 
P
rescribed 
61.3 
(59.8–62.9) 
 
58.2 
(56.6–59.8) 
 
58.8 
(57.3–60.3) 
 
57.3 
(55.9–58.7) 
 
58.7 
(57.2–60.3) 
 
56.1 
(54.7–57.4) 
 
54.5 
(53.2–55.8) 
 
55.9 
(54.5–57.2) 
 
54.4 
(52.8–56.0) 
 
55.8 
(54.5–57.1) 

 
 
G
P
-supplied 
5.3 
(4.6–6.1) 
 
6.4 
(5.5–7.3) 
 
5.9 
(5.2–6.5) 
 
5.5 
(5.0–6.0) 
 
6.0 
(5.6–6.5) 
 
6.0 
(5.5–6.5) 
 
6.7 
(6.3–7.1) 
 
7.1 
(6.6–7.6) 
 
8.9 
(8.3–9.5) 
 
6.8 
(6.2–7.3) 
§ 
 
A
dvised O
TC
 
6.2 
(5.7–6.7) 
 
7.0 
(6.4–7.6) 
 
6.7 
(6.1–7.2) 
 
6.9 
(6.3–7.5) 
 
6.7 
(6.2–7.2) 
 
6.3 
(5.8–6.8) 
 
6.7 
(6.2–7.2) 
 
5.7 
(5.3–6.1) 
 
6.2 
(5.7–6.7) 
 
6.4 
(5.9–6.9) 
—
 
O
ther treatm
ents 
36.2 
(34.6–37.7) 
 
35.7 
(34.1–37.3) 
 
35.1 
(33.5–36.7) 
 
37.6 
(36.0–39.2) 
 
29.9 
(28.5–31.2) 
 
30.1 
(28.6–31.5) 
 
33.9 
(32.4–35.3) 
 
32.8 
(31.5–34.1) 
 
34.3 
(32.6–36.0) 
 
34.4 
(32.7–36.0) 
—
 
 
C
linical* 
26.5 
(25.2–27.9) 
 
25.7 
(24.2–27.1) 
 
25.0 
(23.6–26.4) 
 
27.0 
(25.6–28.3) 
 
20.0 
(18.8–21.2) 
 
19.9 
(18.7–21.1) 
 
22.8 
(21.6–24.1) 
 
22.0 
(20.8–23.2) 
 
22.8 
(21.3–24.3) 
 
23.0 
(21.8–24.8) 

 
 
P
rocedural* 
9.6 
(9.1–10.1) 
 
10.1 
(9.6–10.6) 
 
10.1 
(9.6–10.6) 
 
10.6 
(10.0–11.3) 
 
9.9 
(9.4–10.3) 
 
10.2 
(9.7–10.7) 
 
11.0 
(10.5–11.6) 
 
10.8 
(10.4–11.3) 
 
11.4 
(10.8–12.1) 
 
11.1 
(10.6–11.6) 

 
R
eferrals 
7.3 
(7.0–7.6) 
 
7.7 
(7.4–8.0) 
 
8.0 
(7.6–8.3) 
 
7.9 
(7.7–8.2) 
 
8.2 
(7.9–8.5) 
 
8.2 
(7.9–8.6) 
 
8.3 
(8.0–8.6) 
 
8.9 
(8.6–9.2) 
 
8.7 
(8.4–9.0) 
 
9.3 
(8.9–9.6) 

 
 
M
edical specialist* 
5.1 
(4.9–5.3) 
 
5.3 
(5.0–5.5) 
 
5.4 
(5.1–5.6) 
 
5.3 
(5.1–5.5) 
 
5.6 
(5.4–5.8) 
 
5.4 
(5.2–5.7) 
 
5.3 
(5.1–5.5) 
 
5.8 
(5.6–6.0) 
 
5.5 
(5.3–5.7) 
 
5.6 
(5.4–5.9) 

 
 
A
llied health service* 
1.6 
(1.5–1.7) 
 
1.7 
(1.6–1.9) 
 
1.8 
(1.7–1.9) 
 
1.9 
(1.7–2.0) 
 
2.0 
(1.8–2.1) 
 
2.1 
(1.9–2.2) 
 
2.3 
(2.1–2.4) 
 
2.5 
(2.3–2.7) 
 
2.6 
(2.4–2.7) 
 
2.8 
(2.6–2.9) 

 
 
H
ospital* 
0.3 
(0.3–0.3) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
—
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Table 8.1a (continued): Sum
m
ary of m
anagem
ent (rate per 100 problem
s), 2001–02 to 2010–11 
M
anagem
ent type 
R
ate per 100 problem
s (95%
 C
I) 

 (a) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  (n = 146,141) 
 
E
m
ergency departm
ent* 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 

 
 
O
ther referrals* 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.4 
(0.3–0.5) 

 
P
athology 
21.6 
(20.8–22.5) 
 
22.7 
(21.8–23.6) 
 
24.1 
(23.1–25.0) 
 
25.2 
(24.3–26.2) 
 
26.4 
(25.3–27.5) 
 
28.6 
(27.5–29.6) 
 
28.5 
(27.4–29.6) 
 
29.5 
(28.4–30.5) 
 
29.3 
(28.2–30.4) 
 
29.6 
(28.6–30.7) 

 
Im
aging 
5.5 
(5.3–5.7) 
 
5.9 
(5.7–6.2) 
 
5.6 
(5.4–5.9) 
 
5.7 
(5.5–5.9) 
 
6.0 
(5.8–6.3) 
 
6.0 
(5.8–6.3) 
 
6.3 
(6.1–6.5) 
 
6.3 
(6.1–6.6) 
 
6.4 
(6.1–6.6) 
 
6.4 
(6.1–6.7) 

 
O
ther investigations 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.8) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 

 
(a) 
The direction and type of change is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change, § indicates a non-linear significant  
or m
arginal change, and —
 indicates there w
as no change. 
* 
Includes m
ultiple IC
P
C
-2 or IC
P
C
-2 P
LU
S
 codes (see A
ppendix 4 <purl.library.usyd.edu.au/sup/9781920899875>). 
N
ote: C
I – confidence interval; O
TC
 – over-the-counter. 
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Table 8.1b: Sum
m
ary of m
anagem
ent (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
M
anagem
ent type 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 
(n = 96,688) 
 (n = 101,349)  
(n = 95,839) 
M
edications 
104.5 
(102.2–106.9)  
103.8 
(101.4–106.2)  
104.4 
(102.1–106.7)  
101.5 
(99.3–103.8) 
 
104.4 
(101.8–107.0)  
101.5 
(99.2–103.9) 
 
102.7 
(100.3–105.0)  
106.3 
(104.0–108.5)  
106.6 
(103.6–109.5)  
105.2 
(102.8–107.6) 
—
 
 
P
rescribed 
88.0 
(85.6–90.4) 
 
84.3 
(81.8–86.9) 
 
86.0 
(83.6–88.5) 
 
83.4 
(81.2–85.6) 
 
85.8 
(83.3–88.4) 
 
83.3 
(81.0–85.5) 
 
82.4 
(80.3–84.6) 
 
86.4 
(84.1–88.6) 
 
83.4 
(80.6–86.2) 
 
85.1 
(82.9–87.3) 
—
 
 
G
P
-supplied 
7.6 
(6.6–8.7) 
 
9.3 
(8.0–10.6) 
 
8.6 
(7.6–9.6) 
 
8.1 
(7.3–8.8) 
 
8.8 
(8.2–9.5) 
 
8.9 
(8.2–9.6) 
 
10.1 
(9.5–10.7) 
 
11.0 
(10.2–11.8) 
 
13.6 
(12.7–14.6) 
 
10.3 
(9.5–11.2) 

 
 
A
dvised O
TC
 
8.9 
(8.2–9.6) 
 
10.2 
(9.3–11.1) 
 
9.8 
(9.0–10.5) 
 
10.1 
(9.2–10.9) 
 
9.8 
(9.0–10.5) 
 
9.4 
(8.7–10.1) 
 
10.1 
(9.3–10.9) 
 
8.9 
(8.3–9.4) 
 
9.5 
(8.7–10.3) 
 
9.8 
(9.0–10.5) 
—
 
O
ther treatm
ents 
51.9 
(49.5–54.2) 
 
51.8 
(49.3–54.3) 
 
51.4 
(48.9–53.8) 
 
54.7 
(52.1–57.3) 
 
43.6 
(41.5–45.8) 
 
44.7 
(42.3–47.0) 
 
51.2 
(48.9–53.6) 
 
50.7 
(48.5–52.9) 
 
52.5 
(49.8–55.3) 
 
52.4 
(49.8–55.1) 
§ 
 
C
linical* 
38.1 
(36.1–40.1) 
 
37.2 
(35.0–39.4) 
 
36.6 
(34.5–38.7) 
 
39.2 
(37.1–41.4) 
 
29.2 
(27.3–31.1) 
 
29.5 
(27.6–31.4) 
 
34.5 
(32.5–36.5) 
 
34.0 
(32.1–35.9) 
 
35.0 
(32.6–37.4) 
 
35.5 
(33.2–37.8) 
§ 
 
P
rocedural* 
13.8 
(13.1–14.5) 
 
14.6 
(13.9–15.3) 
 
14.7 
(14.0–15.5) 
 
15.5 
(14.6–16.4) 
 
14.4 
(13.7–15.1) 
 
15.2 
(14.4–16.0) 
 
16.7 
(15.9–17.5) 
 
16.7 
(16.0–17.5) 
 
17.5 
(16.5–18.6) 
 
16.9 
(16.1–17.8) 

 
R
eferrals 
10.5 
(10.1–10.9) 
 
11.2 
(10.7–11.6) 
 
11.6 
(11.1–12.2) 
 
11.5 
(11.1–12.0) 
 
12.0 
(11.5–12.5) 
 
12.2 
(11.7–12.7) 
 
12.5 
(12.0–13.0) 
 
13.7 
(13.2–14.2) 
 
13.3 
(12.8–13.8) 
 
14.1 
(13.5–14.7) 

 
 
M
edical specialist* 
7.3 
(7.0–7.6) 
 
7.6 
(7.3–8.0) 
 
7.9 
(7.5–8.2) 
 
7.7 
(7.4–8.0) 
 
8.2 
(7.8–8.5) 
 
8.0 
(7.7–8.4) 
 
8.0 
(7.6–8.3) 
 
9.0 
(8.7–9.3) 
 
8.4 
(8.1–8.8) 
 
8.6 
(8.2–9.0) 

 
 
A
llied health service* 
2.3 
(2.1–2.4) 
 
2.5 
(2.3–2.7) 
 
2.6 
(2.4–2.8) 
 
2.7 
(2.5–2.9) 
 
2.9 
(2.7–3.1) 
 
3.1 
(2.9–3.3) 
 
3.4 
(3.2–3.7) 
 
3.9 
(3.6–4.1) 
 
3.9 
(3.7–4.2) 
 
4.2 
(3.9–4.5) 

 
 
H
ospital* 
0.4 
(0.4–0.5) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
—
 
(continued) 
65
Table 8.1b (continued): Sum
m
ary of m
anagem
ent (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 

(a) 
 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
M
anagem
ent type 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 
(n = 96,688) 
 (n = 101,349)  
(n = 95,839) 
 
E
m
ergency departm
ent* 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.3–0.3) 

 
 
O
ther referrals* 
0.4 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.3 
(0.2–0.4) 
 
0.4 
(0.3–0.5) 
 
0.6 
(0.5–0.7) 

 
P
athology 
31.0 
(29.7–32.4) 
 
32.9 
(31.4–34.4) 
 
35.2 
(33.7–36.8) 
 
36.7 
(35.2–38.2) 
 
38.6 
(36.9–40.3) 
 
42.4 
(40.7–44.2) 
 
43.1 
(41.3–45.0) 
 
45.6 
(43.8–47.4) 
 
45.0 
(43.1–46.9) 
 
45.2 
(43.4–47.0) 

 
Im
aging 
7.9 
(7.5–8.2) 
 
8.6 
(8.2–9.0) 
 
8.2 
(7.8–8.6) 
 
8.3 
(8.0–8.6) 
 
8.8 
(8.4–9.2) 
 
9.0 
(8.6–9.3) 
 
9.5 
(9.2–9.9) 
 
9.8 
(9.4–10.2) 
 
9.8 
(9.3–10.1) 
 
9.8 
(9.4–10.2) 

 
O
ther investigations 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
1.0 
(0.9–1.1) 
 
1.1 
(0.9–1.2 ) 
 
1.0 
(0.8–1.1) 
 
1.0 
(0.9–1.1) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.7–0.8) 

 
(a) 
The direction and type of change is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change, and —
 indicates there w
as no change. 
* 
Includes m
ultiple IC
P
C
-2 or IC
P
C
-2 P
LU
S
 codes (see A
ppendix 4 <purl.library.usyd.edu.au/sup/9781920899875>). 
N
ote: C
I – confidence interval; O
TC
 – over-the-counter. 
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Table 8.2a: Problem
s for w
hich at least one m
anagem
ent w
as recorded (per cent of problem
s), 2001–02 to 2010–11 
 
Per cent of problem
s
 (95%
 C
I) 

(a) 
 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
A
t least one…
 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  (n = 146,141) 
M
anagem
ent type 
87.3 
(86.7–87.9) 
 
86.4 
(85.7–87.1) 
 
86.8 
(86.2–87.4) 
 
87.1 
(86.4–87.7) 
 
86.2 
(85.6–86.9) 
 
85.3 
(84.6–85.9) 
 
86.3 
(85.6–86.9) 
 
86.3 
(85.6–86.9) 
 
85.8 
(85.1–86.4) 
 
85.9 
(85.3–86.5) 

 
 
M
edication or other 
 
treatm
ent 
76.5 
(75.7–77.3) 
 
75.1 
(74.3–75.9) 
 
75.0 
(74.2–75.8) 
 
74.9 
(74.1–75.7) 
 
73.5 
(72.7–74.4) 
 
71.8 
(70.9–72.6) 
 
73.2 
(72.4–74.1) 
 
72.9 
(72.1–73.7) 
 
72.8 
(71.9–73.7) 
 
72.4 
(71.5–73.3) 

 
 
 
M
edication  
58.0 
(57.1–59.0) 
 
56.8 
(55.8–57.8) 
 
56.6 
(55.7–57.6) 
 
55.2 
(54.2–56.2) 
 
56.5 
(55.4–57.5) 
 
54.5 
(53.5–55.5) 
 
54.1 
(53.1–55.1) 
 
54.3 
(53.4–55.3) 
 
54.2 
(53.2–55.1) 
 
54.0 
(53.1–55.0) 

 
 
 
 
P
rescription 
49.8 
(48.7–50.9) 
 
47.2 
(46.0–48.4) 
 
47.8 
(46.7–48.9) 
 
46.7 
(45.7–47.8) 
 
47.7 
(46.6–48.8) 
 
45.6 
(44.6–46.6) 
 
44.4 
(43.5–45.4) 
 
44.9 
(43.9–45.8) 
 
43.2 
(42.1–44.3) 
 
44.7 
(43.7–45.6) 

 
 
 
 
G
P
-supplied 
4.3 
(3.8–4.9) 
 
5.2 
(4.5–6.0) 
 
4.8 
(4.2–5.3) 
 
6.2 
(5.7–6.7) 
 
4.5 
(4.2–4.9) 
 
4.7 
(4.3–5.1) 
 
5.3 
(5.0–5.7) 
 
5.7 
(5.3–6.1) 
 
7.2 
(6.7–7.7) 
 
5.4 
(5.0–5.8) 

 
 
 
 
A
dvised O
TC
 
5.7 
(5.2–6.1) 
 
6.4 
(5.9–6.9) 
 
6.0 
(5.6–6.5) 
 
4.4 
(4.0–4.7) 
 
6.0 
(5.6–6.5) 
 
5.8 
(5.4–6.2) 
 
6.1 
(5.6–6.5) 
 
5.3 
(4.9–5.6) 
 
5.6 
(5.1–6.0) 
 
5.8 
(5.4–6.2) 
—
 
 
 
O
ther treatm
ent 
31.4 
(30.2–32.6) 
 
30.9 
(29.7–32.2) 
 
30.5 
(29.3–31.8) 
 
32.4 
(31.1–33.6) 
 
26.9 
(25.8–28.1) 
 
27.0 
(25.8–28.2) 
 
30.2 
(29.1–31.4) 
 
29.3 
(28.2–30.4) 
 
30.3 
(29.0–31.7) 
 
30.4 
(29.1–31.7) 
—
 
 
 
 
C
linical treatm
ent 
23.4 
(22.3–24.5) 
 
22.7 
(21.5–23.8) 
 
22.2 
(21.0–23.3) 
 
23.7 
(22.5–24.8) 
 
18.3 
(17.2–19.3) 
 
18.0 
(17.0–19.1) 
 
20.6 
(19.6–21.7) 
 
20.0 
(18.9–21.0) 
 
20.6 
(19.3–21.8) 
 
20.9 
(19.6–22.1) 

 
 
 
 
P
rocedural  
 
 
 
treatm
ent 
9.1 
(8.6–9.6) 
 
9.4 
(9.0–9.8) 
 
9.4 
(8.9–9.8) 
 
9.8 
(9.3–10.3) 
 
9.3 
(8.7–9.7) 
 
9.6 
(9.2–10.1) 
 
10.3 
(9.8–10.8) 
 
10.1 
(9.7–10.5) 
 
10.7 
(10.1–11.3) 
 
10.4 
(9.9–10.9) 

 
 
R
eferral 
7.3 
(7.0–7.6) 
 
7.7 
(7.4–8.0) 
 
8.0 
(7.6–8.3) 
 
7.9 
(7.7–8.2) 
 
8.2 
(7.9–8.5) 
 
8.3 
(8.0–8.6) 
 
8.3 
(8.0–8.6) 
 
8.9 
(8.5–9.2) 
 
8.7 
(8.4–9.0) 
 
9.2 
(8.9–9.5) 

 
 
 
M
edical specialist 
5.1 
(4.9–5.3) 
 
5.3 
(5.1–5.6) 
 
5.4 
(5.2–5.7) 
 
5.4 
(5.2–5.6) 
 
5.6 
(5.4–5.9) 
 
5.5 
(5.3–5.8) 
 
5.3 
(5.1–5.5) 
 
5.9 
(5.7–6.1) 
 
5.6 
(5.4–5.8) 
 
5.7 
(5.5–5.9) 

 
 
 
A
llied health 
1.6 
(1.5–1.7) 
 
1.7 
(1.6–1.9) 
 
1.8 
(1.7–2.0) 
 
1.9 
(1.7–2.0) 
 
2.0 
(1.8–2.1) 
 
2.1 
(1.9–2.2) 
 
2.3 
(2.2–2.4) 
 
2.5 
(2.4–2.7) 
 
2.6 
(2.4–2.7) 
 
2.7 
(2.6–2.9) 

 
 
 
H
ospital 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 

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Table 8.2a (continued): Problem
s for w
hich at least one m
anagem
ent w
as recorded (per cent of problem
s), 2001–02 to 2010–11 
 
Per cent of problem
s
 (95%
 C
I) 

(a) 
 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
A
t least one…
 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  (n = 146,141) 
 
 
E
m
ergency  
 
 
departm
ent 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 

 
 
 
O
ther referral 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.5) 

 
 
Investigation 
15.3 
14.8–15.7) 
 
16.2 
(15.7–16.6) 
 
16.5 
(16.0–17.0) 
 
16.9 
(16.4–17.3) 
 
17.6 
(17.1–18.1) 
 
18.2 
(17.7–18.7) 
 
18.1 
(17.6–18.6) 
 
18.5 
(18.0–19.0) 
 
18.1 
(17.6–18.6) 
 
18.2 
(17.7–18.7) 

 
 
 
P
athology order 
10.8 
(10.4–11.2) 
 
11.4 
(11.0–11.8) 
 
11.9 
(11.5–12.4) 
 
12.2 
(11.8–12.6) 
 
12.7 
(12.2–13.2) 
 
13.4 
(13.0–13.9) 
 
13.1 
(12.7–13.6) 
 
13.6 
(13.2–14.0) 
 
13.2 
(12.8–13.7) 
 
13.3 
(12.9–13.7) 

 
 
 
Im
aging order 
5.0 
(4.7–5.2) 
 
5.3 
(5.1–5.6) 
 
5.1 
(4.8–5.3) 
 
5.2 
(5.0–5.4) 
 
5.5 
(5.3–5.7) 
 
5.5 
(5.3–5.7) 
 
5.7 
(5.4–5.9) 
 
5.7 
(5.4–5.9) 
 
5.7 
(5.5–6.0) 
 
5.7 
(5.5–5.9) 

 
 
 
O
ther investigation 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.6–0.7) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 

 
(a) 
The direction and type of change is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change, § indicates a non-linear significant or m
arginal 
change, and —
 indicates there w
as no change. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 encounters. 
N
ote: C
I – confidence interval; O
TC
 – over-the-counter. 
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Table 8.2b: Encounters at w
hich at least one m
anagem
ent w
as recorded (per cent of encounters), 2001–02 to 2010–11 
 
Per cent of encounters (95%
 C
I) 

(a) 
 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
A
t least one…
 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 
(n = 96,688) 
 (n = 101,349)  
(n = 95,839) 
M
anagem
ent type 
91.8 
(91.3–92.3) 
 
91.3 
(90.6–92.0) 
 
91.5 
(90.9–92.0) 
 
91.9 
(91.3–92.5) 
 
91.2 
(90.6–91.8) 
 
90.4 
(89.8–91.0) 
 
91.9 
(91.3–92.4) 
 
92.2 
(91.7–92.7) 
 
91.3 
(90.7–91.9) 
 
91.5 
(90.8–92.1) 
—
 
 
M
edication or other 
 
treatm
ent 
83.2 
(82.5–84.0) 
 
82.5 
(81.6–83.3) 
 
82.3 
(81.5–83.1) 
 
82.4 
(81.6–83.2) 
 
81.4 
(80.6–82.1) 
 
79.9 
(79.1–80.8) 
 
82.2 
(81.4–82.9) 
 
82.4 
(81.7–83.1) 
 
81.6 
(80.8–82.4) 
 
81.4 
(80.5–82.3) 

 
 
 
M
edication  
66.6 
(65.7–67.5) 
 
65.8 
(64.9–66.8) 
 
65.6 
(64.7–66.5) 
 
64.3 
(63.4–65.2) 
 
65.2 
(64.3–66.2) 
 
63.9 
(63.0–64.9) 
 
64.4 
(63.4–65.3) 
 
65.1 
(64.3–65.9) 
 
64.6 
(63.6–65.5) 
 
64.7 
(63.8–65.6) 

 
 
 
 
P
rescription 
57.4 
(56.4–58.5) 
 
54.9 
(53.7–56.1) 
 
55.7 
(54.6–56.9) 
 
54.8 
(53.8–55.8) 
 
55.6 
(54.5–56.6) 
 
54.1 
(53.2–55.1) 
 
53.6 
(52.6–54.5) 
 
54.6 
(53.7–55.5) 
 
52.4 
(51.3–53.4) 
 
54.3 
(53.3–55.2) 

 
 
 
 
G
P
-supplied 
5.8 
(5.1–6.5) 
 
6.8 
(6.0–7.7) 
 
6.5 
(5.8–7.3) 
 
6.2 
(5.7–6.7) 
 
6.4 
(6.0–6.9) 
 
6.8 
(6.3–7.3) 
 
7.9 
(7.4–8.4) 
 
8.5 
(7.9–9.1) 
 
10.5 
(9.8–11.2) 
 
8.0 
(7.4–8.6) 

 
 
 
 
A
dvised O
TC
 
8.0 
(7.4–8.6) 
 
9.0 
(8.3–9.8) 
 
8.7 
(8.0–9.3) 
 
8.7 
(8.1–9.4) 
 
8.6 
(8.0–9.2) 
 
8.4 
(7.8–8.9) 
 
8.9 
(8.3–9.6) 
 
8.0 
(7.5–8.5) 
 
8.3 
(7.6–8.9) 
 
8.6 
(8.0–9.2) 
—
 
 
 
O
ther treatm
ent 
39.5 
(38.1–41.0) 
 
39.4 
(37.8–40.9) 
 
39.3 
(37.8–40.8) 
 
41.2 
(39.7–42.8) 
 
35.1 
(33.7–36.6) 
 
35.3 
(33.8–36.9) 
 
39.9 
(38.3–41.4) 
 
39.6 
(38.3–41.0) 
 
40.3 
(38.5–42.0) 
 
40.1 
(38.4–41.7) 
—
 
 
 
 
C
linical treatm
ent 
29.7 
(28.4–31.1) 
 
29.2 
(27.7–30.6) 
 
28.9 
(27.4–30.3) 
 
30.5 
(29.1–32.0) 
 
24.0 
(22.7–25.4) 
 
23.8 
(22.5–25.2) 
 
27.5 
(26.1–28.9) 
 
27.3 
(26.0–28.6) 
 
27.7 
(26.1–29.2) 
 
27.9 
(26.3–29.5) 
—
 
 
 
 
P
rocedural  
 
 
 
treatm
ent 
12.7 
(12.0–13.3) 
 
13.2 
(12.6–13.8) 
 
13.3 
(12.7–13.9) 
 
13.8 
(13.1–14.6) 
 
13.2 
(12.6–13.8) 
 
13.8 
(13.2–14.5) 
 
15.0 
(14.3–15.7) 
 
15.0 
(14.4–15.6) 
 
15.7 
(14.8–16.6) 
 
15.1 
(14.4–15.8) 

 
 
R
eferral 
10.0 
(9.6–10.4) 
 
10.6 
(10.2–11.0) 
 
11.0 
(10.5–11.5) 
 
10.9 
(10.5–11.3) 
 
11.3 
(10.9–11.8) 
 
11.5 
(11.0–11.9) 
 
11.8 
(11.3–12.2) 
 
12.8 
(12.3–13.2) 
 
12.4 
(11.9–12.9) 
 
13.0 
(12.5–13.5) 

 
 
 
M
edical specialist 
7.0 
(6.7–7.3) 
 
7.4 
(7.0–7.7) 
 
7.6 
(7.3–8.0) 
 
7.5 
(7.2–7.8) 
 
7.9 
(7.5–8.2) 
 
7.7 
(7.4–8.0) 
 
7.7 
(7.4–8.0) 
 
8.6 
(8.3–8.9) 
 
8.1 
(7.7–8.5) 
 
8.2 
(7.9–8.6) 

 
 
 
A
llied health 
2.2 
(2.1–2.4) 
 
2.4 
(2.2–2.6) 
 
2.5 
(2.3–2.7) 
 
2.6 
(2.5–2.8) 
 
2.8 
(2.6–3.0) 
 
3.0 
(2.8–3.1) 
 
3.3 
(3.1–3.5) 
 
3.7 
(3.5–3.9) 
 
3.7 
(3.5–3.9) 
 
3.9 
(3.7–4.2) 

 
 
 
H
ospital 
0.4 
(0.4–0.5) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
—
 
(continued) 
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Table 8.2b (continued): Encounters at w
hich at least one m
anagem
ent w
as recorded (per cent of encounters), 2001–02 to 2010–11 
 
Per cent of encounters
 (95%
 C
I) 

(a) 
 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
A
t least one…
 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 
(n = 96,688) 
 (n = 101,349)  
(n = 95,839) 
 
 
E
m
ergency  
 
 
departm
ent 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.3–0.4) 

 
 
 
O
ther referral 
0.4 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.3 
(0.2–0.4) 
 
0.4 
(0.3–0.5) 
 
0.6 
(0.5–0.7) 

 
 
Investigation 
19.7 
(19.1–20.3) 
 
20.8 
(20.2–21.5) 
 
21.3 
(20.7–22.0) 
 
21.7 
(21.1–22.4) 
 
22.6 
(21.9–23.3) 
 
23.5 
(22.8–24.2) 
 
23.8 
(23.1–24.5) 
 
24.6 
(23.9–25.3) 
 
24.2 
(23.5–24.9) 
 
24.1 
(23.4–24.8) 

 
 
 
P
athology order 
14.0 
(13.5–14.5) 
 
14.7 
(14.2–15.3) 
 
15.5 
(14.9–16.1) 
 
15.7 
(15.2–16.3) 
 
16.4 
(15.8–16.9) 
 
17.4 
(16.8–18.0) 
 
17.4 
(16.7–18.0) 
 
18.2 
(17.6–18.8) 
 
17.7 
(17.1–18.3) 
 
17.8 
(17.2–18.4) 

 
 
 
Im
aging order 
6.9 
(6.6–7.2) 
 
7.5 
(7.1–7.8) 
 
7.2 
(6.9–7.5) 
 
7.3 
(7.0–7.6) 
 
7.8 
(7.4–8.1) 
 
7.9 
(7.6–8.2) 
 
8.3 
(8.0–8.6) 
 
8.5 
(8.1–8.8) 
 
8.5 
(8.2–8.9) 
 
8.4 
(8.0–8.7) 

 
 
 
O
ther investigation 
0.9 
(0.8–1.0) 
 
1.0 
(0.8–1.1) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 

 
(a) 
The direction and type of change is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change, § indicates a non-linear significant or m
arginal 
change, and —
 indicates there w
as no change. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 encounters. 
N
ote: C
I – confidence interval; O
TC
 – over-the-counter. 
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9 Medications 
This chapter includes data about the medications prescribed, advised or supplied by general 
practitioners from each of the most recent 10 years of the BEACH study from 2001–02 to 
2010–11. The direction and type of change over the study period is indicated for each result 
in the far right column of the tables: / indicates a statistically significant linear change, 
/ indicates a marginally significant linear change, § indicates a non-linear significant or 
marginal change, and — indicates there was no change. 
Significant linear change in rate per 100 encounters can be extrapolated to estimate the 
national increase or decrease in the number of prescribed, supplied, or advised medications 
between 2001–02 and 2010–11. Some examples of extrapolated changes are given in this 
chapter. However, you can apply the extrapolation method described in Section 2.9 to any of 
significant linear changes in rate per 100 encounters. 
GPs could record up to four medications for each of four problems – a maximum of 
16 medications per encounter. Each medication could be recorded as prescribed (the default), 
supplied by the GP or recommended for over-the-counter (OTC) purchase. 
Medication data for the 10 years 2001–02 to 2010–11, are reported in two ways in this 
chapter: as rates per 100 problems managed (for example, Table 9.1a) and as rates per 
100 encounters (for example, Table 9.1b). In describing data over time, the rates per 
100 problems are reported as the primary measure, because there was a significant increase 
in the number of problems managed per encounter over the decade. The tables with rates per 
100 encounters are included to show the basis for the extrapolations discussed above. 
Table 9.1a shows that between the two data periods, total medication rates decreased 
significantly per 100 problems managed. However, there was no significant change in total 
medication rates per 100 encounters between 2001–02 and 2010–11 (Table 9.1b) because of 
that increase in the number of problems managed by GPs per 100 encounters over the study 
period (see Chapter 7). The peak in rates of GP supplied medications in 2009–10 (Tables 9.1 
and 9.2) reflects a rise in influenza virus vaccine which coincided with the H1N1 influenza 
pandemic of 2009. 
9.1 Prescribed medications 
The rate at which medications were prescribed fell from 61.3 per 100 problems managed in 
2001–02 to 55.8 per 100 in 2010–11. This significant decrease means that an average of 
5.5 fewer prescriptions were being written for every 100 problems managed in 2010–11 than  
10 years earlier (Table 9.1a). Even though the rate of prescribed medications per 100 
problems decreased, there was no change per 100 encounters (Table 9.1b) and this is a direct 
consequence of the rise in number of problems managed at encounter. However, in 2010–11 
there were 18.2 million (18%) more encounters claimed through Medicare than there were in 
2001–02 (118.1 million versus 99.9 million). As a result, the extrapolated national effect of this 
change is 12.6 million more prescriptions given by GPs in 2010–11 than in 2001–02. If the 
estimated 26% increase over the 10 years in number of problems managed nationally is 
considered, the increase in number of prescriptions recorded would have been about 
22 million if not for the decrease in GP prescribing rates. 
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Tables 9.2a and 9.2b show prescribing rates of common drug groups over the 10-year period 
at ATC drug group Level 2, because this level is the most stable of the ATC groups. 
Extrapolations showed 1.6 million more prescriptions for agents acting on the renin-
angiotensin system, 970,000 more psychoanaleptics, 1.3 million serum lipid-modifying 
agents, 550,000 more antithrombotics and 190,000 more thyroid medications prescribed in 
2010–11 than in 2001–02. Conversely, there were about 53,000 fewer psycholeptics, 530,000 
fewer drugs for obstructive airways disease, 1.2 million fewer systemic anti-inflammatory 
medications, and 710,000 fewer sex hormones prescribed in 2010–11 than in 2001–02. 
Tables 9.3a and 9.3b show prescribed medication rates at the individual generic level. One of 
the medications with the greatest increase was oxycodone, with an extrapolated estimate of 
1.5 million more prescriptions in 2010–11 than 10 years earlier. The proton pump inhibitor 
esomeprazole was prescribed 1.1 million more times, and non-steroid anti-inflammatory 
meloxicam, 510,000 more times than in 2002–03, which was the year they were first recorded 
in sufficient quantities to allow calculation of differences over time. The lipid-lowering agent 
rosuvastatin was first listed on the PBS in December 2006, and was prescribed an estimated 
760,000 more times in 2010–11 than in 2007–08.  
A number of medications were prescribed less often than in 2001–02, such as roxithromycin 
with an extrapolated decrease of 100,000, simvastatin (190,000 fewer), celecoxib (500,000 
fewer) and cefaclor monohydrate with an estimated decrease of 510,000 between 2001–02 
and 2010–11. 
Number of repeats ordered 
The pattern of the number of repeat prescriptions recorded by GPs changed between 2001–02 
and 2010–11 (Table 9.4). There was a significant decrease in the proportion of prescribed 
medications with no repeats ordered, or one or two repeats. On the other hand, there was a 
significant increase in the proportion of prescriptions for which five repeats were recorded. 
The proportion of prescriptions given five repeats increased from 26.4% in 2001–02 to 35.4% 
in 2010–11. 
9.2 Medications supplied by GPs 
Rates of GP-supplied medications per 100 problems managed increased significantly in the 
10-year period from 5.3 per 100 problems managed in 2001–02 to 6.8 per 100 in 2010–11 
(Table 9.1a). Per 100 encounters, the rate increased from 7.6 to 10.3 between the two data 
periods (Table 9.1b). The extrapolated national effect of this change is 4.5 million more 
medications supplied directly to the patient by GPs in 2010–11 than in 2001–02.  
Table 9.5a shows rates per 100 problems managed of individual medications most frequently 
supplied by GPs between 2001–02 and 2010–11. The majority of these medications were 
vaccines, and rates for many of them increased significantly over the period. The supply of 
influenza virus vaccine rose from 0.6 per 100 problems managed in 2001–02 to 1.7 per 100 in 
2010–11. The rate per 100 encounters increased from 0.9 to 2.7 (Table 9.5b), and the 
extrapolated national effect of this change is that influenza virus vaccine was supplied 
2.3 million more times in 2010–11 than in 2001–02. The move away from prescribing towards 
GP supply of the vaccine was evident in this significant increase in its supply, which 
coincided with the significant decrease in its prescribing rate (Table 9.3a). This change 
follows federal government policy starting in 2001, which made the vaccine available free of 
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charge to all Australians aged 65 years and over, to Aboriginal and Torres Strait Islander 
people aged 50 years and older, and to younger Aboriginal and Torres Strait Islander 
persons with health risks. The vaccines can be ordered by the GP directly from the supplier. 
In Table 9.3, one can also see a peak in the rate of influenza virus vaccine in 2009–10 which 
coincided with the H1N1 influenza pandemic of 2009. GP supply of pneumococcal vaccine 
peaked at 0.6 per 100 problems managed in 2005–06, and has remained at 0.4 per 100 since 
then. 
9.3 Medications advised for over-the-counter 
purchase 
Table 9.6a shows rates per 100 problems managed for the most commonly advised 
over-the-counter medications at the generic level. Rates for individual and total medications 
advised for over-the-counter purchase remained steady between 2001–02 and 2010–11. 
However, as a rate per 100 GP-patient encounters, there were significant increases in the rate 
at which vitamin D was advised, and sodium chloride was recommended for topical and 
nasal use (Table 9.6b).  
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Table 9.1a: R
ates of m
edications prescribed, advised for over-the-counter purchase, supplied (rate per 100 problem
s), 2001–02 to 2010–11 
M
edications 
R
ate per 100 problem
s (95%
 C
I) 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  
(n = 146,141) 
P
rescribed 
61.3 
(59.8–62.9) 
 
58.2 
(56.6–59.8) 
 
58.8 
(57.3–60.3) 
 
57.3 
(55.9–58.7) 
 
58.7 
(57.2–60.3) 
 
56.1 
(54.7–57.4) 
 
54.5 
(53.2–55.8) 
 
55.9 
(54.5–57.2) 
 
54.4 
(52.8–56.0) 
 
55.8 
(54.5–57.1) 

 
G
P
 supplied 
5.3 
(4.6–6.1) 
 
6.4 
(5.5–7.3) 
 
5.9 
(5.2–6.5) 
 
5.5 
(5.0–6.0) 
 
6.0 
(5.6–6.5) 
 
6.0 
(5.5–6.5) 
 
6.7 
(6.3–7.1) 
 
7.1 
(6.6–7.6) 
 
8.9 
(8.3–9.5) 
 
6.8 
(6.2–7.3) 

 
A
dvised O
TC
 
6.2 
(5.7–6.7) 
 
7.0 
(6.4–7.6) 
 
6.7 
(6.1–7.2) 
 
6.9 
(6.3–7.5) 
 
6.7 
(6.2–7.2) 
 
6.3 
(5.8–6.8) 
 
6.7 
(6.2–7.2) 
 
5.7 
(5.3–6.1) 
 
6.2 
(5.7–6.7) 
 
6.4 
(5.9–6.9) 
—
 
Total m
edications 
72.9 
(71.4–74.3) 
 
71.6 
(70.1–73.1) 
 
71.3 
(70.0–72.7) 
 
69.8 
(68.3–71.2) 
 
71.4 
(69.9–72.9) 
 
68.4 
(67.0–69.7) 
 
67.9 
(66.5–69.2) 
 
68.7 
(67.5–70.0) 
 
69.5 
(67.9–71.1) 
 
69.0 
(67.6–70.3) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, and —
 indicates there w
as no change.  
N
ote: C
I – confidence interval; O
TC
 – over-the-counter. 
Table 9.1b: R
ates of m
edications prescribed, advised for over-the-counter purchase, supplied (rate per 100 encounters), 2001–02 to 2010–11 
M
edications 
R
ate per 100 encounters (95%
 C
I) 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 
(n = 96,688) 
 (n = 101,349)  
(n = 95,839) 
P
rescribed 
88.0 
(85.6–90.4) 
 
84.3 
(81.8–86.9) 
 
86.0 
(83.6–88.5) 
 
83.4 
(81.2–85.6) 
 
85.8 
(83.3–88.4) 
 
83.3 
(81.0–85.5) 
 
82.4 
(80.3–84.6) 
 
86.4 
(84.1–88.6) 
 
83.4 
(80.6–86.2) 
 
85.1 
(82.9–87.3) 
—
 
G
P
 supplied 
7.6 
(6.6–8.7) 
 
9.3 
(8.0–10.6) 
 
8.6 
(7.6–9.6) 
 
8.1 
(7.3–8.8) 
 
8.8 
(8.2–9.5) 
 
8.9 
(8.2–9.6) 
 
10.1 
(9.5–10.7) 
 
11.0 
(10.2–11.8) 
 
13.6 
(12.7–14.6) 
 
10.3 
(9.5–11.2) 

 
A
dvised O
TC
 
8.9 
(8.2–9.6) 
 
10.2 
(9.3–11.1) 
 
9.8 
(9.0–10.5) 
 
10.1 
(9.2–10.9) 
 
9.8 
(9.0–10.5) 
 
9.4 
(8.7–10.1) 
 
10.1 
(9.3–10.9) 
 
8.9 
(8.3–9.4) 
 
9.5 
(8.7–10.3) 
 
9.8 
(9.0–10.5) 
—
 
Total m
edications 
104.5 
(102.2–106.9) 
 
103.8 
(101.4–106.2)   
104.4 
(102.1–106.7)  
101.5 
(99.3–103.8) 
 
104.4 
(101.8–107.0)   
101.5 
(99.2–103.9) 
 
102.7 
(100.3–105.0)   
106.3 
(104.0–108.5)   
106.6 
(103.6–109.5)   
105.2 
(102.8–107.6) 
—
 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, and —
 indicates there w
as no change.  
N
ote: C
I – confidence interval; O
TC
 – over-the-counter. 
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Table 9.2a: Prescribed m
edications by A
TC
 Level 2 (rate per 100 problem
s), 2001–02 to 2010–11 
M
edications 
R
ate per 100 problem
s (95%
 C
I) 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  
(n = 146,141) 
A
ntibacterials for system
ic 
use 
9.7 
(9.3–10.1) 
 
9.2 
(8.8–9.6) 
 
9.3 
(8.9–9.7) 
 
9.6 
(9.2–10.1) 
 
10.0 
(9.6–10.4) 
 
9.4 
(9.0–9.8) 
 
9.1 
(8.7–9.5) 
 
9.4 
(9.1–9.8) 
 
9.1 
(8.7–9.5) 
 
9.5 
(9.1–9.9) 
—
 
A
nalgesics 
5.6 
(5.3–6.0) 
 
5.6 
(5.2–5.9) 
 
5.5 
(5.2–5.8) 
 
5.3 
(5.1–5.6) 
 
5.7 
(5.4–6.1) 
 
5.4 
(5.1–5.7) 
 
5.2 
(4.9–5.5) 
 
5.1 
(4.9–5.4) 
 
5.4 
(5.1–5.7) 
 
5.6 
(5.3–5.9) 
—
 
A
gents acting on the renin-
angiotensin system
 
3.5 
(3.3–3.7) 
 
3.4 
(3.2–3.6) 
 
3.7 
(3.5–3.9) 
 
3.8 
(3.6–4.0) 
 
4.2 
(3.9–4.5) 
 
4.4 
(4.2–4.6) 
 
4.4 
(4.1–4.6) 
 
4.6 
(4.3–4.8) 
 
4.2 
(4.0–4.5) 
 
4.3 
(4.1–4.5) 

 
P
sycholeptics 
3.6 
(3.3–3.8) 
 
3.2 
(3.0–3.4) 
 
3.4 
(3.2–3.6) 
 
3.4 
(3.1–3.6) 
 
3.4 
(3.2–3.6) 
 
3.3 
(3.1–3.5) 
 
3.1 
(2.9–3.3) 
 
3.2 
(3.0–3.4) 
 
2.8 
(2.6–3.0) 
 
3.0 
(2.8–3.1) 

 
P
sychoanaleptics 
2.1 
(2.0–2.2) 
 
2.1 
(1.9–2.2) 
 
2.2 
(2.1–2.4) 
 
2.2 
(2.0–2.3) 
 
2.3 
(2.1–2.4) 
 
2.3 
(2.2–2.5) 
 
2.3 
(2.2–2.4) 
 
2.4 
(2.3–2.5) 
 
2.5 
(2.4–2.7) 
 
2.6 
(2.5–2.8) 

 
D
rugs for obstructive 
airw
ay disease 
3.6 
(3.3–3.8) 
 
3.2 
(2.9–3.4) 
 
2.8 
(2.7–3.0) 
 
2.6 
(2.5–2.8) 
 
2.7 
(2.5–2.8) 
 
2.5 
(2.4–2.7) 
 
2.3 
(2.2–2.5) 
 
2.5 
(2.3–2.6) 
 
2.4 
(2.2–2.6) 
 
2.6 
(2.4–2.7) 

 
Lipid m
odifying agents 
1.7 
(1.6–1.8) 
 
1.6 
(1.5–1.8) 
 
1.9 
(1.8–2.0) 
 
2.1 
(2.0–2.2) 
 
2.3 
(2.1–2.4) 
 
2.3 
(2.2–2.5) 
 
2.5 
(2.3–2.6) 
 
2.6 
(2.5–2.8) 
 
2.5 
(2.4–2.7) 
 
2.5 
(2.4–2.7) 

 
A
nti-inflam
m
atory and 
antirheum
atic products 
3.7 
(3.5–3.9) 
 
3.3 
(3.1–3.5) 
 
3.3 
(3.1–3.4) 
 
3.1 
(2.9–3.3) 
 
2.7 
(2.5–2.8) 
 
2.4 
(2.3–2.6) 
 
2.3 
(2.1–2.4) 
 
2.2 
(2.0–2.3) 
 
2.1 
(1.9–2.2) 
 
2.1 
(2.0–2.2) 

 
D
rugs for acid related 
disorders 
1.8 
(1.6–1.9) 
 
1.8 
(1.6–1.9) 
 
2.0 
(1.8–2.1) 
 
1.9 
(1.8–2.0) 
 
2.1 
(2.0–2.2) 
 
2.0 
(1.9–2.1) 
 
2.0 
(1.9–2.1) 
 
2.1 
(2.0–2.2) 
 
2.1 
(1.9–2.2) 
 
2.0 
(1.9–2.2) 

 
D
rugs used in diabetes 
1.5 
(1.4–1.7) 
 
1.3 
(1.2–1.4) 
 
1.5 
(1.4–1.6) 
 
1.4 
(1.3–1.5) 
 
1.7 
(1.5–1.9) 
 
1.6 
(1.5–1.8) 
 
1.7 
(1.5–1.8) 
 
1.9 
(1.7–2.0) 
 
1.7 
(1.5–1.9) 
 
1.8 
(1.7–2.0) 

 
C
orticosteroids, 
derm
atological preparations 
2.0 
(1.9–2.1) 
 
1.8 
(1.7–1.9) 
 
1.8 
(1.7–1.9) 
 
1.9 
(1.8–2.0) 
 
1.7 
(1.6–1.8) 
 
1.8 
(1.6–1.9) 
 
1.7 
(1.6–1.8) 
 
1.7 
(1.6–1.8) 
 
1.5 
(1.4–1.6) 
 
1.7 
(1.6–1.8) 

 
S
ex horm
ones and 
m
odulators of the genital 
system
 
2.6 
(2.5–2.8) 
 
2.6 
(2.4–2.7) 
 
2.4 
(2.2–2.5) 
 
2.1 
(2.0–2.3) 
 
2.1 
(1.9–2.2) 
 
2.0 
(1.8–2.2) 
 
1.9 
(1.8–2.0) 
 
1.7 
(1.6–1.8) 
 
1.6 
(1.5–1.7) 
 
1.6 
(1.5–1.7) 

 
A
ntithrom
botic agents 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.2 
(1.1–1.4) 
 
1.3 
(1.2–1.4) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.2–1.5) 
 
1.5 
(1.4–1.6) 
 
1.5 
(1.3–1.6) 
 
1.4 
(1.3–1.5) 

 
C
alcium
 channel blockers 
1.5 
(1.4–1.6) 
 
1.4 
(1.3–1.5) 
 
1.5 
(1.4–1.6) 
 
1.4 
(1.3–1.5) 
 
1.5 
(1.4–1.6) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.3–1.5) 
 
1.5 
(1.4–1.6) 
 
1.3 
(1.2–1.4) 
 
1.2 
(1.1–1.3) 

 
(continued) 
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Table 9.2a (continued): Prescribed m
edications by A
TC
 Level 2 (rate per 100 problem
s), 2001–02 to 2010–11 
 
R
ate per 100 problem
s (95%
 C
I) 

(a) 
 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
A
TC
 Level 2 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  (n = 146,141) 
B
eta blocking agents 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.1 
(1.1–1.2) 
 
1.3 
(1.2–1.4) 
 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.2) 
 
1.3 
(1.2–1.4) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
—
 
O
phthalm
ologicals 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.1–1.2) 
 
1.2 
(1.1–1.3) 
 
1.2 
(1.1–1.3) 
 
1.2 
(1.1–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.0 
(1.0–1.1) 
 
1.0 
(1.0–1.1) 
—
 
V
accines 
2.7 
(2.4–2.9) 
 
2.9 
(2.6–3.1) 
 
2.3 
(2.0–2.5) 
 
2.0 
(1.8–2.3) 
 
1.7 
(1.5–1.9) 
 
1.2 
(1.0–1.3) 
 
1.1 
(0.9–1.2) 
 
1.0 
(0.9–1.2) 
 
1.1 
(0.9–1.3) 
 
1.0 
(0.8–1.1) 

 
C
orticosteroids for system
ic 
use 
0.9 
(0.9–1.0) 
 
0.7 
(0.7–0.8) 
 
0.9 
(0.8–0.9) 
 
0.8 
(0.8–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.8–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
—
 
D
iuretics 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.1) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.0) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.7–0.8) 

 
N
asal preparations 
0.6 
(0.6–0.7) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
—
 
O
ther nervous system
 
drugs 
0.4 
(0.3–0.6) 
 
0.3 
(0.2–0.4) 
 
0.2 
(0.2–0.3) 
 
0.4 
(0.2–0.5) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.4) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.6) 
—
 
O
tologicals 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
—
 
D
rugs for functional 
gastrointestinal disorders 
0.6 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.5 
(0.4–0.5) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
—
 
A
ntiepileptics 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 

 
Thyroid therapy 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.4) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.5–0.5) 

 
C
ardiac therapy 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 
 
0.5 
(0.5–0.6) 
 
0.4 
(0.4–0.5) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 

 
Total prescribed 
m
edications 
61.3 
(59.8–62.9) 
 
58.2 
(56.6–59.8) 
 
58.8 
(57.3–60.3) 
 
57.3 
(55.9–58.7) 
 
58.7 
(57.2–60.3) 
 
56.1 
(54.7–57.4) 
 
54.5 
(53.2–55.8) 
 
55.9 
(54.5–57.2) 
 
54.4 
(52.8–56.0) 
 
55.8 
(54.5–57.1) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change and —
 indicates 
there w
as no change. 
 
 
N
ote: C
I – confidence interval. 
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Table 9.2b: Prescribed m
edications by A
TC
 Level 2 (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 

(a) 
 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
A
TC
 Level 2 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
A
ntibacterials for system
ic 
use 
13.9 
(13.4–14.4) 
 
13.3 
(12.8–13.9) 
 
13.6 
(13.1–14.2) 
 
14.0 
(13.5–14.6) 
 
14.6 
(14.0–15.2) 
 
14.0 
(13.4–14.5) 
 
13.8 
(13.2–14.3) 
 
14.6 
(14.1–15.1) 
 
14.0 
(13.4–14.5) 
 
14.5 
(13.9–15.0) 
—
 
A
nalgesics 
8.1 
(7.7–8.5) 
 
8.1 
(7.6–8.6) 
 
8.1 
(7.6–8.6) 
 
7.8 
(7.3–8.2) 
 
8.4 
(7.9–8.9) 
 
8.0 
(7.6–8.4) 
 
7.9 
(7.5–8.3) 
 
7.9 
(7.5–8.3) 
 
8.2 
(7.7–8.7) 
 
8.6 
(8.1–9.0) 
—
 
A
gents acting on the renin-
angiotensin system
 
5.0 
(4.7–5.3) 
 
4.9 
(4.6–5.2) 
 
5.5 
(5.1–5.8) 
 
5.5 
(5.2–5.8) 
 
6.1 
(5.7–6.5) 
 
6.5 
(6.1–6.9) 
 
6.6 
(6.2–7.0) 
 
7.1 
(6.7–7.4) 
 
6.5 
(6.1–6.9) 
 
6.6 
(6.2–6.9) 

 
P
sycholeptics 
5.1 
(4.8–5.5) 
 
4.7 
(4.4–5.0) 
 
5.0 
(4.7–5.3) 
 
4.9 
(4.6–5.2) 
 
5.0 
(4.6–5.3) 
 
4.8 
(4.5–5.1) 
 
4.7 
(4.4–5.0) 
 
5.0 
(4.7–5.3) 
 
4.3 
(4.0–4.6) 
 
4.5 
(4.2–4.8) 

 
P
sychoanaleptics 
3.0 
(2.8–3.2) 
 
3.0 
(2.8–3.2) 
 
3.3 
(3.1–3.5) 
 
3.1 
(3.0–3.3) 
 
3.3 
(3.1–3.5) 
 
3.5 
(3.3–3.7 ) 
 
3.5 
(3.3–3.6) 
 
3.7 
(3.5–3.9) 
 
3.9 
(3.6–4.1) 
 
4.0 
(3.8–4.3) 

 
D
rugs for obstructive 
airw
ay diseases 
5.1 
(4.8–5.5) 
 
4.6 
(4.3–4.9) 
 
4.1 
(3.9–4.4) 
 
3.8 
(3.6–4.1) 
 
3.9 
(3.6–4.1) 
 
3.8 
(3.5–4.0) 
 
3.5 
(3.3–3.8) 
 
3.8 
(3.6–4.0) 
 
3.7 
(3.4–4.0) 
 
3.9 
(3.6–4.2) 

 
Lipid m
odifying agents 
2.4 
(2.3–2.6) 
 
2.4 
(2.2–2.6) 
 
2.8 
(2.6–3.0) 
 
3.0 
(2.8–3.2) 
 
3.3 
(3.0–3.6) 
 
3.4 
(3.2–3.7) 
 
3.7 
(3.5–4.0) 
 
4.1 
(3.8–4.3) 
 
3.9 
(3.6–4.2) 
 
3.9 
(3.6–4.1) 

 
A
nti-inflam
m
atory and 
antirheum
atic products 
5.3 
(5.1–5.6) 
 
4.8 
(4.6–5.1) 
 
4.8 
(4.5–5.0) 
 
4.5 
(4.2–4.7) 
 
3.9 
(3.7–4.2) 
 
3.6 
(3.4–3.9) 
 
3.5 
(3.2–3.7) 
 
3.4 
(3.2–3.5) 
 
3.2 
(2.9–3.4) 
 
3.2 
(3.0–3.4) 

 
D
rugs for  acid related 
disorders 
2.5 
(2.4–2.7) 
 
2.5 
(2.4–2.7) 
 
2.9 
(2.7–3.0) 
 
2.7 
(2.5–2.9) 
 
3.1 
(2.9–3.2) 
 
3.0 
(2.8–3.2) 
 
3.0 
(2.9–3.2) 
 
3.3 
(3.1–3.4) 
 
3.2 
(2.9–3.4) 
 
3.1 
(2.9–3.3) 

 
D
rugs used in diabetes 
2.2 
(2.0–2.4) 
 
1.9 
(1.7–2.1) 
 
2.2 
(2.0–2.4) 
 
2.1 
(1.9–2.2) 
 
2.5 
(2.2–2.7) 
 
2.4 
(2.2–2.6) 
 
2.5 
(2.3–2.8) 
 
2.9 
(2.6–3.2) 
 
2.6 
(2.4–2.9) 
 
2.8 
(2.5–3.0) 

 
C
orticosteroids, 
derm
atological 
preparations 
2.8 
(2.7–3.0) 
 
2.6 
(2.5–2.8) 
 
2.6 
(2.4–2.7) 
 
2.8 
(2.6–2.9) 
 
2.5 
(2.4–2.7) 
 
2.6 
(2.4–2.8) 
 
2.6 
(2.4–2.7) 
 
2.6 
(2.5–2.8) 
 
2.4 
(2.2–2.5) 
 
2.6 
(2.4–2.7) 

 
S
ex horm
ones and 
m
odulators of the genital 
system
 
3.8 
(3.6–4.0) 
 
3.7 
(3.5–3.9) 
 
3.5 
(3.3–3.7) 
 
3.1 
(2.9–3.3) 
 
3.0 
(2.8–3.2)  
 
3.0 
(2.7–3.3) 
 
2.9 
(2.7–3.0) 
 
2.7 
(2.5–2.9) 
 
2.5 
(2.3–2.6) 
 
2.5 
(2.3–2.6) 

 
A
ntithrom
botic agents 
1.5 
(1.4–1.7) 
 
1.6 
(1.4–1.7) 
 
1.8 
(1.6–1.9) 
 
1.8 
(1.6–2.0) 
 
1.9 
(1.7–2.1) 
 
2.1 
(1.9–2.2) 
 
2.1 
(1.9–2.3) 
 
2.4 
(2.2–2.5) 
 
2.2 
(2.1–2.4) 
 
2.1 
(2.0–2.3) 

 
(continued) 
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Table 9.2b (continued): Prescribed m
edications by A
TC
 Level 2 (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 

(a) 
 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
A
TC
 Level 2 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
C
alcium
 channel blockers 
2.2 
(2.0–2.4) 
 
2.0 
(1.8–2.1) 
 
2.2 
(2.0–2.3) 
 
2.0 
(1.8–2.1) 
 
2.2 
(2.0–2.4) 
 
2.1 
(2.0–2.3) 
 
2.1 
(1.9–2.3) 
 
2.3 
(2.1–2.4) 
 
2.0 
(1.9–2.2) 
 
1.8 
(1.7–2.0) 

 
B
eta blocking agents 
1.8 
(1.6–1.9) 
 
1.6 
(1.5–1.7) 
 
1.8 
(1.7–2.0) 
 
1.7 
(1.5–1.8) 
 
1.9 
(1.8–2.1) 
 
1.8 
(1.7–2.0) 
 
1.7 
(1.6–1.9) 
 
2.0 
(1.8–2.1) 
 
1.6 
(1.5–1.8) 
 
1.7 
(1.6–1.8) 
—
 
O
phthalm
ologicals 
1.5 
(1.4–1.6) 
 
1.6 
(1.5–1.7) 
 
1.7 
(1.5–1.8) 
 
1.7 
(1.6–1.8) 
 
1.8 
(1.7–1.9) 
 
1.7 
(1.6–1.8) 
 
1.7 
(1.5–1.8) 
 
1.7 
(1.6–1.8) 
 
1.6 
(1.5–1.7) 
 
1.6 
(1.5–1.7) 
—
 
V
accines 
3.8 
(3.5–4.2) 
 
4.2 
(3.8–4.5) 
 
3.3 
(3.0–3.6) 
 
2.9 
(2.6–3.3) 
 
2.5 
(2.2–2.8) 
 
1.7 
(1.5–1.9) 
 
1.6 
(1.4–1.8) 
 
1.6 
(1.4–1.8) 
 
1.7 
(1.4–1.9) 
 
1.5 
(1.3–1.7) 

 
C
orticosteroids for system
ic 
use 
1.3 
(1.2–1.5) 
 
1.1 
(1.0–1.2) 
 
1.3 
(1.1–1.4) 
 
1.2 
(1.1–1.4) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.2–1.5) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 
 
1.4 
(1.3–1.6) 
 
1.4 
(1.3–1.5) 
—
 
D
iuretics 
1.7 
(1.5–1.9) 
 
1.6 
(1.4–1.7) 
 
1.5 
(1.4–1.7) 
 
1.3 
(1.2–1.5) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.3–1.5) 
 
1.2 
(1.1–1.4) 
 
1.3 
(1.2–1.4) 
 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.2) 

 
N
asal preparations 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
—
 
O
ther nervous system
 
drugs 
0.6 
(0.4–0.8) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.3–0.4) 
 
0.5 
(0.3–0.7) 
 
0.6 
(0.4–0.7) 
 
0.4 
(0.3–0.5 ) 
 
0.5 
(0.4–0.6) 
 
0.8 
(0.6–0.9) 
 
0.8 
(0.6–0.9) 
 
0.9 
(0.8–1.0) 

 
O
tologicals 
0.9 
(0.8–1.0) 
 
0.8 
(0.8–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.8–0.9) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
—
 
D
rugs for functional 
gastrointestinal disorders 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.0) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
—
 
A
ntiepileptics 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.6–0.7 ) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.5–0.6) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 

 
Thy roid therapy 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.8) 

 
C
ardiac therapy 
1.2 
(1.1–1.3) 
 
1.0 
(0.8–1.1) 
 
1.1 
(0.9–1.2) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.9 
(0.8–1.0) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 

 
Total prescribed 
m
edications 
88.0 
(85.6–90.4) 
 
84.3 
(81.8–86.9) 
 
86.0 
(83.6–88.5) 
 
83.4 
(81.2–85.6) 
 
85.8 
(83.3–88.4) 
 
83.3 
(81.0–85.5) 
 
82.4 
(80.3–84.6) 
 
86.4 
(84.1–88.6) 
 
83.4 
(80.6–86.2) 
 
85.1 
(82.9–87.3) 
—
 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change and —
 indicates 
there w
as no change. 
N
ote: C
I – confidence interval. 
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Table 9.3a: M
ost frequently prescribed m
edications by C
A
PS generic (rate per 100 problem
s), 2001–02 to 2010–11 
 
R
ate per 100 problem
s (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
G
eneric drug 
(n = 139,092) 
 (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  
(n = 146,141) 
A
m
oxycillin 
2.0 
(1.9–2.2) 
 
2.1 
(2.0–2.3) 
 
2.2 
(2.0–2.4) 
 
2.4 
(2.2–2.6) 
 
2.4 
(2.3–2.6) 
 
2.2 
(2.0–2.4) 
 
2.3 
(2.1–2.5) 
 
2.3 
(2.1–2.4) 
 
2.1 
(1.9–2.3) 
 
2.1 
(2.0–2.3) 
—
 
C
ephalexin 
1.4 
(1.3–1.5) 
 
1.3 
(1.2–1.4) 
 
1.4 
(1.3–1.5) 
 
1.6 
(1.5–1.8) 
 
1.7 
(1.6–1.9) 
 
1.6 
(1.5–1.7) 
 
1.6 
(1.5–1.7) 
 
1.6 
(1.5–1.7) 
 
1.7 
(1.6–1.8) 
 
1.8 
(1.7–1.9) 

 
P
aracetam
ol [plain] 
2.1 
(2.0–2.3) 
 
2.2 
(1.9–2.4) 
 
2.0 
(1.7–2.2) 
 
1.8 
(1.7–2.0) 
 
2.1 
(1.9–2.3) 
 
1.7 
(1.5–1.9) 
 
1.6 
(1.5–1.8) 
 
1.5 
(1.4–1.6) 
 
1.8 
(1.5–2.0) 
 
1.7 
(1.5–1.8) 

 
A
m
oxycillin/potassium
 
clavulanate 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.0–1.3) 
 
1.2 
(1.0–1.3) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.3) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.2) 
 
1.3 
(1.2–1.4) 

 
P
aracetam
ol/codeine [all] 
1.6 
(1.4–1.7) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.2–1.5) 
 
1.4 
(1.3–1.5) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.1–1.4) 
 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 

 
A
torvastatin 
0.7 
(0.6–0.8) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
1.0 
(0.9–1.0) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.3) 
 
1.2 
(1.1–1.3) 
 
1.0 
(1.0–1.1) 
 
1.0 
(1.0–1.1) 

 
O
xycodone 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.4) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.8) 
 
0.9 
(0.8–0.9) 
 
1.0 
(0.9–1.0) 

 
S
albutam
ol 
1.4 
(1.3–1.5) 
 
1.2 
(1.1–1.3) 
 
1.0 
(1.0–1.1) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.9–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 

 
M
etform
in 
0.7 
(0.6–0.7) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.7) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.8–0.9) 
 
0.9 
(0.8–0.9) 

 
E
som
eprazole 
0.0
Ŧ 
(0.0–0.0) 
 
0.2 
(0.2–0.2) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 
 
0.8 
(0.7–0.8) 
 
0.8 
(0.8–0.9) 
 
0.8 
(0.8–0.9) 
 
0.8 
(0.7–0.9) 

 
W
arfarin sodium
 
0.6 
(0.5–0.7) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 

 
P
erindopril 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.6) 
 
0.7 
(0.6–0.7) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.8) 
 
0.9 
(0.8–0.9) 
 
0.8 
(0.7–0.8) 
 
0.8 
(0.7–0.8) 

 
R
oxithrom
ycin 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.7 
(0.7–0.8) 

 
(continued) 
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Table 9.3a (continued): M
ost frequently prescribed m
edications by C
A
PS generic (rate per 100 problem
s), 2001–02 to 2010–11 
 
R
ate per 100 problem
s (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
G
eneric drug 
(n = 139,092) 
 (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  
(n = 146,141) 
D
iazepam
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.7–0.8) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
—
 
Tem
azepam
 
0.9 
(0.9–1.0) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.8–0.9) 
 
0.8 
(0.7–0.8) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.8) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 

 
M
eloxicam
 
0.0
Ŧ 
(0.0–0.0) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 

 
R
osuvastatin 
N
/A
 
 
N
/A
 
 
N
/A
 
 
N
/A
 
 
N
/A
 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.2 
(0.2–0.3) 
 
0.4 
(0.3–0.4) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 

 
C
hloram
phenicol eye 
0.6 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
—
 
Tram
adol 
0.5 
(0.4–0.5) 
 
0.7 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 

 
Fluticasone/salm
eterol 
0.4 
(0.4–0.5) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 

 
Irbesartan 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.6) 
—
 
B
etam
ethasone topical 
0.6 
(0.5–0.7) 
 
0.5 
(0.4–0.5) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
—
 
Levonorgestrel/ 
ethinyloestradiol 
0.8 
(0.8–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 

 
A
tenolol 
0.7 
(0.6–0.8) 
 
0.6 
(0.5–0.6) 
 
0.7 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 

 
Irbesartan/ 
hydrochlorothiazide 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 

 
D
oxycycline 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
—
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Table 9.3a (continued): M
ost frequently prescribed m
edications by C
A
PS generic (rate per 100 problem
s), 2001–02 to 2010–11 
 
R
ate per 100 problem
s (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
G
eneric drug 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  
(n = 146,141) 
G
eneric m
edications frequently prescribed in previous years 
S
im
vastatin 
0.7 
(0.6–0.7) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.7–0.8) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.4 
(0.4–0.4) 

 
C
elecoxib 
1.0 
(0.9–1.1) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 

 
Influenza virus vaccine 
1.0 
(0.9–1.2) 
 
1.0 
(0.8–1.2) 
 
0.8 
(0.7–1.0) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.6–0.9) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.2–0.4) 

 
C
efaclor m
onohydrate 
0.8 
(0.7–0.8) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.4–0.7) 
 
0.5 
(0.4–0.6) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.6) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 

 
Total prescribed 
m
edications 
61.3 
(59.8–62.9) 
 
58.2 
(56.6–59.8) 
 
58.8 
(57.3–60.3) 
 
57.3 
(55.9–58.7) 
 
58.7 
(57.2–60.3) 
 
56.1 
(54.7–57.4) 
 
54.5 
(53.2–55.8) 
 
55.9 
(54.5–57.2) 
 
54.4 
(52.8–56.0) 
 
55.8 
(54.5–57.1) 

 
(a) 
 linear of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant change, 
/
 indicates a m
arginally significant linear change and —
 indicates there w
as no change. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 encounters. 
N
ote: C
I – confidence interval; N
/A – not applicable (that is, drug w
as not available at that tim
e). 
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Table 9.3b: M
ost frequently prescribed m
edications by C
A
PS generic (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 

(a) 
 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
G
eneric drug 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
A
m
oxycillin 
2.9 
(2.7–3.1) 
 
3.1 
(2.8–3.4) 
 
3.3 
(3.0–3.5) 
 
3.5 
(3.2–3.8) 
 
3.6 
(3.3–3.8) 
 
3.3 
(3.0–3.6) 
 
3.5 
(3.2–3.7) 
 
3.5 
(3.3–3.8) 
 
3.2 
(3.0–3.5) 
 
3.3 
(3.0–3.5) 
—
 
C
ephalexin 
2.0 
(1.9–2.2) 
 
1.9 
(1.8–2.0) 
 
2.0 
(1.9–2.2) 
 
2.4 
(2.2–2.6) 
 
2.5 
(2.3–2.7) 
 
2.3 
(2.2–2.5) 
 
2.4 
(2.3–2.6) 
 
2.5 
(2.3–2.6) 
 
2.6 
(2.5–2.8) 
 
2.7 
(2.5–2.9) 

 
P
aracetam
ol 
3.1 
(2.8–3.4) 
 
3.1 
(2.8–3.5) 
 
2.9 
(2.5–3.2) 
 
2.7 
(2.4–2.9) 
 
3.0 
(2.7–3.3) 
 
2.6 
(2.3–2.8) 
 
2.5 
(2.2–2.7) 
 
2.3 
(2.1–2.5) 
 
2.7 
(2.3–3.0) 
 
2.5 
(2.3–2.8) 
—
 
A
m
oxycillin/ 
potassium
 clavulanate 
1.6 
(1.4–1.7) 
 
1.6 
(1.4–1.7) 
 
1.7 
(1.5–1.8) 
 
1.7 
(1.5–1.8) 
 
1.6 
(1.5–1.8) 
 
1.7 
(1.5–1.9) 
 
1.7 
(1.6–1.9) 
 
1.8 
(1.7–2.0) 
 
1.6 
(1.5–1.8) 
 
2.0 
(1.8–2.2) 

 
P
aracetam
ol/codeine [all] 
2.2 
(2.1–2.4) 
 
2.0 
(1.8–2.2) 
 
2.1 
(1.9–2.3) 
 
2.0 
(1.8–2.2) 
 
2.0 
(1.8–2.2) 
 
2.0 
(1.8–2.1) 
 
1.9 
(1.7–2.1) 
 
1.9 
(1.8–2.0) 
 
1.7 
(1.5–1.8) 
 
1.9 
(1.7–2.0) 

 
A
torvastatin 
1.0 
(0.9–1.1) 
 
1.0 
(1.0–1.1) 
 
1.2 
(1.1–1.3) 
 
1.4 
(1.3–1.5) 
 
1.6 
(1.4–1.8) 
 
1.7 
(1.5–1.8) 
 
1.7 
(1.6–1.9) 
 
1.9 
(1.7–2.0) 
 
1.6 
(1.5–1.7) 
 
1.6 
(1.5–1.7) 

 
O
xycodone 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.2) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 
 
1.5 
(1.3–1.6) 

 
S
albutam
ol 
2.0 
(1.8–2.1) 
 
1.7 
(1.6–1.9) 
 
1.5 
(1.4–1.6) 
 
1.4 
(1.3–1.5) 
 
1.5 
(1.4–1.6) 
 
1.4 
(1.3–1.5) 
 
1.3 
(1.2–1.5) 
 
1.4 
(1.3–1.5) 
 
1.4 
(1.2–1.6) 
 
1.4 
(1.2–1.5) 

 
M
etform
in 
0.9 
(0.8–1.0) 
 
0.8 
(0.8–0.9) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.0) 
 
1.2 
(1.0–1.3) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.4 
(1.2–1.5) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.2–1.4) 

 
E
som
eprazole 
0.0
Ŧ 
(0.0–0.0) 
 
0.3 
(0.2–0.3) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.6–0.8) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.1–1.4) 
 
1.2 
(1.1–1.3) 

 
W
arfarin sodium
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.1) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.2) 
 
1.1 
(0.9–1.2) 
 
1.2 
(1.1–1.4) 
 
1.2 
(1.0–1.3) 
 
1.2 
(1.0–1.3) 

 
P
erindopril 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
1.0 
(0.9–1.1) 
 
1.2 
(1.1–1.3) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.5) 
 
1.2 
(1.1–1.3) 
 
1.2 
(1.1–1.3) 

 
R
oxithrom
ycin 
1.4 
(1.3–1.5) 
 
1.3 
(1.2–1.5) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.3) 
 
1.5 
(1.3–1.7) 
 
1.4 
(1.2–1.5) 
 
1.2 
(1.1–1.4) 
 
1.4 
(1.3–1.5) 
 
1.3 
(1.2–1.5) 
 
1.1 
(1.0–1.2) 

 
D
iazepam
 
1.0 
(0.9–1.2) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.3) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.2) 
—
 
(continued) 
82
Table 9.3b (continued): M
ost frequently prescribed m
edications by C
A
PS generic (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 

(a) 
 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
G
eneric drug 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
Tem
azepam
 
1.3 
(1.2–1.5) 
 
1.2 
(1.1–1.3) 
 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.0 
(0.9–1.2) 
 
1.0 
(0.9–1.1) 

 
M
eloxicam
 
0.0
Ŧ 
(0.0–0.1) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.7 
(0.7–0.8) 
 
0.9 
(0.8–1.1) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 

 
R
osuvastatin 
N
/A
 
 
N
/A
 
 
N
/A
 
 
N
/A
 
 
N
/A
 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.3 
(0.3–0.4) 
 
0.6 
(0.5–0.6) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.9–1.0) 

 
C
hloram
phenicol eye 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.9–1.0) 
 
1.1 
(1.0–1.1) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.9–1.0) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
—
 
Tram
adol 
0.7 
(0.6–0.8) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.9–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–0.9) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 

 
Fluticasone/salm
eterol 
0.6 
(0.5–0.7) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–0.9) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.8–0.9) 

 
Irbesartan 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
1.1 
(1.0–1.2) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
0.8 
(0.7–0.9) 
—
 
B
etam
ethasone topical 
0.9 
(0.8–1.0) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
—
 
Levonorgestrel/ 
ethinyloestradiol 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
0.8 
(0.8–0.9) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.8) 

 
A
tenolol 
1.0 
(0.9–1.1) 
 
0.8 
(0.7–0.9) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.8–1.1) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.7–0.8) 

 
Irbesartan/ 
hydrochlorothiazide 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 

 
D
oxycycline 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
—
 
Thyroxine 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.7–0.8) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 

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Table 9.3b (continued): M
ost frequently prescribed m
edications by C
A
PS generic (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 

(a) 
 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
G
eneric drug 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
E
rythrom
ycin 
0.6 
(0.5–0.7) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
—
 
P
antoprazole 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.7) 

 
M
om
etasone 
0.8 
(0.7–0.9) 
 
0.6 
(0.6–0.7) 
 
0.5 
(0.5–0.6) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 
 
0.8 
(0.7–0.8) 
 
0.7 
(0.6–0.7) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.6–0.7) 

 
R
am
ipril 
0.6 
(0.5–0.7) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.7) 
—
 
G
eneric m
edications frequently prescribed in previous years 
S
im
vastatin 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.0–1.3) 
 
1.1 
(1.0–1.2) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.6 
(0.6–0.7) 

 
D
iclofenac sodium
 system
ic 
0.9 
(0.8–1.0) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
1.0 
(0.8–1.1) 
 
1.0 
(0.9–1.1) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.5 
(0.5–0.6) 

 
C
elecoxib 
1.4 
(1.3–1.5) 
 
1.1 
(1.0–1.2) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.5–0.6) 

 
C
efaclor m
onohydrate 
1.1 
(1.0–1.2) 
 
1.0 
(0.9–1.2) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–1.0) 
 
0.8 
(0.6–1.0) 
 
0.8 
(0.6–0.9) 
 
0.6 
(0.5–0.7) 
 
0.8 
(0.7–0.9) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 

 
Influenza virus vaccine 
1.5 
(1.2–1.7) 
 
1.4 
(1.2–1.7) 
 
1.2 
(1.0–1.4) 
 
0.9 
(0.7–1.1) 
 
1.1 
(0.8–1.3) 
 
0.6 
(0.5–0.7) 
 
0.4 
(0.3–0.5) 
 
0.6 
(0.4–0.7) 
 
0.6 
(0.4–0.7) 
 
0.5 
(0.3–0.6) 

 
O
m
eprazole 
0.8 
(0.8–0.9) 
 
0.8 
(0.8–0.9) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 

 
Total prescribed 
m
edications 
88.0 
(85.6–90.4) 
 
84.3 
(81.8–86.9) 
 
86.0 
(83.6–88.5) 
 
83.4 
(81.2–85.6) 
 
85.8 
(83.3–88.4) 
 
83.3 
(81.0–85.5) 
 
82.4 
(80.3–84.6) 
 
86.4 
(84.1–88.6) 
 
83.4 
(80.6–86.2) 
 
85.1 
(82.9–87.3) 
—
 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change  
and —
 indicates there w
as no change. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 encounters. 
N
ote: C
I – confidence interval; N
/A – not applicable (that is, drug w
as not available at that tim
e). 
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Table 9.4: N
um
ber of repeats for prescribed m
edications, 2001–02 to 2010–11 
 
Per cent of prescriptions (95%
 C
I) (a) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(b) 
 
 
N
um
ber of repeats 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 84,540) 
 (n = 81,542) 
N
o repeats 
38.3 
(36.7–39.4) 
 
38.0 
(36.4–39.6) 
 
37.8 
(36.2–39.3) 
 
38.5 
(36.8–40.2) 
 
35.9 
(34.4–37.5) 
 
35.2 
(33.7–36.7) 
 
34.5 
(33.1–35.9) 
 
34.0 
(32.8–35.2) 
 
34.2 
(32.7–35.7) 
 
34.7 
(33.3–36.0) 

 
O
ne repeat 
17.6 
(16.8–18.3) 
 
17.7 
(16.8–18.6) 
 
16.6 
(15.8–17.3) 
 
17.6 
(16.7–18.4) 
 
17.6 
(16.8–18.4) 
 
16.4 
(15.6–17.1) 
 
16.8 
(16.0–17.6) 
 
17.1 
(16.1–18.0) 
 
15.9 
(15.2–16.6) 
 
15.9 
(15.2–16.6) 

 
Tw
o repeats 
13.1 
(12.3–14.0) 
 
12.0 
(11.0–13.0) 
 
11.4 
(10.6–12.1) 
 
10.6 
(10.0–11.3) 
 
10.1 
(9.4–10.9) 
 
10.5 
(9.6–11.4) 
 
10.2 
(9.3–11.1) 
 
9.7 
(9.0–10.3) 
 
9.6 
(8.9–10.3) 
 
9.8 
(9.0–10.5) 

 
Three or four repeats 
4.5 
(4.1–4.9) 
 
4.8 
(4.4–5.1) 
 
5.0 
(4.7–5.4) 
 
4.8 
(4.4–5.2) 
 
4.5 
(3.8–5.2) 
 
4.8 
(4.3–5.3) 
 
4.6 
(4.0–5.2) 
 
4.4 
(4.0–4.8) 
 
3.5 
(3.1–3.9) 
 
4.1 
(3.5–4.6) 
—
 
Five repeats 
26.4 
(25.2–27.7) 
 
27.4 
(26.0–28.7) 
 
29.2 
(27.9–30.4) 
 
28.3 
(27.0–29.6) 
 
31.7 
(30.3–33.1) 
 
33.0 
(31.7–34.4) 
 
33.8 
(32.5–35.1) 
 
34.8 
(33.6–36.0) 
 
35.8 
(34.2–37.4) 
 
35.4 
(34.2–36.6) 

 
S
ix or m
ore repeats 
0.0
 Ŧ 
(0.0–0.0) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.3) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
—
 
(a) 
M
issing data rem
oved. 
(b) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, and —
 indicates there w
as no change. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 encounters. 
N
ote: C
I – confidence interval. 
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Table 9.5a: M
edications m
ost frequently supplied by G
Ps (rate per 100 problem
s), 2001–02 to 2010–11 
 
R
ate per 100 problem
s (95%
 C
I) 

(a) 
 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
G
eneric m
edication 
(n = 139,092) 
 (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  (n = 146,141) 
Influenza virus vaccine 
0.6 
(0.5–0.8) 
 
0.5 
(0.4–0.6) 
 
0.8 
(0.6–1.0) 
 
0.9 
(0.6–1.1) 
 
1.1 
(0.9–1.2) 
 
1.3 
(1.1–1.6) 
 
1.0 
(0.8–1.1) 
 
1.5 
(1.3–1.7) 
 
2.7 
(2.4–3.0) 
 
1.7 
(1.5–2.0) 
§ 
P
neum
ococcal vaccine 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.1 
(0.0–0.1) 
 
0.3 
(0.2–0.4) 
 
0.6 
(0.5–0.7) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
§ 
V
itam
in B
12 (C
obalam
in) 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 

 
D
iphtheria/pertussis/ 
tetanus/hepatitis B
/ 
polio/H
ib vaccine 
N
/A
 
 
N
/A
 
 
N
/A
 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 

 
M
um
ps/m
easles/rubella 
vaccine 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 

 
Triple antigen 
(diphtheria/pertussis/ 
tetanus)  
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
—
 
R
otavirus vaccine 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.1 
(0.1–0.1) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
—
 
D
iphtheria/pertussis/ 
tetanus/polio vaccine 
N
/A
 
 
N
/A
 
 
N
/A
 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 

 
A
D
T/C
D
T 
(diphtheria/tetanus) 
vaccine 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
—
 
M
eningitis vaccine 
0.0
Ŧ 
(0.0–0.0) 
 
0.1 
(0.1–0.1) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 

 
Total G
P-supplied 
m
edications 
5.3 
(4.6–6.1) 
 
6.4 
(5.5–7.3) 
 
5.9 
(5.2–6.5) 
 
5.5 
(5.0–6.0) 
 
6.0 
(5.6–6.5) 
 
6.0 
(5.5–6.5) 
 
6.7 
(6.3–7.1) 
 
7.1 
(6.6–7.6) 
 
8.9 
(8.3–9.5) 
 
6.8 
(6.2–7.3) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, § indicates a non-linear significant change, and —
 indicates no change. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 problem
s m
anaged. 
N
ote: C
I – confidence interval; N
/A – not applicable (that is, drug w
as not available at that tim
e). 
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Table 9.5b: M
edications m
ost frequently supplied by G
Ps (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 

(a) 
 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
G
eneric m
edication 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 
(n = 95,898) 
 
(n = 96,688) 
 (n = 101,349)  
(n = 95,839) 
Influenza virus vaccine 
0.9 
(0.7–1.1) 
 
0.7 
(0.5–0.9) 
 
1.2 
(0.9–1.4) 
 
1.2 
(0.9–1.6) 
 
1.6 
(1.3–1.8) 
 
2.0 
(1.6–2.3) 
 
1.5 
(1.2–1.7) 
 
2.3 
(2.0–2.7) 
 
4.1 
(3.7–4.6) 
 
2.7 
(2.2–3.1) 
§ 
P
neum
ococcal vaccine 
0.0
Ŧ 
(0.0–0.1) 
 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.4 
(0.3–0.5) 
 
0.9 
(0.8–1.0) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.5–0.7) 
§ 
V
itam
in B
12 (C
obalam
in) 
0.0
Ŧ 
(0.0–0.1) 
 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 

 
D
iphtheria/pertussis/ 
tetanus/hepatitis B
/ 
polio/H
ib vaccine 
N
/A
 
 
N
/A
 
 
N
/A
 
 
0.1 
(0.0–0.1) 
 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 

 
M
um
ps/m
easles/rubella 
vaccine 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.3–0.3) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 

 
Triple antigen 
(diphtheria/pertussis/ 
tetanus)  
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.3–0.4) 

 
R
otavirus vaccine 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.1 
(0.1–0.2) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.2–0.3) 

 
D
iphtheria/pertussis/ 
tetanus/polio vaccine 
N
/A
 
 
N
/A
 
 
N
/A
 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.1 
(0.0–0.1) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 

 
A
D
T/C
D
T 
(diphtheria/tetanus)  
vaccine 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
—
 
M
eningitis vaccine 
0.0
Ŧ 
(0.0–0.0) 
 
0.2 
(0.1–0.2) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 

 
Total G
P supplied 
m
edications 
7.6 
(6.6–8.7) 
 
9.3 
(8.0–10.6) 
 
8.6 
(7.6–9.6) 
 
8.1 
(7.3–8.8) 
 
8.8 
(8.2–9.5) 
 
8.9 
(8.2–9.6) 
 
10.1 
(9.5–10.7) 
 
11.0 
(10.2–11.8) 
 
13.6 
(12.7–14.6) 
 
10.3 
(9.5–11.2) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, § indicates a non-linear significant change, 
and —
 indicates there w
as no change. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 encounters. 
N
ote: C
I – confidence interval; N
/A – not applicable (that is, drug w
as not available at that tim
e). 
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Table 9.6a: M
ost frequently advised over-the-counter m
edications (rate per 100 problem
s), 2001–02 to 2010–11 
 
R
ate per 100 problem
s (95%
 C
I) 
 
G
eneric drug 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
(n = 139,092) 
 (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  
(n = 146,141) 
P
aracetam
ol 
1.5 
(1.3–1.7) 
 
1.8 
(1.5–2.0) 
 
1.7 
(1.4–1.9) 
 
1.6 
(1.4–1.8) 
 
1.7 
(1.5–1.9) 
 
1.6 
(1.4–1.8) 
 
1.7 
(1.5–1.9) 
 
1.5 
(1.3–1.7) 
 
1.6 
(1.4–1.8) 
 
1.7 
(1.5–1.9) 
—
 
Ibuprofen 
0.3 
(0.3–0.4) 
 
0.5 
(0.3–0.6) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.4) 
—
 
S
aline bath/solution/ 
gargle 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.2 
(0.1–0.2) 
—
 
S
odium
 chloride topical 
nasal 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
—
 
Loratadine 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
—
 
C
etirizine 
0.1 
(0.1–0.1) 
 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
—
 
E
rgocalciferol (vitam
in D
 
analogue) 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
—
 
D
iclofenac topical 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
—
 
S
odium
/potassium
/citric/
glucose 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
—
 
C
lotrim
azole topical 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
—
 
Total advised 
m
edications 
6.2 
(5.7–6.7) 
 
7.0 
(6.4–7.6) 
 
6.7 
(6.1–7.2) 
 
6.9 
(6.3–7.5) 
 
6.7 
(6.2–7.2) 
 
6.3 
(5.8–6.8) 
 
6.7 
(6.2–7.2) 
 
5.7 
(5.3–6.1) 
 
6.2 
(5.7–6.7) 
 
6.4 
(5.9–6.9) 
—
 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: —
 indicates there w
as no change. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 problem
s m
anaged. 
N
ote: C
I – confidence interval. 
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Table 9.6b: M
ost frequently advised over-the-counter m
edications (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 problem
s (95%
 C
I) 
 
G
eneric drug 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
(n = 139,092) 
 (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  
(n = 146,141) 
P
aracetam
ol 
2.1 
(1.9–2.4) 
 
2.6 
(2.2–2.9) 
 
2.5 
(2.1–2.8) 
 
2.3 
(2.0–2.6) 
 
2.5 
(2.2–2.8) 
 
2.4 
(2.1–2.7) 
 
2.5 
(2.2–2.9) 
 
2.3 
(2.0–2.6) 
 
2.5 
(2.2–2.8) 
 
2.6 
(2.3–2.9) 
—
 
Ibuprofen 
0.5 
(0.4–0.6) 
 
0.7 
(0.5–0.8) 
 
0.5 
(0.4–0.7) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.7) 
—
 
S
aline bath/solution/ 
gargle 
0.1 
(0.0–0.1) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 

 
S
odium
 chloride topical 
nasal 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 

 
Loratadine 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
—
 
C
etirizine 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.2 
(0.1–0.2) 
—
 
E
rgocalciferol (vitam
in 
D
 analogue) 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 

 
D
iclofenac topical 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.1–0.2 ) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2)  
—
 
S
odium
/potassium
/ 
citric/glucose 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
—
 
C
lotrim
azole topical 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
—
 
Total advised 
m
edications 
8.9 
(8.2–9.6) 
 
10.2 
(9.3–11.1) 
 
9.8 
(9.0–10.5) 
 
10.1 
(9.2–10.9) 
 
9.8 
(9.0–10.5) 
 
9.4 
(8.7–10.1) 
 
10.1 
(9.3–10.9) 
 
8.9 
(8.3–9.4) 
 
9.5 
(8.7–10.3) 
 
9.8 
(9.0–10.5) 
—
 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change and —
 indicates there w
as no change. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 encounters. 
N
ote: C
I – confidence interval. 
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10 Other treatments 
This chapter includes data about the other (non-pharmacological) treatments provided in 
general practice from each of the 10 years of the BEACH study from 2001–02 to 2010–11. 
Other treatments included clinical and procedural treatments provided. These groups are 
defined in Appendix 4, Tables A4.4 and A4.5. The survey form allowed GPs to record up to 
two other treatments for each problem managed at the encounter. Between 2005–06 and 
2010–11 the GPs were also asked to indicate (using a tick box) whether the recorded 
treatment was provided by a practice nurse. In this chapter all ‘other treatments’ are 
reported, irrespective of whether they were done by the GP or by the practice nurse. That is, 
the non-pharmacological management provided at general practice patient encounters is 
described, rather than management provided specifically by the GP. However in the analysis 
of procedural treatments, injections given in provision of vaccines were removed, as this 
action was already been counted and reported in medications. Treatments provided by the 
practice nurse (including the injections given for vaccination) are reported separately in 
Chapter 13. 
Routine clinical measurements or observations, such as measurements of blood pressure and 
physical examinations, were not included between 2001–02 and 2004–05. With the inclusion 
of practice nurse activities in BEACH since 2005–06, clinical observations have been 
recorded, but only when done by the practice nurse. 
Other treatments data for the 10 years 2001–02 to 2010–11, are reported in two ways: as rates 
per 100 problems managed (for example, Table 10.1a) and as rates per 100 encounters (for 
example, Table 10.1b). In the text describing changes over time, the rates per 100 problems 
are reported as the primary measure, because there was a significant increase in the number 
of problems managed per encounter.  
The direction and type of change from 2001–02 to 2010–11 is indicated for each result in the 
far right column of the tables: / indicates a statistically significant linear change, 
/ indicates a marginally significant linear change, § indicates a non-linear significant or 
marginal change, and — indicates there was no change. 
Significant linear changes in the rate per 100 encounters can be extrapolated to estimate the 
national increase or decrease in the other treatments provided between 2001–02 and 2010–11. 
Examples of extrapolated change are given. The method used to extrapolate to national 
change estimates is described in Section 2.9. 
10.1 Clinical treatments 
Overall, there was a significant decline in the rate of clinical treatments provided for the 
management of patient problems in general practice from 26.5 per 100 problems managed in 
2001–02 to 23.3 per 100 problems managed in 2010–11 (Table 10.1a). However the change 
was not linear. Table 10.1a shows that the number of clinical treatments provided by GPs 
remained steady from 2001–02 to 2004–05. This was followed by a sharp decline in clinical 
treatments to 20.0 per 100 problems in 2005–06. Since then, rates slowly increased to reach 
23.3 per 100 problems in 2010–11, but there remained a significant decrease over the 10 years. 
When this is considered as a rate per 100 encounters, we can extrapolate this change to 
90
encounters across Australia which equates to 3.9 million fewer clinical treatments given by 
GPs nationally in 2010–11 than 10 years earlier. 
The overall result was reflected in the rates of specific types of clinical treatments.  
• General advice and education was the most common clinical treatment provided. 
Although there was no overall change over the decade, the rate at which general advice 
and education was provided decreased from 4.8 in 2004–05 to 3.3 per 100 problems in 
2005–06. From there, rates have slowly returned to a level just below that of 2001–02.  
• Counselling and advice about nutrition and weight fell from 3.8 per 100 problems in 
2001–02 to 2.6 in 2010–11 (Table 10.1a). From Table 10.1b we estimate there were 730,000 
fewer occasions of provision of counselling and advice about nutrition and weight given 
in 2010–11 than in 2001–02. 
• There was also a significant decrease in the rate at which advice and education about 
treatment was provided from 3.6 per 100 problems in 2001–02 to 2.2 per 100 in 2010–11 
(Table 10.1a). When considered as a rate per 100 encounters, this equates to 1 million 
fewer occasions at which advice and education about treatment was given in 2010–11 
than in 2001–02 (Table 10.1b).  
• There was no overall change in the rate at which advice and education about medication 
was provided over the decade, however, there were significant changes during this time. 
The rate of advice and education about medication more than halved from 2.3 per 100 
problems managed in 2004–05 to 1.1 in 2005–06. Since then, advice and education about 
medication has steadily increased significantly to reach 1.8 per 100 problems in 2010–11 
(Table 10.1a).  
While there was a significant decline in the number of clinical treatments given per 100 
problems managed over the decade, as more problems were managed per 100 encounters in 
2010–11 than in 2001–02 (see Section 7.1) there was no significant change in the total number 
of clinical treatments provided per 100 encounters (Table 10.1b).  
In 2010–11, depression was the problem that accounted for the most clinical treatments 
which were provided at a rate of 1.8 per 100 encounters. This means that for every 100 
encounters in 2010–11, GPs provided clinical treatment(s) in the management of depression 
1.8 times.  
The only significant change in the most common problems managed with clinical 
treatment(s) was an increase in the provision of clinical treatment(s) in the management of 
tobacco abuse. We estimate this increase from 0.3 per 100 encounters in 2001–02 to 0.6 per 
100 in 2010–11 equates to 410,000 more occasions where clinical treatments were provided 
for tobacco abuse nationally in 2010–11 than a decade earlier (Table 10.2). The significant 
increase occurred over the most recent three years and may be associated with the 
availability of prescribed medications to assist in smoking cessation, and to government anti-
smoking campaigns promoting discussion with GPs as a strategy towards quitting.  
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10.2 Procedures 
Overall, the rate at which procedures were performed in the management of patient 
problems increased between 2001–02 and 2010–11, from 9.6 per 100 problems to 11.1 per 
100 problems (Table 10.3a). This increase was reflected in the rates of specific types of 
procedures.  
• As a group, the frequency of dressings/pressure/compression/tamponade rose over the 
decade from 1.3 per 100 problems in 2001–02 to 1.7 per 100 in 2010–11 (Table 10.3b). 
When considered as a rate per 100 encounters, this increase from 1.8 per 100 encounters 
in 2001–02 to 2.5 per 100 encounters in 2010–11 extrapolates to nearly 1.2 million more 
dressings/pressure/compression/tamponade procedures undertaken nationally in 
2010–11 than in 2001–02.  
• The provision of local injections (excluding all local injection/infiltrations performed for 
immunisations) doubled from 0.8 to 1.6 per 100 problems over this period (Table 10.3a). 
From Table 10.3b we estimate a national increase of 1.6 million more occasions in 2010–11 
where local injections were given than in 2001–02. 
In contrast, Table 10.3a shows a significant decrease in the rate in the provision of physical 
medicine/rehabilitation (1.5 per 100 problems in 2001–02 to 0.8 per 100 in 2009–10) and other 
therapeutic procedures/surgery NEC (1.0 per 100 in 2001–02 to 0.5 per 100 in 2010–11). 
There was also an overall increase in the number of problems managed with procedural 
treatments from 2001–02 to 2010–11. Female genital check up/pap smear continued to be the 
most common problem to be managed with a procedure, increasing from 0.6 procedures per 
100 total problems managed in 2001–02 to 0.9 per 100 in 2010–11 (Table 10.4). When 
considering the rate per 100 encounters, we can extrapolate this change to encounters across 
Australia which equates to an estimated 460,000 more procedures performed by GPs 
nationally for female genital check-up/pap smear in 2010–11 than a decade earlier. 
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Table 10.1a: The m
ost frequent clinical treatm
ents (rate per 100 problem
s), 2001–02 to 2010–11 
 
R
ate per 100 problem
s (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
Treatm
ent 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373) 
 (n = 146,141) 
A
dvice/education N
E
C
* 
4.4 
(3.9–4.9) 
 
4.8 
(4.2–5.3) 
 
4.7 
(4.2–5.2) 
 
4.8 
(4.3–5.2) 
 
3.3 
(2.8–3.7) 
 
3.9 
(3.4–4.4) 
 
4.7 
(4.2–5.3) 
 
4.0 
(3.5–4.4) 
 
4.1 
(3.5–4.6) 
 
3.9 
(3.4–4.4) 
§ 
C
ounselling – problem
* 
3.2 
(2.8–3.7) 
 
3.8 
(3.3–4.2) 
 
3.2 
(2.8–3.6) 
 
2.9 
(2.5–3.3) 
 
3.3 
(2.8–3.7) 
 
2.9 
(2.5–3.4) 
 
2.9 
(2.5–3.2) 
 
2.5 
(2.1–2.8) 
 
2.8 
(2.4–3.2) 
 
3.5 
(2.9–4.0) 
—
 
C
ounselling/advice – 
nutrition/w
eight* 
3.8 
(3.5–4.1) 
 
3.6 
(3.2–4.0) 
 
3.2 
(2.9–3.5) 
 
3.7 
(3.3–4.0) 
 
2.5 
(2.2–2.7) 
 
2.3 
(2.0–2.5) 
 
2.8 
(2.5–3.0) 
 
2.6 
(2.4–2.9) 
 
2.4 
(2.2–2.7) 
 
2.6 
(2.3–2.9) 

 
A
dvice/education – 
treatm
ent* 
3.6 
(3.2–3.9) 
 
2.9 
(2.6–3.3) 
 
3.0 
(2.6–3.3) 
 
3.1 
(2.8–3.5) 
 
2.1 
(1.8–2.4) 
 
1.9 
(1.7–2.1) 
 
2.3 
(2.0–2.5) 
 
2.3 
(2.0–2.6) 
 
2.6 
(2.2–3.0) 
 
2.2 
(1.9–2.5) 

 
C
ounselling – 
psychological* 
2.2 
(2.0–2.4) 
 
2.0 
(1.8–2.2) 
 
2.0 
(1.8–2.1) 
 
2.2 
(2.0–2.4) 
 
2.1 
(1.9–2.3) 
 
1.9 
(1.8–2.1) 
 
2.1 
(2.0–2.3) 
 
2.1 
(1.9–2.3) 
 
2.2 
(2.1–2.4) 
 
2.1 
(1.9–2.3) 
—
 
A
dvice/education – 
m
edication* 
2.0 
(1.8–2.2) 
 
1.7 
(1.5–1.9) 
 
2.3 
(2.1–2.5) 
 
2.3 
(2.1–2.5) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.5) 
 
1.5 
(1.3–1.7) 
 
1.6 
(1.4–1.7) 
 
1.8 
(1.6–2.0) 
§ 
O
ther adm
inistration/ 
docum
ent* 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
0.9 
(0.8–1.0) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
1.0 
(0.9–1.1) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.5) 
 
1.2 
(1.1–1.4) 
—
 
S
ickness certificate* 
0.8 
(0.6–0.9) 
 
0.9 
(0.8–1.0) 
 
0.7 
(0.6–0.8) 
 
1.2 
(1.0–1.3) 
 
1.1 
(0.9–1.3) 
 
1.1 
(0.9–1.2) 
 
1.1 
(0.9–1.3) 
 
1.3 
(1.1–1.5) 
 
0.9 
(0.8–1.0) 
 
1.1 
(0.9–1.2) 

 
C
ounselling/advice – 
exercise* 
1.4 
(1.3–1.6) 
 
1.1 
(1.0–1.3) 
 
1.0 
(0.9–1.2) 
 
1.3 
(1.1–1.5) 
 
0.7 
(0.6–0.9) 
 
0.8 
(0.6–0.9) 
 
0.9 
(0.7–1.0) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.7–1.0) 

 
R
eassurance, support  
1.0 
(0.9–1.2) 
 
0.9 
(0.8–1.1) 
 
1.0 
(0.9–1.2) 
 
1.1 
(0.9–1.2) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.9 
(0.8–1.1) 
 
1.0 
(0.8–1.1) 
 
0.9 
(0.7–1.1) 
 
0.9 
(0.7–1.0) 
—
 
C
ounselling/advice – 
sm
oking* 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.6 
(0.5–0.6) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.6 
(0.5–0.6) 
—
 
Total clinical treatm
ents 
26.5 
(25.2–27.9) 
 
25.7 
(24.2–27.1) 
 
25.0 
(23.6–26.4) 
 
27.0 
(25.6–28.3) 
 
20.0 
(18.8–21.2) 
 
19.9 
(18.7–21.1) 
 
22.8 
(21.6–24.1) 
 
22.0 
(20.8–23.2) 
 
22.8 
(21.3–24.3) 
 
23.3 
(21.8–24.8) 
§ 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginal linear change, § indicates a non-linear 
significant or m
arginal change and —
 indicates there w
as no change. 
* 
Includes m
ultiple IC
P
C
-2 or IC
P
C
-2 P
LU
S
 codes (see A
ppendix 4, Table A
4.4, <purl.library.usyd.edu.au/sup/9781920899875>). 
N
ote: C
I – confidence interval; N
O
S
 – not otherw
ise specified; N
E
C
 – not elsew
here classified. 
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Table 10.1b: The m
ost frequent clinical treatm
ents (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
Treatm
ent 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
A
dvice/education N
E
C
* 
6.3 
(5.6–7.0) 
 
6.9 
(6.1–7.7) 
 
6.8 
(6.1–7.6) 
 
7.0 
(6.3–7.7) 
 
4.8 
(4.1–5.4) 
 
5.7 
(5.0–6.5) 
 
7.2 
(6.3–8.1) 
 
6.1 
(5.4–6.9) 
 
6.2 
(5.3–7.1) 
 
6.0 
(5.1–6.8) 
§ 
C
ounselling – problem
* 
4.7 
(4.0–5.3) 
 
5.5 
(4.8–6.1) 
 
4.7 
(4.1–5.3) 
 
4.2 
(3.6–4.7) 
 
4.8 
(4.1–5.4) 
 
4.4 
(3.7–5.0) 
 
4.3 
(3.8–4.9) 
 
3.8 
(3.3–4.4) 
 
4.3 
(3.7–5.0) 
 
5.3 
(4.4–6.2) 
—
 
C
ounselling/advice – 
nutrition/w
eight* 
5.5 
(5.0–5.9) 
 
5.2 
(4.7–5.8) 
 
4.6 
(4.2–5.1) 
 
5.3 
(4.8–5.8) 
 
3.6 
(3.2–4.0) 
 
3.4 
(3.0–3.7) 
 
4.2 
(3.8–4.6) 
 
4.1 
(3.6–4.5) 
 
3.7 
(3.4–4.1) 
 
4.0 
(3.5–4.4) 

 
A
dvice/education – 
treatm
ent* 
5.1 
(4.6–5.6) 
 
4.2 
(3.8–4.7) 
 
4.4 
(3.8–4.9) 
 
4.6 
(4.1–5.0) 
 
3.1 
(2.6–3.5) 
 
2.8 
(2.5–3.1) 
 
3.5 
(3.1–3.8) 
 
3.5 
(3.1–4.0) 
 
3.9 
(3.3–4.5) 
 
3.4 
(2.9–3.8) 

 
C
ounselling – 
psychological* 
3.2 
(2.8–3.5) 
 
2.9 
(2.6–3.1) 
 
2.9 
(2.6–3.1) 
 
3.2 
(2.9–3.5) 
 
3.0 
(2.8–3.3) 
 
2.9 
(2.6–3.1) 
 
3.2 
(2.9–3.4) 
 
3.2 
(3.0–3.5) 
 
3.4 
(3.2–3.7) 
 
3.2 
(3.0–3.5) 
—
 
A
dvice/education – 
m
edication* 
2.8 
(2.6–3.1) 
 
2.5 
(2.2–2.7) 
 
3.4 
(3.1–3.7) 
 
3.4 
(3.0–3.7) 
 
1.6 
(1.4–1.7) 
 
1.8 
(1.6–2.0) 
 
2.0 
(1.8–2.2) 
 
2.3 
(2.1–2.6) 
 
2.4 
(2.2–2.6) 
 
2.7 
(2.5–3.0) 
§ 
O
ther adm
inistration/ 
docum
ent* 
1.5 
(1.4–1.7) 
 
1.6 
(1.4–1.7) 
 
1.8 
(1.6–2.0) 
 
1.3 
(1.2–1.5) 
 
1.0 
(0.9–1.1) 
 
1.2 
(1.1–1.4) 
 
1.5 
(1.4–1.7) 
 
1.8 
(1.7–2.0) 
 
2.1 
(1.9–2.3) 
 
1.9 
(1.7–2.1) 
§ 
S
ickness certificate* 
1.1 
(0.9–1.3) 
 
1.3 
(1.1–1.5) 
 
1.0 
(0.9–1.2) 
 
1.7 
(1.5–1.9) 
 
1.6 
(1.4–1.9) 
 
1.6 
(1.3–1.8) 
 
1.7 
(1.4–2.0) 
 
1.9 
(1.6–2.2) 
 
1.4 
(1.2–1.6) 
 
1.6 
(1.4–1.8) 

 
C
ounselling/advice – 
exercise* 
2.1 
(1.8–2.3) 
 
1.6 
(1.4–1.8) 
 
1.5 
(1.3–1.7) 
 
1.9 
(1.6–2.1) 
 
1.1 
(0.9–1.2) 
 
1.1 
(1.0–1.3) 
 
1.3 
(1.1–1.5) 
 
1.4 
(1.2–1.6) 
 
1.2 
(1.0–1.4) 
 
1.4 
(1.1–1.6) 

 
R
eassurance, support 
1.5 
(1.3–1.7) 
 
1.4 
(1.2–1.5) 
 
1.5 
(1.3–1.7) 
 
1.6 
(1.4–1.8) 
 
1.0 
(0.8–1.2) 
 
1.1 
(0.9–1.3) 
 
1.4 
(1.2–1.6) 
 
1.5 
(1.3–1.8) 
 
1.4 
(1.1–1.7) 
 
1.3 
(1.1–1.5) 
—
 
C
ounselling/advice – 
sm
oking* 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.6–0.7) 
 
0.8 
(0.7–0.9) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.8) 
 
0.9 
(0.8–1.0) 
—
 
C
ounselling/advice – 
lifestyle* 
0.4 
(0.3–0.5) 
 
0.5 
(0.3–0.7) 
 
0.3 
(0.2–0.4) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.3–0.6) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.5) 
 
0.2 
(0.1–0.3) 
 
0.5 
(0.4–0.7) 
 
0.5 
(0.4–0.6) 
—
 
C
ounselling/advice – 
prevention* 
0.3 
(0.2–0.4) 
 
0.3 
(0.2–0.4) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.4–0.5) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.5 
(0.4–0.6) 
 
0.4 
(0.3–0.5) 
 
0.6 
(0.5–0.7) 
 
0.4 
(0.3–0.5) 
—
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Table 10.1b (continued): The m
ost frequent clinical treatm
ents (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
Treatm
ent 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
C
ounselling/advice – 
health/body* 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.4) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.3 
(0.2–0.4) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
—
 
C
ounselling/advice – 
alcohol* 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.5 
(0.4–0.5) 
 
0.3 
(0.3–0.3) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.4) 
—
 
Fam
ily planning* 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 

 
O
bserve/w
ait* 
0.3 
(0.2–0.4) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.4) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.2–0.4) 
 
0.3 
(0.2–0.4) 
 
0.3 
(0.2–0.4) 
 
0.4 
(0.3–0.6) 
 
0.3 
(0.2–0.4) 
 
0.3 
(0.2–0.3) 
—
 
C
ounselling/advice – 
pregnancy* 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.4) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
—
 
C
ounselling/advice – 
other* 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.3 
(0.2–0.4) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 

 
C
ounselling/advice – 
relaxation* 
0.4 
(0.3–0.4) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.4) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 

 
Total clinical treatm
ents 
38.1 
(36.1–40.1) 
 
37.2 
(35.0–39.4) 
 
36.6 
(34.5–38.7) 
 
39.2 
(37.1–41.4) 
 
29.2 
(27.3–31.1) 
 
29.5 
(27.6–31.4) 
 
34.5 
(32.5–36.5) 
 
34.0 
(32.1–35.9) 
 
35.0 
(32.6–37.4) 
 
35.5 
(33.2–37.8) 
§ 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginal linear change, § indicates a non-linear 
significant or m
arginal change, and —
 indicates there w
as no change. 
* 
Includes m
ultiple IC
P
C
-2 or IC
P
C
-2 P
LU
S
 codes (see A
ppendix 4, Table A
4.4, <purl.library.usyd.edu.au/sup/9781920899875>). 
N
ote: C
I – confidence interval.; N
E
C
 – not elsew
here classified.  
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Table 10.2: The m
ost com
m
on problem
s m
anaged w
ith a clinical treatm
ent, 2001–02 to 2010–11 
 
R
ate at w
hich a clinical treatm
ent w
as given for the selected problem
, per 100 encounters
 (a) (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(b) 
 
 
Problem
 m
anaged 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
D
epression* 
1.7 
(1.6–1.9) 
 
1.7 
(1.6–1.9) 
 
1.7 
(1.6–1.9) 
 
1.8 
(1.7–2.0) 
 
1.7 
(1.5–1.8) 
 
1.5 
(1.4–1.6) 
 
1.8 
(1.6–1.9) 
 
1.8 
(1.7–2.0) 
 
1.9 
(1.7–2.1) 
 
1.8 
(1.6–1.9) 
—
 
U
pper respiratory tract 
infection 
2.0 
(1.7–2.2) 
 
1.8 
(1.6–2.0) 
 
1.6 
(1.4–1.8) 
 
1.8 
(1.5–2.0) 
 
1.6 
(1.3–1.8) 
 
1.4 
(1.3–1.6) 
 
1.8 
(1.6–2.0) 
 
1.7 
(1.5–1.9) 
 
1.9 
(1.6–2.2) 
 
1.7 
(1.4–1.9) 
—
 
H
ypertension* 
1.3 
(1.2–1.5) 
 
1.5 
(1.3–1.7) 
 
1.3 
(1.1–1.4) 
 
1.3 
(1.2–1.5) 
 
1.0 
(0.9–1.2) 
 
0.9 
(0.8–1.0) 
 
1.2 
(1.1–1.4) 
 
1.1 
(1.0–1.2) 
 
1.0 
(0.8–1.1) 
 
1.1 
(0.9–1.3) 
—
 
D
iabetes – all* 
1.0 
(0.9–1.1) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
1.1 
(0.9–1.2) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
—
 
A
nxiety* 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
—
 
Lipid disorders 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
1.0 
(0.9–1.1) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.8) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 

 
G
astroenteritis* 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.7) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.6–0.8) 

 
B
ack com
plaint* 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
—
 
Tobacco abuse 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.6 
(0.5–0.6) 

 
Test results* 
0.4 
(0.3–0.4) 
 
0.3 
(0.2–0.4) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.3–0.6) 
 
0.4 
(0.3–0.4) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 

 
O
besity  
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.5) 
—
 
V
iral disease, other/N
O
S
  
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.4) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.5) 

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Table 10.2 (continued): The m
ost com
m
on problem
s m
anaged w
ith a clinical treatm
ent, 2001–02 to 2010–11 
 
R
ate at w
hich a clinical treatm
ent w
as given for the selected problem
, per 100 encounters
(a) (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(b) 
 
 
Problem
 m
anaged 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
A
cute bronchitis/ 
bronchiolitis 
0.5 
(0.4–0.5) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 
—
 
A
cute stress reaction 
0.4 
(0.4–0.5) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
—
 
A
sthm
a 
0.7 
(0.6–0.8) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 

 
Total problem
s w
ith 
clinical treatm
ents 
33.6 
(31.9–35.2) 
 
32.8 
(31.0–34.7) 
 
32.4 
(30.7–34.2) 
 
34.4 
(32.6–36.2) 
 
26.7 
(25.1–28.3) 
 
26.8 
(25.1–28.4) 
 
31.2 
(29.5–33.0) 
 
30.9 
(29.2–32.5) 
 
31.5 
(29.5–33.5) 
 
31.8 
(29.8–33.8) 
—
 
(a) 
R
ate of provision of clinical treatm
ent for selected problem
 per 100 total encounters. 
(b) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginal linear change, and —
 indicates there w
as no 
change. 
* 
Includes m
ultiple IC
P
C
-2 or IC
P
C
-2 P
LU
S
 codes (see A
ppendix 4, Table A
4.1, <purl.library.usyd.edu.au/sup/9781920899875>). 
N
ote: C
I – confidence interval; N
O
S
 – not otherw
ise specified. This table includes individual problem
s that had clinical treatm
ents given at a rate of m
ore than or equal to 0.5 per 100 encounters in any year, and any other 
statistically significant differences of interest. 
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Table 10.3a: The m
ost frequent procedural treatm
ents (rate per 100 problem
s), 2001–02 to 2010–11 
 
R
ate per 100 problem
s (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
Treatm
ent 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  (n = 146,141) 
E
xcision/rem
oval tissue/ 
biopsy/destruction/ 
debridem
ent/cauterisation* 
1.9 
(1.7–2.1) 
 
2.0 
(1.8–2.1) 
 
2.1 
(1.8–2.4) 
 
2.3 
(2.0–2.5) 
 
2.0 
(1.9–2.2) 
 
2.3 
(2.0–2.5) 
 
2.3 
(2.0–2.5) 
 
2.1 
(1.9–2.2) 
 
1.9 
(1.8–2.1) 
 
1.9 
(1.7–2.0) 
—
 
D
ressing/pressure/ 
com
pression/tam
ponade* 
1.3 
(1.2–1.4) 
 
1.3 
(1.2–1.5) 
 
1.3 
(1.2–1.4) 
 
1.4 
(1.2–1.5) 
 
1.4 
(1.3–1.5) 
 
1.5 
(1.4–1.6) 
 
1.5 
(1.4–1.6) 
 
1.5 
(1.4–1.6) 
 
1.6 
(1.4–1.7) 
 
1.7 
(1.5–1.8) 

 
Local injection/ 
infiltration* (b) 
0.8 
(0.6–1.0) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
1.4 
(1.2–1.5) 
 
1.3 
(1.2–1.5) 
 
1.3 
(1.2–1.4) 
 
1.5 
(1.4–1.6) 
 
1.5 
(1.4–1.6) 
 
1.6 
(1.5–1.8) 
 
1.6 
(1.4–1.8) 

 
P
hysical m
edicine/ 
rehabilitation* 
1.5 
(1.3–1.7) 
 
1.5 
(1.3–1.7) 
 
1.1 
(1.0–1.3) 
 
1.4 
(1.2–1.6) 
 
0.9 
(0.8–1.1) 
 
0.7 
(0.6–0.9) 
 
0.8 
(0.7–1.0) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–1.0) 
 
0.8 
(0.7–0.9) 

 
Incision/drainage/flushing/ 
aspiration/rem
oval body fluid* 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.7–0.8) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.8–0.9) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
—
 
P
ap sm
ear* 
0.6 
(0.5–0.7) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.9) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.7) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.5–0.7) 
—
 
R
epair/fixation – suture/ 
cast/prosthetic device 
(apply/rem
ove)* 
0.6 
(0.6–0.7) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.7) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 

 
O
ther therapeutic 
procedures/surgery N
E
C
* 
1.0 
(0.8–1.2) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.6–0.9) 
 
0.8 
(0.6–1.1) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.2–1.0) 
 
0.5 
(0.3–0.6) 

 
IN
R
 test 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
0.1 
(0.0–0.1) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 

 
O
ther preventive procedures/ 
high-risk m
edication* 
0.0
Ŧ 
(0.0–0.0) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 

 
C
heck-up – practice nurse* 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.4) 
 
0.4 
(0.2–0.7) 
 
0.4 
(0.3–0.5) 

 
E
lectrical tracings* 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 

 
(continued) 
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Table 10.3a (continued): The m
ost frequent procedural treatm
ents (rate per 100 problem
s), 2001–02 to 2010–11 
 
R
ate per 100 problem
s (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
Treatm
ent 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373)  (n = 146,141) 
P
hysical function test* 
0.3 
(0.2–0.4) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.2–0.4) 
—
 
U
rine test* 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.3 
(0.2–0.3) 

 
O
ther diagnostic procedures* 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 

 
Total procedural treatm
ents 
9.6 
(9.1–10.1) 
 
10.1 
(9.6–10.6) 
 
10.1 
(9.6–10.6) 
 
10.6 
(10.0–11.3) 
 
9.9 
(9.4–10.3) 
 
10.2 
(9.7–10.7) 
 
11.0 
(10.5–11.6) 
 
10.8 
(10.4–11.3) 
 
11.4 
(10.8–12.1) 
 
11.1 
(10.6–11.6) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginal linear change, and —
 indicates there w
as no 
change. 
(b) 
E
xcludes all local injection/infiltrations perform
ed for im
m
unisations. 
* 
Includes m
ultiple IC
P
C
-2 or IC
P
C
-2 P
LU
S
 codes (see A
ppendix 4, Tables A4.5 and A
4.6, <purl.library.usyd.edu.au/sup/9781920899875>). 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 problem
s. 
N
ote: C
I – confidence interval; N
E
C
 – not elsew
here classified; N
/A – not applicable. 
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Table 10.3b: The m
ost frequent procedural treatm
ents (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
Treatm
ent 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
E
xcision/rem
oval tissue/ 
biopsy/destruction/ 
debridem
ent/cauterisation* 
2.7 
(2.5–3.0) 
 
2.8 
(2.6–3.1) 
 
3.1 
(2.7–3.6) 
 
3.3 
(3.0–3.6) 
 
3.0 
(2.7–3.2) 
 
3.3 
(3.0–3.7) 
 
3.4 
(3.1–3.8) 
 
3.2 
(2.9–3.5) 
 
3.0 
(2.7–3.2) 
 
2.9 
(2.6–3.1) 
—
 
D
ressing/pressure/ 
com
pression/tam
ponade* 
1.8 
(1.7–1.9) 
 
2.0 
(1.8–2.1) 
 
1.8 
(1.7–2.0) 
 
2.0 
(1.8–2.1) 
 
2.1 
(1.9–2.3) 
 
2.3 
(2.1–2.4) 
 
2.2 
(2.1–2.4) 
 
2.3 
(2.1–2.4) 
 
2.4 
(2.2–2.6) 
 
2.5 
(2.4–2.7) 

 
Local injection/ 
infiltration* (b) 
1.2 
(0.9–1.4) 
 
1.5 
(1.3–1.7) 
 
1.6 
(1.4–1.8) 
 
2.0 
(1.7–2.2) 
 
2.0 
(1.8–2.2) 
 
1.9 
(1.7–2.1) 
 
2.3 
(2.1–2.5) 
 
2.3 
(2.1–2.4) 
 
2.5 
(2.3–2.7) 
 
2.4 
(2.2–2.7) 

 
P
hysical m
edicine/ 
rehabilitation* 
2.2 
(1.9–2.4) 
 
2.1 
(1.8–2.4) 
 
1.7 
(1.5–1.9) 
 
2.0 
(1.7–2.3) 
 
1.4 
(1.1–1.6) 
 
1.1 
(0.9–1.3) 
 
1.3 
(1.1–1.5) 
 
1.2 
(1.1–1.3) 
 
1.2 
(1.0–1.5) 
 
1.2 
(1.1–1.4) 

 
Incision/drainage/flushing/ 
aspiration/rem
oval body fluid* 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.0 
(1.0–1.1) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.1–1.4) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 
 
1.4 
(1.2–1.5) 
 
1.2 
(1.1–1.3) 
—
 
P
ap sm
ear* 
0.9 
(0.8–1.0) 
 
1.1 
(0.9–1.2) 
 
1.1 
(0.9–1.3) 
 
1.0 
(0.8–1.1) 
 
1.0 
(0.8–1.1) 
 
0.9 
(0.8–1.0) 
 
1.1 
(0.9–1.2) 
 
1.2 
(1.0–1.3) 
 
1.0 
(0.9–1.2) 
 
1.0 
(0.8–1.1) 
—
 
R
epair/fixation – suture/ 
cast/prosthetic device 
(apply/rem
ove)* 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.8–0.9) 
—
 
O
ther therapeutic 
procedures/surgery N
E
C
* 
1.4 
(1.2–1.7) 
 
1.2 
(1.0–1.4) 
 
1.1 
(0.9–1.3) 
 
1.2 
(0.9–1.5) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.9) 
 
0.8 
(0.6–0.9) 
 
0.9 
(0.7–1.1) 
 
1.0 
(0.4–1.6) 
 
0.7 
(0.5–0.9) 

 
IN
R
 test 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
0.1 
(0.1–0.2) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.4–0.7) 
 
0.7 
(0.6–0.8) 

 
O
ther preventive procedures/ 
high-risk m
edication  
N
/A
 
 
 
0.2 
(0.1–0.2) 
 
0.3 
(0.2–0.4) 
 
0.3 
(0.3–0.4) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.5) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 

 
C
heck-up – practice nurse* 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
N
/A
 
 
 
0.2 
(0.1–0.3) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.2–0.5) 
 
0.7 
(0.3–1.0) 
 
0.6 
(0.4–0.8) 

 
E
lectrical tracings* 
0.3 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.5) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.6) 

 
(continued) 
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Table 10.3b (continued): The m
ost frequent procedural treatm
ents (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 encounters (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
Treatm
ent 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 
(n = 95,839) 
P
hysical function test* 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.7) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.5) 
 
0.6 
(0.4–0.7) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
—
 
U
rine test* 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.2–0.4) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.5) 

 
O
ther diagnostic procedures* 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.3) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.3) 
 
0.2 
(0.1–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.4) 

 
P
regnancy test* 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
—
 
G
lucose test* 
0.2 
(0.2–0.3) 
 
0.1 
(0.1–0.2) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.3) 
—
 
Total procedural treatm
ents 
13.8 
(13.1–14.5) 
 
14.6 
(13.9–15.3) 
 
14.7 
(14.0–15.5) 
 
15.5 
(14.6–16.4) 
 
14.4 
(13.7–15.1) 
 
15.2 
(14.4–16.0) 
 
16.7 
(15.9–17.5) 
 
16.7 
(16.0–17.5) 
 
17.5 
(16.5–18.6) 
 
16.9 
(16.1–17.8) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginal linear change, and —
 indicates there w
as no 
change. 
(b) 
E
xcludes all local injection/infiltrations perform
ed for im
m
unisations. 
* 
Includes m
ultiple IC
P
C
-2 or IC
P
C
-2 P
LU
S
 codes (see A
ppendix 4, Tables A
4.5 and A
4.6, <purl.library.usyd.edu.au/sup/9781920899875>)  
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 encounters. 
N
ote: C
I – confidence interval; N
/A – not applicable; N
E
C
 – not elsew
here classified. 
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Table 10.4: The m
ost com
m
on problem
s m
anaged w
ith a procedural treatm
ent, 2001–02 to 2010–11 
 
R
ate at w
hich a procedural treatm
ent w
as given for the selected problem
, per 100 encounters
(a) (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(b) 
 
 
Problem
 m
anaged 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
Fem
ale genital check-up/ 
P
ap sm
ear*  
0.6 
(0.5–0.7) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–1.0) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
1.1 
(0.9–1.2) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 

 
S
olar keratosis/sunburn  
0.7 
(0.6–0.9) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.1) 
 
0.9 
(0.7–1.1) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.0) 
 
0.9 
(0.8–1.1) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
—
 
Laceration/cut  
0.5 
(0.4–0.5) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.5–0.6) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.7–0.8) 

 
E
xcessive ear w
ax  
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
—
 
M
alignant neoplasm
 skin  
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 

 
W
arts  
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
—
 
C
hronic ulcer skin 
(including varicose ulcer) 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.4 
(0.4–0.5) 

 
G
eneral check-up* 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.3) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.3–0.4) 
 
0.5 
(0.4–0.6) 
 
0.4 
(0.3–0.5) 

 
A
trial fibrillation/flutter  
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.4) 
 
0.3 
(0.2–0.4) 
 
0.4 
(0.3–0.4) 

 
S
prain/strain*  
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.4 
(0.3–0.4) 
 
0.5 
(0.4–0.6) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.5) 
 
0.3 
(0.3–0.4) 

 
V
itam
in/nutritional 
deficiency 
0.1 
(0.0–0.1) 
 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.4) 

 
B
ack com
plaint* 
0.5 
(0.4–0.5) 
 
0.4 
(0.3–0.6) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.6) 
 
0.3 
(0.2–0.4) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.4) 
 
0.3 
(0.2–0.5) 
 
0.2 
(0.2–0.3) 

 
S
kin sym
ptom
/com
plaint, 
other 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.4) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 

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Table 10.4 (continued): The m
ost com
m
on problem
s m
anaged w
ith a procedural treatm
ent, 2001–02 to 2010–11 
 
R
ate at w
hich a procedural treatm
ent w
as given for the selected problem
, per 100 encounters
(a) (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(b) 
 
 
Problem
 m
anaged 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
A
sthm
a 
0.2 
(0.1–0.2) 
 
0.3 
(0.3–0.4) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 

 
S
kin disease, other 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.4) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
—
 
S
kin infection, post 
traum
atic 
0.1 
(0.1–0.1) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 

 
O
steoarthritis* 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.1–0.6) 
 
0.2 
(0.1–0.2) 

 
Total problem
s w
ith 
procedural treatm
ents 
13.1 
(12.4–13.7) 
 
13.6 
(13.0–14.3) 
 
13.7 
(13.1–14.4) 
 
14.3 
(13.5–15.0) 
 
13.6 
(12.9–14.2) 
 
14.3 
(13.6–15.0) 
 
15.6 
(14.9–16.4) 
 
15.6 
(15.0–16.3) 
 
16.4 
(15.4–17.3) 
 
15.9 
(15.1–16.6) 

 
(a) 
R
ate of provision of clinical treatm
ent for selected problem
 per 100 total encounters. 
(b) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginal linear change, and —
 indicates there w
as 
no change. 
* 
Includes m
ultiple IC
P
C
-2 or IC
P
C
-2 P
LU
S
 codes (see A
ppendix 4, Table A
4.1, <purl.library.usyd.edu.au/sup/9781920899875>). 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 encounters. 
N
ote: C
I – confidence interval. This table includes individual problem
s that had procedural treatm
ents done at a rate of >= 0.5 per 100 encounters in any year, and any other statistically significant differences of interest.
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11 Referrals and admissions 
A referral is defined as the process by which the responsibility for part or all of the care of a 
patient is temporarily transferred to another health care provider. Only new referrals arising 
at the encounter were included (that is, continuations were not recorded). For each 
encounter, GPs could record up to two referrals, and each referral was linked by the GP to 
the problem(s) for which the patient was referred. Referrals included those to medical 
specialists, allied health services, hospitals for admission, emergency departments, and those 
to other services (including those to outpatient clinics and to other GPs). 
Referral data for the 10 years, 2001–02 to 2010–11, are reported in two ways: as rates per 100 
problems managed (Table 11.1a) and as rates per 100 encounters (Table 11.1b). In the text 
describing changes over time, the rates per 100 problems are reported as the primary 
measure, because there was a significant increase in the number of problems managed per 
encounter.  
The direction and type of change from 2001–02 to 2010–11 is indicated for each result in the 
far right column of the tables: / indicates a statistically significant linear change, 
/ indicates a marginally significant linear change, § indicates a non-linear significant or 
marginal change, and — indicates there was no change. 
Significant linear changes in the rate per 100 encounters can be extrapolated to estimate the 
national increase or decrease in referrals provided between 2001–02 and  
2010–11. Examples of extrapolated change are given. The method used to extrapolate to 
national change estimates is described in Section 2.9. 
The rate of referral increased significantly, from 10.5 per 100 encounters in 2001–02 to 14.1 in 
2010–11 (Table 11.1b). This suggests there were approximately 6.2 million more referrals 
given at GP encounters in 2010–11 than in 2001–02. Table 11.1b also shows that over time 
there was an increasing likelihood that GP–patient encounters would involve a referral (at 
13.0% of encounters in 2010–11 compared with 10.0% in 2001–02). 
There was a significant increase in the overall number of referrals, from 7.3 per 100 problems 
managed in 2001–02 to 9.3 in 2010–11 (Table 11.1a). Referrals to medical specialists 
significantly increased (per 100 problems), reflected in a significant increase in referrals to 
cardiologists, and marginal increases in referrals to urologists and gastroenterologists. 
The rate of referral to allied health services increased significantly over the decade from 1.6 
per 100 problems in 2001–02 to 2.8 per 100 in 2010–11. There was a significant increase in the 
rate of referrals to psychologists. Extrapolation of the rate per 100 encounters suggests there 
were approximately 610,000 more referrals to psychologists in 2010–11 than in 2001–02. 
Referrals to podiatrist or chiropodists and dentists also showed significant increases. There 
were marginal increases in the rate of referral to dietitians or nutritionists, and to 
physiotherapists per 100 problems. Extrapolation of the rate per 100 encounters shows 
approximately 230,000 more referrals to physiotherapists in 2010–11 than in 2001–02. 
In 2010–11 there was a significant increase in the rate of referrals to emergency departments 
since 2001–02 (Table 11.1a), and there was a marginal decrease in the rate of 
referral/admission to hospitals.
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Table 11.1a: The m
ost frequent referrals (rate per 100 problem
s), 2001–02 to 2010–11 
 
R
ate per 100 problem
s
 (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
R
eferral 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373) 
 (n = 146,141) 
A
t least one referral 
7.3 
(7.0–7.6) 
 
7.7 
(7.4–8.0) 
 
8.0 
(7.6–8.3) 
 
7.9 
(7.7–8.2) 
 
8.2 
(7.9–8.5) 
 
8.3 
(8.0–8.6) 
 
8.3 
(8.0–8.6) 
 
8.9 
(8.5–9.2) 
 
8.7 
(8.4–9.0) 
 
9.2 
(8.9–9.5) 

 
M
edical specialist 
5.1 
(4.9–5.3) 
 
5.3 
(5.0–5.5) 
 
5.4 
(5.1–5.6) 
 
5.3 
(5.1–5.5) 
 
5.6 
(5.4–5.8) 
 
5.4 
(5.2–5.7) 
 
5.3 
(5.1–5.5) 
 
5.8 
(5.6–6.0) 
 
5.5 
(5.3–5.7) 
 
5.6 
(5.4–5.9) 

 
 
S
urgeon 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
—
 
 
O
rthopaedic surgeon 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
—
 
 
D
erm
atologist  
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.4) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
—
 
 
O
phthalm
ologist 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 

 
 
C
ardiologist  
0.3 
(0.3–0.3) 
 
0.3 
(0.3–0.3) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.4) 

 
 
G
astroenterologist 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0. 4) 
 
0.3 
(0.3–0.3) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 

 
 
E
ar, nose and throat 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
—
 
 
G
ynaecologist 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.3) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
—
 
 
U
rologist 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 

 
 
N
eurologist 
0.1 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2)  
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
—
 
 
P
aediatrician  
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
—
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Table 11.1a: The m
ost frequent referrals (rate per 100 problem
s), 2001–02 to 2010–11 
 
R
ate per 100 problem
s
 (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
 
(a) 
 
 
R
eferral 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373) 
 (n = 146,141) 
 
P
sychiatrist 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
—
 
 
C
linic/centre 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
—
 
 
E
ndocrinologist 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
—
 
A
llied health service 
1.6 
(1.5–1.7) 
 
1.7 
(1.6–1.9) 
 
1.8 
(1.7–1.9) 
 
1.9 
(1.7–2.0) 
 
2.0 
(1.8–2.1) 
 
2.1 
(1.9–2.2) 
 
2.3 
(2.1–2.4) 
 
2.5 
(2.3–2.7) 
 
2.6 
(2.4–2.7) 
 
2.8 
(2.6–2.9) 

 
 
P
hysiotherapy 
0.6 
(0.6–0.7) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.8) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.7–0.8) 

 
 
P
sychologist 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 

 
 
P
odiatrist/chiropodist 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 

 
 
D
entist 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 

 
 
D
ietitian/nutritionist 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 

 
H
ospital 
0.3 
(0.3–0.3) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 

 
E
m
ergency departm
ent 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 

 
O
ther referrals 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.4 
(0.3–0.5) 

 
Total referrals 
7.3 
(7.0–7.6) 
 
7.7 
(7.4–8.0) 
 
8.0 
(7.6–8.3) 
 
7.9 
(7.7–8.2) 
 
8.2 
(7.9–8.5) 
 
8.2 
(7.9–8.6) 
 
8.3 
(8.0–8.6) 
 
8.9 
(8.6–9.2) 
 
8.7 
(8.4–9.0) 
 
9.3 
(8.9–9.6) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant change, 
/
 indicates a m
arginal change, and —
 indicates there w
as no change. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 encounters. 
N
ote: C
I – confidence interval; N
O
S
 – not otherw
ise specified. 
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Table 11.1b: The m
ost frequent referrals (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 encounters
 (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
R
eferral 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
A
t least one referral 
10.0 
(9.6–10.4) 
 
10.6 
(10.2–11.0) 
 
11.0 
(10.5–11.5) 
 
10.9 
(10.5–11.3) 
 
11.3 
(10.9–11.8) 
 
11.5  
(11.0–11.9) 
 
11.8 
(11.3–12.2) 
 
12.8 
(12.3–13.2) 
 
12.4 
(11.9–12.9) 
 
13.0 
(12.5–13.5) 

 
M
edical specialist 
7.3 
(7.0–7.6) 
 
7.6 
(7.3–8.0) 
 
7.9 
(7.5–8.2) 
 
7.7 
(7.4–8.1) 
 
8.2 
(7.8–8.5) 
 
8.1 
(7.7–8.4) 
 
8.0 
(7.6–8.3) 
 
9.0 
(8.7–9.3) 
 
8.4 
(8.1–8.8) 
 
8.6 
(8.2–9.0) 

 
 
S
urgeon 
0.8 
(0.7–0.8) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.8–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.8) 
 
0.8 
(0.8–0.9) 
 
0.8 
(0.8–0.9) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.8–0.9) 

 
 
O
rthopaedic surgeon 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.7–0.8) 
 
0.7 
(0.6–0.7) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.8) 
 
0.7 
(0.6–0.8) 
—
 
 
D
erm
atologist  
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.7–0.8) 
 
0.6 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
—
 
 
O
phthalm
ologist 
0.7 
(0.7–0.8) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.7) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.6–0.8) 
 
0.6 
(0.6–0.7) 

 
 
C
ardiologist 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 

 
 
G
astroenterologist  
0.4 
(0.3–0.5) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.5 
(0.5–0.6) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 

 
 
E
ar, nose and throat 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6 ) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
—
 
 
G
ynaecologist 
0.5 
(0.5–0.6) 
 
0.6 
(0.6–0.7) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
—
 
 
U
rologist 
0.2 
(0.2–0.3) 
 
0.3 
(0.3–0.3) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.3) 
 
0.4 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 

 
 
N
eurologist 
0.2 
(0.2–0.2) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 

 
 
P
aediatrician 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 

 
 
P
sychiatrist 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
—
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Table 11.1b (continued): The m
ost frequent referrals (rate per 100 encounters), 2001–02 to 2010–11 
 
R
ate per 100 encounters
 (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 

(a) 
 
 
R
eferral 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
A
llied health service 
2.3 
(2.1–2.4) 
 
2.5 
(2.3–2.7) 
 
2.6 
(2.4–2.8) 
 
2.7 
(2.5–2.9) 
 
2.9 
(2.7–3.1) 
 
3.1 
(2.9–3.3) 
 
3.4 
(3.2–3.7) 
 
3.9 
(3.6–4.1) 
 
3.9 
(3.7–4.2) 
 
4.2 
(3.9–4.5) 

 
 
P
hysiotherapy 
0.9 
(0.8–1.0) 
 
1.1 
(0.9–1.2) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.3) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.3) 
 
1.1 
(1.0–1.2) 

 
 
P
sychologist 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.4–0.5) 
 
0.7 
(0.6–0.7) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 

 
 
P
odiatrist/chiropodist 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 

 
 
D
entist 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.3–0.4) 

 
 
D
ietitian/nutritionist 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 

 
H
ospital 
0.4 
(0.4–0.5) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.5 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.5) 
 
0.4 
(0.3–0.5) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 

 
E
m
ergency departm
ent 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.2 ) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.2) 
 
0.3 
(0.3–0.4) 

 
O
ther referrals 
0.4 
(0.3–0.4) 
 
0.3 
(0.2–0.3) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.3–0.4) 
 
0.5 
(0.5–0.6) 
 
0.5 
(0.4–0.6) 
 
0.3 
(0.2–0.4) 
 
0.4 
(0.3–0.5) 
 
0.6 
(0.5–0.7) 

 
Total referrals 
10.5 
(10.1–10.9) 
 
11.2 
(10.7–11.6) 
 
11.6 
(11.1–12.2) 
 
11.5 
(11.1–12.0) 
 
12.0 
(11.5–12.5) 
 
12.2 
(11.7–12.7) 
 
12.5 
(12.0–13.0) 
 
13.7 
(13.2–14.2) 
 
13.3 
(12.8–13.8) 
 
14.1 
(13.5–14.7) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginal linear change, and —
 indicates there w
as no 
change. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 encounters. 
N
ote: C
I – confidence interval 
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12 Investigations 
Investigations data for the 10 years, 2001–02 to 2010–11, are reported in two ways: as rates 
per 100 problems managed (for example, Table 12.1a) and as rates per 100 encounters (for 
example, Table 12.1b). In the text describing changes over time, the rates per 100 problems 
are reported as the primary measure, because there was a significant increase in the number 
of problems managed per encounter.  
The direction and type of change from 2001–02 to 2010–11 is indicated for each result in the 
far right column of the tables: / indicates a statistically significant linear change, 
/ indicates a marginally significant linear change, § indicates a non-linear significant or 
marginal change, and — indicates there was no change. 
The GPs participating in BEACH were asked to record (in free text) any pathology, imaging 
or other tests ordered or done at the encounter, and to nominate the patient problem(s) 
associated with each test order. This allows the linkage of a test order to a single problem or 
multiple problems. Up to five orders for pathology and two for imaging and other tests 
could be recorded at each encounter. A single test may have been ordered for the 
management of multiple problems, and multiple tests may have been used in the 
management of a single problem. 
A pathology test order may be for a single test (for example, Pap smear, HbA1c) or for a 
battery of tests (for example, lipids, full blood count). Where a battery of tests was ordered, 
the battery name was recorded rather than each individual test. GPs also recorded the body 
site for any imaging ordered (for example, x-ray chest, computerised tomography head). 
Significant linear changes in the rate per 100 encounters can be extrapolated to estimate the 
national increase or decrease in the other treatments provided between 2001–02 and 2010–11. 
Examples of extrapolated change are given. The method used to extrapolate to national 
change estimates is described in Section 2.9. 
Comprehensive investigation of GPs’ pathology and imaging ordering was published in 
several reports. Interested readers may wish to consult: 
• a comprehensive report on pathology ordering by GPs in Australia in 1998, written by 
the then General Practice Statistics and Classification Unit using BEACH data, was 
published on the Internet by the then Department of Health and Aged Care.55 
• a report on imaging orders by GPs in Australia in 1999–00 using BEACH data, published 
as an AIHW–University of Sydney book in the GP series in 2001.56 
• a report on changes in pathology ordering by GPs from 1998 to 2001 using BEACH data, 
published as an AIHW–University of Sydney book in the GP series in 2003.57 
• a review of GP pathology ordering in the National Health Priority Areas and other 
selected problems between 2000 and 2008, reported in Chapter 5 of the AIHW–
University of Sydney publication General practice in Australia, health priorities and policies 
1998 to 2008.58 
• a report Evidence-practice gap in GP pathology test ordering: a comparison of BEACH pathology 
data and recommended testing, produced for the Australian Government Quality Use of 
Pathology Program in June 2009.59 
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12.1 Number of problems or encounters where 
pathology or imaging was ordered 
Table 12.1a shows there was a significant increase in the proportion of problems for which 
pathology and/or imaging was ordered, from 14.9% in 2001–02 to 18.2% in 2010–11. 
• The likelihood of ordering at least one pathology test increased from 10.8% of all 
problems managed in 2001–02 to 13.3% in 2010–11. 
• The proportion of problems generating imaging orders increased from 5.0% in 2001–02 
to 5.7% in 2010–11. 
Between 2001–02 and 2010–11, the number of problems managed per 100 encounters rose 
from 143.4 to 152.5 (Table 5.1). Both the rise in problems generating test orders and the rise in 
the number of problems managed per encounter contributed to an overall increase in the 
proportion of encounters involving a pathology and/or imaging test, from 19.2% in 2001–02 
to 24.1% in 2010–11 (Table 12.1b). This equates to almost 9.3 million more encounters at 
which tests were ordered in 2010–11 than a decade earlier. 
• The likelihood of ordering at least one pathology test increased from 14.0% of encounters 
in 2001–02 to 17.8% in 2010–11, which is over 7 million additional encounters at which 
pathology was ordered in 2010–11 than 10 years earlier. 
• The proportion of encounters generating imaging orders increased from 6.9% in 2001–02 
to 8.4% in 2010–11, resulting in an estimated 3 million more encounters nationally at 
which imaging was ordered in 2010–11 than in 2001–02. 
Both the likelihood of ordering pathology and the total number of pathology tests ordered 
per 100 problems or per 100 encounters have significantly increased over the 10 years to 
2010–11 (Figure 12.1). However, the growth in the number of tests/batteries ordered was 
larger than the growth in likelihood of ordering because, once a decision to order was made, 
the number of tests ordered increased from an average of 1.92 tests/batteries per tested 
problem in 2001–02 to 2.32 per tested problem in 2010–11. 
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Figure 12.1: Encounters w
here pathology w
as ordered, and pathology test order rates per 100 encounters and per 100 problem
s, 2001–02 and 2010–11  
(95%
 confidence interval) 
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12.2 Pathology test orders by MBS groups 
Tables 12.2a and 12.2b show the changes in the total number of pathology test orders, and in 
the distribution of these by MBS pathology groups.60 
The number of pathology tests ordered increased from 21.6 tests/ batteries of tests per 
100 problems managed in 2001–02 to 29.6 per 100 problems in 2010–11 (Table 12.2a). 
The largest increase was in orders for chemical pathology, which increased from 11.5 per 
100 problems in 2001–02 to 17.2 per 100 in 2010–11. Haematology increased at a slower rate, 
from 4.3 per 100 problems in 2001–02 to 5.3 in 2010–11. Microbiology test orders increased 
from 3.4 per 100 problems in 2001–02 to 4.3 in 2010–11. There was a far smaller increase in 
order rates for immunology, a marginal increase in orders for other tests not elsewhere 
classified and simple tests, and no increases in the other test groups. 
The number of pathology tests ordered per 100 encounters increased from 
31.0 tests/batteries of tests per 100 encounters in 2001–02 to 45.2 in 2010–11, which 
extrapolates to approximately 22.4 million more test orders in 2010–11 than in 2001–02 
nationally (Table 12.2b). 
The largest increase was in orders for chemical pathology, which increased from 16.5 per 
100 encounters in 2001–02 to 26.2 in 2010–11. This extrapolates to an estimated 14.5 million 
additional chemistry test orders in 2010–11 than 10 years earlier. Haematology increased at a 
slower rate, rising from 6.2 tests per 100 encounters in 2001–02 to 8.1 in 2010–11, a national 
increase of approximately 3.4 million tests. Microbiology test orders increased from 4.8 per 
100 encounters in 2001–02 to 6.5 in 2010–11, extrapolating to an increase of about 2.9 million 
additional test orders in 2010–11. There were far smaller increases in order rates for 
immunology and simple tests, and no increases in the other test groups. 
12.3 Imaging test orders by MBS group 
Tables 12.3a and 12.3b show the changes in imaging orders by MBS imaging group from 
2001–02 to 2010–11. 
Total imaging test orders increased significantly from 5.5 per 100 problems in 2001–02 to 
6.4 per 100 in 2010–11 (Table 12.3a). Ultrasound imaging increased from 1.7 tests per 
100 problems in 2001–02 to 2.5 per 100 in 2010–11. Computerised tomography increased from 
0.5 per 100 problems in 2001–02 to 0.7 in 2010–11. Magnetic resonance imaging increased 
from less than 0.05 per 100 problems in 2001–02 to 0.1 in 2010–11. Diagnostic radiology and 
nuclear medicine order rates did not change during this period. 
Total imaging test orders per 100 encounters also increased significantly from 7.9 in 2001–02 
to 9.8 in 2010–11, suggesting a national increase of 3.7 million encounters generating an order 
for imaging (Table 12.3b). Ultrasound imaging increased from 2.5 tests per 100 encounters in 
2001–02 to 3.8 per 100 in 2010–11, a national increase of almost 2 million encounters with 
ultrasound orders. Computerised tomography increased from 0.7 per 100 encounters in 
2001–02 to 1.1 in 2010–11, equating to an additional 600,000 encounters. Magnetic resonance 
imaging increased from less than 0.05 per 100 encounters in 2001–02 to 0.1 in 2010–11. 
Diagnostic radiology and nuclear medicine order rates did not change during this period. 
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Table 12.1a: Problem
s for w
hich pathology or im
aging w
as ordered (per cent of problem
s), 2001–02 to 2010–11  
 
Per cent of problem
s (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
 
(a) 
 
 
Test ordered 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373) 
 (n = 146,141) 
A
t least one test ordered 
14.9 
(14.4–15.3) 
 
15.8 
(15.3–16.2) 
 
16.1 
(15.6–16.6) 
 
16.4 
(16.0–16.9) 
 
17.2 
(16.6–17.7) 
 
17.8 
(17.3–18.3) 
 
17.7 
(17.2–18.2) 
 
18.1 
(17.6–18.6) 
 
17.8 
(17.3–18.3) 
 
18.2 
(17.7–18.7) 

 
A
t least one pathology test 
ordered 
10.8 
(10.4–11.2) 
 
11.4 
(11.0–11.8) 
 
11.9 
(11.5–12.4) 
 
12.2 
(11.8–12.6) 
 
12.7 
(12.2–13.2) 
 
13.4 
(13.0–13.9) 
 
13.1 
(12.7–13.6) 
 
13.6 
(13.2–14.0) 
 
13.2 
(12.8–13.7) 
 
13.3 
(12.9–13.7) 

 
A
t least one im
aging test 
ordered 
5.0 
(4.7–5.2) 
 
5.3 
(5.1–5.6) 
 
5.1 
(4.8–5.3) 
 
5.2 
(5.0–5.4) 
 
5.5 
(5.3–5.7) 
 
5.5 
(5.3–5.7) 
 
5.7 
(5.4–5.9) 
 
5.7 
(5.4–5.9) 
 
5.7 
(5.5–6.0) 
 
5.7 
(5.5–5.9) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change. 
N
ote: C
I – confidence interval. 
 Table 12.1b: Encounters at w
hich pathology or im
aging w
as ordered (per cent of encounters), 2001–02 to 2010–11 
 
Per cent of encounters (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
 
(a) 
 
 
Test ordered 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,804) 
 
(n = 95,898) 
 
(n = 96,688) 
 (n = 101,349)  
(n = 95,839) 
A
t least one test ordered 
19.2 
(18.6–19.8) 
 
20.3 
(19.7–21.0) 
 
20.8 
(20.1–21.5) 
 
21.2 
(20.6–21.8) 
 
22.1 
(21.4–22.7) 
 
23.0 
(22.3–23.7) 
 
23.4 
(22.7–24.1) 
 
24.2 
(23.5–24.8) 
 
23.8 
(23.1–24.5) 
 
24.1 
(23.4–24.8) 

 
A
t least one pathology test 
ordered 
14.0 
(13.5–14.5) 
 
14.7 
(14.2–15.3) 
 
15.5 
(14.9–16.1) 
 
15.7 
(15.2–16.3) 
 
16.4 
(15.8–16.9) 
 
17.4 
(16.8–18.0) 
 
17.4 
(16.7–18.0) 
 
18.2 
(17.6–18.8) 
 
17.7 
(17.1–18.3) 
 
17.8 
(17.2–18.4) 

 
A
t least one im
aging test 
ordered 
6.9 
(6.6–7.2) 
 
7.5 
(7.1–7.8) 
 
7.2 
(6.9–7.5) 
 
7.3 
(7.0–7.6) 
 
7.8 
(7.4–8.1) 
 
7.9 
(7.6–8.2) 
 
8.3 
(8.0–8.6) 
 
8.5 
(8.1–8.8) 
 
8.5 
(8.2–8.9) 
 
8.4 
(8.0–8.7) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change. 
N
ote: C
I – confidence interval. 
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Table 12.2a: Pathology orders by M
BS pathology groups (rate per 100 problem
s), 2001–02 to 2010–11  
 
R
ate per 100 problem
s
 (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
 
(a) 
 
 
Pathology test ordered 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373) 
 (n = 146,141) 
C
hem
istry* 
11.5 
(10.9–12.0) 
 
12.2 
(11.6–12.8) 
 
13.0 
(12.4–13.7) 
 
14.0 
(13.4–14.6) 
 
14.9 
(14.1–15.6) 
 
16.5 
(15.8–17.2) 
 
16.5 
(15.7–17.2) 
 
17.4 
(16.7–18.1) 
 
16.9 
(16.1–17.6) 
 
17.2 
(16.5–17.9) 

 
H
aem
atology* 
4.3 
(4.1–4.5) 
 
4.3 
(4.1–4.6) 
 
4.6 
(4.4–4.9) 
 
4.8 
(4.5–5.0) 
 
5.0 
(4.7–5.3) 
 
5.3 
(5.0–5.6) 
 
5.2 
(5.0–5.5) 
 
5.3 
(5.0–5.5) 
 
5.4 
(5.1–5.7) 
 
5.3 
(5.0–5.5) 

 
M
icrobiology* 
3.4 
(3.2–3.6) 
 
3.5 
(3.3–3.8) 
 
3.6 
(3.4–3.9) 
 
3.6 
(3.3–3.8) 
 
3.8 
(3.6–4.1) 
 
3.9 
(3.7–4.2) 
 
3.7 
(3.5–4.0) 
 
3.7 
(3.5–3.9) 
 
4.1 
(3.9–4.3) 
 
4.3 
(3.9–4.6) 

 
C
ytopathology* 
1.1 
(1.0–1.2) 
 
1.2 
(1.0–1.3) 
 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.3) 
 
1.2 
(1.1–1.3) 
 
1.1 
(1.0–1.3) 
 
1.2 
(1.1–1.4) 
 
1.3 
(1.1–1.4) 
 
1.1 
(1.0–1.2) 
 
1.1 
(1.0–1.2) 
—
 
O
ther N
E
C
* 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.7) 
 
0.7 
(0.5–0.8) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.7) 

 
Im
m
unology* 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.4 
(0.4–0.5) 
 
0.4 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.7) 
 
0.5 
(0.5–0.6) 

 
Tissue pathology* 
0.3 
(0.3–0.4) 
 
0.4 
(0.3–0.4) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.4 
(0.3–0.5) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.4 
(0.3–0.5) 
—
 
Infertility/pregnancy* 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
—
 
S
im
ple tests* 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 

 
Total pathology tests 
21.6 
(20.8–22.5) 
 
22.7 
(21.8–23.6) 
 
24.1 
(23.1–25.0) 
 
25.2 
(24.3–26.2) 
 
26.4 
(25.3–27.5) 
 
28.6 
(27.5–29.6) 
 
28.5 
(27.4–29.6) 
 
29.5 
(28.4–30.5) 
 
29.3 
(28.2–30.4) 
 
29.6 
(28.6–30.7) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginal linear change, and —
 indicates there w
as no 
change. 
* 
Includes m
ultiple IC
P
C
-2 and IC
P
C
-2 PLU
S
 codes (see A
ppendix 4, Table A
4.8, <purl.library.usyd.edu.au/sup/9781920899875>). 
N
ote: C
I – confidence interval; N
E
C
 – not elsew
here classified. 
 
114
Table 12.2b: Pathology orders by M
BS pathology groups (rate per 100 encounters), 2001–02 to 2010–11  
 
R
ate per 100 encounters
 (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
 
(a) 
 
 
Pathology test ordered 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,804) 
 
(n = 95,898) 
 
(n = 96,688) 
 (n = 101,349)  
(n = 95,839) 
C
hem
istry* 
16.5 
(15.6–17.3) 
 
17.7 
(16.8–18.6) 
 
19.1 
(18.1–20.1) 
 
20.4 
(19.4–21.4) 
 
21.7 
(20.5–22.9) 
 
24.5 
(23.3–25.7) 
 
24.9 
(23.6–26.2) 
 
27.0 
(25.7–28.2) 
 
25.9 
(24.6–27.2) 
 
26.2 
(25.0–27.4) 

 
H
aem
atology* 
6.2 
(5.8–6.5) 
 
6.3 
(5.9–6.6) 
 
6.8 
(6.4–7.2) 
 
7.0 
(6.6–7.3) 
 
7.3 
(6.9–7.7) 
 
7.9 
(7.5–8.3) 
 
7.9 
(7.5–8.3) 
 
8.2 
(7.8–8.6) 
 
8.3 
(7.8–8.7) 
 
8.1 
(7.6–8.5) 

 
M
icrobiology* 
4.8 
(4.5–5.2) 
 
5.1 
(4.8–5.5) 
 
5.3 
(4.9–5.6) 
 
5.2 
(4.8–5.6) 
 
5.6 
(5.2–5.9) 
 
5.8 
(5.4–6.2) 
 
5.7 
(5.3–6.0) 
 
5.7 
(5.3–6.1) 
 
6.3 
(5.9–6.6) 
 
6.5 
(6.0–7.0) 

 
C
ytolopathology* 
1.6 
(1.4–1.7) 
 
1.7 
(1.5–1.8) 
 
1.8 
(1.5–2.0) 
 
1.6 
(1.5–1.8) 
 
1.7 
(1.6–1.9) 
 
1.7 
(1.5–1.9) 
 
1.9 
(1.7–2.1) 
 
2.0 
(1.7–2.2) 
 
1.7 
(1.5–1.9) 
 
1.7 
(1.5–1.8) 
—
 
O
ther N
E
C
* 
0.7 
(0.6–0.8) 
 
0.8 
(0.6–0.9) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–1.0) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–1.0) 
 
1.0 
(0.8–1.2) 
 
0.8 
(0.7–1.0) 
 
0.7 
(0.6–0.9) 
 
0.9 
(0.7–1.0) 
—
 
Im
m
unology* 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.5) 
 
0.5 
(0.4–0.6) 
 
0.6 
(0.5–0.6) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.6–0.7) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.7–0.9) 
 
0.9 
(0.8–1.0) 
 
0.8 
(0.7–0.9) 

 
Tissue pathology* 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.7 
(0.5–0.8) 
 
0.8 
(0.6–0.9) 
 
0.6 
(0.5–0.7) 
 
0.7 
(0.6–0.8) 
 
0.8 
(0.6–0.9) 
 
0.7 
(0.6–0.9) 
 
0.8 
(0.7–0.9) 
 
0.6 
(0.5–0.7) 
—
 
Infertility/pregnancy* 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
 
0.3 
(0.2–0.3) 
—
 
S
im
ple tests* 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.1–0.2) 
 
0.2 
(0.2–0.3) 
 
0.2 
(0.2–0.2) 
 
0.2 
(0.2–0.3) 

 
Total pathology tests 
31.0 
(29.7–32.4) 
 
32.9 
(31.4–34.4) 
 
35.2 
(33.7–36.8) 
 
36.7 
(35.2–38.2) 
 
38.6 
(36.9–40.3) 
 
42.4 
(40.7–44.2) 
 
43.1 
(41.3–45.0) 
 
45.6 
(43.8–47.4) 
 
45.0 
(43.1–46.9) 
 
45.2 
(43.4–47.0) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, and —
 indicates there w
as no change. 
* 
Includes m
ultiple IC
P
C
-2 and IC
P
C
-2 PLU
S
 codes (see A
ppendix 4, Table A
4.8, <purl.library.usyd.edu.au/sup/9781920899875>). 
N
ote: C
I – confidence interval; N
E
C
 – not elsew
here classified. 
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Table 12.3a: Im
aging orders by M
BS im
aging groups (rate per 100 problem
s), 2001–02 to 2010–11 
 
R
ate per 100 problem
s
 (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
 
(a) 
 
 
Im
aging test ordered 
(n = 139,092)  (n = 146,336)  (n = 144,674)  (n = 137,330)  (n = 149,088)  (n = 136,333)  (n = 145,078)  (n = 149,462)  (n = 155,373) 
 (n = 146,141) 
D
iagnostic radiology* 
3.1 
(3.0–3.3) 
 
3.5 
(3.3–3.7) 
 
3.1 
(3.0–3.3) 
 
3.1 
(2.9–3.2) 
 
3.3 
(3.1–3.4) 
 
3.1 
(2.9–3.2) 
 
3.2 
(3.0–3.3) 
 
3.1 
(2.9–3.2) 
 
3.0 
(2.8–3.1) 
 
3.0 
(2.9–3.2) 
—
 
U
ltrasound* 
1.7 
(1.6–1.8) 
 
1.8 
(1.7–1.9) 
 
1.8 
(1.7–1.9) 
 
1.8 
(1.7–1.9) 
 
2.0 
(1.9–2.1) 
 
2.1 
(2.0–2.2) 
 
2.2 
(2.1–2.3) 
 
2.3 
(2.2–2.4) 
 
2.4 
(2.3–2.5) 
 
2.5 
(2.4–2.6) 

 
C
om
puterised 
tom
ography* 
0.5 
(0.5–0.6) 
 
0.5 
(0.5–0.6) 
 
0.6 
(0.5–0.6) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.6–0.8) 
 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.8–0.9) 
 
0.8 
(0.7–0.9) 
 
0.7 
(0.7–0.8) 

 
M
agnetic resonance 
im
aging* 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 

 
N
uclear m
edicine* 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.0–0.1) 
—
 
Total im
aging tests 
5.5 
(5.3–5.7) 
 
5.9 
(5.7–6.2) 
 
5.6 
(5.4–5.9) 
 
5.7 
(5.5–5.9) 
 
6.0 
(5.8–6.3) 
 
6.0 
(5.8–6.3) 
 
6.3 
(6.1–6.5) 
 
6.3 
(6.1–6.6) 
 
6.4 
(6.1–6.6) 
 
6.4 
(6.1–6.7) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 for im
aging is indicated for each result: 
/
 indicates a statistically significant linear change, and —
 indicates there w
as no change. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 problem
s. 
* 
Includes m
ultiple IC
P
C
-2 and IC
P
C
-2 PLU
S
 codes (see A
ppendix 4, Table A
4.9, <purl.library.usyd.edu.au/sup/9781920899875>). 
N
ote: C
I – confidence interval. 
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Table 12.3b: Im
aging orders by M
BS im
aging groups (rate per 100 encounters), 2001–02 to 2010–11  
 
R
ate per 100 encounters
 (95%
 C
I) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
 
(a) 
 
 
Im
aging test ordered 
(n = 96,973) 
 (n = 100,987)  
(n = 98,877) 
 
(n = 94,386) 
 (n = 101,993)  
(n = 91,805) 
 (n = 95,898) 
 (n = 96,688) 
 (n = 101,349) 
 (n = 95,839) 
D
iagnostic radiology* 
4.5 
(4.3–4.7) 
 
5.0 
(4.8–5.3) 
 
4.6 
(4.3–4.8) 
 
4.5 
(4.3–4.7) 
 
4.8 
(4.5–5.0) 
 
4.6 
(4.4–4.8) 
 
4.8 
(4.6–5.0) 
 
4.7 
(4.5–5.0) 
 
4.6 
(4.3–4.8) 
 
4.6 
(4.4–4.9) 
—
 
U
ltrasound* 
2.5 
(2.3–2.6) 
 
2.6 
(2.5–2.8) 
 
2.7 
(2.5–2.8) 
 
2.7 
(2.5–2.8) 
 
2.9 
(2.7–3.1) 
 
3.2 
(3.0–3.3) 
 
3.4 
(3.2–3.5) 
 
3.6 
(3.4–3.8) 
 
3.7 
(3.5–3.8) 
 
3.8 
(3.6–4.0) 

 
C
om
puterised 
tom
ography* 
0.7 
(0.7–0.8) 
 
0.8 
(0.7–0.9) 
 
0.8 
(0.7–0.9) 
 
1.0 
(0.9–1.1) 
 
1.0 
(0.9–1.1) 
 
1.1 
(1.0–1.2) 
 
1.2 
(1.1–1.3) 
 
1.3 
(1.2–1.4) 
 
1.3 
(1.1–1.4) 
 
1.1 
(1.0–1.2) 

 
M
agnetic resonance 
im
aging* 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.0) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.1 
(0.0–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 

 
N
uclear m
edicine* 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.1) 
 
0.1 
(0.1–0.2) 
 
0.1 
(0.1–0.1) 
—
 
Total im
aging tests 
7.9 
(7.5–8.2) 
 
8.6 
(8.2–9.0) 
 
8.2 
(7.8–8.6) 
 
8.3 
(8.0–8.6) 
 
8.8 
(8.4–9.2) 
 
9.0 
(8.6–9.3) 
 
9.5 
(9.2–9.9) 
 
9.8 
(9.4–10.2) 
 
9.7 
(9.3–10.1) 
 
9.8 
(9.4–10.2) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 for im
aging is indicated for each result: 
/
 indicates a statistically significant linear change, and —
 indicates there w
as no change. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per 100 encounters. 
* 
Includes m
ultiple IC
P
C
-2 and IC
P
C
-2 PLU
S
 codes (see A
ppendix 4, Table A
4.9, <purl.library.usyd.edu.au/sup/9781920899875>). 
N
ote: C
I – confidence interval. 
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13 Practice nurse activity 
This section investigates changes in the activities of practice nurses in association with the 
GP–patient encounters for the years 2005–06 to 2010–11. 
In November 2004, four Medicare item numbers were introduced into the MBS that allowed 
GPs to claim for specified tasks done by a practice nurse under the direction of the GP.18 The 
BEACH recording form for the 2005–06 BEACH year was amended to capture this 
information. 
• GPs were allowed to record multiple (up to three) Medicare item numbers where 
appropriate, rather than be limited to one item number as had been the case in earlier 
BEACH years. 
• In the ‘other treatments’ section, for each problem managed, GPs were asked to tick the 
‘practice nurse’ box if the treatment recorded was provided by the practice nurse rather 
than by the GP. If the box was not ticked it was assumed the GP gave the treatment. 
The survey form allowed GPs to record up to two other treatments for each problem 
managed at the encounter. Other treatments include all clinical and procedural treatments 
provided at the encounters. These groups are defined in Appendix 4, Tables A4.4 and A4.5. 
Over the year more practice nurse item numbers were added to the Medicare Schedule.  
This section investigates changes in: 
• the distribution of the practice nurse Medicare items recorded as claimable at encounters 
• treatments provided by practice nurses in association with the GP-recorded encounters 
• problems for which the practice nurse provided the treatment in association with the 
GP-recorded encounters. 
In Chapter 10, all treatments (other than medications) recorded by the GPs were reported, 
irrespective of whether they were provided by the GP or by a practice nurse. As in previous 
years, injections recorded in the provision of immunisations and vaccinations were not 
included, as these are already counted as pharmacological management. In contrast, in this 
description of practice nurse activity only the treatments indicated as being given by a 
practice nurse (including the injections for immunisation/vaccination that were not counted 
in Chapter 10) are included. GPs are also instructed not to record their own taking of routine 
clinical measurements, such as blood pressure. However, where the practice nurse 
undertook these activities at the consultation and it was recorded as a practice nurse activity, 
they are included in the analysis in this chapter. 
When viewing these results, it must be remembered that these practice nurse data will not 
include activities undertaken by the practice nurse during the GP’s BEACH recording period 
that were outside (not associated with) the recorded encounter. Such activities could include 
Medicare-claimable activities (e.g. immunisations/vaccinations), or other services not 
currently claimable from Medicare (e.g. dietary advice to an individual or in a group 
situation), provided under instruction from the GP but not at the time of the encounter. 
In measuring the changes that have occurred in practice nurse activity over the six years, the 
direction and type of change is indicated for each result in the far right column of the tables: 
/ indicates a statistically significant linear change, / indicates a marginally 
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significant linear change, § indicates a non-linear significant or marginal change, and — 
indicates there was no change. 
Significant linear changes in the rate per 100 encounters can be extrapolated to estimate the 
national increase or decrease in the other treatments provided between 2001–02 and 2010–11. 
Examples of extrapolated change are given. The method used to extrapolate to national 
change estimates is described in Section 2.9, and these methods can be applied to any 
significantly linear change per 100 encounters reported. 
13.1 Overview of practice nurse activity 
Encounters involving a practice nurse as a proportion of all recorded encounters almost 
doubled from 4.2% in 2005–06 to 8.0% in 2010–11. The proportion of problems for which 
practice nurses were involved in association with the GP-patient encounter also increased 
significantly from 2.8% to 5.4%. Encounters including a recorded practice nurse Medicare 
item number formed an increasing proportion of all encounters, rising from 1.7% in 2005–06 
to 4.1% in 2009–10. In 2010–11 there was a marginal decrease to 3.2%, but this proportion 
remained significantly higher than in 2005–06. Extrapolation of these results to national 
Medicare claims for GP consultations in these years suggests that in 2010–11, practice nurses 
were actively involved in provision of care at about 10.3 million encounters, about 6.1 million 
more than in 2005–06. 
There was no statistically significant change in the proportion of practice nurse activity 
encounters for which a Medicare practice nurse item number was recorded, the proportion 
sitting between 35% and 45% over the 10-year period (Table 13.1). 
13.2 Distribution of practice nurse item numbers 
claimed at encounters 
The number of practice nurse items claimed per 100 GP–patient encounters significantly 
increased from 1.7 items per 100 encounters in 2005–06 to 3.2 per 100 in 2010–11 (Table 13.2). 
Extrapolation of these results suggests that the BEACH sample represented about 1.7 million 
claimed practice nurse items in 2005–06, and about 4.9 million in 2009–10, but receded 
somewhat to an estimated 3.8 million in 2010–11. This recent decrease was also reflected in 
Medicare claims data showing there were 3.2 million such claims in 2005–06 climbing to 
about 7.6 million in 2009–10, and receding to about 6.1 million in the 2010–11 financial year.8 
Extrapolation of encounters for which a practice nurse item number was recorded as 
claimable in BEACH to all encounters across the country in each year suggest that the  
2005–06 BEACH sample represented about 53% of the practice nurse activity claimed from 
Medicare during that period, the 2009–10 sample 68.0%, and the 2010–11 sample 62%. The 
balance of the claims to Medicare for practice nurse items would be for services provided by 
the nurse, independent of the GP–patient encounter. 
There was only one significant change over the six year period in the distribution of practice 
nurse item numbers claimed for work associated with the BEACH encounters: there was an 
increase in the proportion of claims made for practice nurse services to a person with a 
chronic disease, since this item was first introduced in 2007–08. 
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Last year we reported a large increase in the proportion of claims accounted for by 
immunisations from 63.5% of practice nurse items recorded in 2008–09, to 74.9% in 2009–10, 
but this increase was not supported by the 2010–11 data which reverted to the 2006–07 level, 
at 67%. This recent change was also reflected in the Medicare claims data8 which 
demonstrated a decrease from 5.5 million claims for immunisation practice nurse items in 
2009–10 but only 3.7 million such claims in 2010–11. The transient rise in Medicare claims for 
practice nurse immunisations in 2009–10 may reflect increased patient demand resulting in 
increased immunisations/vaccinations during the H1N1 epidemic. 
Further, the proportion of claims accounted for by wound treatment, had sat steady at about 
one-third of all BEACH recorded practice nurse item claims, decreased significantly in  
2009–10, to 21.3%. However in 2010–11 this reverted somewhat to reach 28.1%, close to  
the 2005–06 level of 30.0%. Recording of other practice nurse items numbers was rare  
(Table 13.2). 
13.3 Treatments provided by practice nurses 
The rate at which procedures (including tests) were undertaken by practice nurses at  
GP–patient encounters doubled from 4.0 per 100 encounters in 2005–06 to 8.0 per 100 in 
2009–10, the largest portion of this increase occurring between 2008–09 and 2009–10. Practice 
nurses also took over an increasing proportion of the procedural work at the GP encounters, 
increasing from 22.7% in 2005–06 to 38.0% in 2010–11.  
While their provision of clinical treatments (such as advice and health education) remained 
infrequent at GP–patient encounters, there was a significant increase over the study period, 
from 0.2 clinical treatments per 100 encounters in 2005–06 to 0.7 per 100 in 2010–11. Further, 
nurses did a significantly greater proportion of the clinical treatments recorded at 
encounters, rising from 0.7% in 2005–06 to 2.0% in 2010–11. Overall in 2010–11 practice 
nurses provided 15.4% of all ‘other treatments’ recorded at the encounters, a significantly 
greater proportion than in 2005–06 (9.0%) (Table 13.3). 
Individual treatments 
There was also a significant increase in the number of treatments provided by the practice 
nurse at encounters in which they were involved, from 107.4 per 100 encounters in 2005–06 
to 112.8 per 100 in 2010–11. Paralleling the reversion in the number of Medicare claims for 
practice nurses immunisations, described above, local injections/infiltrations reverted to the 
2005–06 level of about 41 per 100 practice nurse involved encounters. The significant 
decrease in dressing/pressure/compression/tamponade procedures done by practice nurses 
that was noted last year was retained and decreases were also apparent in their rates of 
repair/fixations, electrical tracing, excisions/removals/biopsies. International normalised 
ratio (INR) blood testing frequency more than tripled, from 1.8 per 100 practice nurse 
encounters in 2006–07 to 6.8 in 2010–11.  
In clinical treatments, practice nurse provision of administrative procedures (excluding 
sickness certificates) increased from 0.7 per 100 practice nurse involved encounter in 2005–06, 
to 2.3 per 100 in 2008–09 and remained steady to 2010–11, nurse consultation with a primary 
care provider increased from 0.2 to 0.7 per 100 practice nurse involved encounters, perhaps 
reflecting their increasing contribution to the care of patients with chronic disease (reflected 
in the claims data in Table 13.2).  
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13.4 Problems managed with practice nurse 
Paralleling the decreases in claims for immunisations by practice nurses between 2009–10 
and 2010–11 discussed earlier in this chapter, in 2010–11 immunisations/vaccination 
reverted to earlier levels of about 30 per 100 encounters – down from its peak of 40.6 per 100 
practice nurse involved encounters in 2009–10.  
Increases in nurse management of atrial fibrillation/flutter, diabetes, post-traumatic skin 
infections, cystitis/urinary infection and ‘other preventive procedures’ were apparent, with 
decreases in the frequency of their involvement in chronic ulcer skin (including varicose 
ulcer) and malignant skin neoplasms.  
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Table 13.1: Sum
m
ary of practice nurse involvem
ent at encounter, and claim
s m
ade, 2005–06 to 2010–11 
 
N
um
ber 
  
(a) 
  
 
Variable 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
Total encounters  
101,993 
 
91,805 
 
95,898 
 
96,688 
 
101,349 
 
95,839 
. . 
E
ncounters involving practice nurse  
4,295 
 
4,769 
 
5,791 
 
6,183 
 
9,154 
 
7,625 
. . 
 
E
ncounters at w
hich practice nurse activity described 
4,013 
 
4,710 
 
5,712 
 
6,052 
 
8,999 
 
7,432 
. . 
 
E
ncounters w
ith practice nurse item
 num
ber but activity 
 
not described 
282 
 
59 
 
79 
 
131 
 
155 
 
195 
. . 
E
ncounters at w
hich one or m
ore M
B
S
 practice nurse item
 
num
bers w
ere recorded as claim
able  
1,683 
 
1,823 
 
2,060 
 
2,416 
 
4,161 
 
3,068 
. . 
Total problem
s m
anaged  
149,088 
 
136,333 
 
145,078 
 
149,462 
 
155,373 
 
146,141 
. . 
P
roblem
s m
anaged w
ith practice nurse involvem
ent 
4,111 
 
4,922 
 
5,909 
 
6,281 
 
9,542 
 
7,826 
. . 
 
Per cent (95%
 C
I) 
 
E
ncounters involving the practice nurse as a proportion of 
total encounters  
4.2 
(3.7–4.7) 
 
5.2 
(4.6–5.8) 
 
6.0 
(5.5–6.6) 
 
6.4 
(5.8–7.0) 
 
9.0 
(8.2–9.9) 
 
8.0 
(7.3–8.7) 

 
P
roblem
s involving the practice nurse as a proportion of total 
problem
s  
2.8 
(2.4–3.1) 
 
3.6 
(3.2–4.1) 
 
4.1 
(3.7–4.5 ) 
 
4.2 
(3.8–4.6) 
 
6.1 
(5.6–6.7) 
 
5.4 
(4.9–5.8) 

 
P
ractice nurse claim
able encounters as a proportion of total 
encounters 
1.7 
(1.4–1.9) 
 
2.0 
(1.7–2.3) 
 
2.1 
1.9–2.4) 
 
2.5 
(2.2–2.8) 
 
4.1 
(3.6–4.1) 
 
3.2 
(2.8–3.6) 

 
P
roportion of practice nurse involved encounters for w
hich 
one or m
ore M
B
S
 practice nurse item
 num
bers w
ere recorded  
39.2 
(34.7–43.6) 
 
38.2 
(34.0–42.4) 
 
35.6 
(32.4–38.8) 
 
39.1 
(35.9–42.3) 
 
45.5 
(42.1–48.8) 
 
40.2 
(36.9–43.6) 
—
 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change; § indicates a non-linear significant or m
arginal change, and  
—
 indicates there w
as no change 
N
ote: C
I – confidence interval. S
om
e of these results m
ay differ from
 those previously published, because these data w
ere re-analysed for all years to include in the count of total practice nurse activity those encounters at 
w
hich an item
 num
ber w
as recorded but no practice nurse activity w
as described.
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Table 13.2: D
istribution of practice nurse item
 num
bers recorded at encounter, 2005–06 to 2010–11 
M
edicare item
  
num
ber 
 
Per cent of total (95%
 C
I) 
   
(a) 
   
 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
Short descriptor 
(n = 1,696) 
 
(n = 1,835) 
 
(n = 2,073) 
 
(n = 2,438) 
 
(n = 4,215) 
 (n = 3,018) 
00711/10986
(b) 
H
ealth assessm
ent of four year old w
ho has had/ 
is having 4 year old im
m
unisation, by practice nurse 
or registered A
boriginal health w
orker 
N
/A
 
 
N
/A
 
 
N
/A
 
 
0.1 
(0.0–0.2) 
 
0.3 
(0.1–0.5) 
 
0.2 
(0.0–0.4) 
—
 
10993
(c) 
Im
m
unisation by practice nurse 
69.5 
(63.8–75.3) 
 
66.8 
(61.5–72.2) 
 
64.1 
(59.6–68.6) 
 
63.5 
(59.0–68.1) 
 
74.9 
(72.0–77.7) 
 
67.0 
(63.1–70.9) 
§ 
10994
(d) 
C
ervical sm
ear and preventive checks 
N
/A
 
 
0.2 
(0.0–0.5) 
 
0.2 
(0.0–0.4) 
 
0.7 
(0.1–1.2) 
 
0.4 
(0.0–0.7) 
 
0.6 
(0.1–1.1) 
—
 
10995
(d) 
C
ervical sm
ear and preventive checks – w
om
en  
20–69 years, no sm
ear in previous 4 years 
N
/A
 
 
0.1 
(0.0–0.2) 
 
0.1 
(0.0–0.2) 
 
0.4 
(0.0–0.9) 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.0) 
—
 
10998
(f) 
C
ervical sm
ear 
0 
 
0.1 
(0.0–0.3) 
 
0.3 
(0.2–0.5) 
 
0.1 
(0.0–0.2) 
 
0.1 
(0.0–0.1) 
 
0.4 
(0.0–0.8) 
—
 
10999
(f) 
C
ervical sm
ear – w
om
en 20–69 years, no sm
ear in 
previous 4 years 
0.5 
(0.0–0.9) 
 
0.2 
(0.0–0.4) 
 
0.3 
(0.0–0.8) 
 
0 
 
0.0
Ŧ 
(0.0–0.1) 
 
0.0
Ŧ 
(0.0–0.0) 
—
 
10996
(c) 
W
ound treatm
ent (other than norm
al aftercare) 
30.0 
(24.3–35.7) 
 
32.6 
(27.2–40.0) 
 
34.4 
(30.0–38.8) 
 
33.3 
(29.1–37.5) 
 
21.3 
(18.8–23.8) 
 
28.1 
(24.6–31.7) 
§ 
10997
(e) 
S
ervice to a person w
ith a chronic disease by a 
practice nurse or registered A
boriginal health w
orker  
N
/A
 
 
N
/A
 
 
0.7 
(0.2–1.2) 
 
1.9 
(0.9–2.9) 
 
3.0 
(1.7–4.2) 
 
3.6 
(2.5–4.6) 

 
Total practice nurse item
 num
bers – rate per 100 total encounters 
1.7 
(1.4–2.0) 
 
2.0 
(1.7–2.3) 
 
2.2  
(1.9–2.4) 
 
2.5 
(2.2–2.9) 
 
4.2 
(3.7–4.7) 
 
3.2 
(2.8–3.6) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change; § indicates a non-linear significant or m
arginal change, and —
 indicates 
no change. 
(b) 
Item
 00711 – H
ealth check by a practice nurse or registered A
boriginal health w
orker w
as introduced in 2008 and replaced w
ith item
 10986 in M
ay 2010 
(c) 
Item
 num
bers introduced in 2004. 
(d) 
Item
 num
ber introduced in N
ovem
ber 2006. 
(e) 
Item
 num
ber introduced in N
ovem
ber 2007. 
(f) 
Item
 num
bers introduced in N
ovem
ber 2004, but broadened in 2006, so they are not lim
ited to services in rural areas. 
Ŧ 
R
ates are reported to one decim
al place. This indicates that the rate is less than 0.05 per cent. 
N
ote: N
/A – N
ot applicable. There w
ere no recordings in any year of item
s: 10987 – Follow
-up by practice nurse or registered A
boriginal health w
orker for Indigenous person w
ho has received a health assessm
ent;  
10988 – Im
m
unisation provided by a registered A
boriginal health w
orker; 10989 – W
ound treatm
ent provided by a registered A
boriginal health w
orker; 16400 – A
ntenatal services provided by m
idw
ives, practice nurses  
and A
boriginal health w
orkers in rural and rem
ote areas. 
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Table 13.3: Sum
m
ary of treatm
ents provided by practice nurse, 2005–06 to 2010–11  
 
R
ate per 100 encounters (95%
 C
I) 
 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
   
(a) 
   
 
Treatm
ent 
(n = 101,993) 
 
(n = 91,805) 
 
(n = 95,898) 
 
(n = 96,688) 
 
(n = 101,349) 
 
(n = 95,839) 
P
rocedural treatm
ents
(b) 
4.0 
(3.5–4.5) 
 
5.2 
(4.6–5.8) 
 
6.1 
(5.5–6.7) 
 
6.4 
(5.8–7.1) 
 
9.2 
(8.3–10.2) 
 
8.0 
(7.3–8.8) 

 
C
linical treatm
ents 
0.2 
(0.1–0.3) 
 
0.5 
(0.3–0.6) 
 
0.5 
(0.4–0.6) 
 
0.5 
(0.4–0.6) 
 
0.7 
(0.5–0.9) 
 
0.7 
(0.6–0.9) 

 
A
ll other treatm
ents 
4.2 
(3.7–4.8) 
 
5.7 
(4.9–6.4) 
 
6.5 
(5.9–7.2) 
 
6.9 
(6.2–7.6) 
 
9.9 
(8.9–10.9) 
 
8.7 
(7.9–9.6) 

 
 
Per cent of each activity that w
as perform
ed/assisted by the practice nurse (95%
 C
I) 
 
P
rocedural treatm
ents
(b) 
22.7 
(20.2–25.2) 
 
28.1 
(25.5–30.8) 
 
29.7 
(27.5–32.0) 
 
30.4 
(28.0–32.9) 
 
39.6 
(36.5–42.6) 
 
38.0 
(35.4–40.5) 

 
C
linical treatm
ents 
0.7 
(0.5–0.9) 
 
1.5 
(0.9–2.2) 
 
1.3 
(1.0–1.6) 
 
1.4 
(1.1–1.6) 
 
2.0 
(1.4–2.5) 
 
2.0 
(1.6–2.5) 

 
A
ll other treatm
ents 
9.0 
(7.9–10.1) 
 
11.8 
(10.4–13.2) 
 
11.9 
(10.8–13.0) 
 
12.5 
(11.3–13.7) 
 
17.0 
(15.4–18.7) 
 
15.4 
(14.0–16.9) 

 
(a) 
The direction and type of change from
 2005–06 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change. 
(b) 
P
rocedural treatm
ents here include all injections for im
m
unisations/vaccinations. These are not included in the sum
m
ary of the content of encounter in Table 5.1, sum
m
ary of 
m
anagem
ent in Table 8.1 or in the analyses of other treatm
ents in C
hapter 10, because the im
m
unisation/vaccination is already counted as a prescription or G
P
-supplied m
edication. 
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Table 13.4: M
ost frequent treatm
ents done by practice nurses, 2005–06 to 2010–11 
 
R
ate per 100 encounters w
here practice nurse activity described (95%
 C
I) 
   
(a) 
   
 
Treatm
ent 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
(n = 4,013) 
 
(n = 4,710) 
 
(n = 5,712) 
 
(n = 6,052) 
 
(n = 8,999) 
 
(n = 7,625) 
P
rocedural treatm
ents (including tests) 
102.2 
(100.1–104.3) 
 
101.3 
(99.2–103.5) 
 
102.3 
(100.7–104.0) 
 
102.5 
(100.5–104.8) 
 
104.1 
(102.4–105.9) 
 
103.5 
(101.6–105.4) 
—
 
 
Local injection/infiltration* 
41.0  
(36.6–45.4) 
 
37.3  
(33.0–41.6) 
 
37.7  
(34.7–40.7) 
 
38.2 
(34.9–41.6) 
 
50.3 
(47.0–53.6) 
 
41.1 
(37.7–44.5) 
§ 
 
D
ressing/pressure/com
pression/tam
ponade* 
23.7  
(21.3–26.2) 
 
22.4  
(19.8–24.9) 
 
20.7  
(18.7–22.8) 
 
21.2 
(19.2–23.3) 
 
15.8 
(14.2–17.5 
 
19.5 
(17.8–21.2) 

 
 
C
heck-up – practice nurse* 
N
A
v 
 
4.0  
(2.3–5.6) 
 
6.1  
(4.8–7.4) 
 
6.3 
(4.0–8.6) 
 
7.6 
(4.0–11.1) 
 
7.3 
5.2–9.5 
—
 
 
International norm
alised ratio (IN
R
) test 
N
A
v 
 
1.8  
(1.0–2.6) 
 
4.9  
(3.6–6.2) 
 
6.4  
(4.9–7.9) 
 
4.5 
(3.5–5.5) 
 
6.8 
(5.5–8.1) 

 
 
Incision/drainage/flushing/aspiration/rem
oval  
 
body fluid* 
8.1  
(6.2–10.0) 
 
8.8  
(6.7–11.0) 
 
6.8  
(5.6–7.9) 
 
7.4 
(6.0–8.8) 
 
6.8 
(5.4–8.1) 
 
5.7 
(4.7–6.7) 
—
 
 
R
epair/fixation-suture/cast/prosthetic device 
 
(apply/rem
ove – all* 
6.4  
(5.0–7.8) 
 
6.0  
(5.0–7.0) 
 
5.0  
(4.2–5.7) 
 
4.3 
(3.6–5.0) 
 
4.0 
(3.3–4.6) 
 
4.4 
(3.6–5.1) 
—
 
 
E
lectrical tracings* 
5.4  
(4.1–6.7) 
 
4.5  
(3.7–5.2) 
 
5.2  
(4.3–6.1) 
 
4.4 
(3.6–5.2) 
 
3.6 
(3.1–4.2) 
 
4.3 
(3.7–5.0) 
—
 
 
E
xcision/rem
oval tissue/biopsy/destruction/ 
 
debridem
ent/cauterisation* 
7.4  
(5.6–9.2) 
 
5.7  
(4.2–7.2) 
 
4.9  
(3.8–5.9) 
 
4.3 
(3.4–5.2) 
 
2.9 
(2.2–3.6) 
 
3.2 
(2.5–3.9) 

 
 
P
hysical function test* 
3.9  
(2.6–5.3) 
 
4.3  
(2.8–5.7) 
 
3.5  
(2.3–4.7) 
 
2.7 
(2.0–3.4) 
 
2.9 
(2.1–3.6) 
 
2.6 
(2.0–3.3) 
—
 
 
U
rine test* 
1.4  
(0.8–2.0) 
 
1.4  
(0.8–2.0) 
 
2.1  
(1.3–3.0) 
 
1.7 
(1.0–2.4) 
 
1.3 
(0.8–1.8) 
 
2.3 
(1.6–3.0) 
—
 
 
G
lucose test 
0.7  
(0.3–1.1) 
 
1.0  
(0.4–1.5) 
 
1.0  
(0.7–1.3) 
 
1.0 
(0.6–1.3) 
 
0.6 
(0.4–0.8) 
 
1.5 
(0.7–2.3) 
—
 
 
O
ther diagnostic procedures N
E
C
* 
0 
 
0.1 
(0.0–0.2) 
 
0.1 
(0.0–0.2) 
 
0.5 
(0.2–0.8) 
 
0.7 
(0.4–1.0) 
 
1.3 
(0.2–2.3) 

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Table 13.4 (continued): M
ost frequent treatm
ents done by practice nurses, 2005–06 to 2010–11 
 
R
ate per 100 encounters w
here practice nurse activity described (95%
 C
I) 
   
(a) 
   
 
Treatm
ent 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
(n = 4,013) 
 
(n = 4,710) 
 
(n = 5,712) 
 
(n = 6,052) 
 
(n = 8,999) 
 
(n = 7,625) 
 
P
ap sm
ear* 
0.3  
(0.0–0.6) 
 
0.6  
(0.2–0.9) 
 
0.5  
(0.3–0.8) 
 
0.7 
(0.1–1.3) 
 
0.7 
(0.4–0.9) 
 
0.9 
(0.5–1.3) 
—
 
 
P
hysical m
edicine/rehabilitation – all* 
0.9 
(0.4–1.5) 
 
0.6 
(0.2–0.9) 
 
0.6 
(0.2–1.1) 
 
0.4 
(0.2–0.6) 
 
0.9 
(0.5–1.2) 
 
0.9 
(0.5–1.2) 
—
 
 
P
regnancy test* 
0.3  
(0.1–0.6) 
 
0.3  
(0.1–0.5) 
 
0.5  
(0.3–0.8) 
 
0.5  
(0.3–0.7) 
 
0.2 
(0.1–0.4) 
 
0.4 
(0.2–0.7) 
—
 
 
O
ther preventive procedures/high-risk  
 
m
edication* 
0.1 
(0.0–0.2) 
 
0.2 
(0.1–0.4) 
 
0.1 
(0.0–0.2) 
 
0.5 
(0.3–0.8) 
 
0.5 
(0.3–0.7) 
 
0.4 
(0.2–0.7) 

 
C
linical treatm
ents 
5.2  
(3.7–6.7) 
 
8.9 
(5.6–12.1) 
 
7.7 
(6.9–9.2) 
 
7.4 
(6.0–8.8) 
 
7.9 
(5.9–9.9) 
 
9.3 
(7.6–11.1) 

 
 
O
ther adm
inistrative procedure/docum
ent 
 
(excluding sickness certificate)* 
0.7  
(0.4–1.0) 
 
1.1  
(0.7–1.6) 
 
2.0  
(1.4–2.6) 
 
2.3 
(1.6–3.0) 
 
2.3 
(1.6–3.0) 
 
2.2 
(1.6–2.8)  

 
 
C
ounselling – problem
* 
0.9  
(0.2–1.5) 
 
0.8  
(0.3–1.3) 
 
0.6  
(0.3–0.8) 
 
0.5 
(0.2–0.7) 
 
0.6 
(0.3–0.9) 
 
1.2 
(0.6–1.8) 
—
 
 
A
dvice/education N
E
C
* 
0.9  
(0.4–1.3) 
 
1.5  
(0.6–2.4) 
 
1.4  
(0.8–2.1) 
 
0.8 
(0.5–1.1) 
 
1.2 
(0.6–1.9) 
 
1.0 
(0.5–1.4)  
—
 
 
C
onsultation w
ith prim
ary care provider* 
0 
 
0.2 
(0.0–0.3) 
 
0.4 
(0.2–0.7) 
 
0.1 
(0.0–0.2) 
 
0.4 
(0.2–0.6) 
 
0.7 
(0.4–1.0) 

 
 
C
ounselling/advice – nutrition/w
eight* 
0.6  
(0.2–0.9) 
 
1.2  
(0.2–2.1) 
 
0.5  
(0.1–0.9) 
 
0.7 
(0.4–1.1) 
 
0.6 
(0.3–0.8) 
 
0.7 
(0.4–1.0) 
—
 
 
A
dvice/education – m
edication* 
0.2 
(0.0–0.3) 
 
0.2 
(0.0–0.3) 
 
0.4 
(0.2–0.7) 
 
0.2 
(0.0–0.4) 
 
0.4 
(0.2–0.6) 
 
0.5 
(0.3–0.8)  

 
 
C
ounselling/advice – prevention* 
0.2 
(0.0–0.3) 
 
0.4 
(0.1–0.7) 
 
0.4 
(0.2–0.7) 
 
0.3 
(0.1–0.5) 
 
0.6 
(0.2–0.9) 
 
0.5 
(0.3–0.8) 

 
Total practice nurse activities at encounter 
107.4  
(105.0–108.9) 
 
110.2  
(107.7–112.8) 
 
110.0  
(108.4–111.6) 
 
109.9 
(108.1–111.6) 
 
112.0 
(110.3–113.7) 
 
112.8 
(110.9–114.7) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change and  
—
 indicates no change. 
* 
Includes m
ultiple IC
P
C
-2 or IC
P
C
-2 P
LU
S
 codes (see A
ppendix 4, Tables A
4.4–A
4.6 <purl.library.usyd.edu.au/sup/9781920899875>). 
N
ote: C
I – confidence interval; N
O
S
 – not otherw
ise stated; N
A
v – data not available. 
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Table 13.5: The m
ost com
m
on problem
s m
anaged w
ith involvem
ent of practice nurse, 2005–06 to 2010–11 
 
R
ate per 100 problem
 contacts w
ith practice nurse activity described (95%
 C
I) 
     
(a) 
     
 
Problem
 m
anaged 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
(n = 4,013) 
 
(n = 4,710) 
 
(n = 5,712) 
 
(n = 6,052) 
 
(n = 8,999) 
 
(n = 7,625) 
Im
m
unisation/vaccination – all* 
30.9 
(26.9–34.9) 
 
30.8 
(26.5–35.0) 
 
29.5 
(26.7–32.2) 
 
29.5 
(26.2–32.7) 
 
40.6 
(37.3–43.9) 
 
30.7 
(27.3–34.0) 
§ 
Laceration/cut 
6.4 
(5.0–7.8) 
 
6.2 
(5.2–7.2) 
 
6.0 
(5.0–7.0) 
 
6.4 
(5.5–7.3) 
 
4.5 
(3.8–5.1) 
 
6.0 
(5.1–6.8 
—
 
C
heck-up – all* 
3.8 
(2.8–4.8) 
 
4.4 
(3.4–5.4) 
 
5.2 
(4.0–6.4) 
 
5.1 
(3.9–6.2) 
 
5.5 
(4.6–6.3) 
 
5.0 
(4.1–5.9) 
—
 
C
hronic ulcer skin (including varicose ulcer) 
7.1 
(5.9–8.3) 
 
6.5 
(5.3–7.7) 
 
4.8 
(3.9–5.7) 
 
5.9 
(4.9–6.9) 
 
4.0 
(3.3–4.8) 
 
4.4 
(3.7–5.1) 

 
A
trial fibrillation/flutter 
1.2 
(0.6–1.7) 
 
1.4 
(0.8–2.0) 
 
2.8 
(2.0–3.6) 
 
3.4 
(2.6–4.3) 
 
2.5 
(1.8–3.2) 
 
3.6 
(2.8–4.4) 

 
D
iabetes – all* 
1.5 
(0.8–2.1) 
 
2.0 
(1.4–2.6) 
 
2.9 
(2.2–3.5) 
 
3.1 
(2.4–2.7) 
 
2.0 
(1.5–2.4) 
 
3.5 
(2.6–4.3) 

 
E
xcessive ear w
ax 
2.2 
(1.6–2.9) 
 
3.0 
(2.4–3.6) 
 
2.8 
(2.2–3.4) 
 
2.5 
(2.0–3.0) 
 
2.0 
(1.5–2.4) 
 
2.3 
(1.9–2.7) 
—
 
M
alignant neoplasm
 skin 
3.2 
(2.3–4.2) 
 
2.9 
(2.1–3.8) 
 
2.6 
(1.8–3.3) 
 
2.6 
(1.9–3.3) 
 
2.1 
(1.7–2.6) 
 
1.8 
(1.4–2.2) 

 
B
lood test – all* 
0.6 
(0.2–0.9) 
 
1.1 
(0.4–1.8) 
 
1.3 
(0.9–1.7) 
 
1.4 
(0.7–2.1) 
 
1.5 
(0.8–2.2) 
 
1.6 
(1.1–2.1) 

 
S
kin infection – post-traum
atic 
0.4 
(0.2–0.6) 
 
1.7 
(1.2–2.2) 
 
1.6 
(1.0–2.1) 
 
1.9 
(1.5–1.3) 
 
1.8 
(1.3–2.2) 
 
1.6 
(1.2–2.0) 

 
H
ypertension* 
1.1 
(0.6–1.5) 
 
1.6 
(1.0–2.2) 
 
1.8 
(1.2–2.3) 
 
1.8 
(1.2–2.4) 
 
1.8 
(1.2–2.4) 
 
1.5 
(1.0–1.9) 
—
 
R
epair/fixation-suture/cast/prosthetic device 
(apply/rem
ove) – all* 
1.3 
(0.7–1.9) 
 
1.4 
(1.0–1.9) 
 
1.4 
(1.0–1.7) 
 
1.1 
(0.8–1.5) 
 
1.0 
(0.7–1.2) 
 
1.2 
(0.9–1.6) 
—
 
V
itam
in/nutritional deficiency 
0.9 
(0.5–1.3) 
 
0.5 
(0.3–0.8) 
 
1.0 
(0.6–1.4) 
 
1.6 
(1.2–2.1) 
 
1.1 
(0.1–2.1) 
 
1.2 
(0.9–1.6) 
—
 
A
sthm
a 
1.5 
(1.0–2.0) 
 
2.3 
(1.6–3.0) 
 
1.2 
(0.9–1.6) 
 
1.1 
(0.7–1.5) 
 
0.9 
(0.6–1.1) 
 
1.2 
(0.8–1.5) 
—
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Table 13.5 (continued): The m
ost com
m
on problem
s m
anaged w
ith involvem
ent of practice nurse, 2005–06 to 2010–11 
 
R
ate per 100 contacts w
ith practice nurse activity described (95%
 C
I) 
     
(a) 
     
) 
Problem
 m
anaged 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
(n = 4,013) 
 
(n = 4,710) 
 
(n = 5,712) 
 
(n = 6,052) 
 
(n = 8,999) 
 
(n = 7,625) 
C
ystitis/urinary infection, other 
0.3 
(0.1–0.6) 
 
0.5 
(0.2–0.8) 
 
0.7 
(0.4–0.9) 
 
0.5 
(0.3–0.8) 
 
0.5 
(0.3–0.7) 
 
1.1 
(0.8–1.5) 

 
O
ther preventive procedures* 
0.2 
(0.0–0.3) 
 
0.4 
(0.1–0.6) 
 
0.8 
(0.4–1.2) 
 
0.4 
(0.2–0.7) 
 
0.8 
(0.5–1.1) 
 
1.0 
(0.6–1.4) 

 
B
oil/carbuncle 
0.6 
(0.3–0.8) 
 
0.8 
(0.5–1.1) 
 
0.9 
(0.5–1.2) 
 
1.1 
(0.7–1.4) 
 
0.5 
(0.3–0.7) 
 
1.0 
(0.7–1.3) 
—
 
P
regnancy* 
0.6 
(0.1–1.1) 
 
0.8 
(0.3–1.2) 
 
0.6 
(0.2–0.9) 
 
0.8  
(0.4–1.2) 
 
1.0 
(0.8–1.3) 
 
0.9 
(0.6–1.3) 
—
 
O
bservation/health education/advice – all* 
0.4 
(0.0–0.8) 
 
0.6 
(0.3–0.8) 
 
0.6 
(0.3–0.9) 
 
0.5 
(0.3–0.8) 
 
1.1 
(0.1–2.1) 
 
0.9 
(0.6–1.2) 
—
 
B
urns/scalds 
0.9 
(0.5–1.3) 
 
1.2 
(0.8–1.7) 
 
1.1 
(0.8–1.4) 
 
0.9 
(0.6–1.2) 
 
0.6 
(0.4–0.8) 
 
0.9 
(0.6–1.3) 
—
 
A
brasion/scratch/blister 
1.2 
(0.7–1.6) 
 
0.7 
(0.4–1.0) 
 
1.2 
(0.6–1.7) 
 
0.8 
(0.5–1.0) 
 
0.6 
(0.4–0.8) 
 
0.8 
(0.5–1.0) 
—
 
S
kin sym
ptom
/com
plaint N
E
C
 
1.2 
(0.7–1.7) 
 
1.2 
(0.8–1.7) 
 
1.0 
(0.7–1.3) 
 
0.9 
(0.6–1.2) 
 
0.9 
(0.7–1.2) 
 
0.8 
(0.5–1.1) 
—
 
C
ontraception, other than oral 
1.1 
(0.6–1.6) 
 
0.5 
(0.3–0.8) 
 
0.9 
(0.6–1.2) 
 
0.9 
(0.6–1.2) 
 
0.8 
(0.5–0.9) 
 
0.7 
(0.5–1.1) 
—
 
Fracture* 
1.1 
(0.7–1.5) 
 
1.0 
(0.6–1.5) 
 
0.8 
(0.5–1.0) 
 
0.5 
(0.3–0.7) 
 
0.3 
(0.2–0.4) 
 
0.5 
(0.4–0.7) 

 
Injury skin N
E
C
 
1.0 
(0.6–1.4) 
 
0.6 
(0.3–0.9) 
 
0.4 
(0.2–0.6) 
 
0.4 
(0.2–0.6) 
 
0.3 
(0.2–0.5) 
 
0.5 
(0.2–0.7) 
—
 
Total problem
s 
102.4  
(101.7–103.2) 
 
104.5 
(103.3–105.8) 
 
103.4  
(102.7–104.2) 
 
103.8 
(103.1–104.5) 
 
106.0 
(104.8–107.3) 
 
105.3 
(104.3–106.3) 

 
(a) 
The direction and type of change from
 2001–02 to 2010–11 is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change, and 
 —
 indicates no change. 
* 
Includes m
ultiple IC
P
C
-2 or IC
P
C
-2 P
LU
S
 codes (see A
ppendix 4, Table A
4.1, <purl.library.usyd.edu.au/sup/9781920899875>). 
N
ote: Includes only those problem
s m
anaged by practice nurses at a rate of 1%
 or higher in any of the years reported; C
I – confidence interval; N
E
C
 – not elsew
here classified. 
 
128
14 Patient risk factors 
General practice is a useful intervention point for health promotion because the majority of 
the population visit a GP at least once per year – in 2009–10, 83% of Australians visited a GP 
at least once (personal communication DoHA, June 2010). GPs, through ongoing professional 
education, have substantial knowledge of population health, screening programs and other 
interventions. They are therefore in an ideal position to advise patients about the benefits of 
health screening, and to individually counsel patients about their lifestyle choices. 
Since the beginning of the BEACH program (1998), a section on the bottom of each encounter 
form has been used to investigate aspects of patient health or health care delivery not 
covered by general practice encounter-based information. These additional substudies are 
referred to as Supplementary Analysis of Nominated Data (SAND). The SAND methods are 
described in Chapter 2. 
In brief, measured patient risk factors include self-reported height and weight (to calculate 
BMI), alcohol consumption and smoking status. Each GP completes patient risk factors data 
for a subsample of 40 forms. An example of the encounter form with the patient risk factor 
SAND questions is included in Appendix 1. The methods used to investigate patient risk 
factors are summarised in each section of this chapter. Further detail is provided in  
Chapter 14 of the companion report General practice activity in Australia 2010–11.1 
This chapter includes data about the risk behaviours of general practice patients from each of 
the most recent 10 years of the BEACH study from 2001–02 to 2010–11. The direction and 
type of change from 2001–02 to 2010–11 is indicated for each result in the far right column of 
the tables: / indicates a statistically significant linear change, / indicates a 
marginally significant linear change, § indicates a non-linear significant or marginal change,  
and — indicates there was no change. 
14.1 Body mass index 
Method 
Patient BMI was investigated for a subsample of 40 of the 100 patient encounters. Each GP 
was instructed to ask the patient (or their carer in the case of children): 
• What is your height in centimetres (without shoes)? 
• What is your weight in kilograms (unclothed)? 
Metric conversion tables (feet and inches; stones and pounds) were provided to the GP. 
The BMI for an individual was calculated by dividing weight (kilograms) by height (metres) 
squared. The WHO recommendations61 for BMI groups were used, which specify that an 
adult (18 years and over) with a BMI: 
• less than 18.5 is underweight 
• greater than or equal to 18.5 and less than 25 is normal 
• greater than or equal to 25 and less than 30 is overweight 
• of 30 or more is obese. 
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The BEACH data on BMI are presented separately for adults (aged 18 years and over) and 
children (aged 2–17 years). The standard BMI cut-offs described above were applied for the 
adult sample, and the method described by Cole et al. (2000 & 2007) was used for children 
(aged 2–17 years).62,63  
Adults 
Overall prevalence of overweight and obesity in adults attending general practice increased 
significantly from 55.0% in 2001–02 (95% CI: 54.1–55.8) to 61.8% in 2010–11  
(95% CI: 60.9–62.6) (results not tabulated). 
Looking at obesity and overweight individually:  
• there was a significant increase in the prevalence of obesity in adults attending general 
practice, from 21.5% in 2001–02 to 26.7% in 2010–11 (Table 14.1). The significant increase 
in obesity was apparent in both male and female patients (Tables 14.2 and 14.3).  
• the prevalence of overweight in adults also increased from 33.5% in 2001–02 to 35.1% in 
2010–11 (Table 14.1). This significant increase in overweight was only apparent in female 
patients (Tables 14.2 and 14.3). 
Children 
The prevalence of overweight and obesity in children aged 2–17 years attending general 
practice remained static from 2001–02 to 2010–11, with about 10–11% of children being obese 
and about 18% overweight (Table 14.1). 
14.2 Smoking 
Method 
GPs were instructed to ask adult patients (18 years and over): 
• What best describes your smoking status?  Smoke daily 
 Smoke occasionally 
 Previous smoker 
 Never smoked 
Results 
There was a significant decrease in the prevalence of current daily and occasional smoking in 
adults aged 18 years and over attending general practice, from 18.4% and 4.1% respectively 
in 2001–02 to 14.8% and 2.7% in 2010–11 (Table 14.1). These decreases were apparent in both 
male and female patients (Tables 14.2 and 14.3). 
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14.3 Alcohol consumption 
Method 
To measure alcohol consumption, BEACH uses AUDIT-C64 which is the first three items 
from the WHO Alcohol Use Disorders Identification Test (AUDIT),65 with scoring for an 
Australian setting.66 The AUDIT-C has demonstrated validity and internal consistency and 
performs as well as the full AUDIT tool.67 The three AUDIT-C tool is practical and valid in a 
primary care setting to assess ‘at-risk’ alcohol consumption (heavy drinking and/or active 
alcohol dependence).64 The scores for each question range from zero to four. A total (sum of 
all three questions) score of five or more for males or four or more for females suggests that 
the person’s drinking level is placing him or her at risk.66 
GPs were instructed to ask adult patients (18 years and over): 
• How often do you have a drink containing alcohol? Never 
 Monthly or less 
 Once a week/fortnight 
 2–3 times a week 
 4 times a week or more 
• How many standard drinks do you have on a typical day when you are drinking?  
 _______________ 
• How often do you have six or more standard drinks on one occasion?  
 Never 
 Less than monthly 
 Monthly 
 Weekly 
 Daily or almost daily 
A standard drinks chart was provided to each GP to help the patient identify the number of 
standard drinks consumed. 
Results 
The rates of at-risk levels of alcohol consumption among adults attending general practice 
remained static at about 25–26% of adult patients between 2001–02 and 2010–11 (Table 14.1). 
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Table 14.1: Patient risk factors, 2001–02 to 2010–11 
R
isk factor 
Per cent (95%
 C
I) 
 
(a) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
A
dults (aged 18 years and over) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B
ody m
ass index class
(b) (n) 
31,789 
 
32,367 
 
31,890 
 
30,476 
 
33,101 
 
32,334 
 
31,062 
 
33,526 
 
31,932 
 
31,315 
. . 
O
bese 
21.5 
(20.8–22.2) 
 
20.9 
(20.2–21.5) 
 
22.1 
(21.4–22.7) 
 
22.4 
(21.7–23.2) 
 
22.2 
(21.5–22.9) 
 
23.5 
(22.7–24.2) 
 
23.9 
(23.1–24.6) 
 
25.4 
(24.7–26.1) 
 
25.9 
(25.2–26.6) 
 
26.7 
(26.0–27.5) 

 
O
verw
eight 
33.5 
(32.9–34.1) 
 
33.8 
(33.2–34.5) 
 
34.5 
(33.8–35.1) 
 
34.6 
(33.9–35.2) 
 
34.6 
(33.9–35.2) 
 
35.0 
(34.3–35.6) 
 
35.4 
(34.7–36.0) 
 
36.1 
(35.5–36.7) 
 
34.4 
(33.7–35.0) 
 
35.1 
(34.4–35.7) 

 
N
orm
al 
42.1 
(41.3–42.9) 
 
42.4 
(41.6–43.3) 
 
40.7 
(39.9–41.6) 
 
40.3 
(39.5–41.2) 
 
40.5 
(39.7–41.4) 
 
39.0 
(38.1–39.8) 
 
38.3 
(37.4–39.2) 
 
36.1 
(35.3–36.8) 
 
37.3 
(36.5–38. 2) 
 
35.8 
(35.0–36.7) 

 
U
nderw
eight 
3.0 
(2.8–3.2) 
 
2.9 
(2.7–3.1) 
 
2.8 
(2.6–3.0) 
 
2.7 
(2.5–2.9) 
 
2.8 
(2.5–3.0) 
 
2.6 
(2.4–2.8) 
 
2.5 
(2.3–2.7) 
 
2.5 
(2.3–2.7) 
 
2.4 
(2.2–2.6) 
 
2.4 
(2.2–2.6) 

 
Sm
oking status (n) 
31,966 
 
32,651 
 
32,718 
 
31,295 
 
33,558 
 
31,176 
 
31,652 
 
34,194 
 
32,744 
 
32,160 
. . 
D
aily 
18.4 
(17.7–19.2) 
 
17.2 
(16.5–17.9) 
 
17.6 
(16.8–18.3) 
 
18.0 
(17.2–18.7) 
 
17.1 
(16.3–17. 8) 
 
16.1 
(15.4–16.9) 
 
16.5 
(15.8–17.3) 
 
15.3 
(14.6–15.9) 
 
15.1 
(14.4–15.8) 
 
14.8 
(14.2–15.5) 

 
O
ccasional 
4.1 
(3.8–4.4) 
 
4.1 
(3.8–4.4) 
 
4.3 
(4.0–4.7) 
 
3.7 
(3.4–4.0) 
 
3.6 
(3.4–3.9) 
 
3.2 
(2.9–3.4) 
 
2.9 
(2.7–3.2 ) 
 
2.6 
(2.4–2.9) 
 
2.7 
(2.5–2.9) 
 
2.7 
(2.4–2.9) 

 
P
revious 
27.8 
(27.0–28.6) 
 
27.2 
(26.5–28.0) 
 
28.0 
(27.3–28.8) 
 
28.0 
(27.2–28.8) 
 
27.1 
(26.3–27.8) 
 
28.8 
(28.0–29.6) 
 
27.9 
(27.1–28.6) 
 
28.8 
(28.1–29.6) 
 
28.2 
(27.4–29.0) 
 
28.3 
(27.5–29.1) 
—
 
N
ever 
49.7 
(48.7–50.7) 
 
51.4 
(50.4–52.4) 
 
50.1 
(49.1–51.0) 
 
50.3 
(49.4–51.3) 
 
52.3 
(51.3–53.2) 
 
51.9 
(50.9–52.9) 
 
52.7 
(51.7–53.6) 
 
53.3 
(52.4–54.2) 
 
54.0 
(53.1–55.0) 
 
54.2 
(53.3–55.2) 

 
A
lcohol consum
ption (n) 
31,559 
 
32,140 
 
31,721 
 
30,414 
 
32,753 
 
30,347 
 
30,796 
 
33,347 
 
31,771 
 
31,190 
. . 
A
t-risk alcohol level 
26.0 
(25.1–26.8) 
 
26.2 
(25.3–27.1) 
 
26.7 
(25.8–27.6) 
 
26.4 
(25.5–27.3) 
 
25.9 
(25.0–26. 8) 
 
27.0 
(26.1–28.0) 
 
26.2 
(25.3–27.1) 
 
25.2 
(24.3–26.0) 
 
26.5 
(25.7–27.4) 
 
24.8 
(23.9–25.7) 
—
 
R
esponsible drinker 
44.1 
(43.3–45.0) 
 
44.2 
(43.4–45.1) 
 
44.9 
(44.1–45.8) 
 
44.9 
(44.0–45.7) 
 
44.8 
(44.0–45.7) 
 
44.6 
(43.7–45.5) 
 
44.6 
(43.7–45.5) 
 
45.2 
(44.3–46.1) 
 
44.4 
(43.5–45.3) 
 
44.0 
(43.0–44.9) 
—
 
N
on-drinker 
29.9 
(28.9–30.9) 
 
29.5 
(28.5–30.6) 
 
28.4 
(27.3–29.4) 
 
28.7 
(27.7–29.8) 
 
29.3 
(28.2–30.4) 
 
28.3 
(27.3–29.4) 
 
29.3 
(28.2–30.3) 
 
29.6 
(28.6–30.7) 
 
29.1 
(28.0–30.1) 
 
31.3 
(30.2–32.4) 
—
 
 (continued) 
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Table 14.1 (continued): C
om
parative results for all patient risk factors, 2001–02 to 2010–11 
R
isk factor 
Per cent (95%
 C
I) 
 
(a) 
 
 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
C
hildren (aged 2–17 years) (c) (n) 
3,518 
 
3,380 
 
3,189 
 
3,018 
 
3,338 
 
3,087 
 
3,046 
 
2,970 
 
3,183 
 
3,008 
. . 
 
O
bese 
10.9 
(9.7–12.1) 
 
11.9 
(10.5–13.2) 
 
11.8 
(10.5–13.2) 
 
10.8 
(9.5–12.2) 
 
10.9 
(9.7–12.1) 
 
10.6 
(9.3–11.9) 
 
11.2 
(10.0–12.5) 
 
10.5 
(9.3–11.7) 
 
9.6 
(8.4–10.8) 
 
10.6 
(9.3–12.0) 
—
 
 
O
verw
eight 
17.9 
(16.5–19.3) 
 
18.3 
(16.9–19.6) 
 
19.2 
(17.7–20.7) 
 
17.7 
(16.3–19.1) 
 
17.9 
(16.5–19.2) 
 
18.6 
(17.2–20.0) 
 
17.1 
(15.7–18.5) 
 
16.7 
(15.3–18.2) 
 
18.0 
(16.7–19.4) 
 
17.7 
(16.2–19.1)) 
—
 
(a) 
The direction and type of change is indicated for each result: 
/
 indicates a statistically significant linear change, and —
 indicates there w
as no change. 
(b) 
A
dult patients aged 18 years and over w
ith a recorded height outside the Australian B
ureau of S
tatistics height range based on age and sex w
ere excluded. 
(c) 
C
hildren (aged 2–17 years) w
ith height outside the A
ustralian B
ureau of S
tatistics or C
entres for D
isease C
ontrol, height range based on age and sex w
ere excluded. C
hild BM
I w
as re-calculated for 2001–02 to 
2005–06, and w
ill differ from
 data previously published to incorporate this exclusion and to apply a m
ore precise m
ethod for calculating child B
M
I. 
N
ote: C
I – confidence interval. 
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Table 14.2: Patient risk factors am
ong adult m
ales, 2001–02 to 2010–11  
 
Per cent (95%
 C
I) 
 
(a) 
 
 
R
isk factor 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
B
ody m
ass index class
(b) (n) 
12,512 
 
12,450 
 
12,434 
 
12,288 
 
12,882 
 
12,715 
 
12,126 
 
13,595 
 
11,945 
 
12,322 
. . 
 
O
bese 
20.0 
(19.1–20.9) 
 
19.9 
(19.1–20.8) 
 
20.7 
(19.8–21.5) 
 
21.3 
(20.4–22.3) 
 
21.6 
(20.7–22.5) 
 
22.4 
(21.6–23.3) 
 
23.1 
(22.1–24.1) 
 
25.0 
(24.1–26.0) 
 
25.5 
(24.6–26.5) 
 
26.1 
(25.2–27.1) 

 
 
O
verw
eight 
41.0 
(40.0–42.0) 
 
41.5 
(40.5–42.4) 
 
42.3 
(41.3–43.2) 
 
42.0 
(41.0–43.0) 
 
42.6 
(41.6–43.6) 
 
42.3 
(41.4–43.3) 
 
43.0 
(42.0–44.0) 
 
43.6 
(42.7–44.6) 
 
42.1 
(41.1–43.0) 
 
42.2 
(41.2–43.2) 
—
 
 
N
orm
al 
37.4 
(36.3–38.6) 
 
37.2 
(36.2–38.3) 
 
35.6 
(34.5–36.7) 
 
35.3 
(34.2–36.5) 
 
34.3 
(33.3–35.4) 
 
34.0 
(32.9–35.1) 
 
32.7 
(31.6–33.8) 
 
30.3 
(29.3–31.4) 
 
31.6 
(30.2–32.3) 
 
30.6 
(29.5–31.6) 

 
 
U
nderw
eight 
1.5 
(1.3–1.8) 
 
1.4 
(1.1–1.6) 
 
1.5 
(1.3–1.7) 
 
1.4 
(1.1–1.6) 
 
1.5 
(1.3–1.7) 
 
1.2 
( 1.0–1.4) 
 
1.2 
(1.0–1.4) 
 
1.0 
(0.8–1.2) 
 
1.2 
(1.0–1.4) 
 
1.1 
(0.9–1.3) 

 
Sm
oking status (n) 
12,547 
 
12,521 
 
12,692 
 
12,613 
 
13,016 
 
12,257 
 
12,335 
 
13,841 
 
12,260 
 
12,600 
. . 
 
D
aily 
21.6 
(20.5–22.6) 
 
20.4 
(19.4–21.4) 
 
21.0 
(20.0–22.0) 
 
21.2 
(20.2–22.3) 
 
20.7 
(19.7–21.8) 
 
19.4 
(18.3–20.5) 
 
19.8 
(18.8–20.8) 
 
18.1 
(17.2–19.0) 
 
18.1 
(17.1–19.1) 
 
17.8 
(16.9–18.7) 

 
 
O
ccasional 
4.6 
(4.1–5.1) 
 
4.5 
(4.0–5.0) 
 
4.5 
(4.0–4.9) 
 
4.3 
(3.9–4.7) 
 
4.1 
(3.7–4.6 ) 
 
3.8 
(3.4–4.2) 
 
3.3 
(2.9–3.7) 
 
3.0 
(2.6–3.4) 
 
3.1 
(2.8–3.5) 
 
3.1 
(2.7–3.5) 

 
 
P
revious 
36.6 
(35.4–37.9) 
 
36.4 
(35.2–37.6) 
 
37.3 
(36.2–38.5) 
 
36.5 
(35.3–37.6) 
 
35.7 
(34.5–36.9) 
 
37.1 
(35.8–38.4) 
 
36.5 
(35.3–37.7) 
 
37.9 
(36.8–39.1) 
 
36.9 
(35.8–38.1) 
 
36.8 
(35.6–38.0) 
—
 
 
N
ever 
37.2 
(36.0–38.4) 
 
38.7 
(37.5–40.0) 
 
37.2 
(36.0–38.4) 
 
38.0 
(36.8–39.2) 
 
39.5 
(38.2–40.7) 
 
39.7 
(38.5–41.0) 
 
40.4 
(39.2–41.6) 
 
41.0 
(39.8–42.2) 
 
41.8 
(40.6–43.0) 
 
42.3 
(41.1–43.5) 

 
A
lcohol consum
ption
) (n) 
12,464 
 
12,391 
 
12,334 
 
12,294 
 
12,792 
 
12,005 
 
12,071 
 
13,583 
 
11,974 
 
12,321 
. . 
 
A
t-risk alcohol level 
32.0 
(30.8–33.2) 
 
32.8 
(31.6–34.1) 
 
33.1 
(31.9–34.3) 
 
32.6 
(31.3–33.8) 
 
31.6 
(30.3–32.8) 
 
32.5 
(31.2–33.8) 
 
31.7 
(30.5–32.9) 
 
30.1 
(28.9–31.2) 
 
31.6 
(30.4–32.8) 
 
30.0 
(28.8–31.2) 
—
 
 
R
esponsible drinker 
46.8 
(45.7–48.0) 
 
46.6 
(45.5–47.8) 
 
47.3 
(46.1–48.5) 
 
47.7 
(46.4–48.9) 
 
47.9 
(46.7–49.1) 
 
48.0 
(46.7–49.2) 
 
47.6 
(46.4–48.8) 
 
48.9 
(47.8–50.1) 
 
47.6 
(46.4–48.8) 
 
47.7 
(46.5–48.9) 
—
 
 
N
on-drinker 
21.2 
(20.1–22.2) 
 
20.5 
(19.5–21.5) 
 
19.6 
(18.5–20.7) 
 
19.8 
(18.7–20.9) 
 
20.5 
(19.4–21.6) 
 
19.5 
(18.5–20.6) 
 
20.7 
(19.6–21.8) 
 
21.0 
(20.0–22.0) 
 
20.8 
(19.7–21.9) 
 
22.3 
(21.2–23.5) 
—
 
(a) 
The direction and type of change is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change, and —
 indicates there w
as no change. 
(b) 
A
dult patients aged 18 years and over w
ith a recorded height outside the Australian B
ureau of S
tatistics height range based on age and sex w
ere excluded. 
N
ote: C
I – confidence interval. 
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Table 14.3: Patient risk factors am
ong adult fem
ales, 2001–02 to 2010–11 
 
Per cent (95%
 C
I) 
 
(a) 
 
 
R
isk factor 
2001–02 
 
2002–03 
 
2003–04 
 
2004–05 
 
2005–06 
 
2006–07 
 
2007–08 
 
2008–09 
 
2009–10 
 
2010–11 
B
ody m
ass index class
(b) (n) 
19,039 
 
19,670 
 
19,214 
 
17,976 
 
19,976 
 
19,410 
 
18,703 
 
19,671 
 
19,735 
 
18,741 
. . 
 
O
bese 
22.4 
(21.6–23.2) 
 
21.5 
(20.7–22.3) 
 
23.0 
(22.1–23.8) 
 
23.2 
(22.4–24.1) 
 
22.6 
(21.7–23.4) 
 
24.2 
(23.3–25.1) 
 
24.3 
(23.5–25.2) 
 
25.6 
(24.8–26.4) 
 
26.2 
(25.3–27.0) 
 
27.2 
(26.3–28.1) 

 
 
O
verw
eight 
28.5 
(27.8–29.3) 
 
29.0 
(28.2–29.8) 
 
29.4 
(28.6–30.1) 
 
29.3 
(28.6–30.1) 
 
29.3 
(28.6–30.0) 
 
30.1 
(29.4–30.9) 
 
30.4 
(29.7–31.2) 
 
30.9 
(30.2–31.6) 
 
29.6 
(28.9–30.3) 
 
30.3 
(29.6–31.0) 

 
 
N
orm
al 
45.2 
(44.2–46.1) 
 
45.7 
(44.7–46.8) 
 
44.1 
(43.1–45.1) 
 
43.8 
(42.7–44.8) 
 
44.6 
(43.6–45.6) 
 
42.2 
(41.2–43.2) 
 
41.9 
(40.9–43.0) 
 
40.0 
(39.1–41.0) 
 
41.1 
(40.1–42.0) 
 
39.3 
(38.3–40.3) 

 
 
U
nderw
eight 
3.9 
(3.6–4.2) 
 
3.8 
(3.5–4.2) 
 
3.6 
(3.3–3.9) 
 
3.6 
(3.3–4.0) 
 
3.5 
(3.2–3.8) 
 
3.5 
(3.2–3.8) 
 
3.3 
(3.0–3.6) 
 
3.4 
(3.2–3.7) 
 
3.2 
(2.9–3.5) 
 
3.2 
(2.9–3.5) 

 
Sm
oking status (n) 
19,182 
 
19,875 
 
19,780 
 
18,468 
 
20,288 
 
18,718 
 
19,081 
 
20,079 
 
20,224 
 
19,301 
. . 
 
D
aily 
16.4 
(15.6–17.2) 
 
15.2 
(14.4–15.9) 
 
15.4 
(14.6–16.1) 
 
15.7 
(15.0–16.5) 
 
14.7 
(14.0–15.4) 
 
14.0 
(13.3–14.8) 
 
14.4 
(13.7–15.2) 
 
13.3 
(12.6–14.0) 
 
13.3 
(12.6–14.0) 
 
12.9 
(12.2–13.6) 

 
 
O
ccasional 
3.8 
(3.4–4.1) 
 
3.9 
(3.5–4.3) 
 
4.2 
(3.9–4.6) 
 
3.3 
(3.0–3.7) 
 
3.3 
(3.0–3.6 ) 
 
2.7 
(2.5–3.0) 
 
2.6 
(2.4–2.9) 
 
2.4 
(2.2–2.7) 
 
2.4 
(2.2–2.7) 
 
2.4 
(2.2–2.7) 

 
 
P
revious 
22.0 
(21.2–22.9) 
 
21.5 
(20.7–22.3) 
 
22.0 
(21.2–22.8) 
 
22.2 
(21.3–23.0) 
 
21.5 
(20.7–22.3) 
 
23.3 
(22.5–24.2) 
 
22.3 
(21.4–23.1) 
 
22.5 
(21.7–23.3) 
 
22.8 
(22.0–23.7) 
 
22.7 
(21.8–23.5) 
—
 
 
N
ever 
57.8 
(56.7–58.9) 
 
59.4 
(58.3–60.5) 
 
58.4 
(57.3–59.5) 
 
58.8 
(57.7–59.9) 
 
60.5 
(59.5–61.6) 
 
59.9 
(58.8–61.0) 
 
60.7 
(59.6–61.7) 
 
61.7 
(60.7–62.7) 
 
61.5 
(60.4–62.5) 
 
62.1 
(61.0–63.1) 

 
A
lcohol consum
ption (n) 
19,095 
 
19,749 
 
19,387 
 
18,120 
 
19,961 
 
18,342 
 
18,715 
 
19,764 
 
19,979 
 
18,869 
. . 
 
A
t-risk alcohol level 
22.0 
(21.1–22.9) 
 
22.1 
(21.2–23.0) 
 
22.6 
(21.7–23.6) 
 
22.2 
(21.3–23.2) 
 
22.2 
(21.3–23.2) 
 
23.5 
(22.5–24.5) 
 
22.6 
(21.6–23.6) 
 
21.8 
(20.8–22.7) 
 
23.4 
(22.5–24.4) 
 
21.4 
(20.5–22.3) 
—
 
 
R
esponsible drinker 
42.4 
(41.3–43.4) 
 
42.7 
(41.7–43. 8) 
 
43.5 
(42.4–44.5) 
 
43.0 
(41.9–44.0) 
 
42.8 
(41.8–43.9) 
 
42.4 
(41.3–43.5) 
 
42.6 
(41.6–43.7) 
 
42.6 
(41.6–43.7) 
 
42.5 
(41.5–43.6) 
 
41.5 
(40.4–42.6) 
—
 
 
N
on-drinker 
35.6 
(34.4–36.9) 
 
35.2 
(33.9–36.5) 
 
33.9 
(32.7–35.2) 
 
34.8 
(33.4–36.2) 
 
35.0 
(33.6–36.3) 
 
34.1 
(32.8–35.4) 
 
34.8 
(33.5–36.1) 
 
35.6 
(34.3–36.9) 
 
34.0 
(32.8–35. 3) 
 
37.1 
(35.7–38.5) 
—
 
(a) 
The direction and type of change is indicated for each result: 
/
 indicates a statistically significant linear change, 
/
 indicates a m
arginally significant linear change, and —
 indicates there w
as no change. 
(b) 
A
dult patients aged 18 years and over w
ith a recorded height outside the Australian B
ureau of S
tatistics height range based on age and sex w
ere excluded. 
N
ote: C
I – confidence interval. 
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Abbreviations 
ABS Australian Bureau of Statistics 
ACE angiotensin-converting enzyme  
ACRRM Australian College of Rural and Remote Medicine 
AIHW Australian Institute of Health and Welfare 
ASGC Australian Standard Geographical Classification 
ATC Anatomical Therapeutic Chemical (classification) 
BEACH Bettering the Evaluation and Care of Health 
BMI body mass index 
CAPS Coding Atlas for Pharmaceutical Substances 
CI confidence interval (in this report 95% CI is used) 
CT computerised tomography 
DoHA Australian Government Department of Health and Ageing 
DVA Australian Government Department of Veterans’ Affairs 
FACRRM Fellow of the Australian College of Rural and Remote Medicine 
FMRC Family Medicine Research Centre 
FRACGP Fellow of the Royal Australian College of General Practitioners 
FTE full-time equivalent 
GP general practitioner 
HbA1c haemoglobin, type A1c 
ICPC International Classification of Primary Care 
ICPC-2 International Classification of Primary Care – Version 2 
ICPC-2 PLUS a terminology classified according to ICPC-2 
INR international normalised ratio 
MBS Medicare Benefits Schedule 
M,C&S microscopy, culture and sensitivity 
NESB non-English-speaking background 
OTC over-the-counter (medications advised for over-the-counter purchase) 
PBS Pharmaceutical Benefits Scheme 
RACGP Royal Australian College of General Practitioners 
RFE reason for encounter 
RRMA Rural, Remote and Metropolitan Area classification 
SAND Supplementary Analysis of Nominated Data 
SAS Statistical Analysis System 
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URTI upper respiratory tract infection  
WHO World Health Organization 
Wonca World Organization of Family Doctors 
Symbols 
. . intentionally left blank 
< less than 
> more than 
n number 
N/A not applicable 
NAv not available 
NEC not elsewhere classified 
NOS not otherwise specified 
 indicates a statistically significant linear increase over time 
 indicates a statistically significant linear decrease over time 
 indicates a marginally significant increase over time 
 indicates a marginally significant decrease over time 
§ indicates a non-linear significant or marginal change over time 
— Indicates no change over time 
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Glossary 
A1 Medicare items: Medicare item numbers 1, 2, 3, 4, 13, 19, 20, 23, 24, 25, 33, 35, 36, 37, 38, 40, 
43, 44, 47, 48, 50, 51, 601, 602. 
Aboriginal: The patient identifies himself or herself as an Aboriginal person. 
Activity level: The number of general practice A1 Medicare items claimed during the previous 
3 months by a participating GP. 
Allied and other health professionals: Those who provide clinical and other specialised services 
in the management of patients, including physiotherapists, occupational therapists, 
dietitians, dentists and pharmacists. 
Chapters (ICPC-2): The main divisions within ICPC-2. There are 17 chapters primarily 
representing the body systems. 
Chronic problem: see Diagnosis/problem, Chronic problem. 
Commonwealth concession card: An entitlement card provided by the Australian Government 
that entitles the holder to reduced cost medicines under the Pharmaceutical Benefits Scheme 
and a limited number of other concessions from state and local government authorities. 
Complaint: A symptom or disorder expressed by the patient when seeking care. 
Component (ICPC-2): In ICPC-2 there are seven components that act as a second axis across all 
chapters. 
Consultation: See Encounter. 
Diagnosis/problem: A statement of the provider’s understanding of a health problem 
presented by a patient, family or community. GPs are instructed to record at the most 
specific level possible from the information available at the time. It may be limited to the 
level of symptoms. 
• New problem: The first presentation of a problem, including the first presentation of a 
recurrence of a previously resolved problem, but excluding the presentation of a 
problem first assessed by another provider. 
• Old problem: A previously assessed problem that requires ongoing care, including 
follow-up for a problem or an initial presentation of a problem previously assessed by 
another provider. 
• Chronic problem: A medical condition characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last 6 months or more, a pattern 
of recurrence or deterioration, a poor prognosis, and consequences or sequelae that 
impact on an individual’s quality of life. (Source: O’Halloran J, Miller GC, Britt H 2004. 
Defining chronic conditions for primary care with ICPC-2. Fam Pract 21(4):381–6).  
• Work-related problem: Irrespective of the source of payment for the encounter, it is likely 
in the GP’s view that the problem has resulted from work-related activity or workplace 
exposures or that a pre-existing condition has been significantly exacerbated by work 
activity or workplace exposure. 
Encounter: Any professional interchange between a patient and a GP. 
• Indirect: Encounter where there is no face-to-face meeting between the patient and the 
GP but a service is provided (for example, prescription, referral). 
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• Direct: Encounter where there is a face-to-face meeting of the patient and the GP. 
Direct encounters can be further divided into: 
— Medicare-claimable 
▪ Surgery consultations: encounters identified by any one of MBS item numbers 
3, 23, 36, 44, 52, 53, 54, 57, 5000, 5020, 5040, 5060, 5200, 5203, 5207, 5208. 
▪ Home or institution visits (excluding residential aged care facilities): encounters 
identified by any one of MBS item numbers 4, 19, 24, 33, 37, 40, 47, 50, 58, 59, 60, 
65, 87, 89, 90, 91, 003, 5023, 5043, 5063, 5220, 5223, 5227, 5228. 
▪ Residential aged care facility: encounters identified by any one of MBS item 
numbers 20, 35, 43, 51, 92, 93, 95, 96, 5010, 5028, 5049, 5067, 5260, 5263, 5265, 5267. 
▪ Health assessments: encounters identified by any one of MBS item numbers 
700, 702, 704, 706, 708, 709, 710, 712, 713, 714, 717, 718. 
▪ Chronic disease management items: encounters identified by any one of MBS item 
numbers 720, 721, 722, 723, 724, 725, 726, 727, 729, 730, 731. 
▪ Case conferences: encounters identified by any one of MBS item numbers 734, 
736, 738, 740, 742, 744, 762, 765, 773, 775, 778. 
▪ Attendances associated with practice incentive payments: encounters identified by any 
one of MBS item numbers 2497, 2501, 2503, 2504, 2506, 2507, 2509, 2517, 2518, 
2521, 2522, 2525, 2526, 2546, 2547, 2552, 2553, 2558, 2559, 2574, 2575, 2577, 2598, 
2600, 2603, 2606, 2610, 2613, 2616, 2620, 2622, 2624, 2631, 2633, 2635, 2664, 2666, 
2668, 2673, 2675, 2677, 2704, 2705. 
▪ Other MBS encounters: encounters identified by an MBS item number that does 
not identify place of encounter (see A1 Medicare items). 
— Workers compensation: Encounters paid by workers compensation insurance. 
— Other paid: Encounters paid from another source (for example, state). 
General practitioner (GP): A medical practitioner who provides primary comprehensive and 
continuing care to patients and their families within the community (Royal Australian 
College of General Practitioners). 
GP consultation service items: Includes GP services provided under the MBS Professional 
services category including MBS items classed as A1, A2, A5, A6, A7, A14, A17, A18, A19, 
A20, A22 and selected items provided by GPs classified in A11, A15 and A27. 
Medication: Medication that is prescribed, provided by the GP at the encounter or advised for 
over-the-counter purchase. 
Medication rates: The rate of use of all medications, including medications that were 
prescribed, supplied by the GP and advised for over-the-counter purchase. 
Medication status: 
• New: The medication prescribed/provided at the encounter/advised is being used for 
the management of the problem for the first time. 
• Continuation: The medication prescribed/provided at the encounter/advised is a 
continuation or repeat of previous therapy for this problem. 
• Old: See Continuation. 
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Morbidity: Any departure, subjective or objective, from a state of physiological wellbeing. In 
this sense, sickness, illness and morbid conditions are synonymous. 
Patient status: The status of the patient to the practice. 
• New patient: The patient has not been seen before in the practice. 
• Old patient: The patient has attended the practice before. 
Practice nurse involvement: Encounters at which a practice nurse MBS item number and/or a 
treatment (either clinical or procedural) was recorded as done by a practice nurse. 
Prescribed rates: The rate of use of prescribed medications (that is, does not include 
medications that were GP-supplied or advised for over-the-counter purchase). 
Problem managed: See Diagnosis/problem. 
Provider: A person to whom a patient has access when contacting the health care system. 
Reasons for encounter (RFEs): The subjective reasons given by the patient for seeing or 
contacting the general practitioner. These can be expressed in terms of symptoms, diagnoses 
or the need for a service. 
Recognised GP: A medical practitioner who is: 
• vocationally recognised under Section 3F of the Health Insurance Act, or 
• a holder of the Fellowship of the Royal Australian College of General Practitioners who 
participates in, and meets the requirements for, quality assurance and continuing 
medical education as defined in the Royal Australian College of General Practitioners 
(RACGP) Quality Assurance and Continuing Medical Education Program, or 
• undertaking an approved placement in general practice as part of a training program for 
general practice leading to the award of the Fellowship of the Royal Australian College 
of General Practitioners, or undertaking an approved placement in general practice as 
part of some other training program recognised by the RACGP as being of equivalent 
standard. (Source: Commonwealth Department of Health and Aged Care 2001. Medicare 
benefits schedule book. Canberra: DHAC).  
•  Referral: The process by which the responsibility for part or all of the care of a patient is 
temporarily transferred to another health care provider. Only new referrals to specialists 
and allied health professionals, and for hospital and residential aged care facility 
admissions arising at a recorded encounter are included. Continuation referrals are not 
included. Multiple referrals can be recorded at any one encounter. 
Repatriation health card: An entitlement card provided by the Department of Veterans’ Affairs 
that entitles the holder to access a range of Repatriation health care benefits, including access 
to prescription and other medications under the Pharmaceutical Benefits Scheme. 
Rubric: The title of an individual code in ICPC-2. 
Significant: This term is used to refer to a statistically significant results. Statistical 
significance is measured at the 95% confidence level in this report. 
Torres Strait Islander: The patient identifies himself or herself as a Torres Strait Islander 
person. 
Work-related problem: See Diagnosis/problem. 
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Appendices 
Appendix 1: Example of a 2010–11 recording form 
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Appendix 2: GP characteristics questionnaire, 
2010–11 
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Appendix 3: Patient information card, 2010–11 
 
148
 149
Appendix 4: Code groups from ICPC-2 and 
ICPC-2 PLUS 
Available at: <purl.library.usyd.edu.au/sup/9781920899875>, see ‘Electronic editions and 
downloads’. 
Table A4.1:  Code groups from ICPC-2 and ICPC-2 PLUS – reasons for encounter  
and problems managed 
Table A4.2: Code groups from ICPC-2 and ICPC-2 PLUS – chronic problems 
Table A4.3: Code groups from ICPC-2 and ICPC-2 PLUS – problems managed by  
practice nurses 
Table A4.4: Code groups from ICPC-2 and ICPC-2 PLUS – clinical treatments 
Table A4.5: Code groups from ICPC-2 and ICPC-2 PLUS – procedures 
Table A4.6: Code groups from ICPC-2 and ICPC-2 PLUS – clinical measurements 
Table A4.7: Code groups from ICPC-2 and ICPC-2 PLUS – referrals 
Table A4.8:  Code groups from ICPC-2 and ICPC-2 PLUS – pathology test orders  
(MBS groups) 
Table A4.9:  Code groups from ICPC-2 and ICPC-2 PLUS – imaging test orders  
(MBS groups) 
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This report highlights changes in general practice activity 
in Australia over the most recent decade (April 2001 to 
March 2011) of the BEACH program, a national cross-
sectional study of general practice activity.  Over this 
time 9801 participating GPs provided details of  981,000 
GP–patient encounters. The report highlights changes 
that have occurred in the characteristics of general 
practitioners and the patients they see, the problems 
managed, and the treatments provided. Changes in 
prevalence of overweight and obesity, smoking status 
and alcohol use, are also described for subsamples of 
more than 30,000 adults and 3,000 children each year.
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